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During the last decades, numerous studies about stem cells and regenerative medicine high‐
lighted new therapeutic approaches to treat several neurological disorders. It is noteworthy
that the current optimism over potential stem cell therapies is driven by new understand‐
ings of stem cell biolology leading to specific cell fate decision.
The main objective of this book is to offer a general understanding of signaling pathways
underlying the capacity of differentiation of several types of stem cells into neurons, during
the development. Indeed, in this book, we deeply described TGF-beta signaling, Wnt Signal‐
ing, neurotrophin and NF-κ-B signaling and their implication in neuronal fate decision.
The second objective of this book is to understand how those pathways are altered in pathologi‐
cal conditions. We consequently analyzed those pathways in several pathological conditions.
Finally the third objective of this book is to describe advances in cellular therapy that could
be use to restore central nervous system dysfunction in pathological conditions, based on
new molecular biology findings. Several sources of stem cells and their potential benefits
were described in the last part of this book.
Finally, I would like to conclude this preface by expressing my deepest gratitude to all au‐
thors who contributed to the elaboration of this book.
Sabine Wislet-Gendebien, PhD
GIGA Neurosciences
University of Liège, Belgium

Section 1
TGF-Beta Signaling and Neuronal Fate Decision

Chapter 1
Role of TGF-β Signaling in
Neurogenic Regions After Brain Injury
Sonia  Villapol, Trevor T.  Logan and Aviva J.  Symes
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53941
1. Introduction
In 1928 Santiago Ramón y Cajal penned what became the accepted view about neurons in the
central nervous system; “everything may die, nothing can be regenerated”. He later exhibited his
wisdom by adding; “It’s the job of science to rewrite, if possible, this cruel phrase” [1]. Up until 20
years ago, the scientific literature had emphasized that neurogenesis only occurs during
development with no new neurons generated in the adult mammalian brain. However, since
the discovery of adult neurogenesis, an extensive literature has emerged supporting the
constant generation of new neurons in two neurogenic regions of the adult brain: the subven‐
tricular zone around the lateral ventricles (SVZ) and the subgranular zone (SGZ) of the
hippocampal dentate gyrus (DG) [2].
The existence of adult neurogenesis gave hope for recovery and regeneration from the many
different insults that can damage the brain. After stroke or traumatic brain injury (TBI),
immediate massive necrosis occurs followed by a subsequent prolonged period of inflamma‐
tion and further neuronal death [3]. Although brain injury induces massive cell loss, it also
induces an increase in proliferation of NSCs residing in the neurogenic niches [4]. The
environment of the neurogenic niche in adult animals is exquisitely regulated, with a finely-
tuned balance of soluble and cell-intrinsic factors that regulate the many different processes
that are critical to neurogenesis: cell survival, proliferation, differentiation, and migration [5].
Dramatic changes occur in this environment as a consequence of the injury. The careful
regulation of neurogenesis is disrupted by the many different cellular, soluble and vascular
signals detected by the different cell types in the SVZ and DG. This major environmental
alteration leads to increased proliferation of progenitor cells for long periods after the acute
injury, yet the ability of the neural progenitor cells to fully differentiate, migrate and integrate
into the lesioned area is limited [6]. Understanding the signals that regulate adult neurogenesis
© 2013 Villapol et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
in the naïve and injured animals is key to ultimately being able to harness the potential of
neuronal replacement and improve stem cell therapy.
There are many different factors important to regulation of neurogenesis, many of which are
discussed in other chapters in this book. Here we will focus on the role of the transforming
growth factor-β (TGF-β) superfamily and its associated signaling pathways in regulating
neurogenesis after brain injury. Members of this family, including the bone morphogenetic
proteins (BMPs), Activin, and TGF-β1, -β2 and -β3 have a profound influence on the neuro‐
genic process in naïve animals [7]. Many of these cytokines are induced by injury and play
critical roles in many kinds of brain damage related processes around the lesion [3]. We and
others recently started to accumulate data on their induction in the neurogenic niches after
different types of injury. Here we will focus on the relevance of their induction in these specific
brain regions, and the mechanisms through which they may influence the neurogenic response
to injury. As there are significant differences between the behavior of cells contributing to
neurogenesis during development and in the adult, we will restrict our analysis to that
observed in adult animals after injury. Delineation of the specific role of members of the TGF-
β superfamily in injury-induced neurogenesis may provide specific therapeutic targets for
enhancing neurogenesis after trauma.
2. The TGF-β superfamily; cytokines, receptors and signaling
The TGF-β cytokine superfamily is a large group of proteins comprising 33 different members
that include: bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs),
activins, inhibins, nodal, lefty, mülllerian inhibiting substance (MIS) together with the TGF-
β proteins [8, 9]. All members of this cytokine family mediate their effects in a broadly
analogous manner, binding specific type I and II transmembrane serine threonine kinase
receptors and transducing their signal through similar intracellular Smad proteins [10]. These
cytokines are divided into two distinct groups: those of the TGF-β/Activin group which mainly
signal through the type I receptors ALK4, -5 and -7 activating Smad2 and -3, and those of the
BMP/GDF group [11, 12] which employ ALK1, -2, -3 and -6 to activate Smad1, -5 and -8 [13,
14]. The specificity of Smad activation is therefore mainly determined by the identity of the
type I receptor used to transduce the cytokine signal [15] (Figure 1).
TGF-β1, -β2 and -β3 together with some GDFs are unique in that they are synthesized as a
large precursor molecule that is cleaved but remains non-covalently linked to its latency
associated peptides, in either a small or large complex [18]. The bioavailability of TGF-βs is
tightly regulated by the release of active TGF-β from these complexes in the extracellular
matrix, so synthesis of TGF-β does not necessarily provide a reliable indication of available
cytokine to initiate signaling. Similarly, the bioavailability of BMPs is regulated by binding to
secreted extracellular antagonists that prevent BMP (and sometimes Activin) from binding to
their receptor [19]. Expression levels of endogenous antagonists, including noggin, chordin,
follistatin, gremlin and cerberus, thereby regulate the availability, and therefore, active
signaling by their associated ligands [20]. TGF-β signaling is the archetype for signaling by
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this cytokine family. TGF-β binds to the constitutively active TGF-β receptor II (TβRII) which
can then recruit the type I receptor TGF-β receptor I (TβRI/ALK5). Activation of TβRI by
transphosphorylation activates it, initiating downstream signaling [21]. Canonical signaling
Figure 1. TGF-β superfamily signal transduction. TGF-β, nodal or activin ligands bind to Type II receptors, which
then recruit Type I receptors leading to transphosphorylation of type 1 receptors. Activated type I receptors phosphor‐
ylate Smad 2/3 (i.e. R-Smads) which then complex with the co-Smad, Smad4 and translocate to the nucleus to bind
DNA at specific DNA motifs. Smad proteins activate or repress transcription through association with various co-activa‐
tor (Co-Act) or co-repressor proteins. This pathway is inhibited by Smad7. BMP signaling operates by a similar para‐
digm. BMP6 and BMP7 bind to their Type II receptor before the complex recruits the Type I receptors, Alk-3 or Alk-6.
BMP2 and BMP4, however bind first to their type I receptor before recruiting the type II receptor BMPRII. BMP binding
to either receptor can be inhibited by first binding to various extracellular inhibitor proteins, such as noggin. Activa‐
tion of the receptor complex leads to phosphorylation of the receptors and subsequent phosphorylation of Smad1,
Smad5, or Smad8, allowing them to form a complex with Smad4. This heteromeric complex translocates to the nu‐
cleus, to target BMP-regulated genes through interaction with co-activators or repressors. Smad 6 and Smad7 may act
similarly to inhibit the BMP pathway through interactions with the receptor complex and thus inhibiting R-Smad acti‐
vation. TGF-β and BMP pathways induce the expression of proteins involved in proliferation, differentiation, survival
and apoptosis. The diagram is adapted from [16] and [17].
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by these cytokines is through the receptor regulated Smads (R-smads). As previously men‐
tioned, TGF-β and activin signal through activation of Smad2 and Smad3, which are phos‐
phorylated by the Type I receptor, and form a heteromeric complex with the common or co-
Smad, Smad4 [22]. This Smad complex translocates to the nucleus where it regulates the
transcription of numerous genes in cooperation with other transcription factors, coactivators
and corepressors. Inhibitory Smads, or I-smads, are Smad-activated proteins that provide
negative feedback to the Smad pathway through a variety of mechanisms [16, 23]. BMP
signaling is similar in form to TGF-β signaling, although the specifics of individual receptors
and R-Smads (1, 5, 8/9) involved vary according to the specific cytokine. For a full review of
signaling and receptor nomenclature by this cytokine family please refer to some excellent
reviews [14, 24]. The Smad pathway is by no means the only mechanism through which TGF-
β cytokine signals are transduced from the receptor to the nucleus. Smad-independent
pathways include activation of MAPKs, Ras/ERK, JNK, p38, PI3K-Akt, NF-kappaB, JAK/STAT,
PP2A/S6 phosphatases and small Rho-related GTPases (16, 25). Some of the non-Smad kinases
can influence Smad directed signaling by complexing with, or modifying the Smad proteins
directly [16, 25]. Another level of control was found when it was shown that TGF-β/BMP
signaling is both regulated by, and can regulate transcription of miRNAs [26]. Smads can also
influence miRNA biogenesis by binding directly to the pri-miRNA to enhance Drosha
processing of these molecules to pre-miRNA [27]. An intricate balance between Smad and non-
Smad signaling superimposed on cell intrinsic and environmental conditions determines the
specificity and the ultimate response of each cell to TGF-β signaling. Thus, there is a complexity
to TGF-β superfamily signaling that befits cytokines that signal to multiple different cell types,
in context dependent manners to influence many different physiologic processes [28].
Genetic evidence indicates that TGF-β family members regulate embryonic, perinatal or
neonatal development of the mouse embryo. Most mice null for one TGF-β superfamily ligand,
receptor, protein or signaling protein fail in either gastrulation or mesoderm differentiation.







TβRI Failed angiogenesis, Embryonic lethality (E8) [29]
TβRII Embryonic lethality (E10.5) [30]
TβRIII Failed coronary vessel development accompanied by reduced
epicardial cell invasion. Embryonic lethality (E14.5)
[31]
TGFβ-1 Loss of a critical regulator of immune function [32, 33]
TGFβ-2 Perinatal lethal, craniofacial defects [34]
TGFβ-3 Perinatal lethal, delayed lung development [33]






Smad1 Embryonic lethality (E10) [35, 36]
Smad2 Embryonic lethality (E7.5–E12.5) [37]
Smad3 Viable and fertile. Impaired immune function, including defective
neutrophil chemotaxis, and impaired mucosal immunity
[38, 39]
Smad4 Increased number of Olig2-expressing progeny [40]
Smad5 Embryonic lethality: defective vascular development [41, 42]
Smad7 Significantly smaller than wild-type mice, died within a few
days of birth
[43]
Smad8 Viable and fertile [41, 44]
BMPRIA Embryonic lethality (E9.5) [45]
BMPRIB Viable and exhibit defects in the appendicular skeleton [46]
BMPRII Embryonic lethality (E9.5), arrest at gastrulation [47]
BMP2 Embryonic lethality (E7.5-10.5), defective cardiac development
and have defects in cardiac development
[48]
BMP3 Increased bone density in adult [49]
BMP4 Embryonic lethality (E6.5-E9.5), no mesoderm differentiation
and show little or no mesodermal differentiation
[50]
BMP5 Viable, skeletal and cartilage abnormalities [51]
BMP6 Viable and fertile; slight delay in ossification. [52]
BMP7 Perinatal lethal because of poor kidney development, eye defects
that appear to originate during lens induction.
[53-56]
BMP8A Viable: male infertility due to germ cell degeneration [57]
BMP8B Viable: male infertility due to germ cell depletion [58]
BMP15 Viable: female subfertility [59]
Endoglin Embryonic lethality (E11.5) [60, 61]
Activin receptor IA
(ALK2)




Activin-βA Neonatal lethal, craniofacial defects (cleft palate and loss of
whiskers, upper incisors, lower incisors and molars)
[64]








Activin-βB Large litters but delayed parturition; nursing defects;
Eye lid closure defects at birth
[65]
Noggin Perinatal lethal, cartilage hyperplasia [66]
Follistatin Neonatal lethal, craniofacial defects, growth retardation and skin
defects retardation and skin defects
[67]
Table 1. Phenotype of mice that do not express specific TGF-β ligands, receptors or signaling molecules.
3. TGF-β superfamily expression and function in normal adult brain: Role
in neurogenesis
Adult neurogenesis involves proliferation of neural stem cells (NSCs), cell cycle exit, differ‐
entiation, maturation, and integration into the neural circuits, in a process that is involved in
learning and memory in the normal adult brain [68]. The neurogenic niche of the adult
forebrain subventricular zone (SVZ) is comprised of three major proliferative cell types; A, B
and C. Multipotent, self-renewing type B cells occur earliest in the neurogenic lineage of the
SVZ and give rise to the rapidly dividing type C cells, or transit amplifying progenitors. Type
A cells or neuroblasts differentiate from Type C cells and are migratory neuronal progenitors
with proliferative capacity, which migrate to the olfactory bulb where they differentiate into
interneurons (reviewed in [69-71]. In the subgranular zone (SGZ) of the hippocampal dentate
gyrus (DG), type 1 and type 2 slowly-dividing progenitors give rise to more rapidly dividing
intermediate progenitor cells, and these in turn differentiate into immature neuroblasts, which
migrate into the granule cell layer, then differentiate into mature neurons and integrate with
the existing hippocampal circuitry [71].
Within the CNS, all three isoforms of TGF-β are produced by both glial and neuronal cells [72].
Immunohistochemical studies show widespread expression of TGF-β2 and -β3 in the devel‐
oping CNS, and these proteins play a role in regulation of neuronal migration, glial prolifer‐
ation and differentiation [73-76]. In adult brain, TGF-β receptors are found in all areas of the
CNS including the cortex, hippocampus, striatum, brainstem and cerebellum [77, 78]. Immu‐
noreactivity for TβRI and TβRII is detected on neurons, astrocytes and microglia and endo‐
thelial cells located in the cortical gray matter, suggesting that almost every cell type in the
CNS is a potential target for TGF-β signaling [79].
The TGF-β superfamily and its downstream targets are capable of controlling proliferation,
differentiation, maturation and survival of stem cells and precursors in the neurogenic niches
of adult brain [18]. TβRI and TβRII are expressed by Nestin-positive type B and C cells in the
SVZ [80, 81]. Our data show mRNA expression of TGF-β1, -β2, and -β3 in both the adult SVZ
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and DG [82]. In the adult human brain, TGF-β1 protein expression has been reported in the
hippocampus, and the protein levels significantly increased with the age of the individual [83].
As neurogenesis declines with age [84], it has been suggested that TGF-β is a possible regulator
of this age-related decline [83]. Signaling by the Smad2/3 pathway is high in the hippocampus
and specifically the dentate gyrus, indicating a role for TGF-β and/or activin in regulation of
neurogenesis [85, 86]. When TGF-β protein is overexpressed or infused directly into the lateral
ventricles of uninjured animals, hippocampal neurogenesis is dramatically inhibited [81, 87].
This may be due to a direct anti-proliferative effect of TGF-β on type 1 and 2 primary NSCs
[17]. A direct effect of TGF-β on NSCs is supported by in vitro studies showing that TGF-β1
treatment of cultured adult NSCs induces the cyclin-dependent kinase inhibitor (p21) and
leads to cell cycle termination, without altering the differentiation choices of the NSCs [81].
Additionally, overexpression studies lead to increased TGF-β signaling in many different cell
types within the neurogenic niche, making the exact contribution of more restricted, endoge‐
nous TGF-β difficult to determine. Recent data have suggested that TGF-β signaling at later
stages of neurogenesis is critical for newborn neuron survival and maturation in the DG.
Conditional deletion of the TβRI (ALK5) gene specifically in immature and mature neurons,
leads to decreased neurogenesis and reduced survival of newborn neurons [85]. Thus, TGF-
β potentially has opposing roles at different stages of neurogenesis, providing an additional
example of the contextual nature of TGF-β action.
Activin receptors are expressed throughout the brain, with strong expression in the neuronal
layers of the hippocampus [88-90]. We have found that mRNA for activin-A and for activin’s
endogenous high affinity inhibitor, follistatin, are expressed in both the SVZ and DG of the
adult mouse [82] and several recent reports have demonstrated that activin-A modulates
adult  neurogenesis  [88,  91,  92].  Chronic  overexpression  of  follistatin  by  neurons  of  the
hippocampus almost  entirely  ablates  adult  DG neurogenesis,  due to  drastically  lowered
survival of adult-generated neurons [91],  although short-term infusion of follistatin does
not affect neurogenesis in uninjured animals [88]. Infusion of activin to the lateral ventri‐
cle of uninjured mice mildly increases the rate of NSC proliferation and neuron genera‐
tion in the DG, indicating that activin might stimulate division of NSCs. This effect may be
indirect  as activin has a potent anti-inflammatory effect  in the CNS, and may modulate
local microglia to stimulate neurogenesis [88]. Smad3 knockout mice have decreased levels
of cell proliferation in the SVZ and along the rostral migratory stream, and decreased levels
of olfactory bulb neurogenesis [93]. As these mice have defective signaling by both TGF-β
and activin, these data suggest that activin signaling in the SVZ may be the predominant
Smad3-utilizing cytokine in  defining basal  levels  of  neurogenesis.  In  the DG pSmad2 is
normally absent from Sox2-positive type 1 and 2 primary NSCs in the DG of adult mice
[17]. However, Smad3 knockout mice also have reduced proliferation in the DG potential‐
ly pointing to a different role for Smad2 and Smad3 in the DG [93].
The BMP family of proteins regulates cell proliferation and fate commitment throughout
development and within the adult neurogenic niches [19]. Expression of BMP2, -4 and -7
mRNAs have been reported in neurogenic regions of adult rodent brain [94], and the BMP
receptors BMPRIA, -IB and -II are expressed abundantly in neurons, as well as in astrocytes
Role of TGF-β Signaling in Neurogenic Regions After Brain Injury
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and ependymal cells [95]. All three of these receptors are expressed in type A cells of the SVZ,
while type B and C cells express BMPRIA and BMPRII [96]. In the DG, radial stem cells of the
SGZ marked with glial fibrillary acidic protein (GFAP) and Nestin or Sox2 primarily express
BMPRIA but not BMPRIB, while mature neurons express only BMPRIB [97]. BMP ligands are
also expressed in the adult rat brain [98, 99]. BMP2, -4, -6, and -7 are expressed by cells of the
SVZ and DG [96, 97]. In the DG, the BMP signal transducer pSmad1 is strongly expressed in
non-dividing primary NSCs and neuroblasts, but is absent in dividing primary NSCs [97],
while in the SVZ, pSmad1/5/8 has been reported in primary NSCs and transit amplifying
progenitors, but not in DCX-positive neuroblasts [40]. The soluble BMP inhibitor noggin is
also expressed by ependymal cells of the SVZ [96] and by cells of the DG [100].
Changing the ratio of BMP to noggin alters the rates of NSC proliferation and neurogenesis in
adult animals, indicating that these proteins are primary regulators of basal adult neurogene‐
sis [96, 97, 100]. Administration of exogenous BMP4 or BMP7 potently inhibits the division of
NSCs and generation of new neurons in vivo and in vitro [96, 97], as does inhibition of noggin
expression [101]. Conversely, infusion of noggin or genetic deletion of the BMPRIA receptor
causes an increase in NSC proliferation and generation of NeuN-expressing neurons in the DG
[96, 97]. However this increase is transient, there is an eventual depletion of the primary NSC
pool and a drastically reduced level of neurogenesis [97]. Decreased BMP signaling in the DG is
thought to be responsible for increased neurogenesis driven by exercise [102]. It has been
proposed that secretion of noggin from ependymal cells inhibits BMP signaling allowing a low
level of basal neurogenesis to occur, while BMP signaling maintains the overall quiescence of
the primary NSC pool [96, 97, 100]. Exogenous noggin infusion potentially has a different effect
on SVZ NSCs, leaving their proliferation rate unaffected, but causing an increase in the generation
of oligodendrocyte precursor cells from primary NSCs at the expense of immature neuro‐
blasts [40]. This noggin infusion phenocopies the effect of conditionally deleting Smad4 in NSCs
using GLAST-cre [40] and is in contrast to the pro-neurogenic effects of noggin described by Lim
et al [96]. Thus, although there is still some controversy in the field it its clear that the balance
between BMP and noggin is critical to proper maintenance of the adult NSC population.
4. Expression of TGF-β related cytokines in the adult rodent brain after
injury
TGF-β family proteins are present in the brain immediately after injury as they are carried into
the wound by the blood [103]. Additionally, extracellular TGF-β proteins are activated and
released from their latent protein complexes in the brain parenchyma [104]. Local CNS expres‐
sion of TGF-β, activin, and BMP proteins is increased after many different injuries [72, 105, 106].
Following acute brain injury, TGF-β1 levels are elevated in astrocytes, microglia, macrophag‐
es, neurons, ependymal cells and choroid plexus cells with peak expression around 3 days
[107-110]. TGF-β2 and -β3 expression has also been found in astrocytes, microglia, endothelial
cells and neurons after both ischemic and TBI [111, 112]. We have recently found TGF-β2
expression in oligodendrocytes in the lesioned cortex and corpus callosum [113]. Ischemic lesions
as well as TBI show elevated activin-A mRNA as well as mRNA for the BMPRII receptor [90, 94,
Trends in Cell Signaling Pathways in Neuronal Fate Decision10
114]. Smad proteins are also upregulated after injury and were mainly located in the cerebral
cortex, typically in the nucleus and/or in the cytoplasm of astrocytes, oligodendrocytes or neurons
[86, 108, 115, 116]. We have summarized many studies that have examined changes in the TGF-


















































Dentate gyrus Neurons, vessels Protein [124, 125]
Hypoxic-ischemic Cerebral cortex,
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_ _ _ _ _ Astrocytes, Microglia
and blood vessels
Protein [126]
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Excitotoxic Injury _ _ _ _ _ Hippocampus Neurons Protein [133]
Irradiation Cerebral cortex _ _ _ _ _ Macrophages and
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Protein [134]
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Cerebral cortex _ _ _ _ _ Astrocytes and neurons mRNA,
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Cerebral Cortex _ _ _ _ _ Endothelial cells Protein [141]
Smad2 Excitotoxicity Cerebral Cortex Hippocampus Neurons, astrocytes and
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Protein [86]

















































































































Neurons, blood vessels mRNA,
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[105, 146-148]
Table 2. TGF-β superfamily cytokine and signaling intermediate expression after different forms of injury.
Relatively few studies have examined changes in expression of the TGF-β superfamily of
cytokines specifically within the neurogenic regions after brain injury. TGF-β1 expression
increases in the SVZ [119] and DG [117, 118, 124] after ischemic injury. Its expression is also
induced in neurons of the DG after a demyelinating lesion [131] or after local kainic acid
injection [133]. Our group recently found that controlled cortical impact injury increased
mRNA expression of many TGF-β cytokines, including TGF-β1 and -β2, activin-A, and BMPs
-4, -5, -6, and -7 in the DG and SVZ, demonstrating that a distal injury can alter TGF-β signaling
pathways in the neurogenic regions [82]. We have observed upregulation of TGF-β1 and -β3
in GFAP and Nestin positive progenitors in the SVZ and DG after TBI (Figure 2 and unpub‐
lished data). TβRII is expressed in these Nestin positive progenitors in the lateral SVZ (Figure
2d). Phospho-Smad3 (pSmad3) shows strong nuclear localization in these cells as well (Figure
2i and unpublished data) suggesting a role for TGF-β/activin signaling in the regulation of
post-injury neurogenesis. In the DG, TβRII is expressed in GFAP-positive precursors with
strong pSmad3 nuclear staining (Figure 2m, 2r) suggesting a similar role for TGF-β cytokines
in this neurogenic niche.
Role of TGF-β Signaling in Neurogenic Regions After Brain Injury
http://dx.doi.org/10.5772/53941
13
Figure 2. Confocal images of the TGF-β ligands, receptors and signaling proteins in the SVZ and DG in the in‐
jured adult mice brain. Double and triple labelled inmmunofluorescence staining for TGF-β proteins and receptors,
with the following cell-type specific markers: Nestin (for undifferentiated neuronal precursors), NeuN (for mature neu‐
rons), GFAP (for progenitor and astroglial cells), DCX (for neuroblasts). The left column shows coronal sections within
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the subventricular zone (SVZ) at 3 (a-g) and 7 (h and i) days after traumatic brain injury (TBI). TβRII (a, red) is expressed
in Nestin positive (b, green) neural stem cells (NSCs) in the SVZ, and also in ependymal cells (d), lining the walls of the
lateral ventricle (LV). Light TGFβ−1 (green) and predominant TGFβ−3 (red) expression is also found in the walls of the
LV where the adult NSCs reside (e). (f) Neurons (NeuN, green) are co-localized with TGFβ−2 (red) in the damaged stria‐
tum. (h) The majority of Smad 1,5,8 proteins (red) are co-expressed with Nestin (green). (i) pSmad3 (red) colocalizes
with GFAP (green) in the dorsolateral corner of the SVZ. The right column shows coronal sections within the dentate
gyrus (DG) of the hippocampus at 3 (j-q) and 7 (r) days after TBI. (j-m) TGFβ−1 (red, j) and TβRII (green) are colocalized
in astrocytes (GFAP, blue) in the hilus and GCL (granule cell layer) of the hippocampus (n) TGFβ−1 (red) is co-localized
with astrocytes (GFAP positive cells) located in the subgranular zone (SGZ) of the hippocampus. In (o) TGFβ−2 (red) is
co-localized with NeuN (green) positive neurons in the hilus of the dentate gyrus. (p) TGFβ−3 (red) is co-localized with
GFAP positive (blue) immature progenitors in the SGZ but not with DCX (green) positive neuroblasts. (q) Immunos‐
taining with TGFβ−1 (green) and TGFβ−3 (red) show they are almost entirely colocalized in the SGZ. (r) pSmad3 stain‐
ing in the nuclei of GFAP positive progenitor cells in the SGZ and hilus of the hippocampus. Scale bars: (c, d, f, (inset in
i), m, (inset in n), o, (inset in o), p, (inset in r)) 20 µm; (e, g, h, i, q, r) 50 µm.
Local injury to the hippocampus via saline injection produces a strong induction of activin-βA
mRNA in the DG, which can be blocked by inhibiting NMDA receptors [114]. Activin expres‐
sion in the DG is potently induced by seizures, local excitotoxic lesions, hypoxia/ischemia, TBI
or permanent MCAO [89, 114, 146, 148, 149]. Cortical weight drop injury also elevates the
expression of the activin receptor ActR-I and the BMP receptor BMPRII in the DG [90]. BMPRII
expression is also elevated in the DG after global cerebral ischemia [94], and BMP4 levels
increase in the SVZ after a demyelinating lesion [115].
The limited studies available indicate that TGF-β, BMP, and activin signaling may all be active
in the neurogenic regions after injury. However, it is currently unclear the manner in which
they affect the behavior of neural stem cells. Given that these cytokines clearly regulate adult
neurogenesis in the uninjured adult, more research in this area is necessary to fully elucidate
the effect of brain injury on these signaling pathways, and the mechanisms through which
these changes alter post-injury neurogenesis.
5. Injury-induced neurogenesis and its regulation by TGF-β family
proteins
We have described the role of TGF-β proteins in the regulation of neurogenesis under basal
conditions. In response to various injuries, the rate of neurogenesis is increased and the fate
and migration of the neural progenitors is changed. Cerebral ischemia, excitotoxicity and TBI
can all promote neurogenesis in the adult DG and SVZ [88, 150-153]. After injury, the altered
environment changes the basic processes of proliferation, differentiation, migration and
integration. TGF-β related cytokines have the potential to regulate many of these processes.
Alteration in the destination of progenitor cells means that many of the neuroblasts change
their usual trajectory and migrate towards and into the lesion [154]. The cell fate of progenitor
cells can be altered by the changed environment of the injured brain, in both the neurogenic
niche and at the lesion site to which the progenitor cells migrate. The environment around the
lesion is now very different than the normal location of these progenitors and thus further
differentiation and integration occurs in an entirely unique environment [155]. Additionally,
the actions of TGF-β cytokines are highly context dependent, and they can have very different
effects in the injured as compared to the uninjured brain.
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A major component of the brain post-injury in comparison to the uninjured brain is the
inflammatory  response,  both  of  local  CNS  cells  and  invading  macrophages.  While  the
majority of studies have indicated that inflammation is detrimental to neurogenesis, it  is
now appreciated that the effect of inflammation on neurogenesis is multifaceted [156]. Of
particular importance is the response of local microglia and astrocytes in the neurogenic
regions.  Microglia  are  potent  regulators  of  neurogenesis,  and  in  certain  contexts  can
powerfully  inhibit  the  process  [157].  However  microglia  have  also  been  shown to  pro‐
mote neurogenesis  [158,  159],  and studies have described differential  action of  acute vs.
chronically activated microglia on NSC division and neurogenesis,  as well  as for micro‐
glia  activated  by  different  mechanisms  or  by  different  cytokines  [160,  161].  As  TGF-β
proteins are prominent anti-inflammatory molecules [162], their actions after brain injury
can regulate neurogenesis by acting directly on NSCs as well as indirectly through their
effects on the glial inflammatory response [163].
Due to their pleiotropic actions, TGF-β superfamily proteins have been investigated as
potential treatments for a variety of CNS injuries, and several studies have demonstrated
potential uses for these cytokines as therapeutic molecules (see Table 3). They have also
provided insights into the action of these molecules as regulators of neural stem/progenitor
cell (NSPC) proliferation and differentiation, with respect to both endogenous and transplant‐
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Table 3. Therapeutic application of TGF-β proteins in the normal and injured brain that affect neurogenesis.




TGF-β1  treatment  improves  the  outcome  in  several  models  of  injury  as  it  is  strongly
neuroprotective [76, 133, 171, 172] and in certain circumstances can promote neurogenesis
after injury. After middle cerebral artery occlusion (MCAO) in mice, intranasal treatment
with TGF-β1 increases the number of proliferative DCX-positive neural progenitors and the
number of new neurons in the SVZ and striatum, while decreasing the fraction of prolifera‐
tive cells that express GFAP [119]. After adrenalectomy, TGF-β also stimulates neurogene‐
sis. TGF-β1 expression is upregulated and is necessary for the increased rates of neurogenesis
in the SVZ and DG caused by adrenalectomy [163]. In this model TGF-β mediated downre‐
gulation  of  microglial  activation  and  proliferation  may  be  partially  responsible  for  the
increased  neurogenesis  [163,  165].  TGF-β1  can  also  inhibit  chronic  microglial  activation
induced by prenatal LPS exposure, and ameliorate the LPS-mediated decrease in neurogen‐
esis  [166]  suggesting  that  the  anti-inflammatory  action of  TGF-β participates  in  its  pro-
neurogenic effects. Conversely, in naïve animals intracerebroventricular infusion of TGF-β1
lowered the number of DCX-positive neuronal precursors in the neurogenic niches. This
reduced level of proliferation in the TGF-β1 infused brains was strongly correlated with an
increased accumulation of pSmad2 in Sox2/GFAP expressing cells of the SGZ [81]. Transgen‐
ic overexpression of TGF-β1 in naïve mice also leads to reduce neurogenesis [87]. The opposite
effects of TGF-β1 in injured as compared to naïve animals illustrate the difficulty in assigning
one specific role to TGF-β1 due to its context-dependent effects. Chronic inflammation, either
after  lesion  or  in  neurodegenerative  disease,  provides  a  different  environment  for  the
consequences  of  TGF-β  signaling.  The  anti-inflammatory  actions  of  TGF-β  can  have  an
important role in influencing neurogenic processes, independent of direct effects on neural
progenitor cells.  Dysregulation of TGF-β signaling is  being acknowledged as a potential
source for chronic inflammation. Indeed, aberrant TGF-β signaling and consequent accumu‐
lation of activated microglia in the neurogenic regions may play an important role in the
progression of Alzheimer’s disease [171, 173].
5.2. Activin
Recent studies have demonstrated a critical role for activin signaling as a modulator of adult
neurogenesis [91] in addition to its well-established role as a neuroprotective molecule [174,
175]. After local excitotoxic injury to the hippocampus, ablating activin signaling by infusion
of the activin inhibitor follistatin potently inhibits post-injury neurogenesis and exacerbates
the inflammatory response of astrocytes and microglia. Conversely, infusion of activin-A
facilitates neurogenesis and represses gliosis [88]. Perhaps related to its effects on neurogen‐
esis, activin can also regulate anxiety and depression-like behavior in rodents, and the activin
pathway may be a useful therapeutic target for treating depression. Hippocampal infusion of
activin-A or activin-B reduces measures of depression in a forced swim test, with a similar
efficacy to that of the antidepressant fluoxetine [170]. Further, transgenic mice which overex‐
press activin-A, have decreased anxiety measures in spontaneous place preference tests, while
mice which overexpress follistatin, display the reverse [91].
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5.3. BMPs
In the naïve rodent, BMPs usually act to suppress neurogenesis in the SVZ and DG whereas
the BMP inhibitor noggin promotes it [96]. In contrast, inhibition of BMP signaling by upre‐
gulation of the BMP inhibitor chordin after lysolecithin-induced demyelination of the corpus
callosum, led to redirection of SVZ precursors away from a neuronal lineage towards that of
oligodendrocytes [169]. This change in differentiation potential was accompanied by a change
in the migration pattern of the SVZ precursors, away from the rostral migratory stream, and
towards the corpus callosum. Injury-induced changes in expression of regulatory factors often
alter the normal pattern of cell differentiation and migration [176, 177]. In a different model of
demyelination, cuprizone-induced upregulation of BMP-4 resulted in more SVZ precursors
becoming astrocytes, with a concomitant reduction in the number of mature oligodendrocytes
[115]. Intraventricular infusion of noggin in this model increased the generation of oligoden‐
drocytes from the SVZ [115] illustrating that inhibition of BMP signaling has the potential to
promote remyelination in models of multiple sclerosis. The astrogliogenic potential of BMP
has been demonstrated in multiple studies, where various precursors are pushed towards the
astrocytic lineage [168, 178]. This is also true with transplanted neural stem cells or mesen‐
chymal stem cells, where BMPs around the implantation site push the transplanted cells
towards astrocytes [179]. If these cells are being used to enhance repair after spinal cord or TBI,
inhibition of BMP becomes an attractive option to promote neuronal or oligodendrocyte
differentiation rather than that of astrocytes. In contrast to all these studies, one group has
shown that BMP-7 has neuroprotective properties which may enhance the survival of imma‐
ture neurons [142, 180]. In one study, infusion of BMP-7 into the lateral ventricles of rats 24
hours after transient MCAO led to increased numbers of proliferating NSCs and more mature
neurons generated in the SVZ while also facilitating behavioral recovery [145]. However, a
different group has shown that transgenic expression of the BMP-inhibitor noggin in neurons
after permanent MCAO in the mouse enhances functional recovery [167]. These conflicting
data illustrate the sometimes confusing nature of the literature whereby BMP effects, similar
to those of TGF-β are extremely contextual and are dependent on the exact model used. Overall,
although some BMPs may have neuroprotective properties, the vast majority of the literature
supports the view that BMP induction after injury is not beneficial for recovery, and that
inhibition of BMP signaling may have therapeutic potential.
6. Future therapeutic strategies
In spite of extensive research in the field of brain injury or stroke, there is little effective
treatment for these injuries [182]. Many of the neuroprotective treatments that have been
successful in rodents have failed in clinical trials [183]. Harnessing the regenerative capaci‐
ty of the adult brain is one strategy for repairing and replacing injured tissue, together with
enhancing  neurotrophic  support  of  existing  neurons  to  promote  survival  [184,  185].  A
complementary strategy also under development is transplantation of neural stem cells or
committed progenitors into the lesion. However, when multipotent NSCs were implanted
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Figure 3. Modulation of neurogenesis and gliogenesis after adult brain injury by members of the TGF-β cyto‐
kine superfamily. In the top panel, the dentate gyrus (DG) in the hippocampus and subventricular zone (SVZ) of the
lateral ventricles are shown after damage to the cerebral cortex. Note the proliferation and migration of cells from the
SVZ and DG towards the infarcted area (blue arrows). Red dots represent proliferating and migrating neural stem cells
and progenitors cells (NSPCs) located in these neurogenic regions. In the bottom panel, the role of TGF-β proteins at
different stages of neurogenesis or gliogenesis after adult brain injury is illustrated. Proliferation, migration or differ‐
entiation are induced or inhibited by growth factors, such as: TGF-β, BMPs proteins, Activin, Follistatin or Noggin. After
injury to the brain, TGF-β1 can increase proliferation of NSPCs and induce the differentiation of neuroblasts into neu‐
rons within the SVZ, [119]. BMP7 can induce neural stem cell proliferation, neuronal migration and differentiation
[145]; other BMPs proteins (BMP2-7) also can stimulate neuronal migration [94]. The BMP inhibitor proteins noggin
and chordin promote NSPC migration and oligodendrocyte proliferation and differentiation, while decreasing astro‐
cyte proliferation [115, 169]. After injury to the brain, within the DG TGF-β1 can reduce the proliferation of immature
neurons while increasing neuronal migration and differentiation [165, 166]. BMP7 can enhance NSPC proliferation
and neuronal differentiation [96, 145]. Noggin can also increase NSPC proliferation [169]. Generally, BMPs can in‐
crease astroglial differentiation and inhibit oligodendrocyte generation, and the BMP inhibitors Chordin and Noggin
can facilitate oligodendrocyte differentiation and proliferation [181]. Activin can induce NSPCs proliferation, and de‐
crease microglial and astroglial proliferation. The activin antagonist, follistatin, reduces proliferating NSPCs and mi‐
grating neuroblasts [88]. In summary, the proliferation, migration and differentiation of cells in the SVZ and the DG
may be influenced by the spatial and temporal expression profile of these TGF-β proteins after brain injury.
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directly into non-neurogenic regions in the injured brain, such as in the cortex or striatum,
they failed to generate neurons but instead generated glial cells [186, 187]. Endogenous neural
progenitors also are limited in their differentiation potential, presumably because the post-
lesion environment is one that supports glial differentiation in preference to that of neu‐
rons [188]. As TGF-β family members can promote astrogliogenesis [189, 190], it would seem
that in some circumstances, inhibition of specific cytokine signals would increase neuronal
differentiation.  A further consideration for repair and neuronal survival is  promotion of
oligodendrocyte  survival  and differentiation,  since  remyelination is  critical  to  continued
survival and function of many neurons. Inhibition of BMP action through infusion of noggin
can promote oligodendrocyte differentiation after demyelination [115]. Inflammation after
injury is yet one more factor that alters the environment for regeneration. Although often
thought of as a short-lived phenomenon, there can be longer lasting inflammatory changes
that  persist  months  after  injury  [191].  One of  the  major  problems with  development  of
members of the TGF-β superfamily or their inhibitors for therapeutic use are the pleiotrop‐
ic nature of their effects. Thus TGF-β1 itself is neuroprotective and anti-inflammatory, which
should  promote  recovery,  but  it  inhibits  proliferation  of  precursors,  and  also  promotes
development  of  the  glial  scar  through  upregulation  of  many  extracellular  matrix  mole‐
cules, and through enhancing the migration of astrocytes [128, 192].
These cytokines act in a context dependent and concentration dependent manner, which adds
an additional layer of complexity. To develop better therapeutic strategies we need a deeper
understanding of the mechanisms through which the many actions of each cytokine are
mediated. We may then be able to target specific molecules in the downstream signaling
pathways, to avoid the pleiotropic effects that are emblematic of the activity of this cytokine
family.
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1. Introduction
1.1. General overview of insulin/IGF-signalling
The IIS cascades are initiated by binding of Insulin or Insulin-like growth factors (IGF-1 and
-2) to their receptors, the Insulin receptor (IR), and the two Insulin-like growth factor receptor
1 (IGF-1r) and 2 (IGF-2r) (Fig. 1). While high affinity binding occurs between the cognate
ligand-receptor pairs, each ligand binds to the other receptors with lower affinity [2]. IR, IGF-1r
and -2r are dimers that occur as homo- but also as heterodimers, the latter of which are studied
in various cancer cells [3]. Such hybrid receptors are also found in the central nervous system,
however a clear function for them has not emerged as yet [4] although activation of different
signalling cascades followed by a different biological effect is a likely scenario [2]. IR, IGF-1r
and -2r are tyrosine receptor kinases that phosphorylate themself as well as downstream
adaptor proteins like the insulin receptor substrate proteins (IRS-1-4) [5]. Through phosphor‐
ylation, IRS proteins bind to SRC-homology-2 (SH-2) domain-containing proteins like SRC,
SRC homology2-B (SH2-B), protein phosphatases like Tyrosine-protein phosphatase non-
receptor type 1 (PTPN1), or the p85 subunit of phosphatidyl inositol 3-kinase (PI3K).
Two major signalling pathways are activated through IIS: the PI3K- and/or the RAS/Mitogen-
activated protein kinase- (MAPK) pathways that are implicated in the regulation of a plethora
of different cellular processes.
PI3K belongs to a family of lipid kinases that are grouped into three classes. Class IA PI3K are
heterodimers of a p110 catalytic and a p85 or p55 regulatory subunit [6]. Binding of PI3K is
followed by activation of the p110 catalytic subunit of the kinase, which catalyses the increase
© 2013 Vogel; licensee InTech. This is an open access article distributed under the terms of the Creative
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of phosphatidylinositol-3,4,5-triphosphate (PtdIns{3,4,5}P3) lipids. PtdIns{3,4,5}P3 induce
phosphorylation of phosphoinositide-dependent protein kinase 1 (PDK-1), and the AGC
kinase AKT. In mammals, AKT has three different isoforms, AKT-1,-2, and -3. Each of them
has two critical sites in their activation domain, Thr308 and Ser473 that need to be phosphory‐
lated both to achieve full kinase activation. Inactive AKT is localised in the cytosol, but it is
recruited to the plasma membrane together with PDK-1 through association with phosphati‐
dylinositol-4,5- diphosphosphate (PtdIns{4,5}P2) and PtdIns{3,4,5}P3. As a result, PDK-1 and
AKT colocalise at the plasma membrane, which allows PDK-1 to induce phosphorylation of
AKT at Thr308. AKT phosphorylation at Ser473 occurs by integrin-linked kinase (ILK) as well
as mTORC-2 that are therefore PDK-2s for AKT [7]. Substrates of AKT are numerous, including
pro-apoptotic proteins like BAD or anti-apoptotic proteins like BCL-2, NF- κB, and MCL-1,
Forkheadbox transcription factors of the FOXO family as well as GSK-3β. AKT also phos‐
phorylates and inhibits the dimer tuberous sclerosis complex-1/-2 (TSC-1/TSC-2), which acts
as inhibitory GTPase-activating protein for RHEB. The GTPase RHEB can activate mTORC-1,
which has several substrates like p70 ribosomal protein S6 kinase (p70S6K), the translation
initiation regulator 4E binding protein (4E-BP), and the proline-rich AKT substrate PRAS40.
Through this signalling cascade, IIS activates mTORC-1 to promote cellular growth, transla‐
tion, transcription, and autophagy. mTORC-1 activation initiates a negative feed back loop
through active p70S6K that phosphorylates and inhibits IRS, thereby preventing activation of
PI3K in response to IIS. As indicated above, mTORC-2 also influences upstream IIS by
phosphorylating AKT as PDK-2 and is involved in spatial growth by regulating the actin
cytoskeleton. However, little is known about mTORC-2 activation through IIS. Recent data
suggest that mTORC-2 activation through IIS relies on a putative PI3K that is insensitive to
the negative feed back loop that controls activation of mTORC-1 [8].
IIS triggering the RAS/MAPK pathways can lead to activation of a subset of three downstream
kinases, ERK, JNK, and p38 [9] (Fig. 2). Activation of ERK is dependent on the RAS/MAPK
pathway, in which IIS results in phosphorylated IRS or SHC that recruit growth factor receptor-
bound protein 2 (GRB-2). GRB-2 associates with the protein son of sevenless (SOS), which is a
guanine nucleotide exchange factor. SOS acts by binding RAS-GTPase and forcing it to release
bound GDP and to bind GTP instead, which results in an activated state. Activated RAS
phosphorylates RAF, which in turn phosphorylates MEK that is responsible to activate the
MAPK ERK-1/-2. Jun aminoterminal kinases (JNK-1/-2) are further members of the MAPK
pathway that are as well activated through IIS. JNK activation is dependent on PI3K, whose
catalytic subunit does not bind to p85 but to the small RHO-family GTPase CDC42 [10]. This
complex activates MKK-4 (or MAP2K-4 (mitogen-activated protein kinase kinase 4), which
finally phosphorylates JNK-1/-2. The mechanism of p38 activation via IIS is so far unclear [9].
PI3K- and RAS/MAPK-pathways also converge on some downstream molecules like FOXO
proteins. Phosphorylation of FOXO through AKT leads to nuclear exclusion and interference
with target gene expression. Several other sites are phosphorylated through ERK and p38
MAPK. Interference with these posttranslational modifications leads to decreased promoter
binding together with ETS-1 transcription factor (TF) [11].
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2. Insulin/IGF-expression in the central nervous system
Insulin, Igf-1 and -2 as well as the three corresponding receptors are widely expressed in the
developing and mature central nervous system (CNS) (for a recent review refer to [1]).
Expression of Insulin and Igfs is in part under the control of Growth hormone (GH), but action
of several tissue- and developmental-specific transcription factors are also involved in Insulin/
Igf expression as is the nutritional status (our own unpublished observations and [12-14]).
Coordination and regulation of the biological activity of Igf-1 and -2, but not Insulin, is not
only achieved by transcriptional or translational control but also through a set of proteins that
have the ability to bind these ligands, namely the Igf-binding proteins (Igfbp). Upto date there
Figure 1. General overview of PI3K-dependent and mTor-driven IIS cascade and points of interference of serveral in‐
hibitors commony used to study downstream IIS.
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are several Igf-1 and -2 binding proteins as well as Igfbp-related (or -like) proteins that bind
to the ligands with varying affinities. Igfbps serve different functions, such as stabilisation and
regulation of the concentration of diffusible Igfs, as well as facilitating receptor binding and
modulation of Igf-bioavailability in the extracellular space [12]. Altogether, the various
subtypes of Igfbps bind 99% of circulating Igf-1 and -2. Within this fraction, 75% are bound to
Igfbp-3. Only 1% of Igf-1 and -2 is freely available in the extracellular space [15].
Igf-1 and -2 as well as the Igfbps are widely expressed in the brain [16,17]. Their expression
patterns have been described in multiple studies, mainly based on mRNA-detection methods
(summarised in [12]). Accordingly, Igf-1 is strongly expressed in the spinal cord, midbrain,
cerebral cortex, hippocampus and olfactory bulb (OB) during development. Igf-1 transcription
decreases postnatally as cell maturation advances to reach low levels in the adult central
nervous system. In the OB, Igf-1 expression persists at high levels in cells that are constantly
renewed even in the adult organism [18]. Igf-2 is also expressed in various brain regions and
also declines over development. However, it is considered to be the most abundantly expressed
Igf in the adult brain.
Igfbp-1 seems generally not to be present in sufficient amounts for detection in the central
nervous system [1,19]. Expression of Igfbp-2 is found over all gross neuroanatomical structures
of the rat brain, increasing from E15 until adulthood [20]. In preneurogenic stages (E10], rat
Igfbp-2 is strongly expressed in neuroectodermal structures of the neural tube and the
neuroepithelium [21]. In the postnatal brain it is mainly confined to astroglia as well as to the
Figure 2. General overview of IIS activating ERK in RAS/MAPK-dependent and JNK in CDC42-dependent manner.
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choroid plexus and leptomeninges [22]. Accordingly, IGFBP-2 is found closely associated with
human astroglial tumors. In this research field, it serves not only as a staging marker for
glioblastoma but is exploited for therapeutic intervention [23]. IGFBP-2 as well as bound IGF-2
are overexpressed in high-grade astrocytomas. MMP-9-mediated proteolysis of IGFBP-2 leads
to increased IGF-2 levels in these tumours. This accounts for increased aggressiveness of the
tumours through growth- and motility-promoting effects [24]. Expression of Igfbp-3 in the
brain is apparently not studied in great detail. However, Igfbp-3 expression increases after
brain insults and it has been shown to be upregulated in Alzheimer´s disease brains [25].
Igfbp-3 interacts with retinoic acid and might therefore also be implicated in cell differentiation
[26]. Igfbp-4 expression is also detected in most brain regions with declining levels over
development [20], being highly expressed in the hippocampus and cerebral cortex in adult
stages [27]. A function apart from regulation of Igf action has not been described yet. However,
Igfbp-4 expression is decreased in the cerebral cortex, hippocampus and the cerebellum in an
in vivo model for amyotrophic lateral sclerosis (ALS) [28]. Igfbp-5 is expressed mainly within
thalamic nuclei, leptomeninges and the perivascular sheaths in adult rats [27]. Igfbp-6 seems
to be expressed in differentiated but not in proliferating cells. Embryonic expression of Igfbp-6
in the CNS seems restricted to the trigeminal ganglia. Igfpb-6 transcription increases postna‐
tally after approx. 21 days in the forebrain and cerebellum, primarily in GABAergic inter‐
neurons. Higher levels are found in the hindbrain, spinal cord and dorsal root ganglia [29].
According to this strong association of Igfbp-6 expression with the cerebellar sensorimotor
system, overexpression of Igfbp-6 results in a reduced size of the cerebellum [30]. Igfbp-7 is
produced in the adult hippocampus, e.g. in the dentate gyrus (DG) [31]. In the postnatal
hippocampus, all components of the extracellular Insulin/Igf-signalling molecules were
detected apart from Igfbp-1. Variable amounts of individual components were detectable over
two developmental time points studied, as well as in different cellular sources, which comprise
neurons as well as glial and endothelial cells, albeit Igf-familiy member expression in the latter
two cell types were not studied in comprehensive detail.
In rodents, the Insulin-receptor (Ir) is expressed in the olfactory bulb (OB), cerebral cortex,
hippocampus, hypothalamus, pituitary, cerebellum, and the choroid plexus [32]. Expression
is high in early stages of development and declines in the adult, and is also more enriched in
neurons compared to glia. Within mature neurons, enrichment is observed within the
postsynaptic density [4,33]. Accordingly, Ir-signalling including downstream mediators like
Ras/MAPK and PI3K/Akt/mTor are implicated in synaptic connectivity and dendritic structure
[4]. Igf-1r has a similar expression pattern with high expression in the developing cerebellum,
midbrain, OB, and hindbrain [12]. However, although expression of Ir and Igf-1r is observed
in hippocampus, there are local differences in their distriubtion: Ir is enriched in the CA1 region
and Igf-1r is more prominent in the CA3 region. Levels of expression of the Igf-1r are higher
during development and decline to adult levels shortly after birth in the brain parenchyma,
while it stays relatively high in the choroid plexus, meninges and vascular sheaths.
Igf-2 receptor (Igf-2r) is also known as the mannose-6-phosphate (M6P) receptor, which has a
role in lysosomal enzyme trafficking. Accordingly, the main function described so far is to
internalise the Igf-2 ligand through endocytosis and to mediate degradation of Igf-2. However,
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recent studies reveal that Igf-2r is also implicated in specific signal transduction, e.g. in the
context of memory enhancement or fear extinction [13,31]. Igf-2r is also expressed in all major
neuroanatomical structures, with high expressions in the hippocampus, OB, retina, pituitary,
brain stem, and spinal chord. Further it is detected in the choroid plexus, ependymal as well
as endothelial cells [12].
Detailed analyses of expression of the upstream Igf-signalling members has been reported for
the mouse late embryonic and postnatal cerebellum [34]. Igf-1r is ubiquitously expressed,
whereas Igf-1 is detected in a subset of Purkinje cells (PC) at E17.5 and in postnatal stages. Igf-2
is confined to the meninges and blood vessels. Both ligands are not detectable in dividing
cerebellar granule precursor cells (CGP). Igfbp-1 is not detected, but Igfbp-2 is expressed wide
spread in the meninges, PC, internal as well as external granule layer, and choroid plexus.
Igfbp-3 is restricted to PC, Igfbp-4 to meninges and choroid plexus, and Igfbp-5 to Calbindin-
negative cells of the PC layer. Igfbp-6 is only detected in later stages in a subset of PC.
According to the widespread expression of members of the upstream IIS, their developmental
dynamics and cell type specificity, it is conceivable that this signalling pathway exerts
important function for development, maintenance as well as function of the various parts of
the central nervous system. Some of these functions that are mainly attributable to neuronal
development and fate decision will be highlighted in the following sections.
3. Biological effects associated with Insulin/IGF-signalling in neural
development
3.1. Insulin/IGF-signalling in ESC
Insulin and IGF are important factors to keep human ESCs in a proliferative state and to
promote  self-renewal,  where  upon  IGF-1R  has  been  identified  as  essential  component
[35].  Blocking of IGF-signalling results in differentiation, but it  is unclear whether a cer‐
tain  cell  fate  is  favoured  under  such  condition.  Downstream  signalling  of  Insulin  and
IGF has also been studied in this context and revealed that blocking of this pathway at
various points induced differentiation. In this study, blocking is achieved on the level of
PI3K through LY294002, of AKT-1, and of mTOR-1 through Rapamycin. Treatment of hu‐
man ESC with LY294002 results in loss of phosphorylation of the downstream molecules
AKT, p70S6K, S6 as well as GSK-3β [35-38].
Together with stromal cell-derived factor 1 (SDF-1/CXCL-12), pleiotrophin (PTN), and ephrin-
B1 (EFNB1) IGF-2 induces differentiation of human ESC into TH-positive dopaminergic
neurons [39].
Interestingly, retinol/vitamin A also induces Nanog transcription and the signal is transduced
over the IGF-1R, IRS-1, AKT and both mTOR complexes, mTORC-1 and mTORC-2 [40].
Expression of Nanog is a hallmark of proliferating, pluripotent stem cells. However, Insulin
has differentiating capacity into the neuroectodermal lineage when human ESCs are cocul‐
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tured with endodermal derived cells. This effect is dependent on PI3K/AKT signalling [41].
Together, these results reflect context-dependent IIS, and possibly cross-talk with other
signalling pathways activated e.g. in vivo through development or in vitro through cocultures.
3.2. Insulin/IGF effects in embryonic neural precursors
The Insulin-receptor (Ir) is expressed in distinct regions of the CNS, including the olfactory
bulb (OB), hypothalamus and the pituitary. Accordingly, a Nestin-cre mediated conditional,
CNS-specific knock-out of the Ir early during development results in increased Luteinising
hormone (LH) release from the hypothalamic-pituitary axis that leads to a deregulation of
energy homeostasis and endocrinology of the reproductive system [42].
Neurospheres generated from embryonic striatal precursors in the presence of Egf respond to
Igf-1 treatment with increased neuronal differentiation, presumably over an Igf-1r dependent
signalling cascade. However, this has not been addressed comprehensively through receptor
inhibition but was deduced from lower differentiation upon Igf-2 and Insulin stimuli
[16,17,43]. Igf-1 treatment in this setting is not accompanied by increased cell proliferation, but
cotreatment with Insulin increases the fraction of dividing cells. It might be that this effect is
specific to this combined treatment.
In the cerebral cortex, increased Igf-1 expression after Growth hormone (GH) treatment of rat
embryonal neural precursors is involved in increased proliferation of early (E14) and late (E17)
progenitors and is accompanied by increased neuronal differentiation at both time points. In
addition to neuronal differentiation, astrogenesis is also increased but only when late progen‐
itors are exposed to GH. This effect is also blocked in the presence of an Igf-1-blocking antibody
and thus illustrates that IIS is transducing GH-induced effects [42,44].
Increased proliferation of E14 rat cortical progenitor upon Igf-1 is observed in vitro after
treatment of cultured cells, and in vivo after intrauterine Igf-1 injection [45].
Igf-1 function in the brain is highly context-dependent and cell-type specific. This interpreta‐
tion is corroborated by the finding that Igf-1 treatment of E19 rat embryonal hippocampal
progenitors does influence survival of these cells [46].
In another setting, Igf-1 treatment evokes cell survival of mouse E10 neuroepithelial cells [47]
and it is mitogenic for sympathetic neuroblasts [48], showing that progenitor subtypes respond
differently to IIS. It is so far ill defined what kind of signalling events, including cross-talks to
other pathways, are associated with this differential outcome of Igf-1 stimulation. Interaction
with Egf- as well as Fgf-2-signalling and Igf-1 has been studied in striatal-derived neural
progenitor cells (NPCs). In this setting, highest numbers of formed spheres are obtained in the
presence of Igf-1 and Egf or Igf-1 and Fgf-2. Sphere formation in this context is highly de‐
pendent on presence of Igf-1, since no spheres were observed in the absence of IIS [49]. These
data show that Igf-1 is also affecting NPC proliferation in cooperation with other signalling
molecules, emphasising the pleiotrophic nature of IIS.
Igf-1-signalling seems to increase the effects of Fgf-2 on NPC proliferation as has been shown
in various stem cell populations, like rat adult SVZ neurospheres [50], neurospheres from
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mouse E13.5 forebrains [51], mouse embryonic OBSC [52], and mouse embryonic striatal NPC
[49]. Although not shown in all stem cells investigated so far, it is likely that in one scenario
Igf-1 promotes survival and proliferating competence of stem cells but that other mitogens
such as Erk-activators are needed to increase proliferation. However, other stem cell popula‐
tions might proliferate upon IIS without further mitogenic instructions as has been observed
by Fgf-2-independent Igf-1-mediated proliferation in rat embryonic NPCs from the cerebral
cortex and the hippocampus [45,46].
NPCs from neonatal rat forebrain undergo neuronal differentiation upon Insulin-treatment
[53]. The content of GFAP-positive cells in the neurosphere-based assay is unchanged, thus
suggesting a preference for neuronal differentiation in this cellular model.
Embryonal stem cells from the olfactory bulb (OBSC) are strongly dependent on IIS as shown
in vitro as well as in vivo. Igf-1 increases OBSC proliferation as well as differentiation without
strong lineage restriction, thus affecting neuronal as well as glial differentiation [54]. OBSC
proliferation however does not depend strictly on Igf-1, Insulin or pro-Insulin, they rather
potentiate the proliferating effect of Fgf-2 and Egf [52]. This study also showed that Igf-1
induces differentiation into the neuronal and astroglial lineages, but oligodendrocyte differ‐
entiation clearly depends on presence of other growth factors.
Several data support the finding that Igf-1 and -2 increase cerebellar granule cell precursor
(CGP) proliferation as well as survival of the same [34,55]. Different effects were linked to
different concentrations of the cytokine, where lower concentrations favoured survival and
higher proliferation [56]. IIS is supporting Sonic hedgehog (Shh) action that is a potent mitogen
for CGPs. Blocking of signal transduction through the Igf-1r diminishes Shh-mediated cell
proliferation, as well as endogenous supply of Igfbp-5. However, other Igfbps do not interfere
with Shh-mediated proliferation, but decrease Igf-1-dependent cell division [34].
Igf-2 treatment of CGP also results in proliferation. However it is unclear whether this occurs
over the Igf-1r or 2r [57] but it indicates also important function for Igf-2 in the context of
development of the central nervous system.
Igf-1 prevents cell death in primary rat embryonic hippocampal cultures after exposure to
glucocorticoids. While increased levels of corticosterone reduce Akt-phosphorylation and lead
to cell death, Igf-1 rescues cells from dying by increasing pAkt-levels in a PI3K-dependent
manner [58]. The same effect is observed by applying Insulin instead of Igf-1 [59].
Signalling of Insulin/Igf affects NPC proliferation, survival as well as differentiation in vitro
and this finding is corroborated in vivo by studies of knock-out and transgenic mouse models.
Transgene-mediated overexpression of Igf-1, driven by the Nestin-promoter, supports in
vitro finding that Igf-1 influences NPC proliferation as well as neuronal differentiation during
development. Cumulative BrdU-labelling shows that Igf-1 decreases the total length of the cell
cycle through acceleration of the G1-phase. This higher proliferating activity is paired with a
higher rate of cell-cycle re-entry. The overall increased number of progenitors provides a larger
pool of NPCs for neuronal differentiation and thus increases numbers of neurons residing in
the postnatal cortical plate of Igf-1-overexpressing mice [60]. In vivo, Igf-1 also exhibits survival
function since apoptosis is reduced upon its overexpression [61,62] which further contributes
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to increased numbers of neurons in the cortical plate. Igf-1 signalling does not affect all
neuronal populations in a similar manner but shows regional differences. The neuronal
composition of the motor cortex is more increased than the somatosensory cortex of Igf-1-
overexpressing mice, which is however also increased compared to wildtype animals. Neurons
in the cortical plate are also differently affected. Layer 1 neurons comprise the most increased
neuronal fraction in Igf-1-transgenic brains, layer 6 neurons show the smallest increase [63]. It
is thus likely that NPC are more sensitive to IIS during early developmental events of the
cerebral cortex in which neurogenesis of frontal precedes that of caudal regions and layer 1 is
preceding generation of layer 6.
In line with in vivo overexpression studies, complete loss of Igf-1 in mice leads to the opposite
effect of decreased numbers of specific neuronal populations in the cerebral cortex, e.g.
hippocampal granule cells and striatal parvalbumin-positive interneurons. Dopaminergic
neurons of the midbrain, basal forebrain cholinergic neurons, as well as motoneurons in the
spinal cord do not depend on Igf-1 presence [64]. Further analysis of this Igf-1-deficient mouse
revealed Igf-1-dependence of axonal growth and myelination that are strongly impaired.
Overall, Igf-1-deficient mice have a decreased number of myelinated axons. This observation
goes in line with studies of human IGF-I overexpression driven by a mouse metallothionein
promoter, that revealed increased myelin production by an unchanged number of oligoden‐
drocytes in adult brains [65].
Overexpression of Igf-1 driven by the Igf-2 promoter results in general brain overgrowth. The
greatest effect is seen in the cerebellum, although Igf-1 deletion does not lead to an observable
phenotype in this part of the brain, maybe because of compensatory effects from Igf-2 [55,64].
Igf-1r-deficient mice show severe growth retardation and die perinatally. Nestin-cre-mediated
conditional knockout of the Igf-1r also results in death shortly after birth but few animals
survive up to adulthood [66]. Mice that are heterozygote for the conditional Igf-1r deletion
also display severe growth retardation that was studied in detail in the hippocampus. In the
postnatal hippocampus all different parts are affected by increased rates of apoptosis rather
than by an impaired ability to proliferate through loss of the Igf-1r.
Mutations of the type 2 Igf receptor are lethal but are rescued from this perinatal lethality in
Igf-2 and Igf-1r null backgrounds [67]. This observation is attributed to increased Igf-2
signalling due to lack of internalisation of Igf-2, which is thought to be a major function of the
Igf-2r. Although general hyperplasia is observed including the brain, Igf-2r-signalling was not
further investigated in the brain [67-69].
Deletion of Igf-2 in mice results in severe growth-deficiency, but it was reported that Igf-2-
deficient mice do not show striking morphological aberrations [70,71]. However, one source
of Igf-2 during development is the choroid plexus, from which it is released into the cerebro‐
spinal fluid (CSF), and CSF-derived Igf-2 is an important signal for cell proliferation of later
embryonic precursors that have contact to the ventricular surface [72]. Progenitors of the SVZ,
e.g. Tbr-2-expressing cells, do not have contact to the CSF and thus are not influenced by Igf-2-
signalling in their proliferation capacity. Increased proliferation of cortical progenitors is
dependent on the apical (ventricular) localisation of the Igf-1r that is mediated through the cell
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polarity protein Pals-1 (Protein Associated with Lin Seven 1) as part of the apical complex.
Further support for an Igf-1r-mediated effect of Igf-2-signalling in this context comes from the
finding that loss of Pten (Phosphatase and Tensin homolog) opposes the effect of Pals-1-
deficiency: Pten-deficient mice have hyperplasic cortices while Pals-1-deficiency results in
cortical hypoplasia. The phenotypes are partially reverted through combination of both
transgenes [72]. Further downstream signals apart from Igf-1r and PI3K are not analysed in
this context.
The function of different Igfbps has been studied through transgenic mouse models. Thereby
it turned out, that loss of function mutations do not result in gross morphological changes
within the CNS. However, overexpression of Igfbps lead to phenotypes in the CNS, which are
exploited to achieve better understanding of IIS within this organ. Overexpression of Igfbp-1
in transgenic mice using either a phosphogylcerate kinase [73] or a methallothionein [74]
promoter results in similar phenotypes as observed in adult Igf-1-deficient mice: reduced brain
sizes due to loss of mature neurons and decreased progenitor proliferation, impaired myeli‐
nation as well as decreased activation of GFAP-expressing astrocytes in conditions of injury.
However, Igfbp-1 is normally not expressed at detectable levels in the CNS and the observed
findings are therefore attributed to the lack of Igf-1 as consequence of increased presence of
Igfbp-1. Most of the phenotypes observed in mice overexpressing Igfbps resemble those of loss
of Igf-1-signalling, which is mainly characterised by reduced organ size. Whether these
phenotypes are exclusively caused by impaired Igf-1-signalling or whether Igfbps have also
distinct functions, is so far not resolved [75]. Generally, Igfbp-5 is considered to potentiate
Igf-1-signalling, while Igfbp-2 mainly opposes Igf-1 and Igf-2 action [55]. This finding indicates
that some Igfbps might exert additional functions that might only be apparent in transgenic
mice in which the ligands are mutated as well.
3.3. Insulin/IGF effects in adult neural precursors
Igf-1, though not produced in high amounts in adult rodent brains, is required for normal
neuronal functions throughout life. As different source, peripheral Igf-1 is transported to
neuronal cells through an uptake from the blood stream (reviewed in [1]). Neural stem cells
of the adult hippocampus respond to peripheral administered Igf-1 with increased prolifera‐
tion as well as neurogenesis but not with astrogenesis [76]. These data were also confirmed in
vitro using neurospheres generated from the hippocampal dentate gyrus. In this setting, low
doses of Igf-1 mediate, and high doses interfere with neuronal differentiation [77]. Igf-1-
mediated cell proliferation of adult neuronal progenitor from the hippocampal subgranular
zone (SGZ) was also shown in a model of epilepsy [78] as well as in response to physical
excercise [79].
Further in vivo evidence for importance of Igf-1-signalling in the adult hippocampus comes
from a study of Igf-1-deficient rats. In this context Igf-1 supports survival of newly generated
neurons and possibly the maturation of the neuronal phenotype. However, cell proliferation
is not affected in this in vivo model [80]. Igf-1-instructed differentiation mainly into the
oligodendroglial lineage has been shown in rat adult hippocampal NPC [81] (Fig. 3). In this
study, withdrawal of proliferation-promoting Fgf-2 is essential to drive NPCs into differen‐
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tiation upon Igf-1. IIS in this setting induces expression of Bmp-antagonists Noggin and
Smad6, which are involved in the inhibition of an astrocytic cell fate and in favouring neuronal,
but more efficiently oligodendroglial differentiation. Further, this study showed again that
Igf-1 has a major impact on cell survival of adult NPCs.
Overexpression of Igf-1 through an Igf-2 promoter element results in increased numbers of
neurons in the postnatal mouse hippocampal dentate gyrus. This increase in neurogenesis is
transiently accompanied by increased numbers of synapses, which makes it possible that IIS
also influences synaptogenesis [82].
Adult rat NPC derived from the subventricular zone proliferate stronger upon an Igf-1
stimulus. This effect is blocked by the presence of Igfbp-3 that also decreases phosphorylation
of Akt [83]. Igf-1 signalling under Fgf-2-free conditions in adult subventricular stem cells is
also linked to differentiation [84]. Adult mouse NPC are initially cultivated in the presence of
Fgf-2. Subsequent withdrawal of Fgf-2 results in neuronal differentiation that is increased by
complementation with Igf-1. Blocking of the Igf-1 signal with an antibody reverts the effect
[85]. In this setting, the authors also explored the capacity of Igfbp-2 to influence the neurogenic
potential of the NPC, since Igfbp-2 complexes with Igf-1 and proteoglycans like heparin in the
rat OB [86]. Low doses of exogenous Igfbp-2 increase neuronal differentiation, while applica‐
tion of a blocking Igfbp-2 antibody interferes with this effect. These experiments indicate that
Igfbp-2 does not act by sequestering Igf-1 and by limiting its bioavailability, in which scenario
Igfbp-2 would have an opposing effect to Igf-1. Instead, both molecules exert the same
phenotypic differentiation and this indicates that Igfbp-2 function in this context is more likely
a protection of Igf-1 from degradation. It is conceivable that simultaneous interaction of Igfbp-2
Figure 3. Igf-1 signalling in adult rat hippocampal neurospheres [81].
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with proteoglycans decreases its affinity to Igf-1. The net outcome might be a locally increased
amount of free Igf-1 that drives neuronal differentiation of NPC [85]. In another study,
differentiation of SVZ NPC was deduced from reduced expression of the stem cell marker
Nestin after Igf-1 treatment, but it was not specified whether differentiation of a specific cell
lineage was favoured [50].
Further studies in adult mice show that lack of Igf-1 results in disturbed neuroblast exit from
the subventricular zone and their subsequent migration to the olfactory bulb through the
rostral migratory stream. This Igf-1 function is dependent on PI3-kinase activity and Disa‐
bled-1 (Dab-1) phosphorylation via Src-family kinase [87].
Igf-2 is not only provided from the CSF and important for early development of the brain. In
addition, adult mouse hippocampal stem cells from the DG also produce Igf-2, and to a much
lesser extend Igf-2 is also detected in adult SVZ-derived stem cells [19,88]. Challenging Igf-2
expression through siRNA-mediated approaches as well as treatment of DG-derived NPCs
reveals that Igf-2 also influences proliferation. However, SVZ-derived NPCs do not respond
with changed proliferation upon Igf-2 knockdown [88]. Igf-2 but not Igf-1 is involved in
neuronal survival of newly generated neurons in the adult DG in a model of fear extinction,
that is strongly associated with neurogenesis in the hippocampus [31]. Neuronal survival and
fear extinction depend on Igf-1r activity and are opposed by increased levels of Igfbp-7.
However, Igf-1 does not exert any observable effect in this setting.
FoxO proteins are under the control of IIS and therefore a downstream read-out of this
important signalling pathway. GFAP-cre was used to generate a triple allelic knockout of
FoxO1, 3, and 4 in adult NPCs. The observed effect on cell proliferation is dependent on the
age of the animal or passage of cells in culture. NPCs from young (P8) brains displayed
hyperproliferation upon loss of FoxO-proteins and the same was observed for early passages
of NPCs in culture. This initial hyperproliferation is followed by decreased doubling times
and the depleted progenitor pool results in declining neuronal differentiation. FoxOs balance
NPC proliferation and prevent premature loss of NPCs. Microarray studies revealed several
cell-cycle regulating genes that are affected in their expression by the loss of FoxO. Further‐
more, Aspm (asp (abnormal spindle)-like, microcephaly associated) and anatgonists of the
Wnt-signalling cascade, Sfrp-1 (secreted frizzled-related protein) and -2, as well as Sost
(sclerostin), are involved in the FoxO-dependent regulation. In this context FoxO might control
Wnt-induced cell proliferation by expression of Wnt-antagonists [89].
3.4. Insulin/IGF effects in mature neurons
Igf-1 applied to postnatal cerebellar granule neurons (CGN) prevents cell death, thus es‐
tablishing IIS  as  survival  factor  in mature neurons [90].  Another study described a link
of Igf-1-signalling in mature neurons to survival  of  CGN as well  as of  cortical  neurons.
Here, Igf-1 prevents apoptosis through activation of PI3K/Akt, but also through Igf-1r-de‐
pendend transactivation of unliganded Pac-1r (PACAP type 1 receptor) via Src-kinase ac‐
tivity [91] (Fig. 4).
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Figure 4. IIS mediated sur-vival of cortical neurons through activation of Akt and PAC-1r [91].
Data from adult Igf-1-deficient mice show however that cerebellar neurons are not affected by
the loss of this trophic factor in vivo [64]. Contrasting this finding is data showing overexpres‐
sion of human IGF-1 in mouse through a transgene driven by the mouse Igf-2 promoter [92]
that results in cerebellar overgrowth through blockage of the ontogenetic cell death that
normally takes place during early postnatal cerebellar development.
Blocking Igf-1 uptake through systemic application of an Igf-1 antibody not only reduces cell
proliferation in the adult rat and mouse hippocampus, but is also implicated in synaptic
remodelling and interferes with exercise-induced increase of dendritic spines [93]. IIS is also
implicated in neuronal maturation and stimulates neurite outgrowth. In postnatal rat slice
cultures of the somatosensory cortex, Igf-1-treatment leads to increased apical and basic
dendritic branching of pyramidal neurons [94]. As such, Igf-1 is involved in forming mature
neuronal networks and ensuring proper information processing. Further data show that Igf-1
mediates axonal growth by inducing plasmalemmal expansions by incorporation of vesicles
in the growth cone [95]. This Igf-1-, but not Insulin-dependent effect is mediated by signalling
via a growth-cone-specific Igf-1 receptor (βgc), Irs-2, Shp-2, PI3K and Akt. This cascade might
also influence dynamics of the cytoskeleton, namely microtubules and actin, both of which are
required for axonal growth.
Igf-2 has recently been shown to control the number of synaptic connections and plasticity in
mature neurons of the hippocampus [13,14]. Memory enhancement is specifically associated
with Igf-2 function. In this context Igf-2 is regulated by CCAAT enhancer binding protein β
(C/EBP) in adult rat hippocampus. C/EBP is one of the transcription factors necessary for
memory consolidation. In the study of Chen et al. rats are exposed to increased Igf-2 levels in
the hippocampus during memory training which results in improved learning [13]. This effect
is specific to Igf-2, since injection of Igf-1 did not have any observable effect in this memory
consolidation paradigm.
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Taken together, IIS has different effects in the developing and mature CNS that vary among
the different cell types as summarised in Fig. 5. Differences might be mediated through specific
downstream cascades or effector molecules present in only one specific cell or at a specific
developmental time point. Another scenario is the cross-talk between IIS and other cytokines
that are produced by the organism. Posttranslational modification of the receptors might be
another general mechanism that specifies different biological responses to common signal
inducers (ligand/receptor) and common intracellular signal transducers. The IGF-1r is
sumoylated and modulated in its activity. Sehat et al. showed [96] this sumoylation of the IGF-1
receptor that leads to internalisation of the ligand bound protein complex, which is transduced
to the nucleus and binds directly to genomic DNA. Since binding occurs predominantly in
intergenic regions, the biological relevance for differential gene transcription has still to be
shown. But nevertheless this reflects a possible mechanism through which specificity in
activation of different target genes upon the same stimulus might be obtained in different cells
or in the same cells at different developmental time points.
Figure 5. Differences in IIS function in different cell types of the CNS and in developmentThe Insulin-Igf Signalling (IIS)
pathway has multiple effects on different cells of the CNS. The effects, beginning from cues for ESC proliferation and
self-renewal, transcend to those of proliferation, self-renewal, differentiation and fate determination of NPCs. IIS con‐
tributes to either formation of neurons, or glia, oligodendrocytes and myelin.
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4. Insulin/IGF-signalling networks
4.1. Signalling networks in neural progenitors and neurons
Igf-1-dependent embryonal NPC proliferation in rat has been shown to be dependent on the
PI3K/Akt pathway, but not on the MAPK/Erk branch of signalling. Chemical inhibitors of the
latter, U0129 and PD98059, have no effect on NPC proliferation, while PI3K-inhibition through
LY294002 interferes with Akt- and downstream Gsk-3β-phosphorylation as well as prolifera‐
tion. Phosphorylated and thus inactivated Gsk-3β leads to stabilisation of CycD1 (Cyclin D1).
Together with increased expression of CycD3, and CycE as cell cycle promoters, decreased
expression of inhibitory cell cycle proteins p27 and p57 is observed upon Igf-1-treatment and
accounts for the mitogenic effect of Igf-1 [45] (Fig. 6).
Figure 6. Igf-1-dependent embryonal NPC proliferation in rat [45].
Cortical progenitors isolated from mouse E13.5 brains were investigated with regard to
increased Akt-1-signalling. Overexpression of Akt-1 results in increased proliferation as well
as survival of progenitors in vivo and in vitro, consistant with effects of increased IIS. This Akt-1
function does not depend on its action upon p21, but at least in part of mTorc-1, because
proliferation is partially hampered through Rapamycin. Survival is not affected through
mTorc1 inhibition [97]. Differential downstream signalling of Akt in cortical progenitors is
indicated by this study, which also reports that Rapamycin does only block proliferation in a
subset of cells at E13.5, and progenitors of later developmental stages are also insensitive to
Rapamycin with regard to proliferation (Fig. 7).
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Figure 8. Insulin-dependent neuronal differentiation of embryonic neurosheres [50].
Figure 7. Survival and proliferation upon Igf-1 treat-ment in mouse E13.5 cortical cells [97].
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MTorc-1 inhibition through Rapamycin prevents neuronal differentiation of rat embryonic
telencephalon-derived neurospheres that is observed in response to Insulin-signalling [53]. In
this setting, Insulin-treatment results in phosporylation of mTorSer2448 and of pS670K, and
the former is blocked through addition of Rapamycin, indicating that mTorc-1 is implicated
in neuronal differentiation. Apoptosis is not observed under these conditions (Fig. 8).
MTor-1-dependent neuronal differentiation is also observed in P19 embryonic carcinoma cells
that express Pax-6 as well as Hes-5 upon retinoic acid treatment and initiation of neural
differentiation. In this setting, Cdc42 is placed as upstream regulator of mTorc-1, and treatment
with Rapamycin abolished Cdc42-mediated neural lineage specification as well as terminal
neuronal differentiation [98].
MTorc-1 is also implicated in cell proliferation of rat adult hippocampal progenitors that
heavily depend on PI3K-activated Akt-signalling. MTorc-1-dependence is obvious because
presence of Rapamycin interfered with increased cell proliferation under Fgf-2-stimulation.
Although Igf-1 treatment of these cells did not result in increased proliferation, Igf-1 increases
cell division in the presence of Fgf-2 over the rate that is achieved through Fgf-2 alone [99].
Sustained activation of mTor-signalling in mice that are deficient for Tsc-1 results in initially
increased proliferation of NPC and premature depletion of the progenitor pool. Self-renewal
of Tsc-1-deficient and thus mTor-activated NPC is also dramatically impaired. In addition to
increased numbers of cells that differentiate into the neuronal lineage, sustained mTor activity
interferes with terminal differentiation of neurons but seems to promote an increase in
astrocytes [100]. Increased cell proliferation is also a hallmark of Tsc-2-deficient mouse NPC
that are isolated from early (E10.5) developmental time points. This phenotype is also attrib‐
uted to an activation of mTorc-1-signalling [101].
Figure 9. Igf-1-dependent survival of rat hip-pocampal precursors [46].
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Igf-1-initiated survival of E19 rat embryonal hippocampal cells is dependent on PI3K-mediated
Akt-phosphorylation and subsequent phosphorylation of FoxO3. Phosphorylation of FoxO3
is blocked by LY294002 and partially by Rapamycin, and results in increased survival of
hippocampal progenitors. Blocking of MAPK/Erk pathway with PD98059 does not influence
survival of these progenitors [46,102] (Fig. 9).
Figure 10. IIS in regulation of proliferation of adult hippocampal progenitors [77, 78].
Igf-1-mediated proliferation of neural progenitors of the adult DG is mainly but not exclusively
mediated by MAPK/Erk-signalling, since inhibition of MAPKK/Mek-1/2 through a chemical
inhibitor or dominant negative kinases interferes with cell division after Igf-1 treatment.
Blocking of PI3 kinase through LY294002 interferes with proliferation even without addition
of Igf-1. However, blocking of the Akt-downstream signal through use of a dominant negative
kinase also reduces Igf-1-induced mitosis. This finding makes it likely that LY294002-inde‐
pendent activation of Akt might be important for Igf-1-mediated proliferation. Rapamycin
does not have significant effects in this setting, making it likely that mTor-complexes are not
involved in Igf-1-mediated proliferation of adult hippocampal progenitors [77] (Fig. 10).
Further evidence for the implication of Igf-1/MAPK/Erk- signalling in proliferation of adult
hippocampal progenitors comes from the study of increased mitosis after a status epilepticus.
Here, this lesion activates Igf-1-release from microglia. This increase in Igf-1 results in the
activation of the MAPK/Erk-pathway and subsequent cell division. This response is blocked
through inhibition of the Igf-1r as well as through U0129-mediated inhibition of the MAPK-
pathway [78].
It is interesting to point out that the same biological effect can be achieved through Igf-1 by
activating different pathways in different cells: IIS induces proliferation in embryonic rat
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cortical progenitors in an Erk-independent manner, while Igf-1 signalling induces proliferation
of adult hippocampal progenitors via Erk-dependent cytoplasmic downstream signals. On the
other hand, IIS mediates different biological effects in similar cells through similar downstream
molecules, but at different developmental time points: adult hippocampal neurons respond
with proliferation to Igf-1 compared to embryonic hippocampal progenitors that need IIS for
their survival. This summary indicates that we still need comprehensive analyses of overlap‐
ping or distinct target genes activated through overlapping or distinct signalling pathways
during development and in the various cell types of the CNS.
The study of Otaegi et al. of IIS in OBSC also elaborates on downstream signalling by showing
that Igf-1 treatment increases phosphorylation of Akt at Ser473 as well as Thr308 which is
associated with increased proliferation and neural differentiation [54] (Fig. 11). Pten, that
antagonises PI3-kinase induced phosphorylation of phosphatidylinositol (3,4,5)trisphosphate
(PtdIns(3,4,5)P3), reduces basal levels of the activating posttranslational modifications of Akt,
which are however overridden by presence of Insulin/Igf-1. Nevertheless, overexpression of
Pten impaires neural differentiation without affecting progenitor proliferation, and overex‐
pression of a mutant Pten increases OBSC differentiation. Direct inhibition of PI3-kinase
through LY294002 interferes with Igf-1-stimulated Akt-phosphorylation and resultes in
impaired proliferation as well as neural differentiation. Thus, OBSC differentiation is under
control of basic levels of pAkt while increased pAkt-levels through IIS activation affect
additionally proliferation.
Figure 11. IIS affects proliferation and differentiation in adult OBSC [51].
Early postnatal olfactory bulb neurons do survive upon Igf-1-signalling. In this context, a
positive feedback has been proposed between Igf-1 and Bcl-2.  Igf-1 increases expression
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of anti-apoptotic Bcl-2,  and overexpression of Bcl-2 in vivo  results in increased Igf-1 and
Igfbp2 [103].
Figure 12. Survival of CGN upon IIS [90, 104, 105].
Igf-1 action as survival factor for postnatal cerebellar granule neurons (CGN) requires different
intracellular signalling [90]. In this context, Igf-1 activation of PI3K leads to inhibition of Erk
as well as Caspase-3, two pathways exerting different events in cell death, plasma membrane
damage and DNA break-down, respectively. Activated PI3K phosphorylates not only Akt but
also Protein kinase A (PKA). Whereas pAkt activates Caspase-3 and is leading to DNA break-
down, PKA suppresses sustained Erk activation via phosphorylation of cRaf at Ser259 and
prevents plasma membrane damage (Fig. 12).
Further studies of Igf-1-dependent survival of rat CGN links PI3K activation of Akt to
phosphorylation of Bad at Ser136 that is responsible for releasing anti-apoptotic Bcl-XL
[104,105]. This finding is partially corroborated in vivo, where Igf-1 overexpression results in
increased levels of Bcl-XL at early time points (P7) and decreased expression of pro-apoptotic
Bax and Bad at P14 and P21. However, the investigation of the phosphorylation status of Bad
in vivo was not conclusive [92].
Oligodendrogenesis and initiation as well as maintenance of myelination are strongly de‐
pendent on IIS. Several mouse models in which normal IIS was manipulated display pheno‐
types affecting oligodendroglial cells: overexpression of Igf-1 driven by diverse promoters or
administration of Igf-1 into the CSF result in increased numbers of oligodendrocytes and
myelination [106-108], while loss of Igf-1 leads to impaired and lost myelination [109]. IIS in
oligodendrocytes and their precursors is dependent on signalling over the Igf-1r, since Igf-1r-
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deficient mice show retarded growth and initiation of myelination [110]. This phenotype is not
observed in IR-deficient mice and is thus mediated through Igf-1r-signalling [111]. IIS depends
on binding of insulin-response substrate (Irs1-4) to the receptors, which results in their
respective phosphorylation.
Proliferation of oligodendroglial rat precursors increases in response to Igf-1 and is mediated
over a prolonged time period by Pdk-1, Akt Thr308 as well as Ser473 phosphorylation, and
pGsk-3β. Igf-1 treatment also activated the Ras/MAPK-pathway as evidenced by increased
pErk-1/-2, following a fast kinetic over a short period of time [112]. Inhibition of upstream
signalling molecules revealed concerted involvement of PI3K, MAPK as well as Src-kinase in
cell cycle progression, and predominance of Akt-mediated signalling. Although so far ill
defined, cross-talk among the different signalling pathways activated through Igf-1 is a likely
scenario resulting from this study. In continuation of this study it was observed that Igf-1
increases protein synthesis by signalling through PI3K-Akt-mTor-p70S6K-4E-BP1 as well as
by activating Ras/MAPK [113]. Transcription was a prerequisite for mTor-1-dependent protein
synthesis upon Igf-1 in proliferating oligodendroglial precursors. Early differentiation of the
precursors upon Igf-1 also involves transcriptional processes, however subsequent terminal
differentiation is independent. This finding indicates different roles for Igf-1 during oligoden‐
droglial cell development.
Further analyses of these potential downstream signalling components reveal that initiation
of myelination is coupled to the activity of Irs-2 but not to Irs-1. Irs-2-deficient mice display a
defect in timing of myelination and this effect can not be compensated through a simultaneous
upregulation of Igf-1r and Irs-1 expression as well as signalling in these mice [111]. Increased
Igf-1r signalling is shown through increased levels of pAkt, pGsk-3β and pErk-1/2.
Igf-2 influences proliferation of adult DG progenitors [88]. In this study, knockdown of Igf-2
results in decreased mitosis that is paired with reduced phosphorylation of Irs-1 and Akt. This
phenotype is rescued through overexpression of a dominant-active Akt. Blocking of Igf-1r-
signalling reduces proliferation that exceeds the drop observed after Igf-2 knockdown. This
indicates that NPC proliferation in the adult DG is influenced through Igf-1 and Igf-2 ligands
that signal both through the Igf-1r onto Akt.
Signalling of Igf-2 through its cognate Igf-2r has been shown to be important for neuronal
maturation with regard to synapse density and spine morphology [14]. Downstream signals
included the activation of MAPK/Erk- pathway, since changes at the level of the synapses were
inhibited through PD98059.
Igf-2 dependent memory enhancement in adult rat hippocampus requires signalling via the
Igf-2r [13]. This Igf-2 effect is associated with de novo protein synthesis. Further analyses of the
downstream signalling cascade reveales involvement of Gsk-3β, since the Igf-2-specific effect
is blocked by the presence of the Gsk-3β-inhibitor SB216763. It was shown that this cascade
does not act on a widespread cell level but that it mainly regulates molecular events at specific
synapses, e.g. synapses that are "transcriptionally marked" through training. Igf-2 results in
increased synaptic activity as revealed by stable long-term potentiation (LTP). The underlying
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mechanism is therefore deduced to include Igf-2-dependent activation of Gsk-3β that leads to
synaptic mobilisation and expression of the AMPA-receptor GluR1.
Igf-2 is further under control of NF-κB transcription factors. Nuclear import of NF-κB is
prevented by IκB proteins, which are degraded upon activation of the IκB kinase (IKK)
complex. This proteasomal event releases NF-κB into the nucleus. In the adult mouse hippo‐
campus, synaptic IKK/NF-κB signalling is important for function and maturation. Recent data
show that Igf-2 is under control of NF-κB-mediated transcriptional regulation [14]. This study
shows that Igf-2 increases the number of synapses and of mature spines in vitro, while Igf-1
does only have moderate effects in this assay. The Igf-2 effect is predominantly transduced via
the Igf-2r and is prevented through MEK inhibitor PD98059, but not through inhibition of
Gsk-3β or p38 activity. Corroborating these findings in vivo, mice with deficient IKK-2 show
reduced Igf-2 expression and pErk1/2 levels [14].
Igf-2-dependent proliferation of mouse CGP is associated with activation of PI3K, but also
with mTorc-2 activity that is obvious from increased Akt Ser473 phosphorylation [57]. IIS
downstream signalling is followed up to Gsk-3β in this cellular context.
5. Insulin/IGF-signalling cross-talk
5.1. Signalling cross-talk in the central nervous system
In vivo, it is very unlikely that growth factors act alone, but a more likely scenario is the presence
of a plethora of signalling molecules and that a phenotypic consequence is a complicated
interplay of various signalling pathways. Special emphasise is given to know interactions and
cross-talks between such pathways involving IIS, although this is only an emerging field that
awaits further studies.
Cultured NPC from the rat adult SVZ respond with neuronal differentiation upon various
single stimuli, like Fgf-2, Bdnf, Ngf, and Igf-1. When Fgf-2, Bdnf, and Ngf are applied in
combination with Igf-1, significant increases in the number of neurons are observed, indicating
synergistic action upon neuronal differentiation [114]. Another study uses immobilised
growth factors, alone and in different combinations, on which the authors plated NPC from
embryonic rat striatum. Proliferation, neuronal as well as glial differentiation is assessed and
reveals that Igf-1 alone mainly drives neuronal differentiation and does not affect proliferation
or glial differentiation significantly. In combination with Fgf-2, Igf-1 only slightly increases
progenitor states and proliferation, and this effect is even smaller in combination with Egf that
also acts mitotic in single treatments. Bdnf increases neuronal differentiation alone, as does
Igf-1, however the combination of the two factors results in fewer neurons than single
treatments. The differentiation potential of Igf-1 alone is also lowered by presence of the mitotic
growth factors Fgf-2 and Egf. Igf-1 alone does not induce glial differentiation. In combination
with Cntf that induces astrocytic phenotypes alone, Igf-1 decreases Cntf-mediated differen‐
tiation [115].
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The cross-talk of IIS with regard to Fgf-2- as well as Egf-signalling mainly influences stem cell
proliferation, but whether it is synergistically is not yet totally clear [47,49,50,51,52]. A putative
scenario might be that Igf-1 keeps progenitors in a healthy or fit state in which they are ready
for further cell divisions, for which Fgf-2 or Egf are the instructive cues. However, withdrawal
of Fgf-2 is a prerequisite for neuronal differentiation upon Igf-1 presence [85]. Synergistically,
Igf-1-signalling seems to increase the effects of Fgf-2 on NPC proliferation as has been shown
in rat adult hippocampal cells. This effect is dependent on PI3K that is activated upon Fgf-2
treatment [99].
Survival of CNS-derived cells is one of the major and comprehensive effects of IIS in the
developing and adult organism. IIS is only one of several pathways that influence survival,
and thus cross-talk with other pathways might be of principal importance. Bdnf-mediated
signalling is one of such pathways that are studied with regard to IIS. No additive function of
Bdnf- and Igf-1-mediated survival is reported from different cellular sources [102,116],
however other data is contradictory in finding additive affects on prenatal rat hippocampal
cell survival [117] that cumulate on increased pGsk-3β. Consistently reported is a stronger
survival effect under serum-deprivation for IIS compared to Bdnf. The underlying signalling
might again diverge in different cellular systems: hippocampal neurons survive upon Igf-1
and Bdnf through induction of the PI3K-pAkt branch and survival is blocked by LY294002.
Activity of the MAPK-pErk1/2 branch does not mediate survival. However, cortical neurons
that also depend much stronger on IIS than on Bdnf-signalling for their survival also activate
the PI3K-pAkt branch [117], but LY294002 does not completely attribute for survival upon IIS.
In addition, Src-kinase is activated in these cortical neurons upon Igf-1, corroborating the
finding of an involvement of Pac1-r-signalling in IIS-mediated survival in cortical neurons [91].
Nevertheless, Bdnf and IIS have additive effects in the activation of PI3-K, although this is not
detectable on the level of the number of surviving cells. This finding strongly suggests that IIS
is overriding the effects of Bdnf in survival of CNS-derived cells. However, one Bdnf effect on
hippocampal as well as cortical neurons is to slightly activate Irs-1 and -2 phosphorylation,
indicating a potential cross-activation of IIS through Bdnf. Whether this cross-activation is of
physiological significance in the presence of Igf-1, remains to be determined.
Studies of neural cell proliferation provide evidence of IIS cross-talk with the Wnt/β-catenin
pathway. Nestin-expressing neural progenitors as well as oligodendrocytes express different
levels of β-catenin upon Igf-1 deletion or treatment [118,119]. In vitro, Igf-1 induces increase of
β-catenin as well as CycD1 expression in a PI3K-Akt kinases dependent manner in cultured
oligodendrocytes. β-catenin is also known to activate CycD1 and thus defines a point of
intersection between IIS and Wnt signalling [118]. Impaired proliferation of NPCs is observed
after inactivation of the Igf-1r in Nestin-positive cells. Such NPCs of prenatal mouse brains are
dependent on Wnt-signalling when proliferating, and Igf-1r inactivation results in decreased
levels of Gsk-3β and β-catenin, but with increased levels of the Wnt-receptor Frizzeled3 and
Wnt3a. While the former expression changes are influenced through the Igf-1/PI3K/Akt-
pathway, increased levels of Frizzeled3 and Wnt3a are thought to reflect a compensatory
regulation stimulated by low levels of β-catenin. Inactivation of Gsk-3β in this setting reverts
β-catenin levels and overcomes the block of proliferation as consequence of Igf-1r inactivation.
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Overexpression of Igf-1 increases β-catenin-levels and stimulates progenitor proliferation
[119]. These experiments clearly establish an important cross-talk to regulate progenitor
proliferation in the developing brain.
IIS has also been described to cross-talk with the Tgfβ-pathway in numerous systems [120].
However, a comprehensive analysis of the multiple points of intersections was not published
yet for the nervous system. In a general view, Tgfβ-ligands 1, 2, and 3 exert opposing effects
compared to IIS. This has been shown for the potential of NPC proliferation and differentiation
[121] upon Tgfβ-treatment, since these cells stop proliferating and initiate neuronal differen‐
tiation in mouse E16.5 hippocampus and cerebral cortex, in vitro and in vivo. Proliferation and
differentiation of ESCs are also influenced in opposite ways through IIS or Tgfβ-signalling.
Smad4-deficient ESC show increased neuronal differentiation, and hereby preferentially in
neuronal lineages of the mid- and anterior hindbrain [122]. Further, more serotonergic neurons
of the dorsal midbrain are observed in in vitro differentiated Smad4-deficient cultures.
However, Smad4 is a transcriptional mediator of several members of the Tgfβ-superfamiliy,
including Activin-, Gdf-, Nodal-, Tgfβ- as well as Bmp-signalling. Thus, direct correlation to
one specific signalling pathway is not achieved in this study. Neural induction of human ESCs
is also increased in the presence of the Alk4,5,7 inhibitor SB431542 that interferes with Activin-,
Gdf- and Nodal-signalling apart from Tgfβ. Increased differentiation into the neural lineage
is assessed by Pax-6 expression which is accompanied by decreased Bmp-4 and increased
Noggin expression. These dynamics point to a contribution of several members of the Tgfβ-
superfamily of which the Bmp branch has a major contribution [123], but certainly does not
act alone. Of further note, neuronal differentiation of ESC cells is not solely dependent on
signalling of the above mentioned members of the Tgfβ-superfamily, since deletion of the
common effector Smad4 in ESC does not completely abolish the potential for neuronal
differentiation [122]. In contrast, IIS keeps ESCs in a proliferative state and is necessary for self-
renewal. Whether both pathways cross-talk to suppress the respective other one is not
investigated so far, but might be a likely scenario, given the connections described in other
cellular lineages.
FoxO and Smad proteins interact and the FoxO/Smad complex is implicated in transcriptional
control in early mouse cortical NPCs, thereby defining one point of intersection of IIS and
Tgfβ. Smad2 and 3 transcriptions factors are part of the canonical Tgfβ-signalling pathway and
are phosphorylated upon binding of Tgfβ-ligands to the Tgfβ-receptor 1 and 2. The phos‐
phorylated proteins bind to Smad4 and together translocate to the nucleus. This Smad complex
interacts with FoxO1, 3a, and 4, three TF of the forkhead family that are under influence of IIS.
Upon activation of the Igf-1r, FoxO TF are phosphorylated in a PI3K-Akt-dependent manner.
This phosphorylation leads to retention of FoxO proteins in the cytoplasm. Thus, IIS opposes
transcriptional control through the Tgfβ-pathway by interfering with translocation of cofactors
into the nucleus [124].
While survival of cerebellar granule precursors depends on IIS, control of CGP proliferation
indicates cross-talk of IIS and Shh-signalling [34,55,125]. Igf/Shh interaction is reported to occur
on various levels. The study of Fernandez et al. (2010) suggests that IIS via Igf-1r increases Shh-
mediated proliferation, but IIS-mediated proliferation is independent on Shh-signalling. In
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this setting, Igfbp-5 interfered with Shh-mediated cell proliferation. Igf-2-signalling increases
levels of Gli-1, a transcription factor that is mainly activated through Shh-signalling. Gli-1 as
well as Gsk-3β are regulators of CycD1, which might be another point of intersection between
these two signalling pathways besides regulation of Shh-target Nmyc-1 through Gsk-3β
[57,126]. Parathath and colleagues established a role for Irs-1 and mTorc-1 upon Shh-mediated
CGP proliferation. This study shows specific upregulation of Irs-1 protein upon Shh that does
not result in the activation of Akt. Knockdown of Irs-1 abolishes Shh-mediated CGP prolifer‐
ation, which is in turn activated upon Irs-1 overexpression. Irs-1 overexpression increases or
maintains expression levels of CycD2 and Nmyc-1, which are implicated in cell cycle control.
Irs-1 protein stability in CGP is controlled by the negative feed back loop, in which mTorc-1-
activation induces p70S6K that phosphorylates Irs-1 and targets Irs-1 for degradation. Shh-
dependent increase in Irs-1 is dependent on mTorc-1-inhibition that is followed by suppression
of p70S6K-kinase activity [125]. In contrast to this study, Hartmann et al. [57] postulated PI3K/
Akt- and synergistically Shh-dependent transcriptional control of Gli-1 and CycD1 as possible
lines of interaction.
Although these data corroborate tight connections between Shh and IIS, there is need for
further mechanistic investigation to define further knots in the signalling network.
6. Concluding remarks
As pointed out through the many studies of IIS in the CNS, this signalling pathway has an
essential role for development and function of this organ. Albeit studied in many laboratories,
our understanding of this central signalling pathway is far from being complete. Still we do
not understand how the same biological function is achieved by activating different down‐
stream cascades and why it is necessary to have these multiple pathways that respond to one
stimulus. We also do not know why different biological functions are the consequence of IIS
at different developmental time points in cells from the same part of the brain. In this light it
is of major interest that studies are emerging that focus on cross-talks of various stimuli.
Exposure to multiple stimuli at a time probably reflects more the natural environment of a
developing and mature neural cell than exposure to one single growth factor. It is also of major
interest to dissect different functions during development and to define the molecular players
involved into functional switches. In this regard it will be important to dissect different
subcomplexes of PI3Ks or Akts that might be implicated in IIS. It will be also needed to carefully
analyse the balances between the different branches of the signalling cascades and to identify
and close further gaps that might be still in the pathways as they are commonly described
today. Given the central role of IIS in body development, growth and maintenance, this
knowledge will be of utmost interest and will also be exploited for therapeutic medicine in
various contexts.




CA - Cornu ammonis, CGN - Cerebellar granule neurons, CGP - Cerebellar granule precursor,
CNS - Central nervous system, CSF - Cerebrospinal fluid, DG - dentate gyrus, ESC - Embryonic
Stem Cell, GH - Growth hormone, IIS - Insulin/Igf-signalling, Igf - Insulin like growth factor
1, Igfbp - Insulin like growth factor binding protein, Ir - Insulin receptor, mTOR - mammalian
target of rapamycin, NSC - Neural Stem Cell, NPC - Neural Progenitor cell, OB - Olfactory
Bulb, OBSC - Olfactory Bulb stem cell, p - phospho-, SGZ - Subgranular zone, SVZ - Subven‐
tricular zone, TF - Transcription factor.
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1. Introduction
The development of the nervous system, neuralization of ectodermal cells, specification of cell
types as well as generation of neurological diseases are closely linked to Smad proteins, which
play a central role by integrating TGFβ and BMP signalling with other essential pathways. Due
to new findings on Smad activity in neurons and the nervous system, which comprises new
roles for brain plasticity and functions, independent of the canonical signalling pathways, we
reconsider their relevance for neuronal differentiation and dedifferentiation processes and as
therapeutic targets for treatment of neurological diseases. In this chapter we develop a view
at Smad molecules, which attributes them a basic significance and allow proving their specific
contextual molecular, cellular and tissue relationships. In order to facilitate the understanding
of the complex Smad network in the nervous system an overview of the canonical Smad
signalling pathway is briefly summarized in the following paragraph.
Smads are phylogenetic old proteins, which are mediating intracellular signalling of the large
group of solube TGFβ ligands (Figure 1), containing transforming growth factor βs (TGFβs),
bone morphogentic proteins (BMPs), growth and differentiation factors (GDFs), Müllerian
inhibitory factors (MISs), activins and inhibins [4]. Ligand binding to activated heteromeric
receptor complexes, recruited from seven type I and five type II serine/threonine receptors,
results in the specific phosphorylation of receptor-associated Smads (R-Smads) at two C-
terminal serine residues.
Activin, nodal and TGFβ activate R-Smad2 and 3, while BMP acts by R-Smad1,5 and 8
phosphorylation. In the cytoplasm non-phosphorylated R-Smads are sequestrated by inter‐
acting with specific retention proteins e.g. SARA (Smad anchor for receptor activation) [5],
endofin [8], tubulin [3], actin, myosin [11] or filamin [12]. Inhibitory Smad(I-Smad)6 and 7
negatively regulate R-Smad signalling by competing for binding to activated type I receptor
and inhibiting R-Smad phosphorylation. I-Smads can also prevent R-Smad complexing to the
© 2013 Ueberham and Arendt; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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co-operating Smad(Co-Smad)4, which is required for the nuclear translocation of activated R-
Smads to subsequently control Smad sensitive promoter activity. Moreover, I-Smads support
recruitment of HECT-type E3-ubiquitin ligases Smurf1/2, which allow type I receptor ubiqui‐
tination and its degradation. Members of HECT-type and RING-type E3 ubiquitin ligases have
also been implicated in Smad degradation [13]. Regulating Smad activity allows the control of
highly complex developmental networks, e.g. the patterning of ventro-lateral mesoderm, the
decisive development of epidermal/neural cell lineages including the induction and estab‐
lishment of neural plate border, the dorso-ventral patterning of the neural tube, or the
migration of neural crest cells [18-21].
Figure 1. Synopsis of canonical Smad signalling. The upper panel shows the binding of ligands belonging to the
TGFβ superfamily to their serine/threonine kinase receptors types I and II, leading to intracellular activation of R-
Smads by receptor type I induced phosphorylation of the C-terminal Smad motif SSXS. The left and right receptor
complexes represent the TGFβ/activin/nodal linked Smad2/3 signalling and the BMP/GDF linked Smad1/5/8 signal‐
ling, respectiviely. The middle panel also displays a set of relevant binding partners of Smad proteins and shows the
generation of heterotrimer or heterodimer Smad complexes consisting of C-terminally phosphorylated R-Smads and
Co-Smad4, which are transported into the nucleus to excert their transcriptional activity by binding to susceptible pro‐
moter sequences (a). In (b) and (c) examples of the agonist-induced Smad linker phosphorylation mediated by cyclin-
dependent kinases are shown, which increases Smad transcriptional activity prior to signal termination and Smad
degradation [14, 17]. In contrast, the MAPK triggered linker phosphorylation of Smads in cytoplasm diminishes the
receptor type I responsible Smad phosphorylation and favours the cytoplasmic retention and degradation of Smad.
More information is provided in the main text.Note: Numbers in square brackets indicate relevant references included
in the reference list provided at the chapters end.Abbreviations: CDK, cyclin-dependent kinase; dynein, dynein light
chain km23-1 or km23-2; MAPK, mitogen activated protein kinase; MT, microtubuli; Nedd4L, neuronal precursor cell
expressed developmentally down-regulated 4-like ubiquitin ligase; Nuc214, nucleoporin 214; SARA, Smad achor for
receptor activation; Smurf1, HECT-domain ubiquitin ligase Smurf1.
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In R-Smads a linker region, located between the highly conserved N-terminal MH1- and the
C-terminal MH2 region (MH represents Mad homology), is rich in potential serine/threo‐
nine phosphorylation sites. Several kinases (e.g. MAPK, GSK, CDKs, CamKII, SGK1) can
phosphorylate the linker region and determine cellular distribution or protein stability of
Smads [14,23-26]. Linker phosphorylation by mitogen-activated protein kinases (MAPKs) re‐
stricts Smad1 activity by enabling Smurf1 binding, causing polyubiquitination and inhibit‐
ing interaction of Smad1 with nuclear transclocation factor Nup214, thus leading to Smad1
degradation or cytoplasmic retention [15].
A similar mechanism acts on Smad2 and 3, where ubiquitination is controlled by ubiquitin
ligase Nedd4L [17]. A sustained MAPK activation, as reported from dissociated embryonic
ectodermal cells, phosphorylates Smad linker and interrupt a continuing BMP mediated
Smad1 signalling finally resulting in neuralisation of dissociated Xenopus [27]. Remarably, if
linker phosphorylation is performed by extracellular signal regulated kinase (Erk) at nuclearly
localized phosphorylated Smad, the duration of Smad targeted gene transcription can be
increased [28]. Linker phosphorylation by CDK8 and CDK9 promotes both, the Smad tran‐
scriptional action, and the cooperation with YAP, an effector of the Hippo organ size control
pathway, to finally suppress neural differentiation of stem cells [14]. The data demonstrate the
particular role of the linker region for distinct Smad functions.
Numerous Smad binding proteins (e.g. Ski, SnoN) effectively influence essential steps during
neural development mostly by repression of Smad activity [29-33]. The group of Smad
interacting proteins (SIP), containing several zinc finger proteins, complex to Smad and can
directly or indirectly regulate its transcription efficiency [34]. For example, the induction of
neuroectoderm is dependent on SIP1 [35-37], which is also involved in the myelination process
and the oligodendrocyte maturation [38].
2. The role of Smads during neural/non-neuronal development
2.1. Already early development requires Smad expression
During early ontogenesis, development and aging as well as prior to individual cell death
Smad proteins differentially affect cellular function, depending on time and local partners.
Already at very early stages of postnatal rat development Smads1-7 were detectable in the
ovary [39]. At all stages of follicular development (e.g. in primordial, primary and secondary
follicles) Smad proteins are present in oocytes as well as in granulosa cells and theca cells,
though with different concentrations [39-41]. While Smad3,6 and 8 content did not change, the
expression of Smad1,2,4,5,6 and 7 seems to be regulated in ovary [39]. In mice oocytes a clear
and persistent nuclear localization of phosphorylated Smad1,5,9 and Smad2,3 demonstrates
activated activin/GDF9/nodal/TGFβ and BMP/MIS pathways, respectively, and confirms
oocytes as a major target for Smad signalling pathways [42]. Smad proteins play also important
roles already during maturation of human oocytes [43]. In unfertilized oocytes, Smad2 and 3
and TGFβ receptors I and II are present [44]. After fertilization at the 4-cell and 8-cell stages
Smad2 and 3 are also present, while neither of the TGFβ receptors is detectable. Later on in
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the blastocyte stage Smad2 and 3 kept present and TGFβ receptor I again appears [44]. Human
granulosa cells express Smad1-7 and 9, but Smad2,3, and 4 with the highest expression levels
[45]. A mutual interaction between oocytes and granulosa cells is necessary for normal
folliculogenesis. However, if Smad4 is deleted in granulosa cells infertility results, while
deletion of Smad4 in oocytes only marginally effects the primordial follicle stage [46]. How‐
ever, Smad2 reduction in zebrafish oocytes completely blocks activin A-induced oocyte
maturation and a Smad2 knockdown decreases basal and hCG-induced oocyte maturation
demonstrating a key role of Smads during oocyte maturation [47].
2.2. Gastrulation and neurulation
2.2.1. Suppression of Smad signalling specifies neuroectoderm generation
Initially, the ectoderm cells in Xenopus are pluripotent until gastrulation [48]. Early gastrula‐
tion steps are characterized by the formation of mesenchymal cells and the induction of
mesoderm in the marginal-zone by an epithelial-to-mesenchymal transition (EMT) process,
which involves activation of Smad2,3,4 signalling by TGFβ/nodal ligands after binding to
corresponding receptors [49-53].
Mesoderm induction requires a subtle coordination of the canonical TGFβ/nodal signalling,
with Smad4 as a key player. However, initially it was shown, that a simple ectopic Smad4
expression in the Xenopus animal cap was inefficient to induce mesoderm [54], due to its
binding to ectodermin, a RING-type ubiquitin ligase, which is highly expressed in the animal
cap [53]. Ectodermin limits Smad4 function via antagonizing nuclear accumulation of Smad4
and supporting Smad4 degradation by ubiquitin-proteosome pathway [53]. By this, ectoder‐
min ensures that ectoderm cells do only develop to a mesodermal lineage, but also supports
neural differentiation of ectoderm towards neuroectodermal fates by interfering with BMP
signalling via limiting Smad4 function [53]. However, the stable presence of soluble BMP
which prevents the execution of an intrinsic program of ectodermal cells to form neural tissue
can also be undermined by the release of BMP antagonists as noggin, chordin, follistatin or
cerberus, which however, allows creation and development of neural cells. This interrelation
is basically reflected in the ´default model´ of neural induction [55,56]. Confirming this model
it was shown, that the simultaneous depletion of BMP2, BMP4 and BMP7 induces massive
brain formation [57]. Accordingly, during early gastrulation-stage of chick embryo Smad1,5,8
signalling is undetectable [21] but is activated at neurula stage. So, phosphorylated Smad1
becomes detectable only at late gastrulation stages in the posterior territory of the embryo [21].
The default model has been further modified due to experiments showing that inhibition of
BMP/Smad1 signalling, e.g. by Smad6, was insufficient to induce neural markers efficiently
[58], while the additional suppression of Smad2 was sufficient [59]. Moreover, stimulation of
Smad2 signalling blocks neural induction even at gastrula stages and indicate prospective
neural cells to further undergo mesodermal and non-neural fates [59]. These data are sup‐
ported by experiments in sea urchin embryos showing that Smad2 and 3 suppress neural
differentiation in the oral ectoderm [60].
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Remarkably, conversely, it has also been suggested from very early studies on Smad2+/-;
Smad3-/- mutants in zebrafish showing anterior truncations [49], that Smad2 and Smad3, which
are mainly effectors of TGFβ/nodal pathways, are also positively involved in neural develop‐
ment [61]. Dominant negative Smad3 mutants inhibit the expression of early neural markers
sox2 and sox3 at the onset of gastrulation and lead to reduction of anterior and posterior
neuroectodermal markers otx2 and hoxb1b, respectively, during late gastrulation. According‐
ly, elevated Smad2 and Smad3 activities increased sox2 and sox3 expression, probably at least
partly due to its positive impact on chordin expression, which is a BMP antagonist [61]. In
mouse embryo BMP signalling also inhibits premature neural differentiation, but in contrast
to Xenopus [62] and chick [63,64] FGF signalling seems additionally required to induce neural
differentiation [65].
In summary, the data indicate that simultaneous suppression of both Smad1,5,8 and Smad2,3
pathways, e.g. suppression of mesoderm- and ectoderm-inducing Smad signals, respectively,
are required for neural induction. In principle, the `dual Smad inhibition` method is adopted
for induction of efficient neuralization of human (-induced) pluripotent stem cells (hiPSCs,
hPSCs) [66,67].
2.2.2. Neural tube closure
To establish a precise borderline between neuroectoderm (containing low BMP2/4 levels) and
non-neuroectoderm (containing high BMP2/4 levels) regions during early neurulation, specific
strategies are required and examined in urchin embryos, where Fez, a zinc finger protein, drops
down the BMP controlled pSmad1,5,8 levels [68]. It is probable that Fez acts as a transcriptional
repressor of Smad or interferes with genes attenuating intracellular BMP signalling e.g. SIP1,
Smurf1, Ski or SnoN.
Once the neuroectoderm forming is initiated a flat neural plate rolls up, the process of neural
plate folding proceeds and is finished by neural tube closure [69]. The closure of neural tube
is a complex process involving hinge points (HP), representing specialized neural plate cells.
The cells of ventral midline/median hinge point (MHP) as well as both dorso-lateral hinge
points (DLHPs) are affected by dynamic BMP signalling [70-73]. Folding of neural plate is
connected with a two-dimentionally spatiotemporal gradient of phosphorylated Smad1,5,8
(pSmad1,5,8) [71,73]. While initially a mosaic labelling of pSmad1,5,8 was observed at the
apical surface of the presumptive neuroectoderm later two intersecting Smad gradients were
exerted: a lateromedial gradient with the lowest pSmad1,5,8 expression at the MHP and a
second gradient along the apicobasal axis of the presumptive midbrain plate with mosaic
expression in apical nuclei [71]. Some of the apical pSmad1,5,8 positive cells proliferate and
thus support the neural fold elevation [71]. Disturbances of the phosphorylation state of
Smad1,5,8 alter midbrain shape by multiple hinge-like invaginations but do not affect the
ventral cell-fate specification [71]. However, the extent of Smad1,5,8 phosphorylation seems
to control MHP formation during neurulation in vertebrates. The correct MHF formation is
obviously directly linked to the pSmad1,5,8 controlled regulation of apicobasal polarity of
neural plates cells. After phosphorylation, Smad1,5,8 interact with the PAR3-PAR6-aPKC
complex and stabilizes linked tight junctions, while inversely low pSmad1,5,8 phosphorylation
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supports re-arrangement of neural plate cells, a prerequisite for MHP formation and neural
fold elevation [72].
2.2.3. Patterning and developing of the spinal cord
After closure, the neural tube starts to develop the spinal cord pattern along its dorso-ventral
axis which is essentially established by the expression of Wnt and BMPs, the main roof plate
morphogens, and sonic hedgehog (SHH) and TGFβs, the morphogens released from the floor
plate [74-76]. On the basis of provided intricated morphogenic gradients functionally distinct
neurons are generated.
Both roof plate derived BMP6 and BMP7 are evoking Smad1,5,8 phosphorylation and
subsequent induction of distinct dorsal interneurons (dI) via BMP receptor I activation [77-79].
While the BMP7/pSmad1,5 activated induction of dI1, dI3 and dI5 is independent of the
patterned expression of progenitor proteins, e.g. Pax7, Gsh1/2 or Olig3, a Smad regulated
expression of specific proneural proteins, e.g. cAth, and cAscl1, is required [79]. The patterning
of dorsal progenitor proteins could be associated with other BMPs, e.g. BMP4 [80]. Smad1 and
Smad5 activity seems to be important for the maintenance of neural cells as committed
progenitors, because the loss of Smad1,5 reduced the total number of newly generated neurons
and forces cell cycle exit and premature neurogenesis of neural progenitors [79]. The inhibitory
Smad6 also promotes the neuronal differentiation in the spinal cord by interfering with Wnt-
signalling [81]. Hazen and colleagues demonstrated, that the inhibitory Smad6 and Smad7
function to restrict the action of roof plate released BMPs to distinct dorsal interneurons and
participate in the determination of dI4-dI6 spinal neuron number [82].
However, the subsequent orientation of spinal neurons is also controlled by BMP7 but not via
activation of Smad signalling instead using phosphoinosite-3-kinase (PI3K) activation by the
BMP receptor type II [77]. Nevertheless, Smad6 most potently allows blocking dI1 axon
outgrowth [82].
While Smad3 was also expressed in the developing spinal cord, Smad2 was not detected [83].
Contrasting to Smad1,5,8, the expression of Smad3 in the developing spinal cord depends on
progenitor proteins, e.g. Nkx6.1, Olig2, Nkx2.2, which directs the Smad3 expression mainly to
discrete ventral progenitor domains [83]. Smad3 activity in turn reduces expression of
progenitor proteins and promotes activation of neuronal differentiation, e.g. by supporting
cell cycle exit via activating of p27Kip1 expression [83]. The Smad3 expression is sufficient to
promote differentiation of ventral and various dorsal interneurons, while differentiation of
motor neurons is impaired. Therefore Smad3 expression is excluded in the prospective motor
neuron progenitor cells [83].
2.2.4. Induction of neural crest (NC)
Multipotent embryonic cells of the dorsal region of the neural tube, an area existing immedi‐
ately before forming the neural plate border (NPB), are the origin of neural crest cells (NC)
that migrate to initiate a panel of diverse derivatives including various non-neural but also
neural cells e.g. sensory neurons of the peripheral nervous system. The combination of several
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signalling pathways is required [84] for a timely and locally well tuned progression. Besides
Wnt signalling a major role in NC induction plays canonical BMP signalling [85-90] combined
with FGF signalling [21,91]. The inductive step of NPB development during gastrulation
requires a concerted action of activated Wnt signals and inhibition of BMP signalling repre‐
sented by low Smad1,5,8 activity. Later, when neurulation proceeds and NC develops from
NPB, activated Wnt signals cooperate with a robust Smad1,5,8 activation in NPB. While during
the inductive step of NC gastrulation FGF downregulates Smad1,5,8 activity by triggering
MAPK, the catalysed phosphorylation of Smad1,5,8 linker region is nearly completely absent
in NPB during neurulation. In consequence, a strongly elevated Smad1,5,8 signalling is
observed suggesting a ´two step model of NC development´ with respect to activated
Smad1,5,8 signalling [21].
2.3. Peripheral nervous system (PNS)
The further outcome of NC cells including the generation of the PNS also strongly depends
on Smad signalling. Interestingly, Smad expression regulates both the formation of neurons
of PNS as well as early stages of peripheral glial development.
Precursors that emigrate from the neural crest to the bowel generates the enteric nervous
system (ENS) belonging to PNS. If fetal enteral neural crest-derived cells (ENCDC) of gut are
exposed to BMP2 or BMP4 phosphorylated Smad1 translocates to the nucleus and the cells
develop processes, indicating an essential role of Smad phosphorylation for neuron induction
in the gut [92]. However, Smad phosphorylation alone is not sufficient to direct development
of ENCDC towards ENS neurons or glial cells but requires further factors e.g. glial growth
factor 2 (GGF2) [93]. Moreover, besides generation, also maturation of enteric neurons (as well
as regulation of gliogenesis) during postnatal development is Smad-dependent. This function
was identified because mice lacking in the homeodomain interacting protein kinase 2 (HIPK2),
which can interact with Smad1, Smad2 and Smad3 [94] and therefore control transcription of
subsequent Smad-dependent promoters, are characterized by a progressive loss of enteric
neurons and an arrest in synaptic maturation postnatally. Additionally, in the HIPK2-/- mice
the remaining enteric neurons exhibit an increased number of cells with nuclear Smad1,5,8
phosphorylation [95]. Interestingly, both in the enteric nervous system and in the midbrain
[96], HIPK2 reduction severely reduces survival of dopaminergic neurons through interfer‐
ence with Smad signalling pathways, regulated by BMP2/4 or TGFβ, respectively. Whether
altered Smad signalling, affected by HIPK2, is also responsible for Parkinson´s disease and
would allow to develop a therapeutic intervention has to be investigated in the future.
Recent data demonstrate, that Smad1 signalling by BMP2 induction is implicated in differen‐
tiation of primary enteric neurons to catecholaminergic (TH expression) but not to cholinergic
(ChAT expression) neuronal subtypes [97].
Peripheral glia precursors derived from neural-crest and exhibiting characteristic expression
of immature glia markers e.g. nestin, are critically influenced by BMP2/Smad signalling. Using
Smad1 activation, neural-crest precursor cells, that begin to develop along glial pathway are
kept in an undifferentiated immature multipotent state, thus allowing migration to their
postmigratory locations [98] where they later acquire myelinating properties. Smad-linked
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activation of GFAP promoter is part of this process [99]. Generally, oligodendroglial differen‐
tiation of precursor cells is actively suppressed by BMPs concomitant with the stimulation of
astrocytic differentiation [100]. Accordingly, BMP4-activation directs progenitor cells in vivo
to commit to the astrocytic rather than the oligodendroglial lineage [101].
3. Specific cell types and the role of Smad expression for their induction
and maintenance
3.1. Cell type decision, maturation and differentiation
Both generation and differentiation of neurons in the brain (CNS) comprises several different
and complex principles. The initial proliferation of neural precursor cells is followed by the
decision to specify neuronal or glial outcome. Afterwards, the primary neurogenesis of
neuronal progenitors involves migration, settlement and stopping proliferation by cell cycle
exit to enter a terminal differentiation pathway. Many of these basic biological routes as well
as further differentiation steps, e.g. dendritic and axonal growth and orientating, synapse
formation and myelination depend on Smad proteins. The parallel occurrence of long term
and acute Smad-dependent processes require a distinct contextual organisation. For example,
in the developing brain an important neural stem cell is provided by radial glia cells which
can generate both glial cells and neurons. While TGFβ promoted differentiation of radial glia
into astrocytes is mainly regulated by activation of MAPK signalling, neurogenesis is control‐
led by the interplay of Smad2,3 activity and PI3K activity [102].
3.1.1. Glial cells
Radial glial cells can function as neuronal precursors and also control migration of neurons
during cerebral cortex development [103]. Developing neurons are also actively implicated in
the radial glial cell fate commitment [104]. Using TGFβ release, neurons can activate Smad
signalling in radial glia cells and support their transformation to astrocytes [105] and also
induces astrocytic differentiation and GFAP expression [106-109].
Moreover, endothelial cells also promote astrocytic differentiation by BMP-induced Smad
signalling, but inhibit oligodendrocyte differentiation of postnatal cortical progenitors [110],
and therefore participate in the sequential order of the two macroglial cell gliogenesis. The
function of BMP/Smad signalling to drive precursors to astrocytic fate seems a common feature
[111,112] which is also involved in CNS injury processes where oligodendrocyte precursors
are driven towards type II astrocytes [113]. Accordingly, inhibition of BMP induced nuclear
translocation of phospho-Smad1 by FGF2 activated MAPK activity is linked to Smad4
dissociation from Olig2 promoter and results in upregulation of oligodendrogenesis [114]. The
very importance of a spatially and temporally regulated BMP induced Smad activation for the
fate of neurogenic precursor cells was shown in chick spinal cord. At embryonic day 5, in
neuroepithelial progenitors, astrocyte marker expression was inhibited and at embryonic day
6 it was promoted initiating a gliogenic period [115].
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3.1.2. Neurons
The commitment of cell fates in the nervous system is strongly dependent on Smad2,3
signalling cascade. However, there have been contradictory results on the role of Smad3 for
neuronal precursor proliferation and their differentiation, indicating a complex Smad signal‐
ling network dependent on local, temporal and contextual characteristics.
Some reports show, that TGFβ, which activates Smad3 signalling, diminishes neurogenesis in
hippocampus after its chronical increase [116], and in SVZ and DG after intracerebroventric‐
ular TGFβ1 infusion [117] and promotes neuronal differentiation from hippocampal and
cortical progenitors [118]. An clear inhibitory function of Smad3 on neural precursor prolif‐
eration was shown in the developing spinal cord [119], where Smad3 also promotes differen‐
tiation and influences the fate of selected neurons. The antiproliferative role of Smad3 and
Smad4 plays a role during early-postnatal differentiation of cerebellar neurons into postmitotic
neurons, where TGFβ stimulation induces nuclear translocation of phosphorylated Smads and
induction of cyclin-dependent kinase inhibitors p21, p27 and markers of neuronal maturity
[120].
However, other reports show that TGFβ increased neurogenesis in DG after adrenalectomy
[121] or in SVZ after stroke [122].
To clarify the relevance of Smad3 for adult neurogenesis Smad3 null mice were studied
[123,124]. These mice show decreased neurogenesis in the DG and the SVZ and exhibit a
thinner and more disorganized rostral migratory stream (RMS) of neuronal precursor cells
(NPC). Using RMS NPCs migrate from SVZ to reach the olfactory bulb, where they differen‐
tiate into granular and periglomerular neurons. Though a decreased number of proliferating
cells demonstrates the requirement of Smad3 for maintaining a proper cell division rate in
SVZ, the neuronal fate is not altered by Smad3 deficiency [123].
For differentiation of mesencephalic progenitors into dopaminergic (DA) neurons a concerted
interaction of Smad2,3 signalling and p38 MAPK-pathways by TGFβ receptor stimulation is
necessary. Accordingly, treatment of ventral mesencephalic neural progenitors with TGFβ
increased the number of tyrosine-hydroxylase (TH)-positive cells [125]. Though not required
for the neurogenesis, the survival of midbrain dopaminergic neurons depends on function of
the homeodomain interacting protein kinase 2 (HIPK2), which interacts with R-Smads to
activate TGFβ responsive genes [96]. Loss of HIPK2 increases apoptosis in DA neurons during
development. Nevertheless, apoptosis of specific neural progenitors during neural differen‐
tiation also involves Smad phosphorylation as shown for Smad1,5,8 [126,127].
In vitro, treatment of ventral mesencephalic cells with BMP5,6 and 7 also significantly
increased the number of TH-positive neurons via Smad phosphorylation and nuclear trans‐
location [128], while the neurotrophin growth/differentiation factor 5 (GDF5) induced Smad
pathway promotes neuronal but not dopaminergic differentiation [129]. Remarkably, the in
vitro generation of functional dopaminergic substantia nigra neurons for transplantation
requires a protocol which uses the temporarily and contextually distinct roles of Smad
proteins: Firstly, the dual inhibition of Smad signalling in embryonic stem cells is required to
allow induction of floor plate cell state which then passes over to midbrain floor plate cell state.
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Secondly, an activation of Smad signalling using TGFβ pathway is necessary to finally obtain
dopaminergic neurons suitable to threat Parkinson´s like symptoms [130].
In the developing cerebellum, Smad1 is expressed in the external germinal layer and Smad5
is synthesized in newly differentiated granule neurons. In the granule precursor cells, Smad5
overexpression is sufficient to initiate differentiation [131]. In mice lacking Smad4, a decreased
number of cerebellar Purkinje cells and parvalbumin-positive interneurons [132] is found
while no alterations of proliferation of neuronal precursor cells were detectable. Loss of Smad4
also reduces differentiation of noradrenergic neurons [133].
Basal forebrain cholinergic neurons are essentially involved in the organisation of cortical brain
structures, learning and memory. Smad1-5 are expressed in basal forebrain from embryonic
day 14 to the adult age [134]. An intact canonical TGFβ/Smad2,3 cascade is important for the
function of cholinergic neurons. Smad signalling mediates rapid inhibition of calcium influx
in cholinergic basal forebrain neurons [135]. The sleep/wake circadian rhythm controlled by
cholinergic neurons of the pedunculopontine nucleus (PPT) is also dependent on phosphor‐
ylation levels of Smad2 and Smad3. Overactivation of Smad2,3 signalling resulting in increased
nuclear translocation is linked to sleep/wake circadian rhythm amplitude deficits [136]. BMP9
driven Smad1,5 phosphorylation and their formation of complexes with Smad4 are involved
in the induction of the cholinergic phenotype in the basal forebrain [134,137]. Moreover, only
in postmitotic cholinergic neurons, this pathway induces NGF expression, an autocrine/
paracrine cholinergic trophic factor, which stimulates ACh production [138]. Accordingly, it
is of therapeutic relevance for treatment of Alzheimer´s disease, that BMP9/Smad1,5 signalling
can prevent lesion-evoked impairment of the cholinergic septo-hippocampal neurons in adult
mice [139]. The basal forebrain cholinergic neuron specific gene expression pattern is also
basically linked to an interaction of Smad and Sizn1 (Smad-interacting zinc finger protein), a
factor which causes mental retardation if mutated [140,141].
3.2. Axon and synapse formation
Induction of axons and orienting of axon responses are controlled by several Smad molecules
of both the BMP and the TGFβ/activin pathways in a timely and spatially organized manner.
Several different neuronal/neural cell types use individual aspects of the Smad machinery.
3.2.1. Basic role of Smads for neuritic outgrowth
In PC12 cells, which are initially derived from neural crest cells and are used as model system
for neuronal differentiation, BMP2 induces neurite outgrowth [142] by activation of TAK1/p38
kinase signalling pathway [143,144], which is in turn tightly controlled by the simultaneous,
also BMP2-induced expression of the inhibitory Smad6 and Smad7 [142] performed via
activation of Smad1,5,8 pathway. The inhibitory Smads are considered to inversely inhibit
BMP signalling in a concerted action by repressing Smad1,5,8, mediating BMP receptor
degradation by Smurf1 [16,145], and by physical interaction with TAK1-binding protein,
which finally reduces the p38-mediated neuritic outgrowth [143,144]. Neurotrophin 3 induced
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neuritic outgrowth is potentiated by BMP4/6 induced phosphorylation of Smad1,5,8 and their
subsequent inhibition of MEK in chicken neurons [146].
Otherwise, BMP2 inhibits neuritic outgrowth and differentiation of motor neuron-like NSC-34
cells by activation of Smad1,5,8-dependent signalling and subsequent Id genes activation,
which are main targets of Smad signalling and which negatively regulate differentiation of
various cells including neurogenic precursors and motor-neuron precursors [147].
3.2.2. Subtle control of axonal morphogenesis
The axonal morphogenesis is strongly influenced by the TGFβ-regulated signalling protein
Smad2. Endogenous Smad2 is constitutively activated and its phosphorylated form is nucle‐
arly localized in human and mouse hippocampal and cortical neurons [148,149] and in primary
granule neurons of rat cerebellum [150]. In granule neurons Smad2 can form a physical
complex with the endogenous transcriptional modulator SnoN, which is also nuclearly
localized and strongly enhances axonal growth [151] and neuronal branching [152] by
regulating a large number of neuronal genes [153]. SnoN ubiquitination and degradation is
controlled by the nuclear ubiquitin ligase Cdh1-anaphase-promoting complex (Cdh1-APC),
which physically interact with nuclear SnoN thus suppressing axonal growth. [151,154].
Obviously Smad2 binding to SnoN facilitates the ability of Cdh1-APC to control SnoN
degradation. Consequently, if phosphorylation levels of Smad2 are reduced, SnoN levels
increased and axonal growth is stimulated which allow therapeutic potential after brain injury
[150]. The constitutive neuronal expression of axonal growth inhibitors e.g. Smad2, Smad3
[148] and Cdh1 [155] and the reduced expression of axon growth promoters (SnoN) in
terminally differentiated neurons [150] generate an intrinsic axon growth inhibition control,
allowing a balance between steady state and neuronal plasticity.
3.2.3. Axonal regeneration
Axonal regeneration requires the reversal of an age-dependent loss of intrinsic axonal growth
capability [156,157]. In dorsal root ganglion cells (DRG), which possess two branches of a
initially unipolar axon, (a) a central branch containing in the spinal cord and (b) a peripheral
branch innervating sensory targets, the axotomy of the peripheral branch requires function of
transcription factor Smad1 for successful regeneration [158]. While in embryonic DRG neurons
during the phase of active axon growth Smad1 RNA and protein were strongly expressed and
found abundantly C-terminally phosphorylated in the nuclei (while Smad8 expression was
low and Smad5 expression was concentrated to the periventricular zone), in adult DRG
neurons Smad1 phosphorylation was diminished [159]. However, after axotomy, the induction
and nuclear translocation of Smad1 precedes the onset of axonal extension and are maintained
over longer time, demonstrating the importance of Smad1 for the perpetuation of the activated
axonal growth program [158]. Interestingly, Smad1-dependent axonal growth program is an
intrinsic feature of DRG neurons which functions independently of extracellular BMP. Until
now, the detailed underlying mechanism for BMP-independent Smad1 phosphorylation is not
completely elucidated. It is possible, that endogenous cytoplasmic kinases or intracellularly
available BMP/BMP-receptor complexes might be involved. The ligand-independent C-
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terminal phosphorylation of the SSXS domain of Smad2 and Smad3 was already reported [160]
suggesting a possible extracellular ligand-independent universal strategy. Probably, Smad1
signalling is also involved in the axonogenesis of many other classes of neurons, e.g. Purkinje
cells, retinal ganglionic, olfactory and motor neurons which were already found positively
labelled for pSmad1 immunoreactivity [159]. Due to the possible linker phosphorylation of
Smad1 by several kinases (e.g. MAPK, GSK, CDK), the molecule might serve as an integrator
of various pathways relevant for axon growth and regeneration [14,23-26]. However, for
clinical and therapeutic relevance, the transduction of adeno-associated vector encoded BMP4
allows stimulation of Smad1 phosphorylation and activation of axonal growth independent
of axotomy and also promotes sensory axon regeneration after axotomy [159]. At least partly
BMP effects are dependent on its binding to repulsive guidance molecules [161].
While Smad1 positively supports axonal growth, the inhibitory Smad6 can block axon
outgrowth, as shown for post-mitotic dI1 axons of the spinal cord [82] and therefore exert roles
in spatially limiting the influence of BMP signalling on neurons.
In Drosophila, Smad2 is involved in motor neuron axon guidance, as null mutants of Smad2
exhibit axon guidance defects [162]. It is suggested, that a chemoattractant signal of TGFβ
superfamily members provided by muscle cells might guide motor axons to their appropriate
innervation sites.
3.2.4. R-Smads and Co-Smads exert neuronal plasticity
The development of peripheral tissues is connected to axonal growth of peripheral nerves,
linking sensory information to the spinal cord via neuronal cell bodies localized in ganglia.
After initial axon extension for trigeminal sensory neurons in mice, a Smad4-dependent
retrograde signalling from developing face to the neuronal nuclei was found, which control
the expression of genes in neurons of the trigeminal ganglion in dependence on their position.
Extrinsic signals released from developing craniofacial tissue, e.g. BMP4, activate phosphor‐
ylation of Smad1,5,8 at the axon terminals and selectively retrogradely signals this information
to selected trigeminal neuronal cell bodies thus inducing spacially patterned expression of
further transcription factors along the dorso-ventral axis of the trigeminal ganglion [163]. A
comparable retrograde mechanism based on dSmad2 was found in R7 axons in the Drosophila
visual system, where activin, secreted from the R7 cells growth cone in an autocrine manner,
activates its receptor and initiates intracellular Smad2 phosphorylation. The pSmad2 com‐
plexes to the nuclear import adaptor Importin-α3, shuttles to the nucleus and reduces growth
cone motility and synaptogenesis via transcriptional regulation of several target genes [164].
Already in Drosophila, a retrograde Smad-based signalling of the BMP homolog Gbb regulates
synaptic growth in presynaptic motor neurons [165]. The underlying mechanism for the
retrograde Smad-based signalling was recently examined for the BMP4 signalling system. Ji
and colleagues (2012) discovered that endosomes carrying the BMP-signalling complex
containing phosphorylated Smad1,5,8, are essentially linked to a BDNF-induced axonal or
growth cone translation of Smad proteins to retrogradely control transcription in trigeminal
neurons [166,167]. This `two-target-derived signalling´ integrates neurotrophin and BMP
signals on the level of Smad proteins, which are axonally translated on demand. This process
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is involved in the acquisition of positional identity markers during trigeminal ganglia devel‐
opment and selectively works in ophthalmic and maxillary but not in mandibular axons
obviously due to the failure of BDNF in the mandibular target field [166]. The underlying
mechanism suggests to re-evaluate the role and extent of Smad based transcriptional regula‐
tion. (1) Nearly all cellular surfaces/membranes, including dendrites, axons, growth cones and
spines might receive information which could be integrated by Smad signalling. (2) The
retrograde transport of other ligands of the TGFβ group was already reported, e.g. TGFβ2 in
normal and injured motor neurons [168], implicating the question whether axonal Smad
signalling is involved in injury-response. (3) The mechanism might work with all those
extracellular and also intracellular factors that affect Smad translation, and might at least partly
explain neurodegenerative disorders, which are characterized by disturbed axonal transport
and/or neurotrophin deficiency at neuronal terminals
The specific structure of axons and the axonal transport of Smad signals [166] as well as simple
translocation of receptor phosphorylated Smads from cytoplasmic receptor site into the
nucleus require intact microtubule network. Phosphorylated Smad2 is transported using
microtubules by support of kinesin-1 and kinesinATPase activity [169] and also requires
dynein light chain km23-1 [6], whereas pSmad3 transport was dependent on km23-2 function
[170]. Additionally retrograde axonal transport of phosphorylated Smads, which is necessary
for transition of axonal synaptic BMP-like ligand mediated phosphorylation of Smads in
Drosophila, also depends on an intact function of p150Glued protein. P150Glued is a compo‐
nent of the dynactin complex, which is necessarily involved in synapse assembly and stability
[171]. However, a p150Glued knockdown induced disruption of synaptic homeostasis can be
rescued by activation of Smad signalling at the soma [172,173], confirming the important role
of nuclear phosphorylated Smad to synaptic homeostasis.
3.2.5. Astrocytic and oligodenrocytic Smad signalling influences neuronal axonal growth
Astrocytes surrounding synapses are also target of neuronal activity. Glial metabotropic
glutamate 2/3 receptor activation by neuronally released glutamate induces astrocytic TGFβ1
secretion, leading to GFAP gene activation and astrocyte differentiation involving astrocytic
Smad signalling pathways [174].
Chondroitin sulphate proteoglycans (CSPG), mainly synthesized by astrocytes, can inhibit
axonal growth and regeneration. After traumatic brain injury or disruptions of the blood brain
barrier, mature or fibrinogen-coupled latent TGFβ is released into the CNS and increases the
CSPG expression by a Smad signalling manner in astrocytes [175,176]. Both astrocytic Smad2
and Smad3 expression and phosphorylation leads to inhibition of neuronal outgrowth and is
required for astrocytic neurocan synthesis, whereas phosphacan only requires Smad2
[175,176]. Reduced Smad3 levels selectively reduced induction of chondroitin-4- sulphotrans‐
ferase 1 and the amount of 4-sulfated CSPGs secreted by astrocytes and also promoted axonal
growth of neurons which were fed on these astrocytes [175]. Taxol treatment of astrocytes can
reduce CSPG expression by interfering with kinesin-1-dependent pSmad transport into the
nucleus [177] and improve axon regeneration after spinal cord injury.
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The Smad-interacting-protein 1 (Sip1) is an essential modulator for CNS myelination. In
oligodendrocytes, it functions in a dual-mode manner by repressing the differentiation
inhibitory signals of the BMP-receptor activated Smad1,5,8 activity [178] and activating
oligodendrocytes-promoting factors, thus controlling proper myelination in the CNS [38].
3.3. Smads contribute to synapse formation and synaptic transmission processes
Synapse formation and remodelling are results of intrinsic programs and environmental
insults. Synapses are characterized by close cell-to-cell communications, which also include
synaptic transmission and signalling processes mediated by growth factors e.g. members of
the TGFβ superfamily. In spinster a mutation of the inhibitory Smad Dad (Daughters against
dpp) causes synaptic overgrowth [179]. A well investigated synaptic system is the neuromus‐
cular junction (NMJ) of Drosophila, showing the involvement of Smad proteins in synapse
function both in pre- and in postsynaptic cells. The release of muscular BMP4-type ligand Gbb,
which is required for intact function of a large part of postsynaptic muscles [165], allows its
binding to a presynaptic receptor consisting of one type I and one type II receptor, Sax or Tkv
and Wit, respectively [180,181], and the subsequent phosphorylation of the R-Smad, Mothers
against dpp (Mad) [165]. Activated Mad is responsible for presynaptic nuclear propagation of
the postsynaptic muscular BMP signals and finally for regulating synapse growth, morphol‐
ogy and function of motor-neurons at least partly by altering transcription [165,180,182]. The
retrograde transport of Mad utilizes microtubule motor proteins, e.g. dynein complexes, and
is sensitive to disruption of dynein motor function [165]. The Drosophila Co-Smad/Smad4
homolog Medea (Med) is also necessary for presynaptic BMP signalling cascade and essential
for synaptic growth [183]. Both, Med and Mad mutants, exhibit defects in neurotransmitter
release and synaptic ultrastructure [165,183]. It is suggested that an equilibrium exist between
the binding of presynaptic phosphorylated Mad to Med and the binding of Med to the RING
finger E3 ubiquitin ligase Hiw [184], which regulate the synaptic growth in NMJ [183].
Additionally to the retrograde neuronal Mad/Med-mediated Gbb signalling, anterogradely
released TGFβ type ligands activate Mad phosphorylation at the postsynaptic density (PSD)
zone of postsynaptic muscles and NMJ depolarization supports Mad nuclear transition in the
muscles [185]. In summary, a mutual information flow of neuron and muscle on each phys‐
iological state and the synaptic cleft situation is essentially controlled by specific R- and Co-
Smad signalling in both cellular systems.
Importantly, the activation of Mad phosphorylation and nuclear translocation by the BMP
ligand Gbb directs the expression of synaptic homeostasis independently of synaptic growth
control in Drosophila [173]. However, retrograde transport of Mad, which was phosphorylated
at the periphery of the axon terminal due to synaptic Gbb binding, mediates synaptic homeo‐
stasis. Remarkably, Gbb induced phosphorylation of Mad at the soma site of the neuron
compensate for a disturbed retrograde axonal pMad transport completely [173]. The release
of muscular Gbb into the synaptic cleft at the periphery to activate neuronal retrograde pMad
transport, can be regulated by activin, which controls the muscular Gbb synthesis by recruiting
the Drosophila dSmad2 [186]. Cdc42-interacting protein 4 (dCIP4) which is also localized
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postsynaptically at the NMJs co-regulates the phosphorylation of neuronal Mad levels by
inhibiting postsynaptic Gbb secretion [187].
These data indicate, that both activin and BMP directed R-Smad signalling controls synaptic
function at NMJ and affects the development of synaptic homeostasis.
4. Role of Smads for neurological disorders
Several neurological diseases are characterized by disturbed cellular or subcellular Smad
localization and show artificial Smad sequestration or deposition. Especially in neurodege‐
nerative and motor neuron diseases a disruption of Smad controlled transcriptional machinery
was reported.
Neurodegenerative diseases are characterised by selective and progressive loss of specific
populations of neurones. Four disease-classes are proposed based on four major affected
proteins, tau, βA4-amyloid (βA4), α-synuclein and TDP-43, and therefore, neurodegenerative
diseases can roughly be classified into four main groups: amyloidosis, tauopathies, synuclei‐
nopathies and TDP-43 proteinopathies (for review see [188]). Recent data indicate, that in all
four disease groups Smad proteins are essentially involved in the disease progression, finally
indicating a remarkable commonness of these diseases.
4.1. Alzheimer´s disease
Alzheimer´s disease (AD), representing a mixture of both amyloidosis and tauopathy, is a
severe neurodegenerative disorder and the most common cause of dementia in the elderly.
Typical clinical symptoms are memory loss, disturbed activities of daily life and deficiency of
social competence. Common morphological correlates to the clinical features are extracellular
βA4-plaque depositions, intraneuronal tau pathology, neuronal cell death, and cell cycle
activation [189].
In AD, we identified a strong disturbance of the normal constitutive nuclear localization of
phosphorylated Smad2 and Smad3 in hippocampal and cortical neurons [148], which subse‐
quently was confirmed by others [190,191]. In AD brain, a strong colocalization of pSmad2,3
with intracellular neurofibrillary tangles (NFTs) in neurons and with βA4-amyloid plaques in
addition to a sequestration of pSmad2,3 in cytoplasmic granular vesicles is detectable [148].
Additionally a significant reduction of Smad2,3,4, which are involved in activation of cell cycle
proteins was described. Smad4 directly controls cyclin-dependent kinase 4 (CDK4) expression
in neuronal cells and is involved in cell cycle activation of neurons in AD brain [192]. It is quite
possible, that the recently identified TGFβ1-induced antiapoptotic factor (TIAF1), which can
bind and block Smad4-dependent promoter activation [193], participates in the cytoplasmic
Smad sequestration in AD neurons and suppresses Smad-regulated promoter activation.
Environmental stress or TGFβ1, can induce TIAF aggregation, which in turn removes soluble
Smad4, induces apoptosis and activates βA4 generation and its aggregation [193].
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A reason for the intraneuronal dislocation of Smads could be due to the disturbed nucleocy‐
toplasmic transport in hippocampal AD neurons [194,195]. The inner nuclear membrane
comprises integral proteins, e.g. MAN1, which regulate Smad phosphorylation and nuclear
translocation [196], while the outer nuclear membrane is directly continuous with the rough
endoplasmic reticulum. Both membranes are separated by nuclear core complexes, which also
control nucleocytoplasmic shuttling of Smad2 [197]. Altered nuclear membrane integrity [195]
might provoke misrouting of phosphorylated Smads into the associated ER compartment,
indicated by the co-localization of phosphorylated Smad2 granules with a luminal marker
protein of the ER, protein disulphide isomerase [148,198]. ER containing Smad2 could be
secreted and thus explain the extracellular association of pSmad2,3 with amyloid plaques
[148,190]. Alternatively, pSmad2 could interact in early endosomes with βA4-peptides which
are accumulating in the early stages of AD [199], and there also meet BACE, the β-secretase,
generating β-amyloid peptides [200], activated TGFβ receptors type I and II as well as SARA,
a Smad anchor for receptor activation [201-203]. It is also possible, that early endosomes can
fuse to the ER thus allowing a direct route of Smad proteins to the lumen of the ER [204,205].
However, activation of cell cycle is a hallmark of AD and (1) probably supports hyperphos‐
phorylation of tau protein which leads to generation of neurofibrillary tangles and (2) increases
neuronal apoptosis by phosphorylation of retinoblastoma protein and activation of E2F based
apoptotic impacts (for review see [206]. Hyperphosphorylation of tau affects the neuronal
Smad2,3 localization, diminishes its nuclear concentration and thus impedes with transcrip‐
tional Smad functions as shown after βA4 treatment of primary neurons [207]. NFT formation
in AD brain disturbs common intra-neuronal transport mechanisms [208]. This disturbance
could also interfere with retrograde Smad signalling which could be suggested for hippocam‐
pal neurons but so far has only demonstrated for Drosophila motor neurons [173]. Moreover,
we also suggest, that the principle of the two-target-derived signalling integrating neurotro‐
phin (BDNF) and Smad pathway found in rat trigeminal neurons [166,167] might also play a
role for AD progression, because BDNF is deficient in entorhinal cortex and hippocampus in
AD [209,210]. Finally, a disturbed nuclear Smad localization might influence competence of
neurons to express synaptic homeostasis and plasticity, both processes are well investigated
for Drosophila motor neurons.
Pathogenic reduction of neuronal Smads can also support activation of neuronal cell cycle,
resulting in neuronal apoptosis [211] e.g. by repression of cyclin-dependent kinase inhibitors
(CDIs) p15Ink4B, p16Ink4A, or p21Cip, which expression is controlled by TGFβ/Smad signalling
[212-214]. Though the increased levels of TGFβ1 in AD [215,216] does not seem to be able to
compensate for the compromised canonical neuronal Smad pathway [148,190], astrocytes were
shown responsive to this growth factor, which induces amyloid precursor protein (APP)
expression in cooperation with Sp1 [217] and CTCF [218]. Altered APP cleavage by the
concerted action of α-, β- and γ-secretases is a main aspect of AD pathology and results in the
generation of the pathogenetic βA4 peptide 1-42, which is neurotoxic and leads to βA4-amyloid
plaques. Whether βA4 peptide 1-42 can further suppress neuronal TGFβ1/Smad2,3 signalling
by activation of the inhibitory Smad7 in neurons as already shown for human monocytes
cannot be excluded [219].
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Clearance of βA4 peptide was reported by microglia cells [220]. TGFβ released by neurons or
astrocytes stimulates βA4 peptide uptake through Smad3-dependent increased scavenger
receptor SR-A expression and increased phagocytosis [221]. Though the microglial capacity to
remove βA4-plaques is limited [222], peripheral phagocytes, migrating into the brain if their
Smad2,3 signalling is blocked at the expense of Smad1,5,8 phosphorylation, might perform
this task successfully [223].
In other tauopathies, e.g. Pick disease, progressive supranuclear palsy, and corticobasal
degeneration, cytoplasmic phospho-tau bound pSmad2,3 was also identified, though reduced
nuclear pSmad levels were not found [224] suggesting a different impact on Smad signalling
in these diseases compared to AD.
4.2. Parkinson´s disease
Parkinson´s disease (PD) is a progressive neurodegenerative disorder which is characterized
by dopaminergic neurodegeneration in the substantia nigra (SN) pars compacta. The closely
associated loss of dopaminergic inputs into the striatum results in failure of motor programmes
(e.g. voluntary movements) and initiates a striatal plastic change [225,226]. The gradual loss
of dopaminergic neurons is linked to an increase of dopamine turnover [227,228]. α-synuclein
(α-syn) is the major protein component of Lewy bodies, a hallmark of PD. It can aggregate to
form toxic oligomers and fibrillar structures [226,229].
It was shown, that the TGFβ3-Smad-HIPK2 pathway is important for the survival of dopami‐
nergic neurons during development [96,230]. However, recently, a very specific and important
role of Smad3 for the nigrostriatal system was explored in a Smad3 null mouse model
representing an exciting model of PD [231]. These animals show a reduced number of
dopaminergic neurons in the rostral SN, resulting from a postnatal neurodegenerative process.
The selective pro-survival effect of Smad3 for SN dopaminergic neurons was emphasized by
stereological quantifications showing no alterations of the striatal neuronal number. In Smad3
null mice a diminished trophic support provided by Erk1/2 signalling and a reduced astrocytic
support to nigral dopaminergic neurons was detected [231]. Though striatal dopamine levels
were not changed in Smad3 null mice, a strong increase of DA metabolism, including elevated
monoamine-oxidase (MAO) levels were identified, resembling PD findings [232]. Finally,
increased expression and aggregation of α-syn in neurites and cell bodies of several telence‐
phalic, mesencephalic and rombencephalic brain regions and in fibres of the primary and
secondary motor cortex were found [231]. Two possible functional Smad3-based circuits are
suggested. Either Smad3 might directly regulate the α-syn transcription, which further allows
modulating DA metabolism, or the Smad3 deficiency caused elevated DA catabolism gener‐
ates oxidative stress which allow toxic aggregation of α-syn. The data qualify Smad3 as a
possible target for PD therapy. Interestingly, the currently pursued target to re-implant
dopaminergic neurons is also based on modification of Smad signalling during their in vitro
establishment [130,233].
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4.3. Motor neuron diseases
As mentioned above, Smads are essentially controlling the plasticity of NMJ, the intra-axonal
transport and affect axonal repair processes. Accordingly, selective motor neuron diseases
exhibit disturbances of Smad signalling, e.g. spinal muscular atrophy, [234], spinal bulbar
muscular atrophy [235] or amyotrophic lateral sclerosis (ALS).
ALS is a progressive neurodegenerative disease, which targets upper and lower motor
neurons. In the primary motor cortex and the anterior horn of the spinal cord, motor neurons
disappear and the pyramidal tract degenerates [236-238]. The remaining motor neurons exhibit
inclusion bodies e.g. Bunina bodies, hyaline and skein-like inclusions. The pathological
transactive response DNA-binding protein with a molecular weight of 43 kDa (TDP-43) was
shown to be the major disease protein in ALS. Recently, increased nuclear immunoreactivity
for pSmad2,3 in motor neurons was reported from sporadic ALS patients in spinal cord [239].
Motor neurons, where a colocalization of TDP-43 and pSmad2,3 in skeine-like and round
hyaline inclusions was detected [239], show reduced nuclear pSmad2,3 immunoreactivity
[240]. Obviously a disruption of Smad signalling by Smad segregation, comparable to AD or
several tauopathies, enhances the loss of motor neuron function. Smad4 seems actively
involved in the control of motor function as targeted disruption of Smad4 demonstrates [132].
Probably, increased nuclear pSmad2,3 content in the remaining ALS motor neurons indicates
an endogenously initiated approach to a functional improvement. Experiments with an ALS
mouse model support this hypothesis, because TGFβ2 administration ameliorated the motor
performance of the mice [241]. A reduction of TDP-43 containing aggregates by Smad2
overexpression confirms in vitro a protective role of activated Smad signalling in ALS [242].
In summary, initiation and/or progression of many neurological disorders are directly linked
to altered Smad signalling, comprising cytoplasmic Smad aggregation/sequestration, and
nuclear reduction, disruption of transcriptional machinery and stimulating proapoptotic
signalling, therefore disturbing biological processes, which are essential for all phases of
nervous system development and homeostasis.
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1. Introduction
Wnts compromise a large family of secreted glycoproteins that have shown to be part of the
signaling molecules that regulate several aspects of development such as axis formation and
midbrain development [1, 2]. In mammals at least 19 Wnt members have been found. The
interaction of a Wnt protein with members of the Frizzled (Fz) family of seven-pass trans‐
membrane cell-surface receptors triggers the activation of the Wnt signaling pathway [3-5]. In
human and mice, 10 members of the Fz family have been identified. In addition, receptor-like
tyrosine kinase (Ryk) and receptor tyrosine kinase-like orphan receptor (Ror2) have been
identified as alternative Wnt receptors [6-8]. Different Wnt signaling cascades are activated
downstream the Wnt receptors, identified as Wnt/β-catenin or canonical pathway, and β-
catenin-independent or non-canonical pathways. The canonical pathway involves the tran‐
scription of Wnt target genes, while activation of non-canonical Wnt pathways may induce
either an increase in intracellular calcium concentration or activation of the c-Jun-N-terminal
kinase (JNK) cascade [3, 9, 10].
The Wnt pathway participates in the development of the central nervous system (CNS) and
growing evidence indicate that Wnts also regulates the function of the adult nervous system
[11, 12]. In fact, most of the key components including Wnts and Fz receptors are expressed in
the adult brain [13, 14]. Wnt ligands have shown to regulate synaptic assembly as well synaptic
plasticity and neurotransmission [15-20], and more recently it has also been involved in the
adult neurogenesis [21-25].
Deregulation of the Wnt signaling has been associated to several pathologies, been cancer the
most widely documented [26-28]. More recently, altered Wnt signaling have been related to
mental disorders, mood disorders and neurodegenerative diseases [12, 29-32].
© 2013 Inestrosa and Varela-Nallar; licensee InTech. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the first part of this chapter we will address what is currently known about the signaling
cascades of canonical and non-canonical pathways. Then, we will review recent findings
from our and other labs on the specific effects of different Wnt ligands on the structure of
pre-  and  postsynaptic  regions  and  on  glutamatergic  neurotransmission  in  hippocampal
neurons.  The  synaptic  role  of  some  Fz  receptors  will  also  be  reviewed.  Finally,  the
neuroprotective effect of the Wnt signaling activation will be discussed mainly focused on
the protection against the toxicity of Aβ-peptide aggregates associated to the pathogene‐
sis of Alzheimer’s disease.
2. The Wnt signaling pathway: Canonical and non–canonical signaling
cascades
The binding of Wnt ligands to Fz receptors can trigger the activation of different signaling
cascades. In addition to Fz, other proteins have been described as alternative receptors or co-
receptors, such as the low-density lipoprotein receptor-related protein 5 (LRP5), LRP6, Ror1,
Ror2 and Ryk [3, 33-36], increasing the complexity of the Wnt signaling activation. It has been
suggested that the binding of Wnts to specific receptors/co-receptors may selectively activate
distinct signaling pathways.
The  first  Wnt  signaling  pathway  identified  was  the  canonical  Wnt/β-catenin  pathway
(Figure 1). In the absence of Wnt stimulation, the levels of cytoplasmic β-catenin are low
since  it  is  ubiquitinated  and  constantly  degraded  in  the  proteasome  [37].  β-catenin  is
phosphorylated by casein kinase 1α (CK1α) and glycogen synthase kinase-3β (GSK-3β) in
a  multiprotein  complex  composed  also  of  the  scaffold  protein  axin  and  adenomatous
polyposis coli (APC) [38-42]. Phosphorylated β-catenin is recognized by β-TrCP, which is
part of an E3 ubiquitin ligase complex, and is ubiquitinated and subsequently degraded
[43]. Activation of the Wnt/β-catenin pathway initiated by the binding of a Wnt ligand to
a Fz receptor and coreceptors LRP5/6 activates the protein Dishevelled (Dvl)  usually by
phosphorylation, and triggers the recruitment of axin to the phosphorylated tail  of LRP,
inhibiting the degradation pathway consequently inducing the cytoplasmic stabilization of
β-catenin which enters the nucleus and regulates the transcription of Wnt target genes [28].
Recently, it was shown that when the destruction complex is associated with phosphorylat‐
ed LRP, it  may still  capture and phosphorylates β-catenin,  but ubiquitination is blocked
(Figure 1, right panel) [44].
In the nucleus, β-catenin binds to members of the family of T-cell factor (Tcf) and lymphoid
enhancer factor (Lef) [45-47]; this binding displaces Groucho, which is bound to Tcf/Lef and
recruits histone deacetylases (HDAC) to repress the transcription of Wnt target genes [48-51].
Several Wnt target genes have been identified including c-Myc, cyclin D1, Axin2, Calcium/
calmodulin-dependent protein kinase type IV (CamKIV) [52-55]. In addition, by using an in silico
analysis based on multiple Classification and Regression Tree (CART), 89 new genes were
predicted to be targets of the Wnt/β-catenin pathway [56].
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Figure 1. Canonical Wnt/β-catenin signaling pathway. (Left panel) In the absence of a Wnt protein, GSK-3β phos‐
phorylates β-catenin which targets it for ubiquitination by β-TrCP and degradation in the proteasome. (Right panel)
Activation of the signaling pathway by the binding of a Wnt ligand to Fz receptor and coreceptors LRP5/6 triggers the
association of the destruction complex with phosphorylated LRP. In this condition, the complex may still capture and
phosphorylate β-catenin, however the ubiquitination is blocked and it is stabilized in the cytoplasm and enters the
nucleus to regulate the transcription of Wnt target genes.
There  are  at  least  two  β-catenin-independent  pathways:  the  planar  cell  polarity  (PCP)
pathway and the Ca2+  pathway (Figure 2). The PCP pathway was originally identified in
Drosophila  where  it  regulates  tissue  polarity  and  cell  migration  [10,  57].  This  signaling
pathway requires Fz receptors and Dvl and activates small GTPases including Rho and Rac
and the protein kinase JNK. This pathway is also known as the Wnt/JNK pathway. The
activation of  the  Wnt/Ca2+  pathway triggers  the  increase  in  intracellular  Ca2+  levels  and
activates  the  protein  kinases  CamKII  and  protein  kinase  C  (PKC)  [10,  58].  It  has  been
suggested  that  Wnt-mediated  Ca2+  release  involves  heterotrimeric  G  proteins  since  it  is
inhibited by pertussis toxin [59]. As mentioned 10 Fz receptors are known in mammals. Fz
receptors are seven-transmembrane-spanning receptors that belong to the G protein-cou‐
pled receptor (GPCR) list as a separate class [60]. Fz receptors have an extracellular amino-
terminal region that contains a cysteine-rich domain (CRD) consisting of 120 to 125 residues
with 10 conserved cysteines that is relevant for the binding of Wnt proteins [61]. Growing
evidence indicate the involvement of G protein in the Wnt/Fz signaling. The first evidence
came from inhibition of non-canonical Wnt effects by pertussis toxin [62]. Later on, many
reports  have  indicated  that  heterotrimeric  G  protein  participates  of  canonical  and  non-
canonical Wnt signaling in Drosophila, Xenopus and mammals [63-69].
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Figure 2. β-catenin-independent Wnt signaling pathways. In the Wnt/JNK pathway or PCP pathway, a Wnt ligand
through a Fz receptors and Dvl activates small GTPases including Rho and Rac and JNK, which in turns modulate cytos‐
keletal organization. The activation of the Wnt/Ca2+ pathway triggers an increase in intracellular Ca2+ levels which acti‐
vates CamKII and PKC.
3. Roles of the Wnt signaling pathway at central synapses
The Wnt signaling pathway has different roles during development linked to neurite pattern‐
ing and synaptogenesis. Different Wnt ligands have been linked to the presynaptic assembly.
In 1997, Salinas and co-workers demonstrated in cerebellar neurons that Wnt-7a increases the
levels of synapsin I, a protein associated to synaptic vesicles [70]. Moreover, Wnt-7a mutant
mice show a delay in the accumulation of synapsin I [71]. In hippocampal neurons Wnt-7a as
well as Wnt-3a and Wnt-7b increases the number of pre-synaptic puncta suggesting a role for
these ligands in presynaptic assembly [18, 72, 73]. In addition, Wnt-7a was found to stimulate
recycling and endocytosis of synaptic vesicles using FM dyes [74]. In hippocampal neurons,
Wnt-7a was also able to increase the expression as well as the clustering of the α7- nicotinic
acetylcholine receptor (α7-nAChR), indicating that the Wnt signaling regulates the clustering
of presynaptic receptors [75]. Interestingly, all these ligands are able to modulate presynaptic
differentiation by activation of the Wnt/β-catenin signaling pathway, suggesting that some of
the components associated with this pathway may be involved in the presynaptic effect. On
the other hand, the non-canonical ligand Wnt-5a decreases the number of presynaptic
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terminals [72], indicating that canonical and non-canonical signaling pathways may have
promoting and inhibitory effects on presynaptic differentiation respectively. In accordance,
electrophysiological recordings on adult rat hippocampal slices showed that Wnt-7a, but not
Wnt-5a, increased neurotransmitter release in CA3-CA1 synapses by decreasing paired pulse
facilitation and increasing the frequency of miniature excitatory postsynaptic currents
(mEPSC) [73]. Also, Wnt-7a/Dvl1 double mutant mice exhibit decreased mEPSC frequency at
the mossy fiber-granule cell synapse revealing a defect in neurotransmitter release [18].
The Wnt signaling also plays relevant roles in the postsynaptic structure. Wnt-5a, which
activates non-canonical Wnt signaling cascades in hippocampal neurons [19, 76], modulates
postsynaptic assembly by increasing the clustering of the postsynaptic density protein-95
(PSD-95) and increases spine morphogenesis in cultured hippocampal neurons [15, 19]. PSD-95
is a scaffold protein of the postsynaptic density (PSD), which is a multiprotein complex that
interacts with key molecules involved in the regulation of glutamate receptor targeting and
trafficking and regulatory proteins relevant for neurotransmission [77, 78]. In hippocampal
neurons, Wnt-5a induces a fast increase in the number of clusters of PSD-95 without affecting
total levels of PSD-95 protein or presynaptic protein clustering [19]. This postsynaptic effect is
dependent on Wnt/JNK signaling pathway as demonstrated by using JNK inhibitors. In long-
term experiments, we observed that Wnt-5a is also able to increase the total number of synapses
[79]. When hippocampal neurons were incubated with the formylated hexapeptide Foxy-5,
which is derived from the sequence of Wnt-5a and mimics the full Wnt-5a molecule action in
neurons and other systems [19, 80], there was an increase in PSD-95 since 1 hour, but after 24
hours an increase in the synaptic vesicle protein 2 (SV2) clustering was also observed. In
consequence, there was an increase in the total number of synaptic contacts [79].
Also, we determined that Wnt-5a induced a transient formation of dendrite protrusions that
resulted in a net increase of mature dendrite spines. Videomicroscopy revealed that Wnt-5a
induced de novo formation of dendritic spines and also increased the size of the preexisting
ones [15]. Interestingly, treatment with the soluble CRD region of Fz2, acting as a Wnt
scavenger, decreased spine density in cultured neurons, supporting the physiological rele‐
vance of this finding and supporting the implication of Wnt ligands in dendrite spine mor‐
phogenesis. Wnt-7a is also able to increase the density and maturity of dendritic spines through
a CamKII-dependent mechanism [81]. Wnt-7a rapidly activates CaMKII in spines and
inhibition of this kinase abolishes the effects of Wnt-7a on spine growth and excitatory synaptic
strength. This finding implicates the Wnt/Ca2+ signaling cascade in synaptic effects of Wnt
ligands. Interestingly, Wnt-5a and Wnt-7a induces an increase in intracellular Ca2+ concentra‐
tion [15, 81], supporting the activation of this non-canonical Wnt pathway.
In addition to the structural effects of Wnt ligands at the excitatory synapse, different Wnts
have shown modulatory effects on glutamatergic neurotransmission. Wnt-3a modulates the
recycling of synaptic vesicles in hippocampal synapses [73, 82] and is able to induce an increase
in the frequency of mEPSC [20]. In hippocampal slices, blockade of Wnt signaling impairs long-
term potentiation (LTP), whereas activation of Wnt signaling facilitates LTP [17]. In the case
of Wnt-5a, acute application of this ligand in hippocampal slices increases the amplitude of
field excitatory postsynaptic potentials (fEPSP) and upregulates synaptic NMDA receptor
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currents facilitating induction of LTP [15, 16]. Interestingly, Wnt-5a produced a two-step
increase in the amplitude of NMDAR responses [16]. The mechanisms involved in this two-
step effect of Wnt-5a were investigated by the delivery of specific protein kinase inhibitors via
the recording pipette. Specifically, the role of PKC and JNK was investigated, since these are
two known downstream kinases of the non-canonical pathway. Inhibition of Ca22+-dependent
PKC isoforms with Go6976 or the more general PKC inhibitor calphostin C eliminated the first
step of potentiation of NMDAR currents and did not affect the second one. On the contrary,
the slower developing increase in NMDAR currents was blocked by the JNK inhibitors TI-
JIP153-163 and SP600125. This indicate that there are two mechanisms involved in in the
potentiation of NMDAR by Wnt-5a. There is a fast PKC-dependent potentiation and a slower
JNK-dependent potentiation that does not require previous activation of PKC [16].
Wnt-5a also regulates postsynaptically the hippocampal inhibitory synapses [76]. Wnt-5a
induces surface expression and maintenance of GABAA receptor in the membrane of hippo‐
campal neurons, increases the amplitude of GABA-currents due to a postsynaptic mechanisms,
and induces the recycling of functional GABAA receptors through activation of CaMKII [76].
Therefore Wnt-5a is able to modulate both, excitatory and inhibitory synapses which must be
relevant for neurotransmission.
The novel role for Wnt ligands in synaptic transmission provides a mechanism for Wnt
signaling to acutely modulate synaptic plasticity and brain function in later stages of devel‐
opment and in the mature organism. Importantly, neuronal activity modulates the release and
expression of Wnt ligands which may be relevant for the function of these ligands during
neurotransmission. Activation of NMDA receptors increases the expression of Wnt-2 in
hippocampal neurons which then stimulates dendritic arborization [83]. On the other hand,
tetanic stimulation induce NMDA receptor-dependent synaptic Wnt3a release [17]. The role
for endogenous Wnts was supported by incubation of hippocampal slices with secreted Wnt
inhibitors, such as secreted Frizzled-related protein-2 (sFRP-2), which showed that endoge‐
nous Wnt ligands are modulators of glutamatergic neurotransmission being necessary to
maintain basal NMDA receptor synaptic transmission [15, 16].
The in vivo relevance for the role of Wnt signaling in activity-mediated synaptic connectivity
was revealed in mice exposed to an enriched environment (EE). These animals showed
increased complexity and number of large mossy fiber terminals in the CA3 region [84]. EE
increased Wnt7a/b levels in CA3 pyramidal neurons and inhibiting Wnt signaling through
locally applied sFRP-1, suppressed the effects of EE on synapse numbers and further reduced
synapse numbers in control mice.
These findings show that Wnt ligands are important regulators of the synaptic structure during
development and in adult neurons, and that the Wnt pathway is one of the signaling cascades
regulated by neuronal activity that is involved in the regulation of neurotransmission in adult
nervous system.
In addition to the role of Wnts, Fz receptor have also been involved in synaptic structure and
function. In the hippocampus, we have determined that different Fz receptors have very
different patterns of expression during development, being some of them highly expressed in
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adulthood and others during early development [85]. In addition, the distribution of Fzs in
hippocampal neurons is also very specific. Some receptors, are located in the synaptic region,
while others are mainly located in the soma or in the growth cones of young neurons [85].
These findings suggest that these receptors could be important regulators for the specific
activation of the Wnt signaling cascades during the development of hippocampal circuits. In
fact, we determined an association of the distribution with specific functions. In hippocampal
neurons, Fz1 is located in the synaptic region co-localizing with presynaptic proteins and with
active synaptic vesicle recycling sites [82]. Interestingly, overexpression of Fz1 increased the
number of clusters of Bassoon, a component of the active zone involved in the structural
organization of neurotransmitter release sites that is recruited early during synapse formation
[86], suggesting that Fz1 regulates synaptic differentiation. In agreement, treatment with the
extracellular CRD of Fz1 decreased Bassoon clustering which was not observed with the CRD
of Fz2, indicating a receptor specificity for the synaptic effect [82]. Fz5 also has a role in mature
neurons where it modulates the synaptogenic effect of Wnt7a [87]. As well as Fz1, Fz5 is present
in synaptosomes and colocalizes with synaptic markers, and changes in the expression of this
receptor modulates the density of synaptic sites [87]. In addition to its function in mature
neurons, Fz5 was shown to be in high levels in the growth cones of developing hippocampal
neurons [85], and we have recently determined that this receptor is involved in neural
polarization (unpublished results). We determined that overexpression of Fz5 triggers a
mislocalization of axonal proteins such as Tau-1 and phosphorylated MAP1B (MAP1BP),
which change their distribution to the whole cell suggesting altered polarization. When the
expression of Fz5 is knocked-down by shRNA, MAP1BP is not polarized and is almost
completely lost. These findings suggest that in developing hippocampal neurons Fz5 is
relevant for neural polarization. These studies indicate that Fz receptors are relevant players
in both the developing and the adult nervous system and support the notion that the Wnt
signaling pathway is crucial for different aspects of the development and function of the CNS.
4. Role of Wnt signaling in adult neurogenesis
In the adult brain, there are two regions where there is a continuous generation of new neurons
(Figure 3A), the subventricular zone (SVZ) of the lateral ventricles [88] and the subgranular
zone (SGZ) in the hippocampal dentate gyrus [89]. In the SVZ, astrocyte-like neural stem cells
(NSCs), called type B1 cells, generate type C cells that rapidly proliferate and give rise to type
A neuroblasts (Figure 3B). These cells migrate through the rostral migratory stream to the
olfactory bulb where they became interneurons [88] (Figure 3A). In the SGZ, radial and non-
radial neural precursor cells give rise to transient amplifying progenitors that generate
neuroblasts and then became immature neurons that extend dendrites toward the molecular
layer and project their axons through the hilus toward the CA3 region [90] (Figure 3C).
Newborn neurons then mature and fully integrate into the preexisting hippocampal circuitry.
Adult neurogenesis is highly regulated by intrinsic and extrinsic mechanisms. Many signaling
pathways have been identified as regulators of different aspects of neurogenesis. Notch, Shh,
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BMPs, and Wnts are part of the signaling molecules of the niche that regulate the maintenance,
activation and fate specification of neural precursor cells [91, 92].
In Wnt/β-catenin reporter mice (BATGAL) it was shown that this pathway is active in the SGZ
and the dentate granule cell layer [23]. In that study, authors determined that Wnt3 is expressed
in adult hippocampal astrocytes and that adult hippocampal progenitor (AHP) cells express
key components of the Wnt/β-catenin signaling pathway. These findings suggested that the
Wnt pathway may be involved in the regulation of adult neurogenesis. In vitro analysis in
cultured cells revealed that Wnts derived from hippocampal astrocytes stimulate Wnt/β-
catenin signaling in isolated AHPs inducing their neuronal commitment [23]. The effect of the
Wnt signaling was supported in vivo using lentiviral vectors expressing Wnt3a or a secreted
mutant Wnt1 protein that blocks Wnt signaling. Lentiviruses were stereotactically injected into
the dentate gyrus of rats. As assessed by the incorporation of the nucleotide analog BrdU and
immunodetection of the immature neuron protein doublecortin (DCX), blocking the Wnt
signaling decreases adult hippocampal neurogenesis while stimulating this pathway has the
opposite effect [23]. More recently, and by using the same lentiviral approach to block Wnt
signaling in the dentate gyrus of adult rats it was shown that Wnt-mediated adult hippocampal
neurogenesis contributes to learning and memory [93]. In the SVZ, β-catenin signaling also
plays a role in the proliferation of progenitor cells in the adult mouse brain [94]. Retrovirus-
mediated expression of a stabilized β-catenin promoted the proliferation of type C cells and
inhibited their differentiation into neuroblasts. Also in the SVZ, transduction of the β-catenin
inhibitor axin by intracranial lentiviral delivery decreased cell proliferation as revealed by
decreased BrdU labeling [95], further supporting a role for Wnt/β-catenin signaling in neural
stem cell proliferation in the neurogenic areas of adult brain.
The Wnt-mediated effects in neurogenesis may be caused by the transcriptional activation of
NeuroD1 which is dependent on the Wnt/β-catenin signaling activation [25]. NeuroD1 is a
basic helix-loop-helix transcription factor important for the generation of granule cell and
olfactory neuron in the embryonic and adult brain [96]. NeuroD1 gene promoter has overlap‐
ping DNA-binding site for Sox2 and TCF/LEF, then the activation of this gene implies
activation of the canonical Wnt pathway and removal of Sox2 repression from the NeuroD1
gene promoter [25]. More recently, Prox1 was also determined as a target of the Wnt/β-catenin
pathway relevant for neurogenesis [22]. Prox1 is expressed in newborn and mature granule
cells and is required for the proper differentiation and survival of newborn granule cells, but
not for the maintenance of granule cells after they have fully matured [22].
In addition, Wnts could indirectly modulate adult neurogenesis thorough their effects on
neuronal  activity.  As previously described,  different  Wnts regulate glutamatergic  neuro‐
transmission,  and  evidence  indicates  that  neural  progenitor  cells  respond  to  neuronal
activity as part of their differentiation program [97]. GABA is an important modulator of
adult  hippocampal  neurogenesis  being critical  for  the  proper  development  and matura‐
tion of  adult-born neurons [98-100].  Interestingly,  Wnt-5a through activation of  CaMKII,
induces  the  recycling  of  functional  GABAA  receptors  on  hippocampal  neurons  and
modulates inhibitory synapses [76].
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As mentioned, in neurogenic niches Wnts are provided by astrocytes [23], and during aging
it was reported that the levels of Wnt3 protein and the number of Wnt3-secreting astrocytes
declines [101], which may be one of the factors underlying the impairment of neurogenesis
that is observed in aging [102, 103]. On the contrary, running, that is a potent stimulator of
adult neurogenesis in the SGZ [104] was found to significantly increase de novo expression of
Wnt-3 [101], pointing to the Wnt pathway as one of the factors involved in running-mediated
increase in neurogenesis. In addition to astrocytes-derived Wnts, an autocrine Wnt signaling
activity has been observed in adult hippocampal progenitors (AHPs) derived from adult rat
Figure 3. Neurogenesis in the adult brain. (A) Schematic representation of adult rodent brain highlighting the two
neurogenic regions. The hippocampus and the SVZ (boxed). (B) Schematic of the SVZ in the wall of the lateral ventri‐
cles. Distinct stem/progenitor cell types (types B, C, and A) are shown. (C) Neurogenesis in the SGZ of the hippocampal
dentate gyrus. The progression of radial type 1 cells to mature newborn granule neurons is schematized.
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brains. Inhibiting this autocrine Wnt signaling increases the number of neurons formed and
leads to a loss of multipotency among AHPs indicating that this autocrine pathway may
preserve the balance between neural stem cell maintenance and differentiation [105].
The Wnt signaling has also been involved in the mechanism of the orphan nuclear receptor
TLX (also known as NR2E1), which is an important regulator of neural stem cell maintenance
and self-renewal in embryonic and adult brains [106, 107] and is involved in neurogenesis in
the SVZ [108] and hippocampus [109]. To stimulate neural stem cell proliferation and self-
renewal TLX activates the Wnt/β-catenin pathway in adult mouse neural stem cells by
activating the expression of Wnt-7a, which expression was found to be downregulated in TLX-
null mice, through binding to two TLX binding sites present in the Wnt-7a gene promoter [95].
Wnt-7a is important for adult neural stem cell proliferation in vivo since there is a decreased
BrdU labeling in the SGZ and SVZ of adult Wnt7a knockout mice. In TLX-/- mice, intracranial
lentiviral transduction of active β-catenin led to a considerable rescue of cell proliferation in
the SVZ, suggesting that Wnt/β-catenin acts downstream of TLX to regulate neural stem cell
proliferation in vivo [95].
It has been shown that low oxygen is associated with increased levels of β-catenin in vivo, and
that hypoxia inducible factor-1α (HIF-1α) modulates the Wnt/β-catenin signaling in embryonic
stem cells exposed to low oxygen [110]. Recently, we determined in vivo that hypoxia stimulates
the activation of the Wnt/β-catenin signaling pathway in the hippocampus of adult mice (our
unpublished results), and stimulates cell proliferation in the SGZ of 2 month old wild-type
mice.
Altogether, these findings indicate that the Wnt pathway is relevant not only for the develop‐
ment of the nervous system but also for the development of new neurons in the adult brain,
being important for the maintenance and self-renewal of the stem cell pool and for the
commitment and proliferation of new neurons.
5. Wnt signaling in Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive
deterioration of cognitive abilities, cerebral accumulation of extracellular amyloid plaques
composed mainly of amyloid-β peptide (Aβ), and synaptic alterations [111]. In addition to the
accumulation of Aβ aggregates, which is a product of the processing of the amyloid precursor
protein (APP), cytoskeletal alterations associated to the abnormal phosphorylation of the
microtubule associated protein tau [112, 113] are early manifestations that lead to aberrant
remodeling of dendrites and axons, the appearance of dystrophic neurites, synaptic loss [114],
and eventually progressive loss of neuronal populations [112].
During more than a decade, a strong relationship between an impaired Wnt signaling pathway
activity and neuronal damage in AD has been raised [31, 115-118]. Different studies have
shown that Wnt signaling components are altered in AD [119-124], and in addition, the Wnt
signaling pathway has been related to other neurodegenerative disorders such as autism and
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schizophrenia [30, 125]. Among the Wnt components that are affected in AD, it was shown
that β-catenin levels are reduced in AD patients carrying presenilin-1 (PS-1)-inherited
mutations [124], while the secreted Wnt antagonist Dickkopf-1 (Dkk1) is elevated in postmor‐
tem AD brains and brains from transgenic mouse models for AD [121, 126]. A variant of the
LRP6 has been associated with late-onset AD, which confers low levels of Wnt signaling [119].
In addition, genetic studies show a link between Wnt signaling and AD. Epidemiological data
show an increased risk for AD in populations where the allele 4 of apo-lipoprotein E (apoE4)
is present. Interestingly apoE4 causes inhibition of the canonical Wnt signaling in PC12 cells
upon stimulation with Wnt-7a as determined by luciferase activities and nuclear β-catenin
levels [127]. Aβ directly binds to the extracellular CRD of Fz5 at or in close proximity to the
Wnt-binding site inhibiting the canonical Wnt signaling pathway [128], linking directly Aβ to
Wnt impairment. Moreover, the exposure of cultured rat hippocampal neurons to Aβ results
in inhibition of canonical Wnt signaling as determined by destabilization of endogenous levels
of β-catenin, increase in GSK-3β activity, and a decrease in the expression of some Wnt target
genes [129]. Moreover, acute exposure to Aβ increases Dkk1 mRNA levels in hippocampal
brain slices, which seems to be associated to synaptic loss induced by Aβ [130].
As mentioned, one of the hallmarks of AD brains is the abnormal phosphorylation of the tau
protein which accumulates as intraneuronal neurofibrillary tangles [131]. Several kinases can
phosphorylate tau in vitro; however, the bulk of the information supports that Cdk5, extrac‐
ellular signal-related kinase 2, microtubule affinity-regulating kinase and GSK-3β, a key
component of the Wnt cascade, are the most relevant kinases for tau phosphorylation in vivo
[132, 133]. Cultured neurons exposed to Aβ show an increased GSK-3β activity [134, 135], and
active GSK-3β has been found in brains staged for AD neurofibrillary changes, with a con‐
comitant decrease in β-catenin levels and an increase in tau hyperphosphorylation [136]. Also,
neurodegeneration and spatial learning deficits have been observed in GSK-3β conditional
transgenic mice [137, 138]. Interestingly, a study shows that the phosphorylation of tau
antagonizes apoptosis by stabilizing β-catenin; therefore, up-regulation of β-catenin during
tau phosphorylation prevents the cell from going into apoptosis. Increasing levels of phos‐
phorylated tau was correlated with increased levels of nuclear β-catenin, and the knockdown
of β-catenin antagonizes the anti-apoptotic effects of tau [139]. These findings support a role
of β-catenin as a survival element in AD.
Several studies have shown neuroprotective properties of the Wnt signaling activation against
the toxicity of Aβ peptide. In cultured hippocampal neurons, exposure to Aβ aggregates causes
a decrease in endogenous β-catenin levels, and this effect was overcome by direct activation
of the pathway with Wnt-3a conditioned media [117, 129]. The protective effect of Wnt-3a
against the toxicity of Aβ oligomers was shown to be mediated by Fz1 receptor, since this effect
is modulated by the expression levels of Fz1 in both, PC12 cells and hippocampal neurons [14].
Overexpression of Fz1 significantly increased cell survival induced by Wnt-3a and diminished
caspase-3 activation, while knocking-down the expression of the receptor by antisense
oligonucleotides decreased the stabilization of β-catenin induced by Wnt-3a and decreased the
neuroprotive effect elicited by this Wnt ligand [14].
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In agreement with the effect of Wnt-3a, inhibition of GSK-3β by lithium protects hippocampal
neurons from Aβ-induced damage. More importantly, in vivo lithium treatment of double
transgenic APPswe/PSEN1ΔE9 mice, which is a well characterized in vivo model of AD that
shows most hallmarks of the disease [140], reduced spatial memory impairment, decreased
Aβ oligomers and the activation of astrocytes and microglia [141]. In vivo, lithium treatment
activated the Wnt signaling as shown by the increase in β-catenin and by the inhibition of
GSK-3β [141]. These studies suggest that the loss of normal Wnt/β-catenin signaling activity
may be involved in the Aβ-dependent neurodegeneration observed in AD and that the
activation of the pathway might have beneficial effects for the treatment of the disease [12].
APPswe/PSEN1ΔE9 mice show decreased levels of adult neurogenesis [142]. In these mice, we
evaluated the effect of hypoxia on the generation of new neurons in the hippocampus. As
previously mentioned hypoxia induces the activation of the Wnt/β-catenin signaling pathway
in the hippocampus of wild-type mice. Mice were exposed to low oxygen and neurogenesis
was evaluated by incorporation of BrdU and double staining with DCX. It was determined
that hypoxia is a strong stimulator of neurogenesis in AD mice (our unpublished results).
Currently we are evaluating whether this effect is related to the activation of the canonical Wnt
pathway. Also, we have observed that voluntary wheel running strongly increased neuro‐
genesis in APPswe/PSEN1ΔE9 mice and also decreased Aβ burden and tau phosphorylation
(our unpublished results). As previously mentioned, voluntary running was found to increase
de novo expression of Wnt-3 [101], suggesting that the effects observed in runner AD mice could
involve the activation of the Wnt signaling pathway.
In addition to the role of the canonical Wnt signaling, we have studied whether Wnt-5a is able
to protect neurons against Aβ oligomers synaptotoxicity [143]. Synaptic failure is an early event
in AD, and soluble Aβ oligomers are proposed to be responsible for the synaptic pathology
that occurs before the plaque deposition and neuronal death [74, 144]. Electrophysiological
analysis of Schaffer collaterals-CA1 glutamatergic transmission in hippocampal slices dem‐
onstrated that Wnt-5a prevents the decrease in the amplitude of fEPSP and EPSCs induced by
Aβ oligomers, indicating that Wnt-5a prevents the synaptic damage triggered by Aβ [143].
Moreover, Wnt-5a prevented the decrease in the postsynaptic density scaffold protein PSD-95
and synaptic loss in cultured hippocampal neurons [143], supporting that Wnt-5a improves
synaptic function in the presence of Aβ.
Additionally, the activation of several signaling pathways that crosstalk with the Wnt pathway
also supports the neuroprotective potential of the Wnt cascades in AD [12].
6. Conclusions
As we have discussed throughout this Chapter, the Wnt signaling pathway has fundamental
roles in the development and function of the CNS. As discussed, the canonical and non-
canonical Wnt signaling cascades have shown to be important for the formation and structure
of central synapses, and in addition to the structural effects, Wnt ligands acutely modulate
synaptic transmission and plasticity. Also, in the adult brain the Wnt pathway is one of the
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signaling cascades that regulates the generation of new neurons in neurogenic niches.
Importantly, different stimuli that regulate neurogenesis involve the regulation of the Wnt
signaling, implicating this pathway as a relevant player in the modulation of this physiological
process.
Considering all the discussed roles of Wnts, it was expected that alterations in the Wnt cascades
leads to diseases associated to the nervous system. In fact, deregulation of the Wnt pathway
has been related to mental disorders, mood disorders and neurodegenerative diseases. As we
have discussed, a bulk of evidence associate Wnt dysfunction to AD, and strongly point to a
neuroprotective potential of the Wnt cascades as a therapeutic approach. Future work should
focus on explore the therapeutic benefits of stimulating the Wnt signaling pathway in vivo.
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1. Introduction
Parkinson’s disease (PD) is a severe deliberating neurodegenerative disease resulting from
progressive and massive cell death of dopaminergic (DA) neurons in the substantia nigra
[1]. While cell therapy strategy is strongly suggested for clinical cure of PD and DA progeni‐
tors are identified at different developing stages of midbrain, full understanding of key cell
signaling or mechanism in controlling of DA neuronal differentiation from neural stem cells
in vivo raises a great interest in cell therapeutic application for PD [2, 3]. A growing line of
studies has shown that Wnts are lipid-modified factor for stem cell growth and cell differen‐
tiation and regulate midbrain DA neuronal development and hippocampal neurogenesis
through both canonical and non-canonical Wnt signaling pathways [4-7]. The canonical
Wnt/β-catenin signaling appeals a key mechanism in controlling DA neuronal fate decision
from neural stem cells or progenitors in the ventral midbrain during embryonic develop‐
ment and adulthood [8]. This chapter has focused on fast growing knowledge on Wnt/β-cat‐
enin signaling pathway, intracellular cascade or crosstalk, functional roles in controlling DA
neuronal fate decision and neural repair under physiological development and pathological
events, and potential manipulation of Wnt/β-catenin signaling pathway as cell therapeutic
target for treatment of PD in human beings.
2. The Wnt/β-catenin signaling pathway
The Wnt signaling pathway, conserved from low animals to primates, was originally identi‐
fied as the morphogenic signaling for organogenesis. Among three branches of Wnt signal‐
© 2013 Chen; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
ing pathways, the best studied one is the canonical Wnt pathway, which is highlighted by β-
catenin-dependent regulation of down-streaming genes. The canonical Wnt ligands, e.g.
Wnt1, Wnt2 and Wnt3a, can be secreted by surrounding neuronal and glial cells in the nerv‐
ous system, bind to Frizzled and Lrp5/6 receptors in the target cells. At absence of binding
with ligand Wnts, a protein complex in the cytoplasm, namely Axin2/GSK3β/APC complex
makes phosphorylation of β-catenin and degradation of phosphorylated β-catenin, and
keeps cytoplasmic β-catenin at such a low level that β-catenin can not be translocated into
nucleus. Upon Wnt stimulation, the Axin2/GSK3β/APC complex can be deaggregated, the
cytoplasmic β-catenin is accumulated and increased β-catenin imported into nucleus. In the
nucleus, β-catenin is recruited by transcription factors TCF1-4 to the promoter regions of the
target genes for specific biological effects. These TCF-4 downstream targeting genes include
c-myc, mmp-7, cyclin D1, CD44 that are actively and mainly involved in cell proliferation,
cycling and cell differentiation (Figure 1). On the other hand, the non-canonical Wnt signal‐
ing pathways, i.e. PCP pathway and Ca2+ pathway, Wnt ligands bind to Frizzled receptors,
then activate GTPase or increase intracellular Ca2+, transmitting signals by JNK cascade or
without any nucleus events [4-6].
Figure 1. The canonical Wnt/β-catenin signaling pathway in regulation of downstream target genes of DA neurogen‐
esis (From Ref. 48, Ding, et al., 2011)
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3. Role of Wnt/β-catenin signaling in facilitating DA neuronal
development
The canonical Wnt/β-catenin signaling pathways is critical for generation of DA neurons during
development. Differential regulation of midbrain DA neurogenesis by Wnt1, Wnt3a, and Wnt5a
was well studied [9]. The β-catenin was detected in DA precursor cells and β-catenin signaling
took place in the precursor cells by assessment of TOPgal reporter mice. Wnt3a promoted prolif‐
eration of precursor cells expressing the orphan nuclear receptor-related factor 1 (Nurr1) but did
not increase the number of DA neurons. The Wnt1 and Wnt5a increased the number of midbrain
DA neurons in E14.5 possibly by two mechanisms. Wnt1 predominantly increased the prolifera‐
tion of Nurr1+ precursors that acquired a neuronal DA phenotype, up-regulated cyclins D1 and
D3, and down-regulated p27 and p57 expression. In contrast, Wnt5a increased proportion of
Nurr1+ precursors and up-regulated expression of Ptx3 and c-ret mRNA. Moreover, the soluble
cysteine-rich domain of Frizzled-8 (a Wnt inhibitor) blocked endogenous Wnts and effects of
Wnt1 and Wnt5a on proliferation and acquisition of DA phenotype. For the embryonic expres‐
sion, Wnt1 was throughout of midbrain at E8.5, and then restricted to the roof plate, a subset of
floor plate cells and isthemus of midbrain at E9.5. From E10 to E12, Wnt2 was observed in the ven‐
tral midbrain, with highest in the intermediate and marginal zone of ventral midbrain. Wnt3a
was expressed in dorsal midbrain of rat at E11.5. The Wnt5a appeared at E9.5 and became restrict‐
ed to the floor plate of midbrain from E11.5 to E13.5. Functionally, mutation of Wnt1 led to re‐
duced DA neurons in late embryos. Mechanistic study showed that Wnt1 and its downstream
gene Lmx1 formed a loop to regulate the expression of Octx2, Nurr1 and Pitx3, thereby establish‐
ing identity of DA precursors in vivo [10]. This Wnt1-lmx1a regulatory loop synergistically con‐
trolled DA differentiation in the midbrain by antagonizing Shh signaling pathway [11]. Wnt 2
mutation resulted in a decrease in proliferation of DA progenitors and subsequently loss of DA
neurons, partially by phosphorylation of Lrp5/6 and Dishevelled 2/3. Wnt 3a promoted the pro‐
liferation of Nurr1-positive DA progenitors. The Wnt5a, derived by the astrocytes and radial
glial cells, was demonstrated to promote cell fate commitment of precursors into DA neurons
and development of A9-A10 DA neurons in vivo [12, 13]. The Wnt5a also regulated DA axon
growth and guidance in midbrain development [14]. In mouse embryo at E11.5, Wnt5a was
abundantly expressed in the ventral midbrain where it promoted DA neurite and axonal growth.
By E14.5, when DA axons were approaching their striatal target, Wnt5a caused DA neurite re‐
traction. Co-culture of ventral midbrain explants with Wnt5a-overexpressing cell aggregates re‐
vealed that Wnt5a was capable of repelling DA neurites. Antagonism experiments revealed that
the effects of Wnt5a were mediated by the Frizzled receptors and by small GTPase, Rac1. More‐
over, this effect was specifically blocked by Wnt5a antibody. Role of Wnt5a in DA neuronal axon
morphogenesis was further verified in Wnt5a-/-mice, where fasciculation of the medial fore‐
brain bundle as well as the density of DA neurites and striatal terminals were disrupted. Al‐
though Wnts can function via intracellularβ-catenin, Ca2+, and JNK signaling, the canonical
Wnt/β-catenin signaling pathway shows a major position in regulation of DA neurogenesis. It
appeared that all Wnt1, Wnt3a and Wnt5a act in proliferation and DA differentiation of precur‐
sor cells with sequence of proliferation stimulating effect of Wnt1≥Wnt3a≥Wnt5a, or differentia‐
tion facilitating effects of Wnt5a≥Wnt1≥Wnt3a. These findings have evidenced that the Wnt/β-
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catenin signaling is a key regulator of proliferation and differentiation of DA precursors and
different Wnts might have specific and unique activity profiles during DA neurogenesis.
Dynamic temporal and cell type-specific expression of Wnt signaling components was
found in the developing midbrain [15]. The DA neuronal cluster size was determined dur‐
ing early forebrain patterning [16]. Furthermore, temporally controlling modulation of
FGF/ERK signaling directed midbrain DA neural progenitor fate in mouse and human pluri‐
potent stem cells [17]. Dickkopf-1 (Dkk1), a specific Wnt signaling inhibitor, regulated ven‐
tral midbrain DA neuronal differentiation and morphogenesis [18]. Blockade of Wnt/β-
catenin signaling pathway promoted neuronal induction and DA-phenotype differentiation
in embryonic stem cells [19]. Delayed DA neuron differentiation was seen in the Lrp6 mu‐
tant mice [20]. Signaling interactions between Wnt/β-catenin and sonic hedgehog (Shh)
mechanisms functioned to regulate the production of DA neurons. Specific deletion of intra‐
cellular β-catenin in Shh expressing cells resulted in diminished DA progenitors, NgN2,
BrdU labeling cells, and subsequently DA neurons. Permanent stabilization of β-catenin in
Shh expressing cells led to more DA progenitors and DA neurons accordingly, and inhibi‐
tion of GSK-3β also increases the differentiation of DA precursors [21]. HPRT deficiency co‐
ordinately dysregulated canonical Wnt signaling in neuro-developmental regulatory
process [22]. Wnts showed antagonism of Shh signaling pathway and facilitated neurogene‐
sis in the midbrain floor plate [23]. The β-arrestin was also a necessary component of Wnt/
beta-catenin signaling linking Dvl and axin in vitro and in vivo functions [24]. Wnt5a induced
the DA differentiation of midbrain neural stem cells in vitro, and the effect was mediated by
the phosphorylation of Dishevelled protein and activation of GTPase RAC1. Wnt5A stimu‐
lated the GDP/GTP exchange at pertussis toxin-sensitive heterotrimeric G proteins [25]. As
to Wnt receptors, mutation of Lrp6 might not affect the patterning; proliferation and cell
death in the ventral midbrain, but displayed a delay in the onset of DA precursor differen‐
tiation. Lrp6(-/-) mice exhibited 50% reduction in DA neurons and expression of DA mark‐
ers such as Nurr1 and Pitx3 as well as a defect in midbrain morphogenesis in the mutant
embryos at E11.5. The extracellular domain of Lrp5/6 inhibited the non-canonical Wnt sig‐
naling in vivo condition [26]. The mitogen-activated protein kinases promoted Wnt/β-catenin
signaling via phosphorylation of LRP6 [27]. Ectopic Wnt/β-catenin signaling was also in‐
volved in induction of neurogenesis in spinal cord [28]. In addition, Wnt5a was required for
the endothelial differentiation of embryonic stem cells and vascularization via both Wnt/β-
catenin signaling and protein kinase C pathways [29].
4. Role of Wnt/β-catenin signaling in DA neural plasticity or repair in
adulthood
The Wnt/β-catenin signaling pathway also actively functions in neural plasticity and repair
of DA neurons in the midbrain of disease conditions Interestingly, the crosstalk between
Wnt/β-catenin signaling and inflammatory was observed in plasticity of subventricular zone
progenitors in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of
PD, suggesting its involvement in consequences for neuroprotection and functional repair
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[30]. Accumulating evidence indicated that a population of astrocyte was functionally acti‐
vated, named reactive astrocytes with active proliferation, morphological expanding of cell
bodies and increasing generation of various neurotrophic factors, and with predominate dis‐
tribution in the nigra and striatum of PD condition. These reactive astrocytes and Wnt/β-cat‐
enin signaling showed a link of nigrostriatal injury to repair in MPTP model of PD. The Wnt
signaling components Frizzled-1 and β-catenin were dynamically regulated in response to
MPTP insult-induced DA neuronal degeneration and reactive glial activation. Activated or
reactive astrocytes in the ventral midbrain were identified as candidate source of Wnt1.
Blocking Wnt/Fzd signaling with Dkk1 also counteracted astrocyte-induced neuroprotection
against MPP (+) toxicity in primary mesencephalic astrocyte-neuron cultures. Moreover, as‐
trocyte-derived Wnt1 promoted DA neurogenesis from adult midbrain stem cells or progen‐
itor cells. Conversely, lack of Wnt1 transcription in response to MPTP in aged animals and
failure of DA neurons to recover could be reversed by activation of Wnt/β-catenin signaling
in vivo, suggesting MPTP-reactive astrocytes and Wnt1 worked as neuroprotective activity
in DA neural plasticity [31]. Obviously, Wnt1 regulated Frizzled-1/β-catenin signaling path‐
way as a candidate regulatory circuit for DA neuron-astrocyte crosstalk in the ventral mid‐
brain, also implying that Wnt signals might act as the critical messages in neuron-glial
intercommunication in the adult mammalian nervous system [32].
Moreover, The Wnt/β-catenin signaling also involved in Parkin protection of DA neurons [33].
Differential expression of Wnts was observed after spinal cord contusion injury in adult ro‐
dents [34]. Wnt signaling in the activated microglia; cells exhibited proinflammatory effect.
Gene-expression profiling revealed that Wnt3A specifically increased expression of proinflam‐
matory immune response genes in microglia and exacerbated release of IL-6, IL-12, and tumor
necrosis factor α [35]. Heterotrimeric G protein-dependent Wnt5A signaling to ERK1/2 mediat‐
ed distinct aspects of proinflammatory transformation in microglial cells [36]. While combin‐
ing  nitric  oxide  release  with  anti-inflammatory  activity  preserved  DA  innervation  and
prevented motor impairment in the MPTP model of PD [37], switching the microglial harmful
phenotype promoted lifelong restoration of DA neurons from inflammatory degeneration in
the substantia nigra of aged mice [38]. In addition, activation or inhibition of Wnt/β-catenin sig‐
naling could regulate neuronal and glial differentiation in neurospheres, respectively. Inhibi‐
tion of Wnt signaling promoted gliogenesis from neural stem cells. Long-term activation of
Wnt signaling pathway by Wnt-7a or GSK3 inhibitors promoted a moderate increase of neuro‐
nal differentiation and blocked gliogenesis. In contrast, Wnt pathway inhibition by Dkk1over-
expression robustly increased gliogenesis [39]. Accumulating evidences suggested that the
glial cells including reactive astrocytes and microglial cells might present as crucial turning
points for the therapeutic strategy against PD [40, 41]
5. Prospect on manipulation of Wnt/β-catenin signaling for regeneration
medicine
The studies have indicated that transplantation of Wnt primed neural stem cells might result
in improvements of cellular and functional recovery in PD condition. The midbrain neural
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stem cells with Wnt5a-treatment showed beneficial effect for DA cell replacement therapy in
parkinsonian animal model [42], and purified Wnt5a increased dishevelled phosphorylation
and DA neuronal differentiation in the midbrain [43]. Both GSK-3β inhibition and β-catenin
stabilization increased commitment into DA neurons of neural precursors in the ventral
midbrain [44], and the application of GSK-3β inhibitor lithium also influenced DA differen‐
tiation potential of human NT2 cells [45]. Generation of DA phenotype in neural stem cells
could be carried out by engineering Nurr1 and Wnt signals [46]. Wnts also showed regulat‐
ing role on differentiation of noradrenergic neuronal precursors in locus coeruleus [47]. In
addition, the functional involvement of Wnt/β-catenin signaling pathway in link of reactive
astrocytes and plasticity or repair of nigrostriatal system further suggests Wnt/β-catenin sig‐
naling as neuroprotection therapeutic targets [30, 31]. It is hopefully that DA differentiation
of the neural stem cells and the nigrostriatal plasticity may be effectively and specifically en‐
hanced or improved by manipulation targeting on Wnt/β-catenin signaling pathway [48].
6. Summary
Although the DA neuronal cell commitment from neural stem cells or progenitor cells is
highly complicated and precisely regulated process, the canonical Wnt/β-catenin pathway
shows a critical role in controlling differentiation of DA neurons in the ventral midbrain
during development and plasticity or neural repair in adulthood. In addition, Wnt singling
might also act via Ca2+, JNK signaling and function candidate messages in DA neuron-glial
cross-talk as well. Taken together, it is hopefully expected that molecular target manipula‐
tion of Wnt/β-catenin signaling cascades will benefit controlling of DA neurogenesis and es‐
tablishing novel cell therapy for PD in human beings.
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1. Introduction
The human brain is the most complex object in the known universe. It contains ~100 billion
neurons, each forming between 1,000 and 10,000 connections with other neurons to form
interconnecting circuits containing up to 1,000 trillion connections. This extreme complexity
arises from a single cell at conception. Therefore, brain development needs to be tightly
controlled to ensure proper patterning and circuit formation. Defects in this process lead to
debilitating neurodevelopmental disorders, including autism and microcephaly. Until
recently, it was assumed that once an adult brain had matured, it was ‘fixed’ or ‘hard-wired’
and no new neurons were generated. However, research over the last 15-20 years has dem‐
onstrated the existence of neural precursor cells (NPC’s) that produce and incorporate new
neurons into existing circuits of the adult brain, a process known as neurogenesis [1]. Adult
neurogenesis is similar in organisation and mechanism to early brain development [2]. The
ability to control neurogenesis could enable the brain to repair itself following injury (e.g.
stroke, spinal chord injury, head trauma) and to enhance mental functioning (e.g. delay or
prevent age-related cognitive decline and neurodegenerative diseases). Therefore, there is a
clear and urgent need to understand the mechanisms controlling neurogenesis in the devel‐
oping and adult brain.
NPC’s give rise to all cell types in the brain by undergoing asymmetric cell division, generating
one daughter cell that retains pluripotency and another daughter cell that is committed to a
neuronal or glial fate. In adults, this predominantly occurs in the dentate gyrus of the hippo‐
campus and the subventricular zone/olfactory system. Thousands of new cells are generated
every day in the hippocampus, although less than half survive beyond a few weeks to
permanently integrate into adult brain circuits [3]. This process is an important component of
neuroplasticity in the hippocampus, facilitating learning and memory. Other brain regions are
thought to have limited neurogenic potential that might be induced following injury. The fate
of NPC’s is controlled by extracellular stimuli (e.g. growth factors, Wnt, Notch, Hedgehog)
© 2013 Cole; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
that trigger intracellular signalling pathways and changes in gene transcription, although the
transcriptional regulators targeted by these signalling pathways and their target genes are yet
to be fully clarified.
2. GSK3 and neurogenesis
In 1980, Hammond and Dale noticed that lithium treatment of grey collie dogs increased their
blood cell counts, which they suggested was due to increased proliferation of haematopoetic
stem cells [4]. This was confirmed shortly afterwards [5], although the mechanism for lithium’s
action was not understood. In 1996, GSK3 was identified as a key target of lithium in cells [6],
although it was another 8 years before a key role for GSK3 in regulating stem cell pluripotency
was elucidated [7, 8]. Pharmacological inhibition of GSK3 activity was shown to maintain the
undifferentiated phenotype in mouse and human embryonic stem (ES) cells, while its with‐
drawal promoted differentiation into multiple cell lineages [7]. More recently, it was demon‐
strated that the complex mixture of cytokines, growth factors, hormones, serum and feeder
cells traditionally used to maintain self-renewal of ES cells can be replaced with two pharma‐
cological inhibitors; a MAPK inhibitor and a GSK3 inhibitor [8], thus emphasizing the
importance of GSK3 for regulating pluripotency. The GSK3 substrates c-myc [9] and Klf5 [10]
are among several transcription factors that have been used to induce pluripotency (iPS
system). Thus, GSK3 is a key regulator of neurogenesis, although the precise molecular
mechanisms are not yet fully understood. This review provides an overview of the extracel‐
lular stimuli and intracellular signalling pathways controlling GSK3 activity, as well as the
downstream targets of GSK3 directly linking it to cellular proliferation and differentiation in
the brain. GSK3 inhibitors are currently in clinical trials for several neurological disorders
associated with impaired neurogenesis, therefore it is timely that cell fate pathways involving
GSK3 are delineated.
3. GSK3
GSK3 is a Ser/Thr kinase of the CMGC family of proline-directed kinases that is highly
conserved in all eukaryotes. In mammals, it is ubiquitously expressed in all tissues and
subcellular organelles, most highly in the brain [11]. There are 2 isoforms encoded by separate
genes (chromosome 19q13.2 for GSK3α and chromosome 3q13.3 for GSK3β) [11]. Their kinase
domains are 98% homologous and their substrate specificities are similar, but not identical [12].
A splice variant of GSK3β containing a 13 amino acid insert in the catalytic domain is specif‐
ically expressed in the brain [13], although its function is only just beginning to be investigated
[12]. Interestingly, GSK3 is one of the most unusual kinases in the human genome for 3 main
reasons; 1) Most (if not all) substrates require ‘priming’ phosphorylation 4 or 5 residues C-
terminal to the GSK3 target site by another kinase before they can be efficiently phosphorylated
by GSK3 [14]. 2) GSK3 is highly active in cells under basal conditions, opposite to most other
kinases. 3) Phosphorylation of GSK3 at an N-terminal serine residue inhibits its kinase activity
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(Ser21 in GSK3α, Ser9 in GSK3β) [15, 16]. This phosphoserine acts as a pseudo-substrate and
binds to the phosphate-binding pocket on GSK3, preventing interaction with primed sub‐
strates [17]. Phosphorylation is mediated by members of the AGC family of kinases (e.g. Akt)
and commonly occurs downstream of growth factor and PI3K signaling [15]. Activation of the
canonical Wnt signaling pathway also inhibits GSK3 activity, preventing phosphorylation of
β-catenin, although this is not mediated by N-terminal phosphorylation, but by protein-
protein interactions [18, 19]. GSK3 is also modified by phosphorylation at a tyrosine residue
on the activation loop of the kinase domain (Tyr279 for GSK3α and Tyr216 for GSK3β).
Phosphorylation at these sites is absolutely required for kinase activity and is most likely
constitutively modified (i.e. not regulatable) [20, 21].
4. Neurogenesis in GSK3 mutant mice
Valuable information on the role of GSK3 in cell fate determination has been obtained from
mice genetically modified to either increase or decrease expression of GSK3α and β. While
GSK3β-knockout mice die in late development due to defects in heart development and/or
hepatic apoptosis [22, 23], GSK3β-heterozygous mice and GSK3α-knockout (homozygous)
mice are viable and display several behavioural defects, including increased anxiety, decreased
aggression and memory defects [24-28]. Also, GSK3α-null mice exhibit decreased numbers
and size of Purkinje cells in the cerebellum [24]. Conditional overexpression of GSK3β in the
forebrain using the doxycycline/Tet system impaired memory and spatial learning in mice [29].
At the cellular level, GSK3β overexpression increased neuronal cell death, astrocytosis, gliosis
and reduced LTP induction. These effects could be restored by reducing GSK3 activity to
normal levels by silencing the transgene or by treatment with lithium [30, 31]. In another report,
overexpression of GSK3β-S9A in post-natal neurons (Thy-1 promoter) reduced brain size in
adult mice, especially in the cerebral cortex, predominantly caused by reduced size of neuronal
cell bodies and the somatodendritic compartment [32]. Together, these observations clearly
demonstrate that GSK3 is important for healthy development and function of the brain.
In addition to conventional under/over-expression mouse models, GSK3-knockin mice were
developed that are insensitive to growth factor inhibition (Ser21/9 mutated to Ala in GSK3α
and β, respectively), but remain sensitive to Wnt-induced inhibition [33]. These mice are viable
and display no overt developmental or growth defects, but do exhibit increased susceptibility
to hyperactivity, stress-induced depression and mild anxiety, as well as abnormal LTP and
memory functions [34, 35]. NPC’s isolated from GSK3-knockin mice exhibit reduced neuro‐
genesis, despite normal proliferation [36], suggesting defective differentiation/maturation or
survival of NPC’s. In contrast, mice with double homozygous deletion of GSK3α and β
isoforms (i.e. all GSK3 isoforms deleted) display a dramatic increase in proliferation of NPC’s
and decreased differentiation into post-mitotic neurons [37]. This is accompanied by deregu‐
lation of Wnt, Notch, Hedgehog and FGF signalling pathways. In another mouse model, mice
expressing a mutant form of the scaffolding protein Disrupted in Schizophrenia (DISC1),
which is mutated in schizophrenia and mood disorder patients, display increased GSK3
activity, causing inhibition of the Wnt signaling pathway and decreased NPC proliferation
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[38]. Together, these observations suggest that inhibition of GSK3 by the Wnt signalling
pathway promotes NPC proliferation, while inhibition of GSK3 by growth factor signalling
promotes differentiation of NPC’s into post-mitotic neurons.
5. GSK3 and Wnt signaling
Wnt signaling is amongst the most important signaling pathways controlling neurogenesis in
the developing and adult brain. Several studies have shown that attenuation of this pathway
reduces the number of granule neurons and size of the hippocampus, as well as a reduction
in the number of radial glial cells due to proliferation and patterning defects [39-41]. It is well
accepted that Wnt’s help to maintain the proliferative capacity of ES cells and keep them in an
undifferentiated state [7], however there is also evidence for Wnt’s being required to promote
neural differentiation [42, 43]. These seemingly contradictory views are united in a model
whereby Wnt signaling promotes proliferation and inhibits differentiation of pluripotent cells.
Inhibition of this pathway promotes initial stages of differentiation into neural progenitors,
but reactivation of Wnt signaling is required at later stages of the differentiation program to
generate mature neurons [44, 45]. Indeed, in adult neurogenesis in the dentate gyrus of the
hippocampus, Wnt’s are secreted by local astrocytes where they predominantly regulate
differentiation into mature neurons (mostly inhibitory GABAergic interneurons), rather than
proliferation of NPC’s [46-48].
GSK3 is a key component of the Wnt signaling pathway. In unstimulated cells, GSK3 is part
of a multi-protein complex with APC, Axin and other proteins that facilitates phosphorylation
of β-catenin by CK1 at Ser45, followed by phosphorylation of Ser33/37/41 by GSK3. This creates
a recognition site for the E3 ubiquitin ligase βTrCP, which ubiquitinates β-catenin and targets
it for degradation via the proteasome. In Wnt-stimulated cells, this multi-protein complex is
disrupted, preventing phosphorylation and subsequent ubiquination of β-catenin, thus
stabilizing the protein and increasing its cellular abundance. This leads to translocation to the
nucleus, where β-catenin binds to several transcription factors facilitating transcription of
target genes involved in cell fate regulation, including c-myc [49], NeuroD1 [48, 50, 51], Prox1
[52] and LINE-1 [50]. In adult neurogenesis, Wnt-induced expression of NeuroD1 is required
for survival and maturation of adult-born neurons [48, 50, 51]. The prototypcial binding
partners of β-catenin in the nucleus are members of the TCF/LEF family, which have been
shown to be central mediators of tumourigenesis in the colon, breast and other tissues. In
NPC’s, activation of the Wnt pathway and elevated transcriptional activity of β-catenin has
been shown to promote proliferation and inhibit neuronal differentiation [53, 54], while
inhibition of Wnt signaling promotes neuronal differentiation [55, 56]. Accordingly, deletion
of GSK3 isoforms promotes proliferation and inhibits differentiation of stem cells [57],
consistent with pharmacological GSK3 inhibitors and Wnt-induced inhibition of GSK3 activity
[7, 8]. This is dependent on elevated levels of transcriptionally active β-catenin [58], but
surprisingly not by members of the TCF/LEF family. Instead, β-catenin was shown to bind to
another transcription factor called Oct4, which increased expression of the pluripotency
regulator and stem cell marker Nanog [58, 59].
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Some transcriptional targets of the Wnt pathway are also targeted by GSK3 post-translation‐
ally. For example, c-myc is an established target of the Wnt pathway that promotes cell cycle
progression and proliferation [49]. Meanwhile, its protein product is directly phosphorylated
by GSK3 at Thr58, which targets it for ubiquitination by the E3 ligase Fbw7, followed by
proteasome-mediated degradation [60, 61]. Thus, Wnt-induced inhibition of GSK3 activity
could promote high c-myc activity both transcriptionally and post-translationally. However,
it has not yet been proven that Wnt-mediated inhibition of GSK3 reduces phosphorylation of
c-myc, or any protein other than β-catenin for that matter. Alternatively, simultaneous
stimulation of cells by Wnt and growth factors would activate c-myc transcription and reduce
its phosphorylation and degradation, respectively, thus combining to increase c-myc abun‐
dance. This would promote proliferation and inhibit differentiation of NPC’s. Interestingly, a
viral oncogenic form of c-myc is mutated at the GSK3 target site (Thr58) [60]. This mutation
prevents phosphorylation of c-myc by GSK3 and subsequent ubiquitination, thus stabilizing
the protein and driving uncontrolled proliferation in tumourigenesis. Thus, emphasizing the
importance of phosphorylation of c-myc by GSK3 in the regulation of cell fate.
Other isoforms of c-myc are also phosphorylated and targeted for degradation by GSK3 (i.e.
L-myc, N-myc). In NPC’s, deletion of c- and L-myc does not affect proliferation/differentiation,
while deletion of N-myc significantly decreases NPC proliferation and impairs differentiation
into mature neurons [62], suggesting that N-myc is the critical member of this family regulating
neurogenesis and brain development [63, 64]. Like c-myc, GSK3 phosphorylates N-myc at
Thr58 to promote ubiquitination by Fbw7 and degradation by the lysosome [65]. This is
antagonized by growth factor-mediated inhibition of GSK3 activity (e.g. IGF1). Phosphoryla‐
tion of N-myc by GSK3 requires prior ‘priming’ phosphorylation at Ser62 by Cdk1, which is
increased during mitosis, causing increased N-myc degradation [65]. This was shown to be
important for exiting the cell cycle – the first step along the differentiation pathway. Cdk1
activity is dependent on binding to its co-factors cyclin A and B1 [66], whose transcription is
controlled by the Hedgehog pathway, as is the transcription of N-myc [67, 68]. Therefore, N-
myc appears to be a point at which multiple signaling pathways involving GSK3 intersect in
NPC’s to control cell fate.
Some substrates of GSK3 are upstream of the Wnt pathway and can regulate its activity. For
example, hypoxia-inducible factor 1 α (HIF1α) is a basic helix-loop-helix (bHLH)-structured
transcription factor that is induced by low oxygen conditions to activate transcription of genes
that provide protection and adaption of cells to oxidative stress and hypoxic conditions.
HIF1α is phosphorylated by GSK3, promoting its degradation by the proteasome [69, 70].
Recently, it was shown that HIF1α promotes Wnt activation and transcription of TCF/LEF
members in undifferentiated, but not differentiated cells [71]. Low GSK3 activity in undiffer‐
entiated cells would reduce GSK3-mediated phosphorylation and degradation of HIF1α, thus
stabilizing the protein and leading to activation of the Wnt pathway. Simultaneously, low
GSK3 activity (downstream of Wnt) would prevent β-catenin phosphorylation/degradation,
increasing its transcriptional activity with TCF/LEF. Interestingly, the authors show that the
subgranular zone of the dentate gyrus containing NPC’s is hypoxic due to fewer blood vessels
in the region and contains relatively high levels of HIF1α and transcriptionally active β-catenin.
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Thus, decreased oxygen levels could be important for maintaining the NPC niche in the
hippocampus via GSK3, HIF1α and the Wnt pathway. It be should be noted that other groups
have found that prolonged hypoxia increases the activity of GSK3 in cultured cells and in
vivo [69, 72]. This might reflect differences between GSK3-mediated phosphorylation and
degradation of HIF1α in undifferentiated versus differentiated cells.
6. GSK3, DISC1 and mood disorders
GSK3’s involvement in the Wnt pathway is also regulated by the scaffolding protein DISC1.
This protein directly binds to GSK3 to inhibit phosphorylation of β-catenin, preventing its
degradation and activating its transcriptional activity [38]. This promotes NPC proliferation
during embryonic development and in the adult brain. Depletion of DISC1 or expression of
DISC1 mutants associated with mood disorders and schizophrenia reduced NPC proliferation
and induced schizophrenia and depression-like symptoms in mice [38, 73]. These defects were
normalized by administration of pharmacological inhibitors of GSK3. These studies demon‐
strate that DISC1 is a negative regulator of the Wnt pathway and NPC proliferation by directly
inhibiting GSK3-mediated phosphorylation of β-catenin. Interestingly, one schizophrenia-
associated mutant of DISC1 (S704C) did not affect GSK3 activity, Wnt signaling or NPC
proliferation, but instead impaired neuronal migration in the developing cortex via reduced
binding to cytoskeletal proteins (Dixdc1) [73]. Elsewhere, it was shown that DISC1 acts as a
molecular switch between proliferation and migration in NPC’s, whereby DISC1 inhibits
GSK3-mediated phosphorylation of β-catenin and activates its transcriptional activity to drive
proliferation of NPC’s, while in committed, post-mitotic neurons, DISC1 regulates neuronal
migration via another protein called BBS1 and the centrosome [74]. Together, these studies
demonstrate that DISC1 regulates NPC proliferation and neuronal migration through GSK3-
dependent and independent pathways, respectively.
As well as DISC1, other upstream regulators of GSK3 are genetically linked to mood disorders
and schizophrenia, including Akt [75], Neuregulin [76] and the dopamine/β-arrestin signaling
complex [77, 78]. GSK3 kinase activity is also inhibited by several mood-stabilizers, anti-
depressants and anti-psychotic drugs [6, 79, 80], while genetic manipulation of GSK3 activity
in mice produces behaviours correlating with mood disorders [24-28]. A single nucleotide
polymorphism in the promoter region of GSK3β has also been correlated with onset of Bipolar
disorder [81]. Together, these observations strongly implicate elevated GSK3 activity in the
etiology of mood disorders and schizophrenia. Neurogenesis is decreased in these disorders
[82, 83], but is promoted by mood stabilizing drugs, such as lithium [84, 85]. Therefore, mood-
stabilizing drugs may act (at least in part) by promoting neurogenesis via inhibition of GSK3.
If so, promoting neurogenesis using GSK3 inhibitors could also be beneficial to other mental
disorders, including neurodegenerative diseases such as Alzheimer’s disease and age-related
cognitive decline, as well repair following brain injury, such as stroke and spinal chord injuries.
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7. GSK3 and Notch signaling
A role for the Notch signaling pathway in regulating development was discovered almost a
century ago by pioneering work in fruit flies by John Dexter and Thomas Hunt Morgan [86].
It was later found that absence of Notch in flies caused neuronal hyperplasia and a decrease
in glial cells in the brain [87]. Generally, Notch signaling promotes proliferation of NPCs and
inhibits their differentiation, but has also been linked with glial cell specification [88, 89],
neurite outgrowth [90] and learning and memory [91]. Notch is a family of 4 single-pass
transmembrane proteins (Notch1-4) that are expressed at the cell surface of ES cells and NPCs
(especially Notch1). Ligand-mediated activation of Notch leads to its proteolytic cleavage by
Presenillin-g, releasing the Notch intracellular domain (NICD) for translocation to the nucleus
where it binds with the transcription factor RBP-Jk to activate transcription of target genes
including the bHLH transcriptional repressors Hes1 and Hes5. These proteins repress tran‐
scription of pro-neural genes, thus inhibiting differentiation into neurons and maintaining
proliferation of NPC’s. Ligands that activate Notch, such as Delta-like 1 (Dll1) and Jagged1
(Jag1) are themselves transmembrane proteins. These are typically located at the cell surface
of differentiated neurons that bind and stimulate activation of Notch on neighbouring NPC’s.
Thus, Notch signaling functions in a localized fashion, whereby a differentiating neuron
expressing the ligands Dll1 or Jag1 binds Notch on a neighbouring cell to activate downstream
signaling that inhibits differentiation and maintains proliferation of NPC’s, thus establishing
a stem cell niche in the brain. In other words, Notch signaling prevents equipotent cells from
acquiring the same fate.
GSK3 was originally found to be associated with the Notch signaling pathway in Drosophila
development [92]. Since then, it has been shown to bind and phosphorylate the intracellular
domain of Notch, stabilizing the protein by reducing its degradation by the proteasome [93].
However, other studies report that phosphorylation destabilizes Notch and promotes its
degradation [94, 95]. The reason for these contradictory observations are not clear, although
considering that low GSK3 activity and high Notch signaling correlate with the highly
proliferative, undifferentiated nature of ES cells/NPC’s, it is likely that GSK3-mediated
phosphorylation targets Notch for degradation by the proteasome. That is, low GSK3-
mediated phosphorylation and degradation of NICD increases its abundance and transcrip‐
tional activity to promote proliferation/suppress differentiation. This is consistent with many
other proteins that are destabilized by GSK3 phosphorylation, such as c-myc, HIF1α, β-catenin,
etc. It is possible that prior phosphorylation by the cyclin C:Cdk8 complex could prime NICD
for subsequent phosphorylation by GSK3 [96], although this remains to be proven.
Cross-talk between the Notch and Wnt signaling pathways has been suggested by several
studies, although the reports are contradictory. One study shows that Notch binds to the
unphosphorylated, transcriptionally-active form of β-catenin, targeting it for degradation by
the lysosome, thus suppressing expression of Wnt target genes [97]. At first glance, this is
surprising, since both pathways are pro-proliferation/anti-differentiation. However, it should
be noted that Notch-mediated degradation of β-catenin does not require ligand activation.
Therefore, this mechanism might be more relevant to differentiated cells, such that in the
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absence of ligand stimulation, Notch reduces β-catenin levels to antagonize Wnt signaling.
Thus, both pathways are suppressed, consistent with a differentiated phenotype. Another
report has shown that FGF2-mediated inhibition of GSK3 activity leads to an increase in
transcriptionally-active β-catenin in the cell nucleus, which simultaneously activates TCF/LEF
and Notch/RBP-Jk transcriptional complexes, promoting proliferation and inhibiting differ‐
entiation, respectively [98]. Although both pathways promote maintenance of stem cells as
expected, FGF2-mediated inhibition of GSK3 is unexpected, since it is commonly assumed that
growth factors do not influence β-catenin levels in the Wnt pathway [19], although this
observation has been confirmed by several other groups [99, 100]. It is possible that FGF
signaling is an exception to the growth factor rule. All together, it seems clear that there are
interactions between Notch and other cell fate pathways involving GSK3, although the precise
mechanisms are yet to be fully clarified.
8. GSK3 and Hedgehog signalling
The Hedgehog signaling pathway is a critical regulator of cell fate during development and
for maintaining proliferation of cell stem niches in adults, including NPC’s in the brain. In
mammals, there are 3 Hedgehog proteins, with Sonic hedgehog being the most widely studied.
These are secreted proteins that bind to a receptor at the surface of target cells called patched.
When Hedgehog binds to patched, patched is released from another receptor protein at the
cell surface called smoothened, allowing smoothened levels to increase. Smoothened inhibits
the proteolytic cleavage of the zinc-finger proteins Gli (cubitus interruptus in flies), which are
critical effectors of the Hedgehog pathway. Gli1 and Gli2 are transcriptional activators, while
Gli3 is a repressor. These proteins regulate the transcription of cell cycle-related genes, such
as cyclins D and E, N-myc, Bcl2, POU3F1, Runx2 and Tbx2, as well as patched in a negative
feedback loop. In the absence of Hedgehog ligands, Gli associates with a scaffolding complex
containing Cos2 and Fused that facilitates phosphorylation by GSK3 and CK1 (following
priming by PKA). This phosphorylation targets Gli for ubiquitination and proteolysis,
generating a truncated repressor form lacking the C-terminal activation domains [101-105].
But in the presence of Hedgehog, this signaling complex is disrupted, inhibiting phosphory‐
lation and processing of Gli, leading to accumulation of transcriptionally active full-length
protein in the nucleus. Thus, GSK3 antagonises Hedgehog signaling by mediating the
degradation of Gli proteins. The scaffolding protein Sufu, a negative regulator of Hedgehog
signaling, is also phosphorylated by GSK3, which stabilizes the protein and increases degra‐
dation of Gli proteins [106]. Thus, GSK3 promotes Gli degradation directly and via stabilization
of Sufu.
The Hedgehog pathway is similar to the Wnt pathway, in that it utilizes the constitutive activity
of GSK3 to negatively regulate the key transcriptional effector of each pathway (β-catenin for
Wnt, Gli for Hedgehog). Ligand-mediated activation of both pathways reduces phosphoryla‐
tion of these key effectors by disrupting their respective signaling/scaffolding complexes
without directly inhibiting GSK3 activity (i.e. they exclusively reduce phosphorylation of a
specific substrate). In contrast, growth factor signaling directly inhibits GSK3 kinase activity
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via phosphorylation of the N-terminal serine residues. Therefore, it seems that the Wnt and
Hedgehog pathways regulate specific substrates within their respective signaling complexes,
while growth factor stimulation affects a wider range of GSK3 substrates (Fig.1). It should also
be mentioned that signaling complexes containing the scaffolding protein AKAP220 have been
shown to promote inhibitory Ser21/9 phosphorylation of GSK3 [107, 108]. Hence, the number
of scaffolding/signal complex-associated proteins reported to bind and regulate GSK3 activity
is increasing, suggesting that this mechanism might be common, rather than an exception,
although this remains to be proven. Nevertheless, it is highly likely that other signaling



































Figure 1. Signalling pathways regulating cell fate target different subsets of GSK3 substrates. Ligand-stimulated
activation of the Wnt, Notch and Hedgehog pathways prevents phosphorylation of a single substrate by disrupting
multi-subunit signalling complexes required to mediate their phosphorylation, driving proliferation. In contrast,
growth factor-mediated inhibition of GSK3 via phosphorylation of N-terminal serine residues reduces phosphorylation
of many substrates, promoting survival and differentiation of newly generated neurons.
9. GSK3 and growth factor signaling
In general, growth factors positively influence neurogenesis in the developing and adult brain
by supporting differe tiation and survival of newly generated neurons. Direct injection of
many growth factors into the subventricular zone of mice increases neurogenesis, including
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FGF [109], EGF [110], TGF [110], CNTF [111]. Among the most potent growth factors are the
neurotrophins (BDNF, NGF, NT-3, NT-4), whereby direct administration [112] or genetic
deletion [113] increases and reduces neurogenesis, respectively. Accordingly, their receptor
molecules, called Trk receptors, are predominantly expressed by post-mitotic neurons, but not
NPC’s or neural crest cells [114]. BDNF signaling, in particular, has been shown to promote
survival of newly-generated neurons [115], while defects in BDNF signaling have been linked
to decreased neurogenesis and neuronal survival in several neurological disorders, including
Alzheimer’s disease, age-related cognitive decline, Bipolar disorder and Schizophrenia (for
reviews, see [116, 117]).
GSK3 is an established target of many growth factor signaling pathways. Ligand-binding to
their respective receptors at the cell surface induces dimerisation/oligomerisation, activating
their intrinsic kinase activities and autophosphorylation of key tyrosine residues. This
provides binding sites for SH2 and SH3-domain-containing adaptor proteins, such as IRS and
Grb proteins, promoting recruitment and activation of phosphatidylinositol 3 kinase (PI3K).
This lipid kinase converts phosphatidylinositol 4,5 bisphosphate (PIP2) to PIP3, recruiting
members of the AGC family of kinases (e.g. PKB/Akt), where they are phosphorylated and
activated by PDK1. These AGC kinases phosphorylate an N-terminal serine on GSK3 (Ser21
on GSK3α, Ser9 on GSK3β) that binds to the substrate binding site on GSK3, thus acting as a
pseudo-substrate to inhibit phosphorylation of primed substrates [17].
Numerous studies have demonstrated that pharmacological inhibitors of GSK3 promote
survival of neurons subjected to a range of toxic stimuli (for a review, see [118]), while over-
expression of GSK3 promotes neuronal apoptosis in vitro and in vivo [29, 119, 120]. Importantly,
GSK3α/β -knockin mice (S21/9A) that are insensitive to growth factor inhibition exhibit
reduced neurogenesis, despite normal proliferation of NPC’s [36]. As noted previously, this
could suggest defective differentiation patterns in the NPC’s, but could equally represent
decreased survival of newly generated neurons. In addition, several substrates of GSK3 are
associated with cell survival (discussed below). Together, these observations strongly suggest
that growth factor-mediated inhibition of GSK3 appears to be a key mechanism by which
growth factors promote survival of newly generated neurons during neurogenesis.
A key downstream target of GSK3 promoting survival is Mcl1. This anti-apoptotic, pro-
survival member of the Bcl2 family is directly phosphorylated by GSK3 at Ser155 and Ser159,
targeting it for ubiquitination by E3 ligases (Fbw7, βTrCP and/or Trim17) and degradation by
the proteasome [121, 122]. Upon growth factor stimulation, GSK3 is inhibited, reducing GSK3-
mediated phosphorylation of Mcl1, thus stabilizing the protein and promoting neuronal
survival. The Notch signaling pathway has also been shown to promote survival of neurons
via Mcl-1, although the role of GSK3 was not investigated [123]. NPC’s and newly-committed
neurons in the subventricular zone and surrounding areas of mice express high levels of Mcl-1,
while Mcl-1 deficiency caused widespread apoptosis, especially in newly-committed neurons
as they migrate away from this region [124]. This suggests that a key target of growth factor
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and GSK3-mediated protection of neurons is via Mcl-1. Indeed, nutrient deprivation correlates
with decreased levels of Mcl-1 and induction of apoptosis in neurons, which was dependent
on phosphorylation by GSK3 [125, 126]. In contrast, Bax is a pro-apoptotic member of the Bcl2
family. Phosphorylation by GSK3 at Ser163 promotes its translocation to the mitochondrial
outer membrane, where it oligomerizes to form a pore promoting cytochrome c release and
cell death [127, 128]. Inhibition of GSK3 via growth factor signaling or therapeutics (e.g.
lithium) antagonizes Bax translocation and cytochrome c release, promoting cell survival.
Other downstream targets of GSK3 that promote neuronal survival include the transcription
factors HIF1α, HSF1 [129], Mef2D [130] and Bcl3 [131] by activating transcription of pro-
survival genes. For example, increased activity of GSK3 during potassium withdrawal from
cerebellar granule neurons leads to increased phosphorylation and degradation of Mef2D,
which could be blocked by a GSK3-resistant form of Mef2D [130]. The neurotrophins NGF and
BDNF promote Mef2D stability by reducing GSK3-mediated degradation, leading to increased
transcription of its target gene Bcl-w, an anti-apoptotic member of the Bcl-2 family [132].
10. GSK3, ubiquitin ligases and proteasome-mediated degradation
It is noticeable that many substrates of GSK3 are targeted for ubiquitination and proteasome-
mediated degradation following phosphorylation by GSK3. Most of these are transcription
factors that are phosphorylated by GSK3 within an [ST]PPx[ST]P motif, including c-myc [61,
133, 134], c-jun [135], Klf5 [136, 137], cyclin E1 [138], Gli3 [101, 102] and snail [139]. These
transcription factors have short half-lives, largely due to the actions of GSK3, which is highly
active under basal conditions in mature, differentiated cells. However, GSK3 activity levels
are comparatively lower in undifferentiated cells, induced by persistent Wnt, Notch, Hedge‐
hog and/or growth factor signaling to maintain the proliferative capacity of these cells [140].
Here, phosphorylation and ubiquitination of transcription factors by GSK3 is reduced, thus
stabilizing the proteins (prolonging their half-lives) and contributing to stem/precursor cell
proliferation. A common E3 ligase targeting GSK3 substrates is Fbw7. In fact, most of the
reported targets of Fbw7 are established GSK3 substrates (see [141]). Genetic studies in mice
indicate that Fbw7 is required for differentiation and survival of NPC’s. For example, brain-
specific deletion of Fbw7 increased apoptosis of NPC’s, which could be rescued by concomitant
deletion of c-jun [142]. Similar results were observed for cerebellar development in mice [143].
NPC differentiation was also impaired, particularly a decrease in the number of mature
neurons and increased glial progenitors (although no change in mature astrocytes). This was
alleviated by inhibition of Notch signaling. Supporting this, a separate study showed that
brain-specific deletion of Fbw7 skewed the differentiation of NPC’s towards astrocytes, rather
than neurons, which could be restored with a pharmacological inhibitor of the Notch pathway
[144]. Meanwhile, the maintenance/proliferation of the NPC’s was not affected. Together, these
observations show that GSK3 and Fbw7 share common substrates that regulate the differen‐
tiation and survival of neurons.
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11. GSK3 and NPC migration and polarization
Correct positioning of newly generated neurons is crucial during development and for healthy
function of the adult brain. Neuronal migration is tightly regulated by extracellular cues,
including Wnts and growth factors. Accordingly, there is emerging evidence that their
common downstream target, GSK3, may be involved in this process, primarily via regulation
of cytoskeleton-associated proteins. Migration requires cellular polarization and extension at
the leading edge of the cell. This involves dynamic reorganization of microtubules by a variety
of microtubule-binding proteins. Several of these are directly phosphorylated and regulated
by GSK3, including Tau, CRMP2, MAP1B, MAP2C, CLASP2, pVHL and APC (for reviews, see
[145, 146]). Phosphorylation of many of these substrates by GSK3 reduces their ability to bind
microtubules, thus making them less stable. Interestingly, GSK3 activity is typically low at the
leading edge of migrating cells or at the tips of growing neurites in neuronal polarization
[147-149]. This would promote substrate binding and stabilization of microtubules, facilitating
forward movement of the cell’s leading edge or growing neurite. Similarly, local inhibition of
GSK3 activity is essential for polarization of newly generated neurons and growth of the
nascent axon [150, 151]. Meanwhile, global inhibition of GSK3 induces formation of multiple
axons [150, 152]. Several upstream inhibitors of GSK3 have been implicated in this process,
including Cdc42 [149], ILK [153], LKB1 [147] and Akt [150]. Apart from the latter, these
signaling proteins are not established regulators of GSK3 activity, so the precise molecular
mechanisms by which they inhibit GSK3 activity await clarification.
12. Conclusions
It is clear that GSK3 is an important target of several signaling pathways controlling cell fate
in the brain. It is also clear that many of these pathways can be activated simultaneously in the
same cells/tissues. One possibility is that GSK3 acts as an integrator of these simultaneous
inputs to determine the cellular outcome. That is, GSK3 acts as a node for multiple signaling
pathways and the sum of these inhibitory signals dictates cell fate. This is unlikely, since
although each of these pathways target GSK3, their downstream targets are different. For
example, growth factor signaling inhibits phosphorylation of CRMP2, but not β-catenin, and
vice versa for Wnt [19, 154, 155]. An alternative explanation is that different subsets of GSK3
substrates are selectively affected by particular stimuli. That is, ligand-stimulated activation
of the Wnt, Notch and Hedgehog pathways prevents phosphorylation of a single substrate (β-
catenin, Notch and Gli, respectively) by disrupting multi-subunit signaling complexes
required to mediate their phosphorylation. This increases the stability of these proteins,
translocation to the cell nucleus and regulation of gene transcription programs that promote
proliferation of ES cells/NPC’s. In contrast, growth factor-mediated inhibition of GSK3 via
phosphorylation of N-terminal serine residues reduces phosphorylation of many substrates
(although not β-catenin), promoting survival and differentiation of newly generated neurons.
It is possible that signaling complexes associated with β-catenin (and perhaps Notch and Gli)
are able to surmount the inhibitory N-terminal serine phosphorylation induced by growth
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factor signaling. Indeed, the protein phosphatase PP2A is a known component of the β-catenin/
APC/Axin signaling complex [156] and PP2A is able to activate GSK3 by dephosphorylating
its N-terminal serine residue [157]. If this is true, these signaling complexes could be seen to
activate GSK3 activity (at least phosphorylation of a particular substrate e.g. β-catenin). It might
be more accurate to say that GSK3 is not inhibited by these pathways, but rather GSK3
antagonizes them. Then upon ligand stimulation, this function of GSK3 is alleviated by
disruption of the signaling complex, activating the pathway. It is important to catalogue the
pathway-specific targets of GSK3 and their effects on cell fate and survival, since this knowl‐
edge could identify novel therapeutic targets for artificially controlling neurogenesis and
promoting recovery in diseased or damaged brains.
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Neurotrophins are small proteins vital for neuronal growth, differentiation, survival, and
plasticity [1]. Members of the mammalian neurotrophin family include nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotro‐
phin-4/5 (NT-4/5). Their neurotrophic effects are mediated by the tropomyosin receptor kin‐
ase (Trk) receptors, membrane-bound receptor tyrosine kinases (NGF for TrkA, BDNF and
NT4/5 for TrkB, and NT-3 for TrkC) which activate various cell signaling pathways linked to
growth, differentiation, and survival [2]. The importance of neurotrophin signaling in brain
development is highlighted by findings showing that knockout mice for any one of the neu‐
rotrophins or their receptors are fatal or exhibit severe neural defects [3].
1.2. BDNF and Alzheimer’s disease
The neurotrophin, NGF, is reduced in the nucleus basalis, a region concentrated in basal
forebrain cholinergic neurons, which show substantial degeneration in Alzheimer's disease
(AD) [4, 5]. However, there is conflicting evidence demonstrating that NGF levels are un‐
changed or even increased in other brain regions including the frontal cortex and hippocam‐
pus, two major brain regions affected in AD [6-9]. In contrast, BDNF is more highly
expressed and widely distributed in the brain compared to NGF, and its expression and
growth promoting actions are critical for survival and plasticity of a variety of neurons
throughout the brain, particularly in brain regions heavily affected in AD such as hippocam‐
pal, cortical, and cholinergic neurons [10-14]. Moreover, in cell culture and animal models,
functioning of the BDNF signaling pathway has been repeatedly demonstrated to be critical
for neuronal differentiation, survival, plasticity, and cognition [3, 11, 13, 15-21]. Independent
© 2013 Wong; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
lines of evidence suggest that dysfunction in BDNF signaling may contribute to the neuro‐
degeneration in AD. Brain regions associated with reduced BDNF expression are those dis‐
playing the highest levels of neurodegeneration (eg. hippocampus). The role of BDNF in AD
has been studied extensively. In AD brains, BDNF mRNA and protein levels have been
found to be reduced in the hippocampus and neocortex [8, 22-27]. With findings of reduced
BDNF expression in AD, interest emerged in the role of the TrkB receptor, as reductions in
BDNF signaling may also occur through alterations in and/or through decreased expression
of this BDNF receptor.
1.3. The BDNF receptor − TrkB
The TrkB receptor is the principal component of the BDNF signaling pathway. In the human
brain, multiple isoforms of TrkB are expressed. There are three major isoforms of the TrkB
receptor characterized to date: the full-length (TrkB-TK+) and two C-terminal truncated
TrkB receptors (TrkB-TK- and TrkB-Shc) that are generated by alternative splicing of the
TrkB pre-mRNA [28]. The full-length TrkB receptor, TrkB-TK+, is the principal mediator of
the neurotrophic effects of BDNF. Upon ligand binding, monomeric TrkB-TK+ homodimer‐
izes and undergoes trans-phosphorylation at key tyrosine residues in the C-terminal domain
that couple it to downstream signaling pathways that promote neuronal survival, growth,
differentiation, and plasticity including mitogen-activated protein kinase kinase (MEK),
phosphatidyl inositol 3 kinase (PI3K), and phospholipase C-gamma (PLCγ) [29-32] (Figure
1). The two truncated TrkB receptor isoforms include TrkB-TK- and TrkB-Shc. Both truncat‐
ed isoforms are generated from alternatively spliced transcripts and are truncated at the C-
terminus, thus lacking the tyrosine kinase domain [28, 33]. However, the TrkB-TK- and
TrkB-Shc receptors differ in that each contain unique amino acid sequences at their C-termi‐
nus. The TrkB-Shc isoform includes the sarc homology containing (Shc) binding domain that
is absent in TrkB-TK- [28].
1.4. TrkB and Alzheimer’s disease
Previous reports on TrkB-TK+ and TrkB-TK- expression levels in AD have been variable due
to brain cohort differences and the variable techniques used to measure their expression. In
general, reductions in TrkB-TK+ in neurons have mostly been found in the hippocampus
and the frontal and temporal cortices in AD [27, 34]. Conversely, up-regulation of TrkB-TK-
has been found in association with senile plaques in AD, and is suggested to be linked to
increases in reactive glial cells [9, 27, 34]. Furthermore, increases in TrkB-TK+ have also been
found in glial cells in the hippocampus [27]. Surprisingly, while the existence of TrkB-Shc
has been known for some time, its role in AD has not been defined.
1.5. Importance of TrkB
Neuron viability and function is dependent upon BDNF-stimulated TrkB-TK+ signaling. In
AD, much evidence suggests that BDNF/TrkB-TK+ signaling is reduced [8, 22-27, 34-36]. In
addition to changes in BDNF expression, neuronal BDNF/TrkB-TK+ signaling can also be
modulated by alterations in the ratio of full-length (TrkB-TK+) to truncated (TrkB-TK- and
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TrkB-Shc) TrkB expressed [31, 37]. Homodimers of TrkB-TK+ receptors bind to BDNF and
initiates intracellular second messenger signaling (Figure 1). Changes in TrkB alternative
transcript expression or protein stability, such as increased TrkB-TK- and/or TrkB-Shc, will
have a profound negative impact on BDNF/TrkB-TK+ signaling as homodimers of truncated
receptors and heterodimers of full-length and truncated receptors can not initiate BDNF-
stimulated second messenger signaling (Figure 2). This is important because changes in the
ratio of full-length to truncated TrkB expression in neurons may underlie reductions in neu‐
rotrophic support in AD, which ultimately lead to neurodegeneration and profound neuron
and brain volume loss. Considering that TrkB-Shc is a brain- and neuron-specific TrkB iso‐
form that has been demonstrated to inhibit BDNF/TrkB-TK+ signaling, it is important to es‐
tablish what role TrkB-Shc plays in AD development and progression.
Figure 1. BDNF/TrkB-TK+ signaling pathway. Activation of TrkB-TK+ by BDNF leads to auto-phosphorylation of tyro‐
sine residues in the intracellular C-terminal domain. This leads to the activation of TrkB-TK+-linked second messenger
signaling pathways including PLCγ (phospholipase C-gamma), MEK (mitogen-activated protein kinase kinase), and
PI3K (phosphatidyl inositol 3 kinase), which are linked to downstream processes involved in cell adhesion/migration,
cells survival, synaptic plasticity, neurogenesis, and neuronal differentiation. This figure is modified from the BDNF
Pathway Figure (Protein Lounge Pathway Templates) from ProteinLounge using Pathway Builder Tool.
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Figure 2. TrkB receptor dimer combinations. All dimer combinations of TrkB receptors can bind to BDNF. However,
only a homodimer of TrkB-TK+ can initiate second messenger signaling. This figure utilizes modified ProteinLounge
graphics created using the Pathway Builder Tool (www.proteinlounge.com).
2. Evidence that TrkB-Shc alternative transcripts are selectively increased
in the hippocampus during severe, late stage AD
In Wong et al. (2012) [38], we measured changes in TrkB alternate transcript levels in control
and AD postmortem human brain tissue derived from the hippocampus, temporal cortex, oc‐
cipital cortex, and cerebellum (Braak stages V and VI) [38]. By quantitative real-time PCR, us‐
ing primers specific for each TrkB alternative transcript, we found significant increases in
TrkB-Shc mRNA expression in the hippocampus but not in any other brain region (Figure 3).
Considering that brain homogenates contain a mixed population of cells, we determined
whether the changes found in TrkB transcript expression using the hippocampal tissue ho‐
mogenates also occur in neurons exposed to an amyloidogenic environment. Here, changes
in TrkB transcripts were assessed by incubating differentiated SHSY5Y cells (a human neu‐
roblastoma cell-line which express TrkB) with different species of amyloid beta 1-42 (Aβ42)
peptides at various stages of aggregation. Oligomers and fibrils were prepared as described
in Ryan et al. [39] and characterized by western blotting and atomic force microscopy imag‐
ing [38]. A significant increase in TrkB-Shc mRNA levels was found when cells were incu‐
bated with preparations of Aβ42 containing fibrils compared to controls (Figure 4). The small
magnitude of change was expected as the Aβ42 fibril preparation contained mixed Aβ42 spe‐
Trends in Cell Signaling Pathways in Neuronal Fate Decision184
cies and the absolute amount of fibrils would be low (fibrils were absent in the monomer
and oligomer Aβ42 preparations). Further, in comparison to the Aβ42 monomer and oligomer
preparations, the Aβ42 fibril preparations would be most representative of all Aβ42 species
present in the AD hippocampus as this preparation comprises a mix of all three species [38].
These results were consistent with findings of increased TrkB-Shc mRNA levels in the AD
hippocampus (Figures 3 and 4).
Figure 3. TrkB alternative transcript expression in various control and AD brain regions. Expression of TrkB alter‐
native transcripts in the (A) hippocampus, (B) temporal cortex, (C) occipital cortex, and (D) cerebellum of control (CON)
(white) and Alzheimer’s disease (AD) (black) postmortem human brain tissue were measured by qPCR. ** P=0.004; #
P=0.07. Figure is from Wong J, et al. Amyloid beta selectively modulates neuronal TrkB alternative transcript expres‐
sion with implications for Alzheimer’s disease. Neuroscience 2012;210 363-374.
In regards to the brain regions examined, AD brain pathology from most severe to least af‐
fected is: hippocampus>temporal cortex>occipital cortex>cerebellum. The selective increase
in TrkB-Shc transcripts observed only in the hippocampus suggested that the elevated TrkB-
Shc transcript levels were occurring in brain regions that are most severely affected in the
diseased state and that the observed increase may likely be influenced by the neuronal cell
population present. This was supported by our in vitro AD cell culture model showing that
TrkB-Shc mRNA levels in the differentiated SHSY5Y neuronal cells can be increased by ex‐
posure to preparations of Aβ42 containing fibrils. Aβ42 fibril species are increased in the ad‐
vanced stages of AD [40]. While it is widely accepted that soluble oligomers are the more
neurotoxic of the Aβ42 species, evidence also suggest that the neurotoxicity of Aβ42 requires
its aggregation in the fibrillar form, particularly in the form of protofibrils [41, 42]. In our
Aβ42 preparations, we detected various sizes of fibrils in the Aβ42 fibril preparations, includ‐
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ing protofibrils which can be ~100 nm in length. If we consider that Aβ42 fibrils are predomi‐
nant in the advanced stages of AD [40], that the hippocampus is the most affected brain
region, and that the CA1 subregion (the hippocampal region assessed) is the most severely
impacted subregion of the hippocampus in AD, altogether, our findings suggest that the se‐
lective increase in the TrkB-Shc alternative splice transcript in the AD hippocampus may be
specific to severe, late stage pathology.
3. TrkB-Shc inhibits TrkB-TK+ function and BDNF/TrkB-TK+ signaling
The elevated levels of TrkB-Shc in AD suggested that it may have a functional impact on
cellular TrkB-TK+ signaling in vivo. Previous studies have demonstrated that TrkB-Shc can
function as a dominant negative receptor by inhibiting TrkB-TK+ phosphorylation [28]. In
Wong et al. (2012) [38], we confirmed this finding and extended it by showing that TrkB-Shc
can decrease downstream second messenger signaling linked to TrkB-TK+, supporting a
dominant negative function of TrkB-Shc on BDNF/TrkB-TK+ signaling. In particular, we
found that when TrkB-Shc was overexpressed in SHSY5Y cells (which express endogenous
TrkB-TK+), BDNF/TrkB-TK+ stimulated MEK pathway signaling was selectively attenuated.
The ratio of phosphorylated ERK1/2:total ERK1/2 (a measure of ERK1/2 activity) was re‐
Figure 4. Effect of different structural forms of Aβ42 on TrkB alternative transcript expression in differentiated SHSY5Y
neuronal cells. SHSY5Y cells were differentiated for 9 d and incubated in the absence (white bars) or presence of 1 μM
Aβ42 monomers (AβM) (gray bars), oligomers (AβO) (black bars), and fibrils (AβF) (hatched bars) for 6 h and harvested.
Expression of TrkB alternative transcripts were then measured by qPCR. Data are expressed as mean + SEM relative to
the control (white bars) condition that was set to 1. * P=0.03. Figure is from Wong J, et al. Amyloid beta selectively
modulates neuronal TrkB alternative transcript expression with implications for Alzheimer’s disease. Neuroscience
2012;210 363-374.
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duced but little change was observed for phosphorylated TrkB:total TrkB-TK+ and phos‐
phorylated AKT:total AKT ratios (Figure 5).
Figure 5. Effect of TrkB-Shc overexpression on BDNF-stimulated TrkB-TK+ second messenger signaling in differentiat‐
ed SHSY5Y neuronal cells. Differentiated SHSY5Y cells were transfected with either empty vector (EV; blue) or myc-
tagged TrkB-Shc (pink) for 24 h and treated with increasing concentrations of BDNF for 15 min and harvested.
Proteins were separated by Western blotting and immunoprobed. (A) Representative Western blot images. (B) Bands
were quantitated by densitometry and presented as protein expression ratios of phosphorylated protein to non-phos‐
phorylated protein (pTrkB-TK+:TrkB-TK+; pAKT:AKT; pERK1:ERK1; pERK2:ERK2) -/+ SEM. * P=0.02 for pTrkB:TrkB-TK+
at 25 ng, P=0.03 for pERK1:ERK1 at 5 ng BDNF and P=0.049 for pERK1:ERK1 at 15 ng BDNF. Figure is from Wong J, et
al. Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheim‐
er’s disease. Neuroscience 2012;210 363-374.
In a parallel study [43], we determined how TrkB-Shc exerts its dominant negative effect on
BDNF-stimulated TrkB-TK+ signaling. Using a non-neuronal cell-line, Chinese Hamster
Ovary K1 (CHOK1) cells (which do not express endogenous TrkB receptors), we transiently
overexpressed TrkB-Shc protein and examined its effect on TrkB-TK+ protein stability. We
used cycloheximide to block protein synthesis as this would prevent newly synthesized pro‐
tein from replacing protein that has been degraded. From this, we found that TrkB-Shc pro‐
tein levels were rapidly decreased when cells were exposed to exogenous BDNF. Moreover,
in co-expression experiments where TrkB-Shc and TrkB-TK+ were co-expressed, cyclohexi‐
mide treatment revealed increased protein degradation of phosphorylated TrkB-TK+ pro‐
tein, a process that is accelerated by BDNF exposure (Figure 6A and B) [43]. Interestingly,
while the reduction of phosphorylated TrkB-TK+ protein was more pronounced in the pres‐
ence of TrkB-Shc following BDNF exposure, the stability of TrkB-Shc protein itself was in‐
creased (Figure 6C).
4. Discussion
Our recent findings have important implications in regards to the role of TrkB-Shc and its
impact on BDNF-mediated TrkB-TK+ signaling in neurons in AD. MEK signaling through
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ERK1/2 phosphorylation is increased in vulnerable neurons in AD and is implicated in the
abnormal phosphorylation of tau and neurofilament proteins [44]. Our finding of a selective
attenuation in MEK signaling activity in neurons with elevated levels of cellular TrkB-Shc
implicates that elevated levels of this neuron-specific truncated TrkB receptor in AD may oc‐
cur as a response to the disease. However, our finding that cells may increase TrkB-Shc pro‐
tein levels in response to BDNF stimulation to regulate TrkB-TK+ activity by increasing
degradation of activated receptor complexes also has ramifications for BDNF/TrkB-TK+ sig‐
naling in AD. In the non-diseased or control state, this process is akin to feedback regulatory
loops observed in metabolic pathways (Figure 7). While BDNF/TrkB-TK+ signaling is impor‐
tant in multiple aspects related to neuronal viability and differentiation, overactivation or
inappropriate temporal and spatial activation of BDNF/TrkB-TK+ signaling during brain de‐
velopment or “leakage” of BDNF to adjacent neurons or brain regions can negatively impact
brain function. However, in AD, elevated levels of TrkB-Shc in association with reduced
BDNF protein levels (which is well documented) and no change in TrkB-TK+ expression
may also result in an overall increase in the degradation of phosphorylated TrkB-TK+ recep‐
tors, and thus, reduce overall BDNF/TrkB-TK+ activity in neurons in AD.
Figure 6. Effect of TrkB-Shc on the stability of phosphorylated TrkB-TK+. CHOK1 cells co-transfected with either
empty vector + TrkB-TK+ or TrkB-TK+ + TrkB-Shc for 24 h were treated with 15 ng BDNF for 15 min and then incubated
with cycloheximide for 3 h before harvest. Proteins were separated by Western blotting and immunoprobed. (A and
C) Representative Western blot images. (A) and (C) are from the same blot and have the same exposure. (B) Bands in
(A) were quantitated by densitometry and presented as protein expression normalized to β-actin + SEM. **P = 0.007.
Figure is from Wong, J and Garner, B. Biochemical and Biophysical Research Communications 2012; 420 331–335.
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Figure 7. Summary diagram. Upper panel: In the normal, non-diseased state, binding of BDNF to TrkB leads to auto-
phosphorylation of TrkB-TK+ homodimers (but not other TrkB dimer combinations). This leads to activation of down‐
stream second messenger signaling pathways including PLCγ (phospholipase C-gamma), MEK (mitogen-activated
protein kinase kinase), and PI3K (phosphatidyl inositol 3 kinase), which are critical for neuronal viability and function.
TrkB-TK+ homodimers can also be auto-phosphorylated in the absence of BDNF, although activation of downstream
signaling pathways are less intense. BDNF-stimulation of TrkB receptors also leads to their degradation. The arrow
thickness indicates the magnitude of effect. The magnitude of decrease in protein levels are greatest for the following
receptor combinations when stimulated with exogenous BDNF: TrkB-TK+/TrkB-Shc>TrkB-TK+/TrkB-TK+>TrkB-Shc/
TrkB-Shc. Lower panel: In AD, there is Aβ plaque accumulation. Neurons are exposed to mixed species of Aβ, including
Aβ42 fibrils and oligomers at various stages of aggregation. BDNF protein expression has been reported to be reduced
in AD (indicated by red arrow) and TrkB-Shc levels have been reported by us to be increased in AD (hippocampus,
CA1) (indicated by green arrow) and in response to Aβ42 fibril exposure. The increase in TrkB-Shc is predicted to in‐
crease heterodimer combinations of TrkB-TK+/TrkB-Shc and homodimer combinations of TrkB-Shc, which would lead
to an overall reduction in downstream signaling. Moreover, the increase in TrkB-Shc dimer combinations also increas‐
es TrkB receptor degradation. Thus, the combination of reduced BDNF expression and increased TrkB-Shc expression
in the AD hippocampus would likely result in an overall decrease in BDNF/TrkB-TK+ signaling. Figure utilizes modified
ProteinLounge graphics created using the Pathway Builder Tool (www.proteinlounge.com). Insert panel: Atomic force
microscopy image of the Aβ42 fibril preparation used in Wong J, et al. Amyloid beta selectively modulates neuronal
TrkB alternative transcript expression with implications for Alzheimer’s disease. Neuroscience 2012;210 363-374. This
contains mixed species of Aβ42 monomers, oligomers, and fibrils of various sizes. Scale represents 1 μm.




Neurotrophin signaling via BDNF/TrkB-TK+ is critical for neuronal viability and function.
Further research into this topic area is required to determine when changes in BDNF/TrkB-
TK+ signaling begin to occur and whether changes in TrkB-Shc expression, function, and in‐
teraction with TrkB-TK+ at different stages of the disease process, in response to Aβ, or in
response to other amyloidogenic factors may be protective or deleterious.
Nomenclature
Aβ  (amyloid  beta),  AD  (Alzheimer’s  disease),  Akt  (protein  kinase  B),  BDNF  (brain-de‐
rived neurotrophic factor), CA1 (Cornu Ammonis area 1), CHO (Chinese hamster ovary),
ERK (extracellular  signal-regulated  kinase),  MEK (mitogen-activated  protein  kinase  kin‐
ase), NGF (nerve growth factor), NT (neurotrophin), PI3K (phosphatidyl inositol 3 kinase),
PLCγ (phospholipase C-gamma), Shc (sarc homology containing), Trk (tropomyosin recep‐
tor kinase).
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1. Introduction
During neural induction, the ectoderm stem cells overlying the notochord of the mesoderm
convert into neuroepithelial cells (NECs) that proliferate/differentiate rapidly to form neural
plate in response to diffusible inhibitory signals (neural inducer) produced from the noto‐
chord. Neural plate folds to form neural groove, which fuses to form neural tube. Within the
neural tube, NECs undergo asymmetric dividing to generate neural stem cells (NSCs, or
called radial glia cells) due to the expression of B-cell translocation gene 2 (BTG2) [1, 2, 3, 4].
NSCs differentiate sequentially into neural progenitor cells (NPCs) and various lineage-re‐
stricted neural blast cells, which include neuroblast and glioblast. These neural blast cells
migrate to the target region where they mature and integrate into the existing neural net‐
work [5]. The generation of different lineage occurs in a temporally distinct yet overlapping
pattern. In rodents, neuronogenesis peaks at embryonic day (E) 14, astrocytogenesis at post‐
natal day (P) 2, and oligodendrocytogenesis at P14 [6, 7]. It remains largely unclear at which
step the fate of neuronal lineage has been decided, from embryonic stem (ES) cells to NECs,
to NSCs and to terminally-differentiated neurons. The transcriptional factor NFκB plays a
pivotal role in inflammation, immunity, cancer and neural plasticity [8, 9]. Constitutive and
inducible activation of NFκB has been reported in many types of human tumors and chronic
diseases including neurodegenerative diseases [10, 11, 12, 13, 14]. However, moderate acti‐
vation of NFκB signaling on many physiological conditions may benefit the whole process
of neuronal fate decision, including neurodevelopment and adult neurogenesis [15].
2. NFκB initiates and maintains neuronal fate decision from neural stem
cells
NFκB is activated through a series of signaling cascades (Figure 1). The NFκB family con‐
tains 5 members including RelA(p65), RelB, c-Rel, p50/p105 (NFκB1) and p52/p100 (NFκB2),
© 2013 Zhang and Hu; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
which form various combination of homodimers or heterodimers [8, 16]. In non-stimulated
cells, the NFκB dimer is sequestered in the cytoplasm by the Inhibitor of NFκB (IκB), which
include at least 8 members. Upon stimulation, IκB is degraded via a phosphorylation-de‐
pendent proteasome-mediated mechanism and the released NFκB is translocated to the nu‐
cleus where it binds to the κB-sites and regulates the transcription of target genes. The
phosphorylation of IκB is regulated by the IκB kinase (IKK) that is activated by its upstream
IKK kinases. The classical IKK complex contains 2 catalytic subunits IKK1/2 or IKKα/β and 1
regulatory subunit IKKγ [8, 16]. Three distinct signaling pathways for NFκB activation have
been identified: classical (canonical), non-classical (non-canonical, alternative) and atypical
pathways, all of them rely on sequentially activated kinases (Figure 1) [17]. The classical
pathway involves the activation of classical IKK complex [9]. This pathway generally regu‐
lates the activation of classical NFκB complexes (e.g. p65/p50), in response to a wide range
of stimuli such as pro-inflammatory cytokines tumor necrosis factor α (TNFα) and interleu‐
kin (IL) 1β, Toll-like receptor agonists (LPS), antigens, etc. The activated IKK complex phos‐
phorylates IκB members (IκBα, IκBβ, IκBε and p105) on a consensus motif DSGFxS (e.g.
Ser-32/Ser-36 for IκBα and Ser-19/Ser-23 for IκBβ) and the phosphorylated serines act as
binding site for β-TrCP, the substrate recognition subunit of a Skp1-Cullin-F-box (SCF)–type
E3 ubiquitin-protein ligase complex, named SCFβ-TrCP. This process, then, leads to the ubiqui‐
tination on specific lysine and the ubiquitinated IκBs are directed to 26S proteasome for full
degradation, leaving free NFκB complexes to enter into the nucleus. The kinetics of phos‐
phorylation and degradation of IκBβ or IκBε are much slower than that of IκBα and may
reflect different substrate specificities of the IKK complex. The non-classical pathway in‐
volves TNF receptor associated factor 3 (TRAF3)-mediated activation of the NFκB-inducing
kinase (NIK) and IKKα [18, 19]. Activated IKKα phosphorylates p100 on specific serine resi‐
dues. After phosphorylation, p100 is ubiquitinated by SCFβ-TrCP E3 ligase and cleaved by 19S
proteasome, instead of completely degraded by 26S proteasome, to generate the NFκB subu‐
nit p52. This process is generally slower than the activation of the classical pathway and
leads to a delayed activation of nuclear p52-containing complexes, such as RelB/p52. The
mechanisms of p52 generation are either constitutive (by cotranslational processing) or in‐
ducible (by post-translational cleavage). The non-classical pathway is triggered by some par‐
ticular members of TNF family, such as Lymphotoxin (LT) β, B-cell activation factor (BAFF),
CD40 ligand (CD40L). The function of classical pathway has been well investigated but non-
classical pathway remains in its infancy. In the following discussion, the role of NFκB sig‐
naling in the nervous system relates primarily to classical pathway.
In adult nervous system, NFκB signaling plays a sword-edge role after injuries or diseases
[15, 20, 21, 22, 23]. The final outcome is attributable to the cell types, disease stages, and tar‐
get genes. In most cases, NFκB signaling in immune cells, microglia/macrophage and astro‐
cytes is neurodestructive due to overwhelming production of inflammatory mediators and
neurotoxic molecules [22, 23]. However, neuronal NFκB signaling is neuroprotective via its
crucial role in maintaining neuronal survival, synaptogenesis, neural plasticity, learning and
memory [22, 23, 24, 25]. Recent studies demonstrate a striking enrichment of phosphorylat‐
ed IκBα and IKK in the axon initial segment [26, 27] and the nodes of Ranvier [28], suggest‐
ing a novel role of NFκB signaling in regulating axonal polarity and initial axonal formation.
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In a mouse inducible IκBα transgenic model, NFκB in NSCs/NPCs is necessary for axogene‐














































Figure 1. Classical and non-classical signaling pathways of NFκB activation.
In the zones of active neurogenesis in both postnatal and adult mouse brain, various mem‐
bers of the NFκB family are highly expressed [29], indicating for the first time that NFκB is
actively involved in the proliferation, migration and differentiation of adult NSCs/NPCs [30,
31]. The presence of NFκB in adult neurogenic zone is further validated by the studies using
immunofluorescent microscopy [32, 33]. Direct evidence for the in vivo effect of NFκB signal‐
ing on the proliferation of NSCs/NPCs derives from p65 and p50 double knockout mice [34]
as well as overexpression of super inhibitor IκBα mutant in NSCs/NPCs [35, 36, 37, 38]. Lit‐
tle is known about the role of NFκB signaling in regulating neural differentiation of NSCs/
NPCs. A recent study demonstrates that toll-like receptor 2 (TLR2) induces neuronal differ‐
entiation via protein kinase C (PKC)-dependent activation of NFκB whereas TLR4 inhibites
proliferation and neuronal differentiation of NPCs [30]. In p50-deficient mice, the neuronal
differentiation of adult hippocampal NSCs is reduced by 50% while the proliferation does
not change [39]. In our recent study, we demonstrate that NFκB signaling regulates the early
differentiation of NSCs [32]. During early differentiation of NSCs, NFκB signaling becomes
activated [32]. Addition of TNFα to activate NFκB signaling under proliferation conditions
induces neural differentiation of NSCs/NPCs [32, 40, 41]. TNF-like weak inducer of apopto‐
sis (TWEAK) induces neuronal differentiation of NSCs/NPCs, under proliferation condition,
through NFκB-dependent down-regulation of Hes1 that prevents neuronal differentiation
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[42]. Selective inhibition of classical NFκB signaling by various pharmacologic inhibitors,
small interfering RNA and NSC-specific transgene dominant-negative IκBα retain the tripo‐
tential ability of differentiation and restore or enhance self-renewal capability of NSCs, sug‐
gesting that NFκB signaling is essential for early neural differentiation [32]. The critical role
of NFκB in the initial differentiation step of NSCs highlights a novel molecular mechanism
for neurogenesis. We hypothesize that moderate activation of NFκB signaling promotes
NSC differentiation into NPCs and maintains a continuous source for adult neurogenesis
under physiological conditions. However, persistent and repeated overactivation of NFκB
signaling in NSCs may exhaust NSC pool and thus lead to reduced neurogenesis as seen in
aging patients [43, 44] and chronic stress [45].
To further test this hypothesis, we generated double transgenic mice expressing constitu‐
tively active form of IKKβ (IKKβCA) [46, 47] driven by the promoter of glial fibrillary acid
protein (GFAP) by crossbreeding GFAP-Cre mice (Jackson Lab, 004600) with Rosa26-
StopFloxed-IKKβCA mice (Jackson Lab, 008242). In vitro studies using the NSCs/NPCs cultured
from the brain of GFAP-IKKβCA mice validated the over-activation of NFκB signaling (Fig‐
ure 2), the loss of NSCs during passage as determined by the reduced number of GFAP+/
Nestin+ NSCs (Figure 3) as well as the inhibition of NSC selfrenewing and tripotential ca‐
pacity (Figure 4) [32]. The in vivo effect of persistent over-activation of NFκB on GFAP+
NSCs and their progeny in brain neurogenic zones of adult animals and their correlations
with aging are currently under investigation.
Figure 2. Over-activation of NFκB signaling in brain neural stem/progenitor cells from GFAP-Cre-IKKβCA mice deter‐
mined by Western blot analysis (A) and adenovirus-mediated NFκB-luciferase reporter assay (B). A. Whole cell lysates
of primary neurospheres cultured from brain subventricular zones (SVZ) of littermate wild-type (WT) or transgenic
(TG) adult mouse were immunoblotted with antibodies against phosphorylated p65 (Ser-536) or β-actin (as loading
control). B. Dissociated neural stem/progenitor cells were plated on 96-well plate and infected with adenovirus carry‐
ing NFκB firefly-luciferase at 50 multiplicity of infection (MOI) for 24 h. Luciferase activity was measured with OneGlo™
luciferase assay and cell viability was determined with CellTiter-Glo™ luminescent assay. Data are expressed as relative
fold change after cell number normalization. ** p<0.01 indicates statistical significance from WT control.
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Figure 3. Over-activation of NFκB signaling in cultured brain neural stem/progenitor cells from GFAP-Cre-IKKβCA mice
reduced the number of GFAP+/Nestin+ neural stem cells (Arrow). Passage 2 neurospheres cultured from brain subven‐
tricular zones (SVZ) of littermate wild-type (WT) or transgenic (TG) 5-week-old mouse were dissociated into single
cells. Cells were plated in matrigel-coated 8-well chamber slide and cultured under proliferation media containing 20
ng/mL of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) for 3 d. After fixation for 10 min at
room temperature with 4% paraformaldehyde, the cells were immunostained simultaneously with goat anti-GFAP
polyclonal antibody and mouse anti-Nestin monoclonal antibody followed by donkey anti-goat Alexa Fluor® 488 and
donkey anti-mouse Alexa Fluor® 594 secondary antibodies. The nuclei were counterstained with Hoechst 33258.





















































Figure 4. Over-activation of NFκB signaling in cultured brain neural stem/progenitor cells from GFAP-Cre-IKKβCA mice
led to loss of stemness (selfrenewal and tripotency). A. Diagram of modified stemness assay. Passage 2 neurospheres
cultured from brain subventricular zones (SVZ) of littermate wild-type (WT) or transgenic (TG) 5-week-old mouse were
dissociated into single cells for monolayer culture under differentiation media for 24 h. Then dissociated single cells
(500 per well) were cultured in semisolid medium containing 20 ng/mL of epidermal growth factor (EGF) and basic
fibroblast growth factor (bFGF) for 12 d. The clones with more than 300 μm in diameter were picked, dissociated and
cultured as neurosphere. The biggest secondary clones were dissociated into single cells plated on matrigel-coated
96-well plate. After 5 days’ differentiation, the cells were fixed in 4% paraformaldehyde and cell lineage differentia‐
tions were examined with multi-labeled fluorescent immunocytochemistry using cell type-specific antibodies against
neuron (N, Tuji1), astrocytes (A, GFAP) and oligodendrocytes (O, myelin basic protein). B. Fraction of primary clones
that show different multipotency. Tripotential clone: differentiating into three types of neural cells; bipotential clone:
differentiating into either two cell types; monopotential clone: differentiating into one cell type. C. The percentage of
primary clones with selfrenewal and tripotency over the plated single cells.
3. Regulation of proneuronal genes by NFκB signaling
At each step of neurogenesis, cells undergo symmetric and asymmetric dividing to maintain
stemness and generate daughter progeny. The self-renewal and neuronal fate decision of
NECs/NSCs during embryonic neurogenesis are regulated by various transcription factors
and their signaling pathways including the nuclear hormone receptor TLX (tailless), the
high-mobility-group transcription factor Sox2, the basic helix-loop-helix transcriptional fac‐
tor Hes (hairy and enhancer of split), the tumor suppressor phosphatase Pten (phosphatase
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and tensin homolog deleted on chromosome 10), and the Drosophila membrane-associated
protein Numb homologs, Numb and Numblike [48]. Neuronal fate decision also relies on
the intrinsic proneuronal genes in NECs/NSCs/NPCs [49]. The proneuronal factors specify
distinct neuronal identities in different regions of the nervous system [49, 50]. Transcription‐
al activation and epigenic modification of the proneuronal genes are essential for neuronal
lineage progression [51]. Little is known about the effect of NFκB signaling on the expres‐
sion or function of proneuronal factors during neurogenesis. The Hes family plays key but
opposing role in regulating neurodevelopment. Hes1 and Hes5 are activated by Notch sig‐
naling and repress the expression of proneuronal factors such as Mash1, Neurogenin, Math
and NeuroD [52, 53, 54]. In contrast, Hes6 promotes neuronal differentiation but inhibits as‐
trocyte differentiation [55, 56]. Notch signaling is regulated by NFκB signaling, and thus it is
speculated that NFκB signaling may regulate the expression of proneuronal genes during
neural induction and neurogenesis [57, 58, 59]. The tripartite motif-containing protein 32
(Trim32) promotes asymmetric dividing and neuronal differentiation of NSCs/NPCs by reg‐
ulating protein degradation and microRNA activity [60, 61], and enhancing retinoic acid re‐
ceptor-mediated transcription [62]. Our studies demonstrated that NFκB inhibition blocks
the asymmetric distribution of Trim32 and maintain NSC selfrenewal [32], implying that
NFκB signaling may initiate neuronal differentiation through suppressing Trim32 function.
4. Regulation of neural induction and neural plate patterning by NFκB
signaling
NFκB signaling is essential for embryonic development (http://www.bu.edu/nf-kb/gene-re‐
sources/gene-knockouts/) because p65 knockout mice died on E15 and p65/p50 or p65/c-rel
double knockout mice died on E13 due to liver degeneration [63, 64]. Such embryonic lethal‐
ity precluded further investigation on the role of NFκB in late embryonic brain develop‐
ment. Additional knockout of TNF receptor 1 (TNFR1) in these p65-null mice rescued
embryonic lethality [65], providing an opportunity to investigate the role of NFκB signaling
in regulating embryonic neurogenesis [34]. However, the distribution pattern of NSCs/NPCs
and cell lineage analysis in neurogenic zones of these mutants have not yet been examined.
IKKα/IKKβ double knockout mice died on E12 due to apoptosis of NECs leading to impair‐
ments in neurogenesis [66].
Several lines of clinical studies identified the correlation of NFκB signaling defects to vari‐
ous neurodevelopmental disorders. Among 6 genes associated with nonsyndromic autoso‐
mal-recessive mental retardation [67, 68, 69], two, NIK- and IKKβ-binding protein (NIBP)
[67, 68, 69] and coiled-coil and C2 domain-containing protein 2A (CC2D1A) [70, 71], have
been shown to regulate NFκB signaling through the classical IKKβ pathway, implying the
important role of NFκB signaling in mental retardation and possibly other neurodevelop‐
mental diseases. In autism spectrum disorders, activation of NFκB signaling is significantly
increased [72, 73, 74], although the role and mechanism of the activated NFκB signaling re‐
main to be determined.
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During neural induction, the ectodermal epithelial cells transit into NECs due to the inhibi‐
tion of bone morphogenetic protein (BMP) signaling by the neural inducer (Chordin, Nog‐
gin and Follistatin). In this original “default model”, high activity of BMP signaling defines
epidermis, while absence of BMP specifies neural plate [75, 76, 77]. However, this model can
no longer explain the complicate process of neural induction, which involves additional sig‐
naling pathways such as Wnt/β-catenin, FGF, Sox2, and Notch signaling [77, 78, 79, 80, 81,
82]. NFκB signaling is shown to inhibit BMP signaling in oesteoblastogenesis [83, 84]. We
speculate that NFκB may regulate neural induction. Previous studies showed that the grad‐
ed activation of NFκB/c-rel protein in the dorsal region determine the dorsal-ventral pat‐
terning in Drosophila [85, 86, 87, 88] and Xenopus laevis [89]. During mouse embryogenesis,
virtually all members of the NFκB pathway are expressed in embryonic, trophoblast, and
uterine cells [90]. It is proposed that NFκB may protect the embryos exposed to embryopath‐
ic stresses, possibly through its anti-apoptotic effect [90]. However, there is no direct evi‐
dence for the role of NFκB signaling in the in vivo neural induction (Figure 5).
5. Importance of NFκB signaling in mediating early differentiation of
ES/iPS
In vitro neural induction from cultured ES cells or induced pluripotent stem (iPS) cells has
been established [80, 82, 91, 92], but the signaling mechanisms remain largely unknown.
Such induction is an excellent in vitro model to recapture the in vivo neural induction and
embryonic neurogenesis [80]. The signaling pathways identified during endogenous embry‐
onic morphogenesis can be applied to the neural induction and patterning, such as BMP,
FGF, Wnt, Shh and Notch signaling [77, 78, 79, 80, 81, 82]. We speculate that NFκB signaling,
through crosstalk with these signaling pathways, play an important role in the neuronal in‐
duction from ES or iPS cells (Figure 5) [80].
During murine spermatogenesis, NFκB is activated in a stage-specific manner [93]. During
oocyte maturation and early embryonic development, NFκB is activated [94, 95]. In Droso‐
phila melanogaster, the mRNA of the p65 homologue, named Dorsal, is maternally ex‐
pressed and is concentrated in the egg cortex [85]. In Xenopus, NFκB activation is observed
during oocyte maturation [96] and in late blastulae and gastrulae [97]. In zebrafish, NFκB
signaling regulates notochord differentiation via activating the expression of no tail (ntl)
gene [98]. In mouse embryos, NFκB activation is crucial to engage development beyond the
2-cell stage [94]. NFκB mediates the neurogenic effect of erythropoietin in neurosphere cul‐
tures from E14 mouse ganglionic eminence [99]. Recently, it has been shown that murine
and human ES cells possess a low level of NFκB activity that increases significantly during
the differentiation process [100, 101, 102]. In human ES cells, the classical NFκB pathway
regulates differentiation while the non-classical pathway maintains pluripotency [103]. The
transcription factor Nanog is essential in maintaining pluripotency of ES cells [104]. During
ES cell differentiation, endogenous NFκB activity and target-gene expression are increased
(Figure 5) [101, 102, 105]. NFκB inhibition increases expression of pluripotency markers [106,
107]. Nanog binds to NFκB proteins, inhibits NFκB activity and cooperates with Stat3 to
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maintain pluripotency [100]. ES cell-specific miR-290 maintains the pluripotency and self-re‐
newal of ES cells through repressing classical NFκB signaling [107]. Forced expression of
p65 causes loss of pluripotency, promotes differentiation of ES cells, and leads to an epithe‐
lial to mesenchymal transition [107]. These data define p65 as a novel target gene of miR-290
cluster and provide new insight into the function of ES cell-specific miRNAs [107]. Taken
altogether, NFκB signaling is activated and required during the early differentiation of vari‐
ous stem cells and embryogenesis (Figure 5).
Zygotes 2-cell stage ESC
Neural induction and neural fate decision
EB NEC Rossette NSCs NPCs Neuroblast Neuron
Stage-specific effects of NFkB signaling
Figure 5. Potential regulatory sites of NFκB signaling during neuronal cell fate decision. Solid green arrows indicate
the sites supported by limited reports, while the dotted red arrows indicate the stages that need experimental sup‐
ports. ESC, embryonic stem cells; EB, embryoid body; NEC, neural epithelial cells; NSCs, neural stem cells; NPCs, neural
progenitor cells.
6. Promotion of iPS reprograming by pharmacological or genetic
inhibition of NFκB signaling.
Various somatic cells have been successfully reprogramed into the ES-like pluripotent stem
cells by a combination of factors or a single factor [108, 109]. During the reprogramming
process, the classical NFκB signaling is inhibited [103, 106, 107]. Therefore, we speculate that
NFκB inhibition might directly induce or promote the reprograming of iPS. Many specific
inhibitors for NFκB signaling have been developed and some of them are applied to clinical
trial [110]. In addition, fibroblasts or other somatic cells from transgenic mice deficient in
NFκB signaling or clinical patients with mutation of NFκB signaling components can be
easily accessible. It will be imperative to use NFκB inhibitors or genetic sources for easy and
fast generation of iPS for drug discovery and cell transplantation studies.
7. Concluding remark and future direction
NFκB signaling is a key mediator for numerous niche factors that regulate various stages or
phases of neural induction and neurogenesis. The classical pathway of NFκB activation
plays important role in regulating selfrenewal/multipotency and early differentiation of
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NSCs and ES/iPS cells. During neural induction both in vitro and in vivo, NFκB signaling is
required. However, further studies are needed to determine the expression and function of
NFκB signaling during the formation of embryoid body and neural rosette (Figure 5). The
upstream regulation and downstream mechanism will be important targets to better under‐
stand the essential role of NFκB signaling in initiating early differentiation of both neural
induction and neurogenesis. These studies will open a potential avenue for the development
of therapeutics for the treatment of neurodevelopmental disorders and neurodegenerative
diseases. Emerging evidence suggests that non-classical and atypical NFκB pathways are
implicated in ES cell differentiation [101, 102, 111]. It will be important to evaluate the differ‐
ent role of three NFκB pathways during neuronal fate decision.
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1. Introduction
The mammalian telencephalon, which comprises the cerebral cortex, olfactory bulb, hippo‐
campus, basal ganglia (striatum and globus pallidum), and amygdala, is a highly complex
and evolutionarily advanced brain structure. All higher brain functions including the inte‐
gration and processing of sensory and motor information, the memory storage and retrieval,
and the regulation of emotional and drive states take place at the telencephalic level. In hu‐
mans, the telencephalon also governs the ability to make rational decisions, to plan for the
future and to have the creative impulses [1].
At cellular level, the telencephalon is populated by a large diversity of neurons, including
glutamatergic projection neurons, GABA (γ-aminobutyric acid)-ergic interneurons and
projection neurons, as well as cholinergic interneurons and projection neurons.
Many neurological pathologies are caused by malfunction of telencephalic neurons, as a re‐
sult of neurodegenerative processes (e.g. Alzheimer disease), genetic mutations (e.g. Hun‐
tington disease), or abnormal development (e.g. autism, schizophrenia and epilepsy), all
with devastating consequences for the normal brain function.
During the past ten years much progress has been made in elucidating the mechanisms that
orchestrate the generation of different telencephalic neuronal subtypes. A combination of
fate-mapping studies with genetic loss-of-function and gain-of-function experiments has
been successfully used to uncover important molecular players in the development of the
rodent telencephalon.
At early stages of  its  development,  the telencephalon is  divided into two main regions:
dorsal  (pallium) and ventral  (subpallium).  The pallium is  further  subdivided into three
longitudinal zones: dorsal,  medial,  and lateral.  The dorsal pallium gives rise to the neo‐
© 2013 Nat et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
cortex -  the most complex structure of the mammalian brain. The medial pallium devel‐
ops into the hippocampal formation (archicortex), cortical hem and the choroid field. The
lateral pallium matures into the paleocortex (olfactory and some limbic areas).  From the
ventral  telencephalon medial,  lateral  and caudal  ganglionic  eminences  (MGE, LGE  and
CGE)  emerge  giving  rise  to  the  basal  ganglia  and  parts  of  the  amygdala,  but  also  to
neurons that migrate into the cortex and olfactory bulbs. The progenitor domains in the
embryonic telencephalon generate specific types of neurons which finally form the com‐
plex neural networks of the mature telencephalon.
Understanding the developmental ontogeny of the diverse telencephalic neuronal popula‐
tions provides an essential framework for the design of rational approaches towards pluri‐
potent stem cell differentiation for cellular models and cell replacement therapies for
telencephalic related diseases.
In the first part, we review the stages of the mouse telencephalic development, the morpho‐
gens and the transcription factors (TF) that are intimately involved in the telencephalic pat‐
terning and neuronal subtype specification (Sections 2-5).
In the second part, we present recently reported protocols for differentiation of mouse and
human pluripotent stem cells into telencephalic populations, following the development
principles and reflecting the in vivo signaling pathways; we point on the relevant morpho‐
gens and TF in each stage, where the level of expression of relevant sets of TF can be consid‐
ered as a milestone between each differentiation step in vitro [2] (Sections 6-8).
Finally, we describe our model system in which the in vitro differentiation of human and
mouse embryonic stem (ES) cells are temporally aligned to each other and compared with
mouse telencephalic neurogenesis in vivo [3]. Since the telencephalic development has been
extensively studied in animal models, it is important to strengthen the interspecies compara‐
tive approaches in order to gain further insights into the human telencephalic development.
We provide evidence for differences in the default differentiation of mouse and human plu‐
ripotent stem cells that proves the utility of the comparative system for optimizing the di‐
rected telencephalic differentiation of human pluripotent stem cells. We also exemplify how
Hedgehog (Hh) signaling pathway is implied in telencephalic neuronal fate decision in vitro
and in vivo (Section 8).
2. Telencephalic neuronal cell diversity
The neurons populating the mature telencephalon are generally classified based on their in‐
trinsic properties: neurochemical profile, morphology and electrophysiological responses.
The understanding of how the telencephalic neuronal subtypes are specified encompasses
not only the signaling pathways that act in spatial-temporal sequences to confer positional
and molecular identity but also the location of the progenitors early in development and the
migration pathways they undertake to reach their final destination in the mature brain. The
main neuronal types and telencephalic domains in the adult and embryonic mouse brain are
schematically presented in Figure 1.
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Schematic mouse mature (left side) and embryonic (right) brain; telencephalic subdivision: olfactory bulb (Ob), neo‐
cortex (Ncx), palleocortex (Pcx), archicortex (Acx), hippocampus (Hi), striatum (St) and globus pallidum (GP), pallium
(pink) medial ganglionic eminence (MGE-violet), lateral ganglion eminence (LGE-light green), caudal ganglionic emi‐
nence, (CGE-dark green); domains and origins (as arrows) of telencephalic glutamatergic (red), GABAergic (green) and
cholinergic (blue) neurons.
Figure 1. The domains of telencephalic neurons in adult and embryonic mouse brain
Glutamatergic projection (pyramidal) neurons comprise the majority (70-80%) of cortical
neurons, they are generated in the dorsal telencephalon; have an excitatory role in the corti‐
cal and include many subtypes. Each subtype is characterized by a specific combination of
laminar position, morphology, marker expression and connectivity pattern [4;5].
Cajal-Retzius neurons are a transient population expressing reelin and playing a key role in
the formation of the cerebral cortex. They die during the first postnatal week [6].
GABAergic neurons are generated in the ventral telencephalon and also include many sub‐
types of interneurons and projection neurons.
GABAergic cortical interneurons, comprising 20-30% of the cortical neurons, have an inhibi‐
tory role in the cortical circuits; they originate in the ventral telencephalon and subsequently
migrate dorsally into the developing cortex.
Other types of GABAergic neurons include the interneurons and projection neurons that
populate the striatum, pallidum, olfactory bulb and other forebrain ventral regions.
Different subclasses of GABAergic interneurons arise from different progenitor domains in
the subpallium: somatostatin (Sst) subclasses of GABAergic interneurons that ultimately re‐
side in the cortex and the basal ganglia are generated in dorsal MGE (dMGE) [7;8]. Parvalbu‐
min (Pv) subclasses of GABAergic interneurons, constituting the majority of the cortical
interneurons, are generated in ventral MGE (vMGE) [9;10]. Calretinin (Carl), NPY and reelin-
expressing GABAergic cortical interneurons are produced primarily in CGE [11;12]. Calr ex‐
pressing GABAergic interneurons, which ultimately reside in the olfactory bulbs and
amygdala, arise from the dorsal LGE (dLGE) [13].
GABAergic projection neurons, such as the medium spiny neurons (MSN) which constitute
the majority of the striatal neurons, express DARPP32 and Calr and arise from the ventral
LGE (vLGE) [13;14].
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Cholinergic neurons in the telencephalon (both interneurons and projection neurons) are gen‐
erated in the MGE. First, cholinergic projection neurons are produced by vMGE, followed
by the production of cholinergic interneurons from dMGE, at later time points. Cholinergic
interneurons populate the striatum; cholinergic projection neurons populate the pallidum
and the septum and project mainly to neocortex and hippocampus, respectively [15].
3. Stages in telencephalic development
A fundamental feature of the nervous system development is the precise temporal sequence
of cell type generation. The first neural cells, neuroepithelial (NE) cells, arise from the pluri‐
potent stem cells of the early blastocyst that differentiate from the ectoderm towards the
neuroectoderm through a process named neural induction [16;17].
Morphologically, NE cells are columnar epithelial cells which form the neural plate and later
on the ventricular zone (VZ) of the neural tube. They are considered to be primordial neural
stem cells that give rise to various types of neurons, followed by glial cells [18-20]. The ela‐
borated process by which NE cells progress towards telencephalic neurons can be divided
into several discrete stages:
1. Early anterior/posterior (A/P) patterning. The NE cells in the neural plate acquire an
A/P identity; the anterior ones give rise to the telencephalic primordium.
2. Dorsal/ventral (D/V) patterning. Once the neural tube is formed and the telencephalic
primordium is established, it is subdivided into discrete territories where the NE cells
proliferate and transform into neural progenitor (NP) cells that reside in the adjacent
newly-formed subventricular zone (SVZ). In the dorsal telencephalon, the NP cells are
radial glia and basal (or intermediate) progenitors [5;21-23]. Different progenitor do‐
mains are formed in the ventral telencephalon: MGE, LGE and CGE.
3. Neuronal specification. Each of the progenitor domains produces specific types of neu‐
rons which further develop different neurotransmitter identities and connectivity patterns.
The signaling pathways controlling the neural cell fate specification during these stages
have been the focus of intense research in the recent years [4;19;24-27]. Extrinsic factors,
named morphogens, induce two or more different cell fates in a concentration-dependent
manner by modulating the expression and activity of specific TF. The TF can in turn modu‐
late the secretion of morphogens. The combinatorial expression of these TF instructs each
unique NP population to generate progenies that are committed to specific neural fates.
4. Stage-related morphogens in mouse telencephalic neurogenesis
The  morphogens  known  to  play  a  role  during  telencephalon  development  are:  sonic
hedgehog (SHH), fibroblast growth factors (FGFs), bone morphogenetic proteins (BMPs),
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Wingless/INT  proteins  (WNTs),  transforming  growth  factors  (TGFs)  and  retinoic  acid
(RA).  They are  secreted from specific  centers,  named organizers,  during early  stages  of
development [28].
Genetic evidence based on loss- and gain-of-function studies have indicated that the role of
these morphogens can be rather complex. Depending on the developmental stage it ranges
from establishment of general patterning characteristics to neuronal specification
[5;21;23;26;29-33].
4.1. Early A/P patterning
A/P patterning starts to emerge in parallel with neural induction, prior to and during gas‐
trulation. At embryonic day (E) 8.5, in regions of the embryo protected from the influence of
caudalizing factors, such as WNTs, BMPs, and RA, or where their antagonists are secreted,
such as Dickkopf1 (DKK1), an inhibitor of the WNT signaling pathway, and Noggin, an in‐
hibitor of the BMP signaling pathway, the NE cells develop an anterior character and form
the prospective forebrain (future telencephalon and diencephalon) [28;33-35]. FGFs (e.g.
FGF8, FGF15, FGF3) are expressed early on at the anterior tip of the neural plate and then
maintained in the anterior limit of the neural tube [32]. Although not a primary inducer of
the telencephalic fate, FGF signaling influences the telencephalic gene expression [32;36].
4.2. D/V patterning
With regard to the location and timing of telencephalic progenitor generation, different ex‐
trinsic factors are involved in their patterning and self-renewal. WNTs and BMPs pattern
the telencephalic progenitors dorsally, while SHH patterns them ventrally. BMPs are ex‐
pressed dorso-medially and are required for the formation of the choroid plaque and the
cortical hem [31;37;38]. WNTs are secreted from the cortical hem and promote the develop‐
ment of the hippocampus [30]. The expression of SHH is first observed at E8.5 in structures
adjacent to the ventral telencephalon, and by E9.5 in the MGE and preoptic regions [29].
SHH promotes the formation of all ventral telencephalic subdivisions [29;39-41]. FGFs are
involved in both ventral and dorsal patterning [27;30;32;42;43]. Activin, a TGF-related mole‐
cule, acts ventrally in the CGE patterning [44]. RA contributes to the patterning of the lateral
telencephalon and participates in setting-up the D/V boundary [45-49].
4.3. Neuronal specification
The balance between the signaling inputs that control NP self-renewal and differentiation is
critical for the initiation of the terminal differentiation program. FGFs and SHH, in addition
to their patterning activities, promote self-renewal and prevent differentiation, while RA
promotes neuronal differentiation [1;47]. Notably, it has been shown that the expression of
SHH is required during distinct developmental windows for the specification of neuronal
identity [29]. FGF signaling may ultimately influence the generation of cell diversity within
the ventral telencephalon [30;50]. WNT promotes neuronal differentiation in different late
cortical progenitor cell populations [51]. BMPs inhibit neurogenesis but could participate in
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late neuronal specification and maturation of different subpopulations [52]. Activin is also a
potent neurotrophic factor that induces differentiation of telencephalic neural precursors in‐
to calretinin-positive cortical interneurons [44].
5. Stage-related TF in mouse telencephalic neurogenesis
The main TF involved in the early patterning and specification belong to homeobox domain
(HD) and basic helix-loop-helix (bHLH) families, however other TF such as zinc-finger
proteins also have essential functions.
The main HD containing TF families are: paired-box (e.g. Pax6), forkhead box (e.g. Foxg1),
NK2 homeobox (e.g. Nkx2.1, Nkx6.1), orthodenthicle homeobox (e.g. Otx1/2,), sine-oculis
homeobox (e.g. Six3), GS homeobox (e.g. Gsh2), distal-less homeobox (e.g. Dlx1-6), LIM ho‐
meobox (e.g. Isl1, Lhx2, Lhx6, Lhx8), empty-spiracle homeobox (e.g. Emx1/2), T-box: (e.g.
Tbr1/2). Other TF, such as Mash1, Ngn1/2 and Olig2, belong to bHLH class. Gli members are
zinc-finger proteins.
5.1. Early A/P patterning
The telencephalic neuroepithelium is first characterized by the expression of FoxG1 (also
named BF1) [53], Pax6 [54;55] and Gli3 [56]. The anterior phenotype also expresses Six3,
Otx1 and Otx2 [57-59].
5.2. Dorsal/ventral patterning
In the mouse dorsal embryonic telencephalon, Pax6, Emx1 and Emx2 are specifically ex‐
pressed in VZ and SVZ progenitor domains (Figure 2A).
Pax6 which is essential for setting up the sharp border between ventral and dorsal telencepha‐
lon is mainly expressed in the prospective neocortex, while Emx1 and Emx2 are medially ex‐
pressed  in  the  archicortex  (later  hippocampus);  Lhx2  is  expressed  in  both  regions
[30;31;45;60;61], Tbr2 is expressed in the SVZ corresponding to basal progenitor domains
[62;63].
Nkx2.1  expression  is  the  hallmark  of  the  MGE  development.  At  E9.5,  Nkx2.1  appears
within the ventral telencephalic domain, defines the MGE at the molecular level and per‐
sists in this region throughout development (Figure 2A). Around E10.0 the expression of
Gsh2 accompanies the emergence LGE and further to CGE, with a lower expression level
in MGE (Figure 2A). Nkx6.2 is expressed along the MGE/LGE sulcus and at high levels
in the dMGE [1;64].
The mutual antagonism between Pax6 and Nkx2.1 and later on between Pax6 and Gsh2 is
required for the correct positioning of the D/V boundary [65-67]. FoxG1 is involved in both
ventral and dorsal patterning [27;30;32;42;43;52].
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The central mechanism that determines NP D/V patterning is the activity of the Gli family of
transcriptional regulators–Gli1, Gli2, and Gli3. SHH promotes the formation of a ventral tel‐
encephalic subdivision by inhibiting the dorsalizing effects of Gli3 [27;35;56;68]. Gli3 is high‐
ly expressed dorsally, with lower expression in the LGE and MGE. Gli1 is expressed
ventrally, at high levels in the progenitor domain of the dMGE and vLGE, whereas Gli2 is
highly expressed in the progenitor domain of the dorsal telencephalon, with a lower expres‐
sion in the LGE (Figure 2B).
Figure 2. The domains of the main transcription factors implied in dorsal-ventral patterning in mouse embryonic
telencephalon.
5.3. Neuronal specification
The mechanisms of neuronal specification in the dorsal telencephalon have been extensively
studied in the context of cerebral cortex development. The dorsal progenitors produce neu‐
rons, in a tightly controlled temporal order from E10.5 to E17.5. Pax6, Ngn1 and Ngn2 in‐
struct glutamatergic identity and inhibit astroglial differentiation [69-72]. The differentiation
by Ngns involves the sequential activation of the expression of other TF such as NeuroD,
Tbr1 and Tbr2 [69]. NeuroD has been implicated in the terminal differentiation of the hippo‐
campus [73]. The differentiation of specific populations of projection neurons is controlled
by neuronal subtype-specific genes, which have only begun to be identified. The timing of
cortical neurogenesis is encoded within lineages of individual progenitor cells, with differ‐
ent locations [74].
The earliest born neurons form a layered structure termed the preplate, which is later split
into the superficial marginal zone and the deeply located subplate. The cortical plate, which
will give rise to six-layered neocortex, begins to develop between these two layers. The later
born neurons arriving at the cortical plate migrate past earlier born neurons [5;74]. During
development, neurons in different layers are generated in an inside-first, outside-last order,
and newly postmitotic neurons are specified to adopt the laminar positions characteristic of
their birthdays [5;24;75].
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Mash1 is the main neurogenic TF in the ventral telencephalon and is involved also in the
neurotransmitter identity specification, being a selective instructor of GABAergic identity
[70;76-82]. Olig1/2 can promote both neuronal and oligodendroglial fates while inhibiting
astrogliogeneis [83].
Dlx genes (Dlx1, 2, 5 and 6) are expressed in ventral progenitors and neurons in MGE, LGE
and CGE, and are likely to play a role in neural specification [78;84;85].
Interestingly, MGE, LGE and CGE progenitor domains do not give rise to homogeneous
populations of neurons, which is most likely due to a further subdivision of these domains
into regions with spatially restricted expression of specific TF.
There is also a temporal control of the specification of various neuronal subtypes; as a gener‐
al pattern, the earlier- born ventral cells give rise to projection neurons while the more dor‐
sally positioned later-born cells generate interneurons [24;82;86-88].
MGE is characterized by the early production of cholinergic projection neurons from its
ventral part, followed by the late production of GABAergic and cholinergic interneurons
from  the  dorsal  domains.  Two  TF  are  detected  at  E12.5  exclusively  in  the  MGE:  Lhx6
and Lhx8 (or Lhx7) [89],  suggesting a role in the specification of MGE-derived neurons.
Lhx6-expressing neurons have the characteristics of proto-GABAergic neurons with dual
differentiation potential, while Lhx8 seems to be involved in the differentiation of specif‐
ic cholinergic neurons [15;90]. The differentiation of a common proto-GABAergic precur‐
sor  into  mature  subtypes  is  regulated  by  the  combinatorial  activity  of  the  Lhx6,  Lhx8
and Isl1. Those proto-GABAergic neurons that maintain the expression of Lhx6 differen‐
tiate into mature GABAergic striatal  interneurons.  By contrast,  induction of Isl1 and the
combined  activity  of  Lhx7/8  and  Isl1  results  in  down-regulation  of  Lhx6  and  commit‐
ment  along  the  cholinergic  interneuron  sublineage  [90-92].  Thus,  it  appears  that  a  LIM
HD  transcriptional  code  determines  cell-fate  specification  and  neurotransmitter  identity
in neuronal subpopulations of the ventral telencephalon.
Ventral LGE generate GABAergic projection neurons that also express Isl1 during early
specification, followed by the expression of other striatal-specific TF such as FoxP1, FoxP2,
and Ctip2 [93-95]. Later in development, dLGE generates interneurons that migrate to the
olfactory bulbs [13;95].
6. Telencephalic neurons generated from mouse ES cells
Mouse ES (mES) cells have emerged as a powerful tool for developmental biology. Several
studies have focused on mES-derived telencephalic progenitors and the specific neuronal
populations they generate in vitro and in vivo [3;96-101]. 
6.1. Early A/P patterning
After  the  first  generation  of  defined  telencephalic  precursors  from  mES  cells  based  on
studies  of  forebrain  development  [101],  significant  improvements  regarding  the  success
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of  neural  induction and telencephalic  patterning have been reported during the  follow‐
ing years [96;100].
Blocking  the  WNTs  and  BMPs  pathways  by  applying  the  antagonists  DKK1  and
BMPR1A-FC,  respectively,  cause  neural  induction  in  more  than  90%  of  mES  cells  and
maintained around 35% of the progenitors as telencephalic, expressing FoxG1 [101]. Oth‐
er  following  studies  has  reported  a  massive  FoxG1  expressing  telencephalic  progenitor
generation  in  serum-free,  RA-free  conditions  [96-98;100],  while  using  a  RA  treatment,
FoxG1 expression has not been detected [98].
6.2. Dorsal/ventral patterning
SHH or a Hh agonist treatment on telencephalic progenitors suppresses the dorsal marker
Pax6 and induced the ventral marker Nkx2.1. SHH application does not cause substantial
difference in the level of Gsh2 expression [100;101].
The  majority  of  mES  cell-derived  progenitors  exhibit  by  default  a  ventral  phenotype
which has been attributed to the high level  of  endogenous SHH signaling.  Blocking the
Hh signaling  converts  most  of  the  ventral  telencephalic  precursors  into  dorsal  progeni‐
tors,  with the majority expressing typical markers of the dorsal telencephalon:  Pax6 and
Emx1/2 [3;97;99].
6.3. Neuronal specification
The  telencephalic  progenitors  derived  from  mES  cells  can  be  directed  to  neurons  that
express  the  excitatory  neurotransmitter  glutamate  and  the  inhibitory  neurotransmitter
GABA [3;102-106].
The dorsal progenitors have been shown to produce mature neurons with many features of
cortical pyramidal neurons in a temporal manner similar with in vivo corticogenesis. The
first neurons generated in these cultures are reelin-positive Cajal-Retzius-like and subplate-
like neurons expressing Tbr1, followed by the glutamatergic neurons generated in an inside-
first, outside-last manner. The majority of the cells generated by Gaspard et al. express
markers of deep cortical layer V and VI neurons, like Tbr1, Otx1, Ctip2 and FoxP2 [102]. Eir‐
aku et al. have also generated deep layer neurons, positive for Ctip2 and Emx1 in the first 9
days of neuronal differentiation of dorsalized progenitors [96].
By transplantation of dorsally patterned progenitors into postnatal murine cerebral cortex,
the production of cortical projection neurons with the correct morphology and axonal con‐
nectivity has been demonstrated [98]. The pyramidal neurons express Otx1, Emx1, and
Ctip2, corresponding to deep layers neurons. They integrate and appropriately project long-
distance axons to subcortical targets, without forming tumors [98].
Regarding the protocols for ventral neuronal specification, it has been shown that Nkx2.1
and Gsh2 expressing progenitors give rise both to GABAergic and cholinergic neurons
[3;100;101].
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Furthermore, the use of Lhx6::GFP ES cells has allowed the isolation of cells with potential
for developing into ventral telencephalic subpopulations and their follow-up during trans‐
plantation into the postnatal brain. Transplanted Lhx6::GFP cells demonstrate the ability to
retain migratory capacity and neuronal commitment without forming tumors and exhibit
cortical interneuron characteristics [100].
7. Telencephalic neurons generated from human ES cells
Neural  induction  takes  place  in  human  ES  (hES)  cells  similar  to  mES  cells,  however
with  a  different  timing.  Under  serum-free  conditions,  without  adding  known  morpho‐
gens  [3;101;105-110],  by  co-culture  with  stromal  cells  [111;112]  or  by  using  a  recently
defined  protocol  with  dual-SMAD-inhibition  [113],  it  has  been  demonstrated  that  hES
cells  differentiate  into  a  synchronized  population  of  NE  cells  organized  into  neural-
tube-like rosettes  within 2 weeks,  a  time corresponding to the development of  the neu‐
ral  plate/tube  in  a  human  embryo.  Around  day  8-10,  the  primitive  NE  cells  express
PAX6,  and  the  neural  fate  is  consolidated  by  SOX1  expression  around  day  14
[3;100;105;106;108-110].
7.1. Early anterior/posterior patterning
In the absence of exogenous morphogens, hES cells differentiate into progenitors that uni‐
formly expressed anterior TF, including FOXG1, OTX2, SIX3, LHX2 but not posterior TF
[3;107;106;109]. Even when the neural induction is performed by co-culturing with stromal
cells, a large population of neural progenitors exhibit anterior characteristics [112]. FOXG1
appears at approximately day 10 and it is still expressed at day 24 and even in postmitotic
neurons, 1 month after differentiation. PAX6 is co-expressed in nearly all of the FOXG1 tele‐
ncephalic progenitors (95% of all cells) one month after differentiation, in the absence of
growth factors or morphogens [3;106;114].
7.2. Dorsal/ventral patterning
WNT proteins and their downstream molecules have been found to be highly expressed
right after the generation of NE cells. In minimal medium and in the absence of known
morphogens, hES cell-derived telencephalic progenitors exhibit a dorsal telencephalic trait,
which has been attributed to endogenous WNT signaling [115]. The activation of SHH
and/or inhibition of WNT permitts the specification of ventral telencephalic progenitors.
At the lower dosage, SHH reduces the PAX6-expressing cell population and increases the
NKX2.1 cell population. At the higher dosage, SHH almost completely eliminates the PAX6-
expressing cells, while increasing the NKX2.1 ventral progenitors. The combination of DKK1
and SHH at the lower dosage significantly increases NKX2.1 and decreases PAX6 and GLI3
expression. High concentrations of SHH significantly inhibits GLI3 expression compared
with low concentrations of SHH. The specification of dorsal-ventral progenitors by WNT
and/or SHH has been partially achieved through differentially regulating the expression of
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active and repressive forms of GLI3. Using of a low concentration of SHH alone results in
the differentiation of both LGE and MGE progenitors, whereas additional WNT inhibition
(by DKK1) further ventralizes the human neural progenitors, resulting in a predominant
population of NKX2.1 expressing MGE progenitors [115]. Aubry et al. have patterned the tel‐
encephalic progenitors by SHH and DKK1 treatment for 12 days in adherent culture and
have found a significant up-regulation of the LGE markers GSH2 and DLX2 [111].
7.3. Neuronal specification
The regionalized dorsal and ventral human telencephalic progenitors further differentiate
into functional  cortical  glutamatergic  neurons and telencephalic  GABAergic neurons,  re‐
spectively.
Cortical glutamatergic neurons have been efficiently generated in the absence of morpho‐
gens. This indicates the intrinsic tendency of hES cells to generate cortical neural cells
[3;109]. Neurons differentiated from dorsal progenitors in the absence of exogenous morph‐
ogens for 6 weeks exhibits a pyramidal morphology, with extensive neurite outgrowth, and
expressed TBR1 and CTIP2 [96, 115].
Ventral telencephalic GABAergic neurons have been induced with a high concentration of
SHH, a low dose of SHH together with WNT inhibitors [115] or by using SHH agonists [3].
Additionally, Aubry et al. have focused to the characterization of the striatal-like progeni‐
tors, showing that more than a half of the specified neurons were DARPP32 and Calr posi‐
tive, exhibiting phenotypic features of MSN. Transplantation of the LGE-patterned
progenitors in quinolinic acid–lesioned rats (a model for Huntington disease) has confirmed
the in vivo specification toward striatal MSN [111].
Human ES cell-derived telencephalic glutamatergic and GABAergic neurons have been re‐
ported to be electro-physiologically active [111;115;116] and also to integrate in the mature
telencephalon after transplantation [117].
8. Modulation of Hh signaling pathway in telencephalic cells generated
from mouse and human ES cells
We recently proposed a novel model system in which the in vitro differentiation of hES and
mES cells are temporally aligned to each other and compared with mouse telencephalic neu‐
rogenesis in vivo. In this comparative model system, we tested the in vitro role of Hh signal‐
ing for ES cell-derived telencephalic differentiation (Figure 3) [3].
Neural differentiation of 2 lines of mES cells and 2 lines of hES cells was studied under
identical,  defined  conditions,  but  following  different  time-schedules  for  mouse  and  hu‐
man cell  cultures.  The in vitro  time schedules were based on data from in vivo  develop‐
ment  as  a  reference  for  the  stages  of  neural  induction,  neural  patterning,  and neuronal
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specification.  In  addition,  we  developed  a  specific  profile  of  marker  genes,  which  was
derived from in vivo studies.
Our results demonstrated that neural differentiation took place in mES cell-derived cultures
resulting in the generation of neural progenitors and neurons in a time-frame which mirrors
telencephalic neurogenesis in vivo. The expression levels of telencephalic markers were com‐
parable between in vivo and in vitro differentiated populations. We demonstrated that the
neural differentiation in human cells can be temporally aligned with mouse cells in the pro‐
posed neurogenic time-windows. Thus, our temporally aligned, comparative cell culture
model offered a novel platform for analyzing the effect of signaling molecules on the gener‐
ation of specific telencephalic populations in mouse and human cell cultures.
Figure 3. Hh signaling for modulation of dorsal ventral patterning in mouse and human telencephalon in vivo and in
vitro, in ES stem cell-derived cell cultures (modified from Nat et al 2012 [3]).
To exemplify the value of this approach we analyzed in greater detail a single process, the
step of D/V telencephalic patterning. Thus, we monitored the effect of pharmacological
modulators of the Hh signaling pathway, purmorphamine—an agonist and cyclopamine—
an antagonist acting on the Smoothened receptor (Smo), regarding the expression of region-
specific TFs and signaling molecules relevant for telencephalic development in vivo.
Purmorphamine strongly up-regulated the expression of telencephalic ventral markers Nkx2.1,
Nkx6.2, Lhx6, and Lhx8 in mouse and human cells, thus reflecting the in vivo process of the MGE
patterning and specification. Cyclopamine up-regulated the expression of telencephalic dorsal
markers, but at lower levels in human compared with mouse cells. Interestingly, the modula‐
tion of Smo in vitro differentially affected the expression of molecules of the Hh pathway, espe‐
cially the Gli1 and Gli3 effectors and Ptch receptors, in mouse vs human cells.
We additionally examined how the SHH expression itself was modulated by Smo agonist or
antagonist treatment. We reported that SHH expression is regulated in a very dynamic way
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by Hh pathway modulation, both in mES and hES cell-derived models. In particular, a very
robust up-regulation of SHH by purmorphamine was observed in the human model, where
SHH was not expressed in untreated controls. Shh was expressed in both progenitor cells
and neurons in our cultures. This might be explained by the non-cell autonomous mecha‐
nisms recently described in the mouse embryonic telencephalon, where both Lhx8 and Lhx6
genes controlled the expression of Shh in the mantle zone of the MGE, corresponding to ear‐
ly-born neurons [118]. Thus, Lhx6 and Lhx8 appear to regulate MGE development by pro‐
moting Shh expression in MGE neurons, which, in turn, promotes the developmental
program of the dMGE.
The activation of Hh signaling via Smo with purmorphamine converts the primitive dorsal
telencephalic precursors to ventral progenitors. These progenitors differentiate into neuro‐
nal subtypes including GABAergic and cholinergic neurons.
Our results provided evidence for the different default telencephalic differentiation of
mouse and human ES cells: ventral and dorsal, respectively. Additionally, it proved the util‐
ity of the comparative system for optimizing the directed differentiation of human pluripo‐
tent stem cells.
9. Conclusion
Recent studies have shown that both mES cells and hES cells differentiate into region specif‐
ic progenitors, following the same developmental principles that have been identified by
studying mouse CNS development. Together with previous findings, our own data support
the model in which the human neural progenitors in culture develop a reverse default D/V
phenotype compared with mouse. However, early human NE cells can be efficiently differ‐
entiated into dorsal and ventral telencephalic progenitors via modulating similar molecular
pathways as described in rodents.
Therefore, mES and hES cell-derived models, directly compared in parallel experiments and
temporally aligned to in vivo telencephalic development, offer a platform for testing the ef‐
fect of morphogens, growth factors, and pharmacological substances for the generation of
specific neuronal subtypes.
Additionally, telencephalic progenitors and neurons generated in vitro from human pluripo‐
tent cells provide a unique paradigm to study the human telencephalic development.
Even more importantly, the telencephalic differentiation of human induced PS (IPS) cells
has recently been reported [119;120].
The application of optimized telencephalic differentiation protocols to IPS cell cultures de‐
rived from patients with neurodegenerative or neurogenetic diseases will provide unique
new opportunities to develop in vitro models of human diseases such as Alzheimer’s dis‐
ease, Huntington’s disease, epilepsy, and neuropsychiatric disorders. These models, based
on human neurons in culture, will critically complement existing animal models, which do
not fully reflect important features specific for the normal and pathological human brain.
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1. Introduction
Two decades ago it was discovered that the adult mammalian brain contains neural stem
cells (NSCs) and neural precursor cells (NPCs) capable of producing new neurons and glial
cells [1-3]. This has led to a great deal of research to understand the biology of these cells
and to determine signalling pathways that can be targeted to promote repair of the dam‐
aged nervous system. There are two primary regions in the adult mammalian brain that
contain adult NSCs/NPCs. These are the subventricular zone (SVZ) lining the lateral walls of
the lateral ventricles and the subgranular zone (SGZ) of the hippocampal dentate gyrus.
NPC fate is regulated by intrinsic (e.g. transcription factors and signalling mediators) and
extrinsic (e.g growth factors and extracellular matrix) factors which involve effects on prolif‐
eration, migration and differentiation of new neurons and glial cells.
This review will highlight the major signalling cascades involved in neuronal fate from birth
to integration. It will begin with a discussion of pathways involved under normal physio‐
logical conditions, which will be followed by discussion of changes to these signalling cas‐
cades following neural damage due to injury or disease. Finally, there will be a more
focused examination of the roles of suppressor of cytokine signalling (SOCS) molecules and
related pathways in the context of signalling in adult neurogenesis under basal conditions
and following neural damage.
© 2013 S. Basrai et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Adult neurogenesis
2.1. Hippocampal neurogenesis
NPCs in the SGZ become neurons of the granular cell layer of the dentate gyrus in the hip‐
pocampus. In the SGZ, the most immature NPCs (Type 1) are radial and horizontal NPCs
that transition to intermediate progenitors (type-2a, 2b and 3) and then to immature granule
neurons which become dentate granular neurons. These then make large mossy fibre projec‐
tions with CA3 pyramidal neurons [4].
2.2. SVZ neurogenesis
The SVZ produces NPCs that form neuroblasts which migrate along the rostral migratory
stream and become neurons in the olfactory bulb. These new neurons primarily become GA‐
BAergic granule neurons that provide lateral inhibition between mitral and tufted cells. A mi‐
nority  of  the  new  neurons  become  periglomerular  neurons  that  are  involved  in  lateral
inhibition between glomeruli, and a small number of these cells are dopaminergic. Similar to
the SGZ, there is a progression of NPC development in the SVZ. Slowly proliferating astro‐
cytes in the SVZ (Type B cells) are the NSCs and these generate the highly proliferative transit-
amplifying Type C cells.  These then generate post-mitotic neuroblasts (the Type A cells)
destined for the olfactory bulb via migration along the rostral migratory stream (RMS) [5-7].
3. Signalling cascades regulating NPC fate under basal conditions
NPCs from the dentate gyrus and SVZ have the potential to differentiate into neurons and
glial cells. Multiple signalling pathways are activated to produce a neuron from NSCs.
These cascades can involve both intrinsic and extrinsic factors as the NSC is created, mi‐
grates, and finally integrates into its final location.
3.1. Proliferation and neuronal fate
Many pathways important for embryonic neural development are conserved in adult neuro‐
genesis. The Wnt pathway, for example, is a key regulator of proliferation and differentiation
in development and a key regulator of adult hippocampal neurogenesis [8]. Wnt signalling re‐
sults in the activation of the GSK3β/β-catenin that leads to the increased expression of Neu‐
roD1 and promotes neuronal differentiation in NSCs [9]. Activation of Wnt, Sonic Hedgehog
(Shh), Notch, and the Sox family of genes, in particular Sox2, are also important for the forma‐
tion and proliferation of NSCs [10-12]. At early stages of differentiation, Sox2 is required for
neuronal fate; while downregulation of Sox9 by miR-124 is required for neuronal differentia‐
tion [13, 14]. Other Sox members are important for neuronal specification, including Sox3, Sox 4
and Sox 11 [15-19]. Notch signalling is important for maintaining NSCs/NPCs, however this is
dependent on the mitotic state of NSCs/NPCs [20]. Bone morphogenic protein (BMP) signal‐
ling inhibits neuronal differentiation; however expression of noggin and neurogenin-1 (Ngn1)
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in the SVZ and SGZ can obstruct this cascade [21-23]. Inhibition of the BMP pathway increases
neurogenesis initially, however it results in depletion of the NSC pool leading to decreased
neurogenesis [24]. In the dentate gyrus, the RNA-binding protein FXR2 regulates neurogene‐
sis by reducing the stability of noggin mRNA leading to an increased activation of the BMP
pathway [25]. Proliferation in the SVZ is under epigenetic control via histone HZAX phoso‐
phorylation which can limit proliferation and overall neurogenesis [26].
Proneural proteins, basic-helix-loop-helix (bHLH) transcription factors also control neuronal
fate commitment of NPCs. Type C cells of the SVZ fated to become GABAergic interneurons
in the olfactory bulb express Ascl1 [27]. Ngn2 and Tbr2 are expressed in dorsal SVZ progeni‐
tors that become glutamatergic juxtaglomerular neurons [28], while Sp8 is required for par‐
valbumin-expressing interneurons in the olfactory bulb [29]. In the SGZ, Neurog2 and Tbr2
are expressed in NPCs destined to become glutamatergic neurons in the hippocampus [27,
30, 31], while over-expression of Ascl1 produces oligodendrocytes [32].
Neurotrophic growth factors have been studied extensively in the SVZ. Many, including,
epidermal growth factor (EGF), transforming growth factor (TGF), and vascular endothelial
growth factor (VEGF) can augment SVZ progenitor proliferation and migration of newly de‐
rived cells into structures beside the lateral ventricles; however these cells primarily differ‐
entiate into oligodendrocytes [33-36]. Fibroblast growth factor-2 (FGF-2) signalling promotes
proliferation in both the SVZ and SGZ [37-39]. FGF-2 and TGF synthesis and secretion can
be augmented by ATP, which can increase proliferation, and provide a potential explanation
for the reduced neurogenesis in purinergic receptor knockout mice (P2Y1) [40, 41]. Other
factors also play a role in neurogenesis, including neuregulin-1, which has been implicated
in dentate gyrus neurogenesis in addition to having antidepressant effects [42] and Growth
Hormone (GH) which augments EGF and FGF2-induced proliferation [43]. Growth factor
signalling often leads to activation of Akt through phosphoinositide-3 kinase (PI-3K); one
negative regulator of this pathway is the phosphatase and tumour suppressor PTEN, which
has a role in regulating neurogenesis as demonstrated by increased proliferation and differ‐
entiation in mutant mice [44]. Furthermore, IGF-2 also regulates proliferation in the dentate
gyrus in an Akt-dependent manner [45].
The gp130-associated cytokines, ciliary neurotrophic factor (CNTF) and leukemia inhibitory
factor (LIF), activate Janus kinase (JAK/signal transducer of transcription 3 (STAT3)), mito‐
gen activated protein (MAP) kinase and PI-3K/Akt pathways following ligand binding.
These cytokines have been shown to regulate NSC proliferation and differentiation [46-49].
Specifically in the dentate gyrus, the activation of STAT3 from CNTF appears to be essential
for the formation and maintenance of the NSCs [50]. The role of the JAK/STAT pathway will
be discussed in more detail later. The MAPK pathway is important for neurogenesis as dem‐
onstrated by conditional knockdown of extracellular signal-related kinase 5 (ERK5) which
limits neuronal differentiation and neurogenesis resulting in impaired contextual fear ex‐
tinction and remote fear memory [51, 52].
Other molecules shown to have a role in controlling neuronal differentiation include Prese‐
nilin-1 (PS1), which is the catalytic core of the aspartyl protease gamma-secretase. Reduction
of PS1 enhances differentiation, primarily through its transducers the EGF receptor and β-




catenin [53]. Interferon-γ, which signals via STAT1, and interferon-β which does not, both
inhibit cultured adult NPC proliferation, but only interferon-γ promotes neuronal differen‐
tiation [54, 55].
3.2. Migration and integration
Migration from the SVZ along the RMS involves long distances and multiple pathways [56]
For example, it is dependent on Shh signalling, as evident by a decrease of neuroblasts in
the olfactory bulb following Hedgehog signalling interruption [11]. Shh is a chemoattractant
cue extrinsic to the neuroblast that guides migration to the olfactory bulb. Neurotrophic
growth factor signalling is also important for migration, in particular insulin-like growth
factor (IGF-1) null mice show an abundance of neuroblasts in the SVZ that have failed to mi‐
grate to the olfactory bulb [57]. Guidance cues from EphB2/ephrin-B2 pathways also enable
formation of the chain migration from the SVZ to the olfactory bulb [58]. Recently, endocan‐
nabinoid signalling has been shown to regulate migration and neurogenesis in both the SVZ
and dentate gyrus [59, 60]. Other molecules involved in this migration include polysialated
neural cell adhesion molecule (PSA-NCAM) [61-63], Slit-Robo [64] and integrins [65, 66].
Many of these factors signal via the Rho kinase pathway, which is a downstream regulator
of NPC migration [67]. In addition adult NPCs express a range of chemokine receptors and
chemokines are expressed in different brain regions, with the highest levels in the olfactory
bulb, suggesting an as yet largely unexplored role for chemokines in regulating basal adult
NPC migration [68].
The migration distance for new neurons from the SGZ is relatively short as they travel into
the granular layer above the SGZ, where guidance molecules may control this movement.
NMDA receptor signalling is required for the proper migration of newborn granular cells in
the dentate gyrus [69]. This is achieved through the activation of Disrupted-in-schizophre‐
nia (DISC1), as neurons without DISC1 migrate further into granular layer and into the mo‐
lecular layer [69, 70]. DISC1 also controls the dendritic maturation of newborn granule cells
through GABA depolarization of NKCC1 and activation of the Akt-mTOR pathway [70, 71].
New neurons must integrate into existing circuitry or they will not survive. The vast majority
of new neurons do not survive past 4 weeks. Interestingly, NMDA receptors expressed in neu‐
roblasts along the RMS are crucial to the integration of these neurons in existing olfactory bulb
circuitry [72]. Glutamate is released from astrocyte-like cells that surround the neuroblasts.
NMDA receptor activation in newly-born dentate gyrus granule cells also increases survival.
Initial GABA depolarization plays a role in the maturation of neurons in the dentate gyrus and
olfactory bulb [73, 74]. This depolarization and subsequent Ca2+ influx are required for den‐
drite initiation and elongation [75]. This process involves coordinated expression of the GABA
receptor subunit alpha2 that controls the maturation of the new neurons [76]. In addition, ag‐
rin signalling is necessary for integration and survival of newborn neurons in the olfactory
bulb, as demonstrated by a loss of agrin leading to improper synapse formation while an over‐
expression of agrin results in an increase in dendritic spines [77].
Neurotrophin signalling has important role in the survival and integration of new neurons.
Brain-derived growth factor (BDNF) binding to the TrkB receptor tyrosine kinases increases
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the number and survival of NSCs in the SVZ and olfactory bulb [78-80]. Similarly, knock‐
down of TrkB receptors and disruption of BDNF signalling in dentate gyrus progenitors
leads to shorter dendrites and reduced spine formation, culminating in a lack of survival
[81]. Fibroblast growth factor (FGF-2) has a role in neurogenesis and memory consolidation
in this context [39].
Intrinsic factors are also necessary for the maturation and survival of newly born neurons.
In the dentate gyrus, Prox1 [18], NeuroD [82, 83] and Kruppel-like factor 9 [84] play impor‐
tant roles in survival. In the SVZ, Pax6 and Dlx-2 influence neuronal fate, leading to the pro‐
duction of dopaminergic periglomerular cells in the olfactory bulb [85-87]. New neurons in
the dentate gyrus rely on cyclic response element binding protein (CREB) signalling for ma‐
turation and integration into the network. Interestingly, CREB activates miR-132 which reg‐
ulates dendrite maturation in newborn dentate gyrus granular neurons [88]. The collapsin
response mediator protein-5 (CRMP5) is expressed in both the SVZ and dentate gyrus and
CRMP5-/- mice show an increase in proliferation and neurogenesis in addition to displaying
an increase in apoptosis of granular cells in both the olfactory bulb and dentate gyrus [89].
4. Signalling cascades regulating NPC fate following neural damage
Neurogenesis and gliogenesis are known to be initiated following brain damage, such as is‐
chemia, seizures, traumatic injury and neurodegenerative diseases [90-92]. However, these
new neurons and glia usually do not effectively replenish those that were lost. Many of the
normal signalling cascades are altered following injury. Below is a discussion of the major
changes in these cascades that influence neuronal fate of the NSCs generated in the SVZ and
SGZ following injury or disease.
4.1. Brain injury
A traumatic lesion to the brain cortex results in an increase in proliferation of NSCs in the
SVZ, although varied locations and degrees of injury have resulted in an incongruity of re‐
sults across the literature [93-98]. Nonetheless, it is generally agreed that the increase in pro‐
liferation results in an increase in neurogenesis at the SVZ [99]. Expression of growth factors
such as BDNF, FGF2, GDNF, IGF-1 and VEGF are increased following ischemia and exoge‐
nous application further augments NSC proliferation and survival [100-105]. Shh expression
is also upregulated in the SVZ following ischemia, potentially playing a role in the increase
of proliferation, while Wnt expression does not change [106, 107]. Phosphorylated CREB is
upregulated following ischemia and induces hippocampal neurogenesis [108].
Following proliferation these cells must migrate and integrate to damaged cortical tissue.
The majority of research on ectopic migration from the SVZ has been performed following
an ischemic insult and has demonstrated that cells do reach the injured striatum [90,
109-114]. It appears that the cells no longer migrate in a chain formation and carry on indi‐
vidually, interestingly, at the expense of the RMS population [109, 115]. This change in mi‐
gration is the direct result of chemoattractive cues expressed from the injury site.




Chemokines and their receptors can attract neuroblasts from the RMS, for example it has
been shown that Stromal cell-derived factor-1 (CXCL12) and its receptor CXCR4 are upregu‐
lated at the injury site [116, 117]. Expression of several chemokines and their receptors is up‐
regulated on adult NPCs by inflammatory cytokines, such as interferon-γ and TNF-α [68].
Migration is also altered following an epileptic seizure: the NSCs migrate along the RMS
more quickly, while in the dentate gyrus there is faster integration and maturation [118,
119]. There are morphological changes to the hippocampal region including mossy fibre
sprouting, dispersion of the granular cell layer, and ectopically migrated dentate granule
cells in the hilus (reviewed in [120]).
When cells do migrate to the correct location they must differentiate into neurons to recover
function of neurons lost. Unfortunately, this does not appear to be consistent. Recent work on
ischemia has demonstrated that new neurons from the SVZ are found in the cortex near the le‐
sioned area, while injury of the somatosensory cortex showed the generation of astrocytes and
microglia/macrophages without any new neurons [98, 121]. Other work has found the produc‐
tion of astrocytes and oligodendrocytes near the injury site as a result of expression of repress‐
ors of neuronal fate [122, 123]. For example, the BMP antagonist, chordin, and the transcription
factor Olig2 both induce glial expression in neuroblasts at the injury site [124, 125]. However,
following ischemia, pro-neuronal transcription factors are expressed in primate progenitors in
the SGZ, including Emx2, Pax6 and Ngn2 [126]. Recently it has been shown that following thir‐
ty and sixty days after stroke, Ascl1/Mash1 expressing cells in the ischemic striatum gave rise to
GABAergic neurons and mature oligodendrocytes [127]. Even when a NSC differentiates into
a neuron, the survival of these neurons is very low. Recent work has demonstrated that the
Ras-related GTPase, Rit, is an important component in the survival of young granular cells in
the dentate gyrus following a brain injury. Rit-/- mice show a marked increase in new neuron
death following injury [128]. Recently, the small non-coding RNA molecule, miR-124a, was
shown to be altered following stroke. Interestingly, it can mediate stroke induced neurogene‐
sis via the Notch signalling pathway [129]. Inhibition of the Notch pathway increases neuro‐
genesis after spinal cord injury in zebrafish resulting in higher proliferation and more motor
neurons [130]. Lentiviral expression of Wnt3 increased neurogenesis following focal ischemia
and improved functional recovery [131].
4.2. Neurodegenerative diseases
Reports on neurogenesis in neurodegenerative diseases are highly dependent on the disease
model used. Variations in transgenic mice and other drug induced models are the most
probable cause for the conflicting results. In many models of Alzheimer’s disease, Parkin‐
son’s disease and Huntington’s disease there is impaired neurogenesis (reviewed in [132]).
Alzheimer’s disease (AD) is characterized by degeneration of basal forebrain cholinergic
neurons in the cortex and hippocampus from the deposition of neurofibrillary tangles and
amyloid-β plaques [133]. The neuropathologic hallmark of AD is the amyloid-β plaques;
however small oligomeric amyloid-β appears to be the noxious component. Neurogenesis
can be both increased and decreased in AD, depending on the transgenic model used (re‐
viewed in [132]). Early in the disease, oligomeric amyloid-β may transiently promote the
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generation of immature neurons from NPCs. However, reduced concentrations of multiple
neurotrophic factors and higher levels of FGF2 seem to induce a developmental arrest of
newly generated neurons. Further, there is a down-regulation of Olig2 and over-expression
of Ascl1 caused by amyloid-β that switches the cell fate to death [134, 135]. Generally, there
is a decrease in proliferation and survival of NSCs in the dentate gyrus and SVZ with AD. A
better understanding on the effects of amyloid-β on NSC proliferation and maturation is
needed to improve this decrease in neurogenesis.
Parkinson’s disease (PD) is the outcome of the loss of dopaminergic neurons in the substan‐
tia nigra of the midbrain (reviewed in [136]). In transgenic mouse models, there is a decrease
in newly generated neurons in both the dentate gyrus and olfactory bulb [137, 138]. Altera‐
tions in neurogenesis have been linked to a decrease in Notch1 and Hes5 expression [138].
Lack of proliferation could be the explanation for a lack of migration of NSCs to the dam‐
aged regions in PD and AD [139]. Along these lines, manipulations that increase prolifera‐
tion also demonstrate migration, for example intraventricular injection of clustering ephrin-
A1-Fc increased proliferation in the SVZ, followed by migration to the striatum and
differentiation into dopaminergic neurons in a rodent model of Parkinson’s disease [140].
Furthermore, exogenous application of EGF and FGF2 showed similar results [141]. Exciting
research in salamanders has shown regeneration of dopamine neurons following ablation
involving neurogenesis in quiescent cells. This activation is due to the loss of dopamine,
demonstrating a control of dopamine signalling maintaining homeostasis [142]. Replace‐
ment of dopaminergic neurons relies on NSC differentiation into the proper neuronal fate.
Recent studies have elucidated the transcription factors necessary to produce dopaminergic
neurons. The combination of Ascl1/Mash1, Nurr1 and Lmx1a result in the generation of func‐
tional dopaminergic neurons from mouse and human fibroblasts [143]. Other studies have
shown that Foxa2 in combination with Nurr1 can also induce the production of nigral (A9)-
type midbrain neurons from NPCs [144].
Other neurodegenerative diseases such as Huntington’s disease have shown a decrease in
neurogenesis. NPC proliferation is decreased in Huntington's disease in both the SGZ and
SVZ, with some reports of reduced numbers of newly born neurons (reviewed in [132]). In a
rat model of Huntington's disease, SGZ progenitor cell proliferation is decreased due to an
increase in Sox2-positive quiescent stem cells and a decrease in CREB signalling [145].
Overall, further investigation is needed to clarify the changes in signalling pathways follow‐
ing neurodegenerative disease. One pathway that has been extensively studied both in basal
neurogenesis and after injury is the suppressor of cytokine signalling (SOCS) family of pro‐
teins. The following section will discuss research involving the SOCS proteins and related
pathways.
5. SOCS molecules and cytokine signalling pathways
As discussed in the previous section, a diversity of signalling cascades are involved in regu‐
lating neuronal cell proliferation, differentiation and survival. However, JAK-STAT signal‐




ling seems to be one of the central pathways in the regulation of adult neurogenesis. Since
its discovery twenty years ago, this pathway has been studied extensively due to its key
roles in modulating many different physiological processes through responses to various
regulatory molecules [146].
5.1. JAK/STAT signalling
The JAK-STAT pathway can be activated by a range of cytokines, growth factors and hor‐
mones. In the regulation of adult neurogenesis, activation of this pathway is carried out by a
group of neuroregulatory cytokines. Members of this cytokine group include CNTF, LIF and
cardiotrophin 1 (CT-1), all of which belong to the interleukin 6 family of cytokines. These cyto‐
kines initiate JAK-STAT activation by binding and signalling through the LIF receptor-β
(LIFRβ)/ glycoprotein 130 (gp130) receptor complex. The receptor complex bound by CNTF
differs slightly in that it has a third extracellular receptor component, the CNTF receptor-α
(structurally related to gp130), that is held to the membrane via a glycosylphosphoinositol
[147].
Cytokine binding results in the dimerization of LIFRβ and gp130 receptors to form a com‐
plex [148]. This initiates autophosphorylation and activation of JAK proteins which are asso‐
ciated with the intracellular domains of the LIFRβ and gp130 receptors [149]. Members of
the JAK protein family include JAK1, JAK2, JAK3 and TYK2. Cytokines signalling through
the LIFRβ/gp130 pathway have been found to activate at least JAK1, JAK2 and TYK2 [150].
In terms of the CNS, only JAK1 and JAK2 expression has been found at significant levels
[151]. JAK2 is highly expressed in the developing brain compared to JAK1, thus, a role for it
in the regulation of neurogenesis in the developing brain has been suggested [151].
After activation, JAKs phosphorylate tyrosine residues in the intracellular domains of LIFRβ
and gp130. These phosphorylated residues become binding sites for SH2 domain containing
proteins such as STAT. STAT proteins are a family of transcription factors comprised of
STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 [152]. Upon binding to the ac‐
tivated receptor complex, STAT proteins are phosphorylated by JAKs resulting in their di‐
merization. Dimerized STAT proteins are now able to translocate into the nucleus and
induce gene expression of target neural genes such as glial fibrillary acidic protein (GFAP),
peripherin and vasoactive intestinal peptide [46]. Other SH2 domain containing proteins can
also bind the activated LIFRβ/gp130 receptor complex to activate the Ras/MAPK and
PI-3K/Akt signalling pathways [49].
The LIFRβ/gp130 pathway is essential for the regulation of astrogliogenesis in the develop‐
ing and adult brain. In cultured cortical precursors, CNTF, LIF and CT-1 all promote astro‐
cyte formation through LIFRβ/gp130 activation [153-155]. Integral to this pathway is
signalling via STAT3, as highlighted by the observation that STAT3 activation in neural
stem cells induces glial differentiation, while its inhibition promotes a neuronal fate [156,
157]. Also, in neuroepithelial cells, STAT3 activation promotes astrogliogenisis via LIF in‐
duced bone morphogenetic protein 2 expression [158]. In addition to regulating astroglio‐
genesis, STAT3 induction by CNTF was found to be essential in the maintenance of the SGZ
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neurogenic niche [50]. Further, it has an important role in the positive regulation of reactive
astrocytes in the injured CNS [159].
An important aspect to cytokine signalling via a pathway such as JAK-STAT is the need for
its downregulation following activation. Thus far, JAK-STAT signalling is known to be neg‐
atively regulated by protein inhibitors of activated STATs (PIAS), the SH2-containing pro‐
tein tyrosine phosphatases (SHPs) and suppressors of cytokine signalling (SOCS) proteins
[160]. In this section, SOCS proteins will be the focus of discussion as the negative regulation
of the JAK-STAT signalling pathway by SOCS has several effects on the regulation of neuro‐
genesis and NPC fate.
5.2. The suppressors of cytokine signalling
The SOCS family consists of eight members, namely, SOCS1-7 and cytokine-inducible Src
homology 2 (SH2) protein (CIS). They are characterised by a central SH2 domain, a C-termi‐
nal SOCS box and a variable N-terminal domain. In addition to these, SOCS1 and SOCS3
also contain a small kinase inhibitory domain. CIS was the first member of this protein fami‐
ly to be cloned. It is also unique to the rest of the SOCS family as a result of its SH2 domain
which differs in a few amino acids from most all other known SH2 domains [161].
SOCS expression is induced following activation of the JAK-STAT pathway. This initiates a
classic negative feedback loop whereby the SOCS proteins activated by JAK-STAT signal‐
ling now go on to inhibit it. SOCS proteins achieve downregulation of signalling by binding
to tyrosine phosphorylated proteins via their SH2 domain. The exact mechanism by which
signalling inhibition is achieved varies depending on the SOCS protein in question. For ex‐
ample, SOCS1 and SOCS3 both work to block the kinase activity of activated JAK proteins.
In the case of SOCS1, this is achieved by directly binding and blocking access to the activat‐
ed JAK. In the case of SOCS3, this is achieved by its binding to the activated gp130 receptor
such that STAT proteins can no longer dock onto the phosphorylated tyrosine residues and
be activated by JAK. One mechanism of action for SOCS2 is by blocking STAT access to the
activated receptor [162].
SOCS proteins are also able to regulate activity of target proteins, including other SOCS pro‐
teins, through interaction with their SOCS box [163, 164]. Interestingly, SOCS2, SOCS6 and
SOCS7 have the potential to interact with all members of the SOCS protein family including
themselves [164]. In terms of SOCS2, when expressed at high levels, it is able to inhibit the
action of SOCS1 and SOCS3 by targeting them for proteasomal degradation [164]. This has
also been proposed as a mechanism for the dual action of SOCS2 on GH signalling as ob‐
served in the overgrowth phenotypes of SOCS2 knockout and overexpressing mice descri‐
bed below [165].
Signalling via the JAK-STAT pathway has an important role in neural precursor prolifera‐
tion and differentiation [153, 166-168]. Following the discovery that SOCS proteins regulate
the JAK-STAT pathway, the next obvious step was to examine them for possible roles in the
nervous system. In doing so, analysis of the SOCS family gene expression in the developing
mouse forebrain brought SOCS2 into the spotlight [168]. The genes SOCS1 – SOCS3 and CIS




were found to be expressed at all ages (E10 to P25) with a common peak in expression be‐
tween E14 and P8. However, the level of SOCS2 expression was much higher in comparison.
The spatial pattern of SOCS2 expression also distinguished it from the other SOCS genes,
with moderate to high levels of expression in neurogenic regions and in newborn neurons.
In the adult, SOCS2 was maintained in the CA3 region of the hippocampus and at a moder‐
ate level in the dentate gyrus, compared to other SOCS genes whose expression was not lo‐
calized, if expressed at all under basal conditions. SOCS2 expression was also present in the
cerebral cortex and other regions such as the olfactory bulb, forebrain and cerebellum. Inter‐
estingly, SOCS2 was first upregulated at the time of neuronal differentiation, which is be‐
tween the developmental stages E10 and E12, suggesting a role for SOCS2 in neural
precursor differentiation [168].
6. SOCS2 in the brain
This interesting spatiotemporal expression of SOCS2 instigated further research into its pos‐
sible role in neuronal development. The generation of the SOCS2 knockout (SOCS2-/-) and
SOCS2 overexpressing transgenic (SOCS2Tg) mice has been instrumental in the functional
characterisation of SOCS2 [169, 170]. SOCS2-/- mice display an overgrowth phenotype where
adult mice are up to 40% heavier than their wild-type counterparts, mainly attributed to an
increase in organ size and bone length [170]. This phenotype suggested an involvement of
SOCS2 in the negative regulation of GH, a regulator of postnatal growth. To address this hy‐
pothesis, SOCS2Tg mice were generated [169]. Interestingly, SOCS2Tg mice also display an
enhanced growth phenotype, indicating a potential dual action of SOCS2 where at high lev‐
els it may enhance rather than inhibit growth hormone signalling [169].
In-vitro, neural stem cells from SOCS2-/- mice show a marked reduction in the number of neu‐
rons generated [171], as opposed to SOCS2Tg mice which show an increase in neuron number
[172-174].  Additionally,  PC12 cells  and neural cells  from SOCS2Tg mice demonstrate in‐
creased neurite outgrowth in tissue culture [171, 174-176]. GH is an inhibitor of neural differen‐
tiation  and  its  negative  regulation  by  SOCS2  is  evident  by  the  reduction  in  neuronal
differentiation in neural stem cell cultures of SOCS2-/- mice [171, 174]. The importance of GH/
SOCS2 signalling in neuronal differentiation can be illustrated by their involvement in the reg‐
ulation of the Ngn1 basic helix-loop-helix transcription factor [171]. Ngn1 has an important
role in promotion of neurogenesis by at the same time inhibiting glial differentiation [177]. Im‐
portantly, Ngn1 is subject to inhibition by GH and this inhibition is overcome by SOCS2 over‐
expression [171]. Thus, a model has been proposed where GH and SOCS2 regulate neural stem
cell differentiation through the modulation of Ngn1 expression [178].
GH binds and signals through the GH receptor (GHR) which belongs to the class I super‐
family of cytokine receptors. Like the LIFRβ/gp130 complex, signal transduction is carried
out through the JAK-STAT pathway. GH binding activates GHR resulting in JAK activation.
JAK2 is the major contributor to GH signalling and it phosphorylates tyrosine residues on
the GHR that become binding sites primarily for STAT5a or STAT5b. Activated STAT5 then
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induces SOCS gene expression [179]. JAK2 may also activate STAT1 and STAT3, however
this can be cell type specific [180, 181]. One mechanism by which SOCS2 may block STAT5
activation is via its binding to phosphorylated tyrosine residues at the STAT5 binding site
on the GHR [182].
SOCS2 can also regulate signalling via the EGF receptor (EGFR) [175, 176]. The main physio‐
logical target for EGFR is EGF. EGFR primarily activates and signals through the Ras/MAPK
pathway [183]. In terms of the neuronal effects of EGF, it has been shown to enhance neurite
outgrowth and survival of different populations of cultured neurons [175, 183]. Relevant to
this review, it also has an important role in neurogenesis. As described above, in the adult
SVZ and dentate gyrus, EGF regulates neural precursor cell proliferation [37]. The impor‐
tance of this role is evident when, in response to brain injury, there is an expansion of neural
stem cell numbers in the SVZ as a result of an increased responsiveness to EGF due to EGFR
upregulation [184]. Important for SOCS2 interaction, EGF also activates STAT5, a process in‐
volving the Src tyrosine kinase [185-187]. Overexpression of SOCS2 in PC12 cells inhibited
this EGF induced STAT5 phosphorylation [176]. The EGFR was also constitutively phos‐
phorylated at the Src binding site, Tyr845, in SOCS2 overexpressing PC12 cells. It was there‐
fore proposed that SOCS2 competitively bound to Tyr845 and blocked its dephosphorylation
by the phosphatase SHP2 to allow prolonged Src activation and enhancement of neurite out‐
growth [176].
However, while SOCS2 regulated SVZ-derived neurogenesis in a GH dependent manner
during development, in the adult SVZ it appears to regulate neurogenesis via regulation of
erythropoietin signalling [188]. Further, the mechanism by which SOCS2 regulates adult
hippocampal neurogenesis is different and does not appear to involve GH or erythropoietin,
although Epo transiently enhanced SGZ NPC proliferation [189, 190]. Hippocampal neuro‐
genesis was studied under control and voluntary exercise conditions (to enhance basal hip‐
pocampal neurogenesis) in wildtype, SOCS2Tg and GHR-/- mice. Mice of all 3 genotypes had
similar basal levels of neurogenesis and equivalently increased neurogenesis in response to
exercise at early timepoints (8 days) aimed at measuring extent of NPC proliferation. How‐
ever, at later timepoints (35 days) aimed at examining newborn neuron survival, there was a
50% increase in the survival of adult hippocampal neurons in SOCS2Tg mice, under basal
conditions and following voluntary exercise. Additionally, SOCS2Tg mice performed better
than wildtype animals in the Morris Water Maze which probes hippocampal-dependent
cognition [190]. This was an exciting result, as it identified SOCS2 as a potential therapeutic
target that could enhance the survival of newly born neurons following brain injury. How‐
ever, given that GHR-/- mice showed no differences in adult hippocampal neurogenesis
compared to wildtype, the mechanism by which SOCS2 promotes survival in this case re‐
mains to be determined. One possible explanation for this increase in neuronal survival in
SOCS2Tg mice may be that the enhanced neurite outgrowth observed in SOCS2Tg neurons
may aid functional integration into existing circuitry and the consequent maturation and
survival of neurons.




7. Roles of other SOCS proteins in the CNS
Other SOCS proteins also have roles in the modulation of signalling in the adult CNS. Other
than SOCS2, SOCS3 is the best functionally characterised SOCS protein thus far. SOCS3
plays a role in the regulation of neural stem cell fate. Its overexpression in neural stem cells
has been shown to inhibit astrogliogenesis and promote neurogenesis through the inhibition
of STAT3 transcriptional activity [156]. More recently, SOCS6 involvement in neuronal dif‐
ferentiation was also established. Exogenous IGF1 was found to enhance neurite outgrowth
and dendritic branching of neural stem cells through the induction of SOCS6 expression.
The same phenotype was produced independently of IGF-1 by SOCS6 overexpression alone.
Similar to SOCS2, SOCS6 is activated through the JAK2/STAT5 pathway, however, in this
case it is activated through signalling via the IGF receptor. Activated STAT5 induces SOCS6
expression, which goes on to inhibit STAT5 mediated signalling following the classic nega‐
tive feedback loop [191]. SOCS7 also plays a major role in the brain with SOCS7 null mice
exhibiting severe hydrocephalus in early adulthood [192]. While the mechanism by which
this occurs has not been elucidated, given the close relationship of ependymal cells and the
ventricular space to NPCs in the SVZ, it is tempting to speculate that SOCS7 may also regu‐
late adult NPC biology.
8. SOCS proteins and CNS injury
SOCS2, SOCS3 and SOCS6 all seem to have potential for use as therapeutic targets involving
regulation of NPCs following CNS injury. As described earlier, SOCS2 overexpression in‐
creases the survival of newly born neurons in the adult brain under basal, physiological con‐
ditions. It would therefore be very interesting to look at the effects of SOCS2 overexpression
under injury conditions in order to determine whether this phenotype would aid in func‐
tional recovery. Similarly, neurogenesis in an SOCS6 overexpressing system under basal
and injury conditions should be examined. SOCS3 does not appear to affect neurogenesis
per se but instead negatively regulates the proliferative and self-renewal effects of LIF on
neural precursor cells [193].
SOCS3 has been studied the most extensively under various neural injury conditions, usual‐
ly in concert with effects on neuroinflammation and astrocytes [194-196]. SOCS3 expression
is induced or upregulated in various brain regions including hippocampus and lateral ven‐
tricles in response to CNTF administration [197], ischemic stroke [198, 199] and seizure,
which also showed transient downregulation of hippocampal SOCS2 expression but no up‐
regulation of SOCS1 [200]. Conversely, after transient forebrain ischemia, SOCS2 expression
was upregulated in the hippocampus, not only in astrocytes but also a subset of nestin posi‐
tive NPCs [201].
Expression of SOCS molecules following CNS damage has functional consequences. It was
proposed that a major contributor to the poor axonal regeneration after injury was a com‐
promised responsiveness to injury-induced growth factors and cytokines [202]. For example,
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it was suggested that the transient neuroprotective effect of CNTF on injured neurons was
due to CNTF induced negative regulation of cytokine signalling by upregulation of SOCS
proteins. Use of a cyclic AMP analogue as an inhibitor of SOCS expression enhanced CNTF
induced signalling [203], identifying a new route through which the outcome of neurotrau‐
ma treatments may be improved. Whether such an approach will also regulate and potenti‐
ate effects of cytokines on NPCs remains to be determined. Further, SOCS3 deletion resulted
in an enhancement of axonal regeneration in retinal ganglion cells post optic nerve injury in
a mouse model, by lifting its inhibitory effects on JAK-STAT signalling [202]. Similarly,
PTEN deletion enhanced axon regrowth post injury [204]. PTEN is a negative regulator of
signalling via the mammalian target of rapamycin (mTOR) which can be activated through a
number of means, one of which being the PI-3K/Akt pathway [205]. Interestingly, much
more robust axonal regrowth is achieved upon a simultaneous deletion of PTEN and SOCS3
through a synergistic activation of mTOR and STAT3 signalling pathways [206]. SOCS3 also
inhibits the beneficial effects of LIF-mediated oligodendrocyte survival following demyeli‐
nation, with enhanced STAT3 activation and survival of oligodendrocytes from SOCS3 null
mice [207].
Thus, it is apparent that there are many aspects to signalling in the processes of adult neuro‐
genesis. The JAK-STAT signalling pathway is one important player, although it is apparent
that SOCS proteins can regulate pathways other than JAK/STAT in a cell type dependent
manner. The regulation of JAK-STAT signalling by SOCS proteins has enhanced our under‐
standing of the mechanisms of adult neuro- and astrogliogenesis under basal and injury
conditions and has opened avenues into the search for potential therapeutic targets for CNS
repair.
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1. Introduction
Central nervous system (CNS) repair and regeneration following traumatic injury or disease
pathology is a widely studied and widely debated field. This book chapter will outline the
pathology of spinal cord injury (SCI) with particular focus on how it lends itself to cell-based
intervention. Next, we will outline the different populations of cells proposed for SCI treat‐
ment, including neural stem/progenitor cells (NSPC), and methods of generating clinically
relevant NSPCs from adult tissue, embryonic stem (ES) cells and induce pluripotent stem (iPS)
sources. Lastly, we will examine the use of NSPCs in SCI models with a specific focus on how
the environment affects the transplanted population and how the transplanted cells modulate
the spinal cord niche.
2. Pathology of spinal cord injury
Spinal cord injury (SCI) is a devastating event that significantly affects the morbidity and
quality of life in adults (Average age of patients at the time of injury is 38.0 years old). [1] The
prevalence of traumatic SCI worldwide is approximately 750 per million with an increasing
annual incidence. [2] In order to be able to develop effective treatments for SCI, it is necessary
to have a detailed understanding of the pathophysiological events that happen during SCI in
the body and how they interact with each other to cause the functional deficits seen in patients.
These events have complicated roles post-SCI. For example, the inflammatory response and
reactive astrogliosis that are seen post-SCI have damaging and neuroprotective and –restora‐
tive effects. [3]
© 2013 Salewski et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The pathophysiology of SCI is biphasic; it consists of a “primary” and a “secondary” stage.
The primary injury is the result of an initial mechanical insult, which is followed by a series of
cellular and molecular events that, in turn, lead to further destruction of the spinal cord tissue.
It is well known that the mechanical injury seldom results in complete transection of the spinal
cord. Most fracture dislocations or burst fractures of the spine result in disc displacement into
and laceration or compression of the cord resulting in blood vessel, axonal and cellular
membrane disruption.
Decreased blood supply to the tissue and cells of the spinal cord results in nutrient and oxygen
deficiency in the injured tissue, which in turn is followed by a cascade of biochemical or
“secondary” events that eventually lead to further tissue necrosis. [3-5] Thus, the primary
insult precedes sequential pathological changes such as further vascular dysfunction and
hemorrhage, edema, ischemia, excitotoxicity, electrolyte shifts, free radical production,
inflammation, axonal and neuronal necrosis, demyelination, cyst formation and infarction. [5]
The events will be discussed in further detail in following sections and are summarized in
Figure 1.
Figure 1. Mechanisms of Injury in SCI. SCI pathology results from several mechanisms occurring both concurrently and
in sequence. Primary mechanical insult results in initial loss of axons (1) and demyelination (2). Subsequent secondary
injury is characterized by further neuronal/axonal cell death (1) and myelin degradation (2), usually due to secondary
inflammation from infiltrating lymphocytes and monocytes (3) and also reactive oxygen species secreted by activated
astrocytes composing the glial scar (4). Both the glial scar (4) and post-traumatic cyst or syrinx formation (5) pro- vide
physical impediments to regeneration, and cyst formation can further damage neurons by exerting physical pressure
on their damaged axons. * from Ruff and Fehlings. (2010). Panminerva Med 52:125-147, with permission
SCI is a complex set of damaging events that occur at the cellular level and it can be divided
into four main stages: the immediate, acute, intermediate, and chronic phase of SCI.[3] The
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first two hours post-SCI is the immediate stage during which the body is going through
processes as a result of the primary injury itself. Severing of axons, neural and glial death, and
spinal shock, all instantly result in loss of function below and at the level of the injury. The
spinal cord becomes swollen which is accompanied by hemorrhage into the grey matter,
cellular necrosis, vascular disruption and ischemia. Vascular disruption leads to further
hemorrhage into the white matter and, as a result of the combined effect of edema and
hemorrhage, many segments of the spinal cord, rostral and caudal to the site of injury, become
ischemic. [6] Even though gross histopathological changes may not be visible at this stage,
many pathophysiological events have already started. For example, activation of microglial
cells and an instantaneous increase in pro-inflammatory cytokines TNFand IL and excitotoxic
levels of extracellular glutamate can be detected within minutes of an injury. [3, 7, 8]
2.1. Stages SCI progression
2.1.1. Acute stage
During the acute stage of the SCI, the events of the secondary injury prevail. This is subdivided
into early acute (2-48 hours) and subacute (2 days-2weeks). Vascular disruption, hemorrhage,
and the resulting ischemia are central constituents of the early acute stage [5, 7], which result
in the loss of normal autoregulatory mechanisms. The loss of ionic homeostasis immediately
following SCI and excitotoxicity are closely related processes that each significantly contribute
to the propagation of cellular injury after SCI. The ionic deregulation plays an important role
in increasing necrosis and cell death following SCI. For instance, irregularity of Ca2+ concen‐
tration initiates activation of calpains and caspase cascades which in turn cause further cellular
apoptosis. [9] Additionally, activated microglia express FAS ligand receptors and signaling
through the p75 neurotrophin receptors that initiate the caspase and calpain cascade leading
to proteolysis and DNA cleavage by effector caspases and trigger even further apoptotic cell
death. [10] As a result of these events, a large number of cells, including oligodendrocytes, die.
In addition to death of the neural cells, loss of calcium, sodium and potassium ionic channel
homeostasis, and demyelination disrupt signal transduction in the spinal cord and result in
sensorimotor inactivity and paralysis. [3-5]
The extracellular levels of glutamate rise rapidly due to direct injury to cells and failure of
energy-dependent transporters, notably the Na+K+ adenosine triphosphatase membrane
transporter that normally functions to regulate extracellular concentrations of ions, glutamate,
and other molecules. [11] Excessive activation of glutamate receptors leads to an increase in
the influx of Na+ and Ca2+ through the NMDA and alpha-amino-3-hydroxy-5-methyl-
isoxazoleproprionate/kainate receptors and excitotoxicity. [12] This causes further neural and
glial death.
Reactive oxygen (O2) species (ROS) is at detectable levels 12 hours after SCI and remains
elevated for almost one week, returning to preinjury levels 4-5 weeks post-injury. The
increased amount of ROS leads to increased membrane lipid oxidation and an increase in




shown that Peroxynitrite, which is generated through reaction of ROS and nitric acid, is directly
involved in the induction of neural apoptosis in rat SCI. [13]
The brain blood barrier (BBB) is a highly selective endothelial filter for transport of compounds
in and out of the central nervous system. This becomes highly permeable as a result of the
primary mechanical insult to the cord and presence of inflammatory mediators. It has been
shown that peak BBB permeability occurs at 24 hours following injury in the rat and returns
control levels by 2 weeks. [15] Two inflammatory mediators – TNF and IL-1 - are known to
increase vascular permeability. In addition, other compounds released by glial cells or
invading immune cells which are believed to play a role in increasing BBB permeability include
ROS, nitric oxide, histamine, matrix metalloproteinases, and elastase. [3, 13] Additionally,
disruption of the vasculature following SCI results in the breakage of the BBB, leading to an
inflammatory response and infiltration of astrocytes, microglia, T cells, neutrophils, and
invading monocytes. Invasion of macrophages and neutrophils to the site of injury increases
cellular disruption and causes further inflammatory-triggered necrosis. Inflammation then
results in activation of microglia which, together with leukocytes, cause malfunction of
oxidative metabolism in demyelinated axons and proliferation of astrocytes as well as
increased expression of glial fibrillary acid protein (GFAP) and the formation of a glial or
astrocytic scar. [2-4] Further to this, a multitude of noncellular mediators, including TNF,
interferons, and ILs play important roles.
The inflammatory response in SCI is a highly complex event with a dual nature. Some aspects
of the inflammatory response further advance the secondary injury phase, while others are
beneficial in removing cellular debris and starting the regenerative process [16]. For instance,
TNF plays an important role in cellular death post-SCI and its inhibition has been shown to
result in functional neurological recovery after SCI. However, it has also been shown to have
a neuroprotective role in in vitro and murine models of SCI. [17, 18]
2.1.2. Subacute phase
The subacute phase lasts from 2 days to 2 weeks after the initial injury. This is the stage where
it is hoped that therapeutic strategies currently in development, including cellular treatments
and strategies, will be helpful. For instance, we have shown in our lab that transplantation of
adult murine neural precursor cells at 2 weeks post-injury promotes remyelination and
functional recovery. Such effects were not seen when the cells were transplanted at later time
points or during the chronic stage of the injury. [19] Keirstead et al, have also reported the
failure of transplanted human ESC-derived oligodendrocyte progenitor cells to survive,
migrate and promote functional recovery when they were injected to the site of injury either
at the time of injury or after the subacute phase. [20]
During the initial hours to days following SCI, astrocytes undergo cytotoxic edema and
necrotic cellular death; however, a second delayed astrocytic response happens during the
subacute phase. During this stage, there is a significant increase in the astrocytic intermediate
filament GFAP as a result of the proliferative and hypertrophic activity of astrocytes. These
reactive astrocytes form the astrocytic (gliotic) scar through their interweaving cytoplasmic
processes, which becomes a physical and chemical barrier to axonal regeneration. It is
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important to note that in humans, there is significantly less astroglial scarring observed than
is observed in rodent SCI models. [21] Other than scar formation, astrocytes also promote the
reestablishment of ionic homeostasis and the integrity of the BBB, which is beneficial in
decreasing edema and immune cell infiltration. [22]
During the subacute stage of the injury, there is a significantly higher phagocytic response
observed in the CNS compared to the PNS. While this could partly account for the lack of
regenerative ability seen in the CNS, the phagocytic response is believed to be efficient in cell
debris removal and, to some extent, in promotion of axonal growth inside the lesion. [13]
2.1.3. Intermediate phase
The intermediate phase starts at two weeks and continues to 6 months post-injury. Main
characteristics of this stage are continuous maturation of the gliotic scar and the start of axonal
regeneration. Regenerative axonal sprouting has been observed in corticospinal tract axons in
rat models of contusive SCI from 3 weeks to 3 months following injury, and reticulospinal
fibers have been observed from 3 to 8 months post injury. [23] It is encouraging to observe that
regenerative potential still exists in adult spinal cord, however, these regenerations have not
been able to produce significant functional recovery in severe SCI.
2.1.4. Chronic phase
The chronic phase starts about 6 months after the initial SCI and lasts throughout the lifetime
of the SCI patient. Further gliotic scar formation, development of cysts and syrinxes within the
lesion, and continuous Wallerian degeneration of severed and injured axons are the main
characteristics of this stage. [3, 23-25] Two to three years post-injury, the lesion has usually
stabilized and is characterized by formation of a cyst cavity and mayelomalacia, which is the
final stage of necrotic death. [26] Treatment strategies at this stage focus on rehabilitative
approaches to promote plasticity, regeneration and remyelination of injured axons. Unfortu‐
nately, to date there has not been any report of the application of stem cells at this stage
resulting in any significant functional improvement.
2.2. Cell-based approaches in SCI
As explained in the previous section, in the pathophysiology of SCI, some processes can be
considered to be double-edged swords with both positive and negative effects and interations.,
These are not yet completely understood. One example of such an interaction is the astrocytic
response which, on one hand results in the development of astrocytic scar limiting axonal
regeneration and functional recovery, and on the other results in reestablishment of the BBB,
ionic homeostasis, and decreased immune cell infiltration. What makes the pathophysiology
of SCI and the translation of treatment strategies into the clinic even more complicated is its
variance and uniqueness among different patients with different cases of injury. Experimental
SCI models, which are mostly rodent models, consist of a homogeneous population, in contrast




Two main aims of cell-based treatment for SCI are replacing lost or injured cells such as
oligodendrocytes and neurons, or providing the cells with a microenvironment that supports
or enhances the neuroprotective and regenerative ability of cells within the lesion. Stem and
progenitor cells, and Schwann cells are examples of cells that are being used in studies to
replace lost cells. Additionally, many studies have shown that these cells have the ability to
remyelinate axons in the injury site while also providing them with supportive growth and
neuroprotective factors. [1, 19, 27-29]
3. Cell populations for SCI treatment
Even though modern surgical and medical treatment approaches have dramatically decreased
mortality rate due to SCI, current clinical techniques provide only modest efficacy in improv‐
ing outcomes for patients, especially during the chronic stages of the disease. Thus, there is a
need for new techniques that could improve recovery for SCI patients. Cell replacement
strategies use stem cells because of their long-term proliferative abilities and the trophic
support they provide to the regenerating tissue. In the following sections we will briefly review
different types of stem cells that are being investigated as cell sources in therapeutic ap‐
proaches for SCI.
3.1 Cell types used in SCI therapy
3.1.1. Mesenchymal stem cells
Multipotent mesenchymal stem cells (MSCs) are non-hematopoietic multipotential progenitor
cells that were initially characterized by Caplan as cells with self-renewing capacity that can
give rise to skeleton and other lineages of the mesenchyme through the mesengenic process
[30, 31]. However, with the exception of a few stem cells, which are progenitors with “clonal
self-renewal and multilineage potential”, MSCs represent a non-homogenous population of
cells and not all of the cells have the same potential for differentiation. Therefore, the Interna‐
tional Society for Cellular Therapy (ISCT), suggests usage of the term, “Multipotent mesen‐
chymal stromal cells”, for the plastic adherent population of cells isolated from stromal tissue
of bone. [32] Additionally, in 2006 Dominici et al., from the International Society for Cellular
Therapy, defined a minimum set of criteria for MSCs some of which include lacking hemato‐
poietic cell surface markers such as CD34 (endothelial marker) and CD45 (pan-leukocyte
marker), and containing cell surface markers such as CD105 (endoglin), CD90 (Thy-1), and
CD73 (ecto 5’ nucleotidase) and to be able to generate at least three lineages of the mesenchyme
[33]. MSCs are primarily isolated from bone in adults but they also reside in adipose tissue,
cartilage, synovium, periosteum, muscles and fetal tissue such as placenta and umbilical cord.
There are many studies on the application of MSCs to SCI models with variable reports on the
ability of the cells to survive, integrate, and differentiate into neuronal lineages. [34] MSCs
from both rats and humans have been shown to be capable of generating neural morphology
and expressing neural and astrocytic markers in vitro. However, they have similar differen‐
tiation profiles only when transplanted into an embryonic or developing CNS. When trans‐
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planted into adult rat CNS, neither rat nor human MSCs were able to differentiate into neuronal
cells. Mostly, they generated perivascular macrophages in the rat brain. [35-37]
There are other studies in which transplanted MSCs were tracked in rat or mouse injury models
through GFP or electromagnetic tagging coupled with immunochemistry and MR imaging.
Even though both types of studies report functional improvements, only a fraction of cells are
reported to show expression of neuronal or astrocytic markers and only a very small number
of cells are reported as having differentiated into neurons. [37-39] There are differing reports
on the extent of MSC transplantation benefits in functional recovery. MSCs have shown to be
effective at 4 weeks up to 1 year after the injury [41], depending on the timing of transplantation
from the time of injury [40] to 1 week [37, 38, 41], or 3 months post injury [42]. Other studies
show lack of any functional benefit observable through the Basso Beattie Bresnahan (BBB) open
field locomotor scoring system. [43] However, all of the mentioned studies report on the ability
of MSC transplants to preserve the injured tissue, both gray and white matter, and to provide
micro environmental cues supportive of axonal growth, rather than replacing lost cells. [42,
43] Given the inconsistency seen in the results of transplanting MSCs into SCI models in rats,
mice and primates, it is necessary to have a better understanding of the type of cells in the MSC
population that are being transplanted[44] and investigate all the possible mechanisms behind
the functional recovery observed in these models.
3.1.2. Schwann cells
Schwann cells are the myelinating cells in the peripheral nervous system. Since the first
transplantation of SCs into SCI by Duncan et al. in 1981 [34], these cells have been used in many
different SCI models and have been shown to be able to remyelinate axons and provide a
permissive environment for them to regenerate and grow. Binge et al. [45] showed that SCs
also have a small but significant effect on increasing functional recovery. However, their
remyelinating and regenerating ability does not go beyond the growth-permissive surface,
which explains why there is only a slight improvement in functional recovery. [3, 44-46]
Additionally, it has been shown that axons in the corticospinal tract (CST) remain unaffected
by SC transplants. [34] Also, they have been shown to generate a more active astrocytic
response compared to other cell types such as NPCs which results in less efficient integration
of these cells into the injured spinal cord. [34] As a result, the clinical application of SCs alone
for SCI treatment appears extremely limited.
To overcome this limitation, many combinatorial strategies have evolved which associate SCs
with growth factors or bioengineering scaffolds and other cells types to enhance recovery. [4,
47-50] Additionally, new sources for SCs are being investigated such as skin derived precursor
cells from the dermis of the skin [51-54] and MSCs. [55-58] However, it is yet to be proven
whether these cells hold any advantage in treating SCI compared with SCs that are derived
from the PNS.
3.1.3. Olfactory ensheathing cells
OECs are glial cells derived from the olfactory bulb or lamina propria of the olfactory mucosa
and are termed olfactory nerve Schwann cells due to morphological similarities to SCs. Having




regenerating receptor neurons in the PNS in the olfactory mucosa to the target neurons in the
CNS in the olfactory bulb glomeruli, has made them an excellent candidate for cell treatment
strategies in SCI. [58, 59] They may be specifically advantageous when co-transplanted with
SCs, since they can overcome SCs’ limitations in passing the transplant graft and entering the
injured CNS environment to produce functional synapses. [3, 60, 61]
OECs create a permissive environment for axonal growth and regeneration by interacting with
the astrocytes in the glial scar and promoting angiogenesis. [62] This neuroprotective effect
has led to their use in numerous clinical trials outside North America. However, they all report
mixed results with none showing a significant benefit. [3, 27] Additionally, there are numerous
axonal regeneration claims seen in OEC literature, which have not been confirmed by other
studies and there are inconsistent reports on their regenerative capacity in vivo. The reasons
for such discrepancies are not completely understood but could be attributed to variability in
cell sources, cultures, and injury models studied. [63, 64] Thus, there is a need for further
studies on the biology of OECs and more refined criteria set for isolation of these cells in order
for their translation into the clinic to be feasible. [34]
3.1.4. Neural stem/progenitor cells
Neural Stem/Progenitor Cells (NSPCs) are multipotent stem cells that self-renew and differ‐
entiate into lineage-specific neural precursor cells, which can give rise to neurons, astrocytes,
and oligodendrocytes through asymmetric cell division. [30] Indeed, neural precursor cells
and oligodendroglial precursor cells have been shown to replace damaged cells, secrete trophic
factors, regulate gliosis and scar formation, reduce cystic cavity size and axonal destruction,
as well as to remyelinate axons.[3, 27, 65] However, the scarcity of adult NSPCs limits the
clinical translation of transplanting these cells in injured tissue. Therefore, alternative routes
to derive NSPCs have been studied.
4. Generation of NSPC from various sources
4.1. Adult tissue derived NSPCs
NSPCs can be derived from various regions along the neuroaxis during embryonic develop‐
ment and in adult life [66, 67]. These cells retain their mulipotentiality and can generate neural
cells in culture. NPSCs have been isolated from the subependymal zone of the adult mammali‐
an brain and from ependymal and non-ependymal regions of the adult mammalian spinal cord.
[68-70] Single adult NPSCs can be isolated in vitro in the presence of growth factors (epithelial
growth factor, EGF; fibroblast growth factor, FGF) that enable the proliferation and formation
of clonally-derived free-floating colonies. The differentiation and survival of cellular subpopu‐
lations can be promoted in vitro by exposure to bone morphogenetic proteins (BMPs) to produce
astrocytes [71, 72], insulin-like growth factor (IGF)-I, interleukin-1 (IL-1), Neuregulin-1 (Nrg-1)
to generate oligodendrocyte [73, 74], and neurogenin-2 to produce neurons [75, 76].
For experimental purposes neurospheres can be generated from the germinal zone of the adult
mouse brain, according to well-established techniques [77, 78]. Briefly, the subventricular zone
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(SVZ) of the forebrain of mice can be dissected and transferred to a low calcium aCSF solution.
Cells are plated on uncoated tissue culture flasks in serum free medium containing FGF2 and
EGF for 7 days. The neurospheres are passaged weekly by mechanical dissociation in the same
medium. This method of generating NSPCs has obvious clinical limitations as it requires brain
tissue to generate the renewable cell population.
4.2. Embryonic stem cell (ESC) derived-NSPCs
The first isolation of a pluripotent population of cells from the mouse embryo over 30 years
ago revolutionized the emerging field of regenerative medicine. [79, 80] Once a similar
population of cells were identified and isolated from a human source, [81] the possibilities and
potential for clinical application for the derivatives of these cells became limitless. Neurons
and glial cells were among the first differentiated cells to be generated from these pluripotent
cells. Although there are some differences between human and murine ES cells, such as LIF
responsiveness in vitro [82], many of the neural differentiation protocols established for mouse
ES cells have been adapted for use with human ES cells. There are multiple strategies that are
implemented to generate neural cells from ES cells with varying degrees of cell homogeneity,
differentiation potential, efficiency and time requirements. In general, two strategies exist to
direct ES cells to NSPC: the first uses embryoid body (EB) formation to mimic the physiological
neurodevelopment of the embryo and the second involves removal of all cues that would direct
the cells to a non-ectoderm lineage by limiting cell-cell interactions with low cell density culture
and environmental signals, with serum-free media.
4.2.1. NSPC generation with EB intermediate
Using EB intermediates to generate NSPCs and their differentiated products mimics the
physiological environment that produces neuroectoderm. [83, 84] In brief, the ES cells are
transferred from their expansion conditions on feeder cells to a suspension culture and allowed
to form aggregates. Within a few days, the EBs formed resemble an anterior pre-streak stage
embryo with an epiblast-like core. [85] At this stage the cells are still able to form cells from all
three germ layers. Next conditions are such that they drive the neuroectoderm lineage while
inhibiting the endoderm and mesoderm fates concentrating the NSPC population and thus
yield cells that can differentiate to neurons and glial cells.
The use of retinoic acid (RA) with the EB based neuralization protocols can vastly improve the
neural lineage cells produced. [86, 87] Many studies have shown that RA plays a key role
during neurogenesis, both in vitro conditions as well as physiologically. RA treatment directs
cell towards those of the posterior CNS. [88] The general culturing process involves EB
formation, as described above, for 4 days, followed by RA treatment (4-/4+) and then 1 week
of adherent conditions. A high proportion of the differentiated cells have neural properties,
with positive identification for both glutamatergic and motor neurons. [88, 89]
Other neuralization protocols that use an EB intermediate, such as culturing with carcinoma
or stromal cell-line conditioned media or via selection in defined media conditions, can be used
to generate NSPCs with relatively high efficiency. [90, 91] However, a key limitation with
NSPCs generated from EB intermediates exists; despite success with these approaches,




creates a risk for the persistence of non-neural cells in the final population. This has been
associated with teratoma formation and increase tumorigenicity. The persistence of non-neural
cell can be traced back to the non-specific differentiation pattern associated with the initial
aggregation of EB.
4.2.2. NSPC generation from default pathway
In order to circumvent EB intermediates, and its limitations, during neuralization of pluripo‐
tent cells, our lab has opted to use the default pathways to direct ES cells to a neural lineage.
([92]; Figure 2) This pathway relies on the fact that, in the absence of extrinsic signaling to form
non-ectoderm lineage, the cells will adopt a neuroectoderm fate. [93, 94] The default mecha‐
nism is based on studies that showed the inhibition of BMP signaling by protein inhibitors or
by gene expression manipulation leads to neural lineage commitment. A small percentage
(0.2%) of single ESCs cultured under serum-free, low cell density condition proliferate in the
presence of LIF to form floating neurospheres of cells that express the neuroepithelial markers
Nestin and Sox1, but downregulate the ES cell markers Oct4 and SSEA1. [93, 94] Moreover, a
small proportion of cells derived from primary neurospheres can generate secondary colonies
when subcloned, which are independent of LIF, but are dependent on FGF2. These cells have
been termed definitive (dNSPC). [94]
In order to assess the clinical potential of the NSPCs generated by this method, with specific
focus on SCI, our lab has extensively characterized the ES-derived dNSPCs in vitro. [92] In brief,
ES cells were directed to primitive and definitive NSPC fates. Their mRNA profile was evaluated
using RT-PCR and in vitro differentiation patterns were quantified and compared to aNSPCs
populations isolated from the SVZ. The ES-dNSPC populations were similar to aNPCs analyzed
at the mRNA level with a significant decrease in pluripotency (Nanog, Oct4) and stemness (Tdgf1,
Dnmt3b, Gaf3) markers with increased transcription of neural-specific markers (Pax6, Nestin,
Olig2, Synaphysin). The pNSPC retained many of the pluripotency and stem markers associat‐
ed with undifferentiated ES cells reflecting the importance of driving the NSPC to a definitive
state. To assess the in vitro differentiation pattern of the ES-derived NSPCs and aNSPC controls,
the cells were cultured on matrigel for one week with 1% FBS media. The cells were immunola‐
belled for NSPCs (Nestin), neurons (BetaIII Tubulin), astrocytes (GFAP), and oligodendro‐
cytes (Olig2, PDGFRa, CNPase). Both ES-dNSPCs and aNSPCs yielded primarily differentiated
neural cells with the majority being astrocytes (~65%). The largest proportion of cells from the
ES-pNSPCs  were  undefined  or  retained  the  NSPC  marker  Nestin.  Although  astrocytic
differentiation may not be the desired cell, this differentiation into astrocytic cells demon‐
strates that the in vitro environment is very different from the in vivo niche.
The potential of these cells to survive, integrate, and differentiate in vivo is critical to evaluating
their role in regenerative medicine applications. Since remyelination following SCI is a likely
potential mechanism of recovery, our lab uses a dysmyelinated Shiverer mouse to assess the
in vivo potential of our ES-dNSPC. Shiverer mice lack compact myelin basic protein (MBP) and
therefore are an ideal candidate to evaluate the myelination ability of these cells. [95] In general,
the Shiverer mouse, under isoflurane anaesthesia, received a T6-T7 laminectomy followed by
4 intraspinal injections of ES-dNSPC (100,000 in 2ul of media). The mice were immune
suppressed with continued cyclosporine A treatment. Six weeks following transplantation the
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animals were perfused and spinal tissue was fixed with 4% PFA. Cryosections of tissue were
immunohistochemically labeled for neural cell markers. The ES-dNSPCs were able to survive
and integrate into the host tissue in a similar pattern to that previously described with aNPCs.
The transplanted cells preferentially migrated to the white matter tracts and differentiated to
oligodendrocytes with multiple processes that expressed MBP. The quantification of the
differentiation pattern showed that the transplanted cells become primary mature APC+
oligodendrocytes with limited astroglial and neuronal fates. The variability between in vivo
and in vitro differentiation potential can be attributed to the instructive nature of the spinal
cord niche. The Shiverer spinal cord has been shown to have greater amounts of NG2-express‐
ing oligodendrocyte progenitors. [96] The environment that leads to the excess of these
progenitors is also acting on the transplanted cells. This instructive/permissive niche could be
a result of signaling molecules such as GRO-1 [97] and neuregulin (NGR) [98], both of which
are released by astrocytes and neurons.
ES cells are the most defined source of readily available pluripotent cells that can be used in
cell-based treatment for SCI. Although, they have some safety and ethical concerns, this
population will remain extremely relevant in the future of spinal cord regeneration.
Figure 2. Default neural differentiation of embryonic stem cells. (A) Schematic representation of neural induction of
ESCs through the default pathway: Individual ESCs when cultured at low density in minimal serum-free media con‐
taining LIF acquire a neural identity through a default mechanism. These neural stem cells colonies are termed
pNSPCs, are LIF- dependent, and divide to form clonally-produced floating neurosphere colonies. pNSPC-derived neu‐
rospheres can be dissociated into single cells and passaged indefinitely in serum-free media containing LIF or can be
passaged into serum-free media containing FGF2 to produce a distinct population of FGF2-dependent cells termed
dNSPCs that also divide to form clonally-produced neurospheres. These spheres can also be passaged indefinitely and
when differentiated produce all three cell types of the neural lineage. (B) Phase-contrast image of a neurosphere colo‐
ny generated by a pNSPC. (C) Phase-contrast image of a neurosphere colony generated by a dNSPC. (D) Phase-con‐
trast image of a neurosphere generated by adult neural stem cells derived from the subependymal layer of the adult
mouse forebrain. For B–D, bar equals 50 mm. ESCs, embryonic stem cells; LIF, leukemia inhibitory factor; dNSPC, defi‐
nitve neural stem cell; pNSPC, primitive neural stem cell; FGF2, basic fibroblast growth factor; Olig2, oligodendrocyte




4.3. Induced pluripotent stem cells (IPSC) derived NSPCs
Given the aforementioned concerns with ES cells combined with the immunogenicity that arises
from allograft transplantation, the search for a patient-specific and accessible cell source has
been  a  principle  endeavor  of  regenerative  medicine.  Historically,  many  techniques  and
strategies have been developed to accomplish this aim, most notably somatic cell nuclear
transfers (SCNT). SCNT is the process by which the nucleus of the somatic cell being reprogram‐
med is transferred to an enucleated ooctye [99]. This technique became famous in the late 1990s
when Dr. Ian Wilmut cloned the first mammal, a sheep named “Dolly”. [100] Although there
is no obvious mechanism that would preclude SCNT from reprogramming human cells, this
technique has yet to be successfully applied in human cells. Furthermore, the requirement for
donor ooctyes, combined with an inefficient and technically difficult processes makes SCNT
unlikely to be a viable option for clinical application even in the most ideal circumstances.
The discovery of IPS cell technology has made a significant stride towards realizing the promise
of patient-specific regenerative medicine. IPS cells are somatic cells that have been reprogram‐
med to ectopically express certain transcription factors that induce an ES cell-like state, in terms
of their differentiation potential and response to in vitro culture conditions. [28] This technolo‐
gy allows for a constant and relatively easy method of generating cells for autologous transplan‐
tation from readily available cell sources such as skin cells. In 2006, Takahashi and Yamanaka
used retrovirus transfected with 24 transcription factors in mouse embryonic fibroblasts (MEF).
[101] Through careful elimination they were able to reduce the required genes to four: OCT4,
Sox2, KLF4 and c-myc. The expression of these four genes was sufficient to revert the MEFs to
an undifferentiated, pluripotent state that was verified using teratoma formation and contribu‐
tion to a chimeric mouse. Since the initial characterization of the iPS cells there has been a
tremendous amount of research further expand and refine the technology. The Yamanaka
factors have been used to reprogrammed various cells from tissues from a variety of species
including mice [101], rats [102], rhesus monkeys [103], and humans [104-107].
The first generation of iPS cell technology is not without its shortcomings and clinical obstacles.
The process of reprogramming can be slow and inefficient and includes oncogenic potential
of the factors themselves, insertion mutatgenesis, and the risks associated with the use of viral
vectors. All of this can contribute to limited clinical translational potential. Fortunately,
substantial research has rapidly developed iPS techniques that are viral vector and mutation
free. For example, piggyBac transposition is a viral-free system that can be used to deliver the
reprogramming factors in both human and mice fibroblasts [108, 109]. A single transposon
containing all four iPS transcription factors is introduced to the cells and reprogrammed
colonies are selected. IPS cell lines with a single insertion site are identified and transposon is
seamlessly excised yielding stable, reprogrammed cell lines that are do not contain any
exogenous DNA or have any insertion mutation. Other viral-free and mutation-free methods
exist including using lentiviruses [110, 111],an episomal system [112], and the use of recombi‐
nant proteins [113], to generate more clinically relevant iPS cells.
Even with the advancement in iPS cell generation, intrinsic differences between ES and iPS
cells exist. IPS and ES are often described as “indistinguishable”, however, key differences
have been identified. The initial characterization of the iPS cells from Takahashi and Yamanaka
noted variation in global gene expression as well as differences in epigenetic characters,
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specifically histone methylation.[101] Epigenetic memory of iPS cells can influence the
differentiation potential and the differentiation of the iPS cells, favouring the identity of the
tissue of origin. [114] The impact of epigenetic variability still remains an area of debate and
methods to optimize iPS cells are underway.
4.3.1. Neuralization of IPS cells
The conceptual outline of how iPS cells may be used in the treatment of SCI is described in
figure 3. [28] Many of the in vitro neuralization protocols outlined above for generating NSPCs
and terminally differentiated neural cells, neurons, astroglia and oligodendrocyte, from ES
cells can be applied to iPS cells. iPS cell have been used in models of Parkinson’s [110, 115],
spinal muscular atrophy (SMA) [116], amyotrophic lateral sclerosis (ALS) [117], and SCI [118].
Although there have been positive results using iPS-derived neural cells for cell-based
treatment, the variation in iPS cells has resulted in variability in the safety and neuralization
of these cells. A comprehensive evaluation of NSPCs from mouse iPS cell lines generated from
various tissue sources and reprogramming methods has shown differences in tumorigenesis
between iPS cell lines compared to NSPCs from ES cell lines. [119]
4.3.2. Improving the IPS neuralization using NOTCH pathway agonism
The variation in neuralization potential between iPS cell lines and their ES cell counterparts
represents an area of regenerative medicine that, if not addressed, could be an obstacle to clinical
translation. Our lab specifically examined the difference in neuralization potential of multi‐
ple iPS cells lines. [120] We used iPS cells generated using piggyBac transposon technology to
eliminate variation that could be attributed to the resurgence of the silenced transgenes or due
to insertion mutations. [108, 109] Furthermore, the default pathway of neuralization was utilized
to avoid issues associated with the EB formation as an intermediate step in generating NSPCs
from a pluripotent cell source. Even with the additional precautions to help generate safe and
clinically-relevant cells, there was retention of plurioptency markers as well as persistence of
non-ectoderm lineage markers. In order for the potential for iPS technology to be realized,
methods to effectively and consistently generate definitive cells must be developed.
We examined the role of BMP antagonism during the initial neuralization of the pluripotent
IPS cells. We identited this as a possible area where IPS cell neuralization could be improved.
Noggin, a BMP antagonist, has previously been shown to increase the number of neurospheres
generated using the default pathway and ESCs.[94] BMPs are involved in directing pluripotent
cells to an endoderm lineage fate. Although the inclusion of Noggin during the in vitro culture
of primary primitive NSPCs did increase the number of neurospheres, it did not affect the
character of the NSPCs as determined by a battery of gene markers analyzed by RT-PCR.
Furthermore, there was no difference on the subsequent mRNA profile between definitive
NSPCs with or without Noggin treatment. These data led us to conclusion that the variability
in the PB-IPS cells’ response to the default pathway is not a result of poor initial neuralization
but likely due to incomplete transition from primitive NSPC to definitive NSPCs state.
The NOTCH pathway has been shown to be involved in many aspects of neurodevelopment




reduction in NSPCs while conversely the induction of this pathway promotes NSPCs in vivo.
[123, 124] The NSPC niche of the SVZ expresses receptors and ligands of the NOTCH pathway.
[125] Delta-like ligands (DLL) or Jagged are the principle ligands of the NOTCH pathway, and
interact with the membrane-bound NOTCH receptor. The NOTCH intracellular domain
(NICD) is cleaved by gamme-sectrase. NICD is translocated to the nucleus to facilitate the
transcription of targets such as Hair and enhancer of split, HES genes. [126] Furthermore,
NOTCH appears to play a critical role in transition from primitive to definitive neural state.
Primitive NSPCs were readily generated in LIF-dependent culture conditions from ES cells as
well as NSPCs isolated from E7.5 embyros from NOTCH-deficient sources. However, passage
of these cells to a definitive state was disrupted indicating a crucial role for NOTCH. [124,
127] Using these data we hypothesized that agonizing the NOTCH pathway during the
neuralization of PB-iPSs would improve the neural character of the definitive NSPCs generated
and thus, improve the clinical relevance and translation potential of the cells.
We demonstrated that the addition of recombinant mouse DLL4 to the definitive culture
conditions of the default pathway of neuralization improved the generation of definitive
NSPCs compare to those cells grown in parallel using standard default conditions. [120] DLL4
was selected to this pathway since DLL4 is most avid ligand for the NOTCH1 receptor.[128]
The definitive neurospheres treated with DLL4 produced a greater number of spheres that
retained a free-floating phenotype while untreated spheres showed extensive adhesion and
signs of differentiation. Also, the mRNA profile of the DLL4 treated dNSPC showed a
reduction in pluripotency markers (Lin28, Nanog, Oct3/4) as well as reduction or elimination
of endodermal markers (Gata6, Afp) compared to control cells. This pattern was confirmed at
the protein level with immuncytochemistry. The dNSPCs were also cultured in chamberslides
matrigel in SFM containing 1% FBS to induce the differentiation of the cells. The differentiation
profile of the DLL4-treated definitive NSPCs reflected the ES-derived dNSPCs as well as
aNSPCs. Primarily differentiated neural cells were identified following 1 week of differentia‐
tion with mostly GFAP+ astrocytes in the iPS-dNSPC(+DLL4) group compared to non-treated
iPS-dNSPCs that were primarily positive for the undifferentiated NSPC marker Nestin or were
not labeled by any of the neural markers used. Lastly, the neurons, oligodendrocytes and
astrocytes from DLL4-treated dNSPCs were shown to be electrophysiologically functional.
In addition to the NOTCH pathway, Sonic Hedgehog (SHH) and WNT signaling are both known
to play roles in neurodevelopment. These pathways have been shown to have independent and
interconnected mechanisms of action and there is evidence of considerable crosstalk with
NOTCH signaling. SHH expression can be up-regulated in a time dependent profile with the
Jagged1 in NSPCs in vitro. [125] WNT signaling has been shown to influence the transition of
primitive NSPCs to definitive state through the manipulation of Hes expression. [129, 130]
iPS cell technology combined with the default pathway of neuralization has tremendous
potential to revolutionize the treatment of SCI. Patients could someday use their own skin cells
to regenerate and repair their injury (Figure 3).
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Figure 3. A general schematic representation of the generation of iPS cells, the promotion of neural precursor cells,
and their use in spinal cord remyelination. A: Following a spinal cord injury, demyelination occurs resulting in vulnera‐
ble axons and impaired CNS function. B: The patient’s fibroblasts, or skin cells, are harvested. C: Reprogramming con‐
ditions/factors are introduced to induce self-renewal and pluripotency properties. D: The cells are now iPS cells. E:
When full and independent reprogramming is achieved, reprogramming condition/factors are removed. F: Neuraliza‐
tion of the iPS cell to NPCs under minimal conditions. G: Growth factors (i.e., FGF) further differentiate the cells to be‐
come definitive neurospheres. H: iPS cell-derived neural stem/precursor cells can be injected into the injured spinal
cord. I: Once transplanted, these cells can differentiate CNS cells such as myelinating oligodendrocytes. J: iPS-NPC-
mediated remyelination, or by some unidentified neuroprotective effect, can result in functional recovery following
spinal cord injury. * from Salewski et al., 2010, J. Cell Physiol. 222; 515-521, with permission
5. Transplantation of neural stem/progenitor cells into the injured spinal
cord
5.1. Model of SCI and NSPC transplantation
The in vivo  regenerative and neuroprotective effect  of  the cell-based treatments must be
evaluated in preclinical animal models. The rodent clip compression model of SCI developed
in our lab mimics injuries observed in human SCI, in terms of primary and secondary injury
processes and, in particular, with regards to lesion and cavity formation. This creates a situation




characterizing and evaluating the safety and efficiency of our NSPCs in a clinically relevant
small animal model prior to their implementation into larger animal models or a clinical trial.
In general, our SCI model involves injured rats that receive a clip compression injury of spinal
cord either at the cervical or thoracic level. [19, 65] The model characteristics, histopathology,
assessment of axonal integrity, molecular examination of axonal structure, and behavioural
assessment have been extensively characterized. [131-134] This model of moderately severe
SCI, results in a central cavitation and loss of 80% of axons in the spinal cord white matter,
demyelination of the surviving axons in the residual subpial rim and spastic paraparesis.
Following acute (2 week) or chronic (6 weeks) SCI, we have administered four intraspinal
injections of aNSPCs in growth media to the rats at locations 2mm caudal and 2mm rostral to
the injury site. To enhance the survival of the transplanted cells, growth factors [PDGF-AA
bFGF and EGF] in a solution containing aCSF, BSA (100 µg/ml) and gentamycine (50 µg/ml)
has been infused intrathecally to the area of transplantation for 7 days using a microcatheter
connected to an osmotic minipump. A battery of behavioural tests, histological outcomes and
electrophysiological measures are used to determine the therapeutic effect aNPC transplan‐
tation.
5.2. Effect of transplant on subacute and chronic injury
In our study of subacute intervention following SCI, transplantation was delayed to two weeks
following injury. [19] The animals were examined using a number of measures of locomotor
function, including the BBB scale, ladder walk analysis and gait/coordination assessment, for
eight weeks post-SCI. At the eight week endpoint of the experiment, the animals were
euthanized and their tissue collected for histological and electron microscopy.
The transplanted NSPCs had substantial survival (~40%) in the spinal cord when the growth
factor mini osmotic pump was used and these cells demonstrated multipotency. In contrast to
their in vitro differentiation profile, the transplanted cells mostly became oligodendrocytes in
the injured spinal cord. In fact, the cells preferentially migrated to the white matter tract and
showed extensive myelination. ([19]; Figure 4) The role of myelination will be fully addressed
when we discuss potential mechanisms of neuroprotection/neurorepair. Behavioral and
functional benefits from aNSPC engraftment were observed. There was significant locomotor
recovery compared to the injured control groups. The BBB is a 21 point scale that is used to
evaluate hindlimb locomotion in an open field. [43] Immediately following the SCI, all rats
were fully paraplegic and exhibited no hindlimb function. The control rats were able to recover
to a BBB score of 8, denoting plantar placement of the paw without weight support. The
experimental group that received the aNSPC treatment was able to reach a score of 10 on the
BBB. Although a 2-point increase may seem negligible, the BBB is a non-linear scale and these
animals show occasional weight supported plantar stepping which is a substantial functional
improvement. Furthermore, the animals that received the transplanted cells show improve‐
ment on other independent behavioral tests including grid walk and footprint tests. Our results
show that the improved recovery of locomotor function in the transplanted groups was a result
of the effects of the aNPCs since there was no significant difference in the walking ability of
the plain injured or sham controls in all behavioral tests used.
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Figure 4. YFP-NPCs in the spinal cord of a subacutely injured rat 8 weeks after transplantation. A, A confocal image
from a longitudinal section of an injured spinal cord taken from the dorsal spinal cord of a transplanted rat above the
central cavity. A low-magnified image shows the extent of YFP-NPC survival within the injured spinal cord 8 weeks
after transplantation. Grafted YFP-NPCs (green) were dispersed along the rostrocaudal axis of the spinal cord 5 mm
away from the implantation sites (*). YFP-NPCs also migrated to the contralateral site of the spinal cord to a lesser
extent. Double labeling with the neuronal marker betaIII tubulin (Tuj1) showed that YFP-NPCs reside predominantly in
the white-matter area (A–D). Our histological data showed no signs of tumor formation in the spinal cord. E, Confocal
image of a transverse section of the spinal cord from a transplanted rat (8 weeks after transplantation) showing the
distribution of YFP-NPCs in the lateral columns. F, G, YFP cells mainly showed multipolar morphology and extended
numerous branches in the white-matter tissue along the length of axons. WM, White matter; GM, gray matter. * from
Karimi-Abdolrezaee et al, 2006, J Neurosci 26:3377-3389, with permission
The successful implementation of the NSPC therapy in the subacute model is a key step
forward in spinal cord regenerative medicine. It has a relevant therapeutic window, although
narrow, and requires intervention shortly after the initial injury. The chronic injured popula‐
tion represents a large section of the SCI community and currently many of the proposed
treatments cannot be used to repair their injuries. The chronic injured environment is charac‐
terized by many additional challenges including cell loss, a cystic cavity and the inhibitory




We noted that when aNSPCs were transplanted at 6 weeks post-SCI, the chronically injured
spinal cord was not an hospitable environment. To address this, we examined methods to
modify the SCI environment to create a permissive environment. Our data suggested that
expression of chondroitin sulfate proteoglycans (CSPG) reduces the survival and thus, the
therapeutic potential of our aNPC treatment. [65] Chondroitinase ABC (ChABC) was admin‐
istered to the chronic SCI environment to breakdown CSPGs that were upregulated as a result
of the injury. We then analyzed the synergistic effect of the transplanted aNSPCs with ChABC
and growth factor pump on the repair and plasticity of the chronically injured spinal cord.
Survival, integration and migration of the transplanted cells in the chronic SCI with ChABC
was extensive compare to treatment without ChABC and growth factors where survival was
low and the transplanted cells remained at the injection site. ([65]; Figure 5) The differentiation
potential of the aNSPCs was similar to that observed in the subacute injury/transplanted
paradigm with the majority of cells displaying oligodendrocyte markers. There was also
improvement observed at the functional locomotor level. The animals that received the
combinatorial treatment of ChABC followed by aNSPCs and GF pump had a significant
improvement on the BBB scale as well as with ladder-walk analysis. These behavioral im‐
provements were also linked to neuroanatomical changes associated with the aNPC therapy.
This is the first successful application of an aNSPC-based treatment for chronic SCI and
represents a critical step forward improving the lives of patient currently living with SCI.
Figure 5. ChABC treatment greatly optimizes NPC transplantation in the chronically injured spinal cord. A–D, Confocal
images of longitudinal and cross sections of chronically injured spinal cord transplanted with NPCs at 9 weeks after
transplantation show a significant increase in the number of surviving NPCs (green) in ChABC-treated spinal cord (C,D)
compared to the vehicle-treated spinal cords (A, B). D, The majority of NPCs integrated within white matter areas in‐
cluding dorsal, lateral, and ventral columns. Quantification of transplant volume revealed a 6.2-fold increase in
ChABC-treated rats (n6, 3.70.79mm3) compared to vehicle-treated rats (n6, 0.60.24mm3) (p0.01, Student’s t test).
NPC cell survival analysis also showed a 5.7-fold increase in number of surviving NPCs (YFP/DAPI-positive cells) in
ChABC-treated rats (28.256.77%) relative to the vehicle-treated ones (4.91.96%) (p0.01, Student’s t test). ChABC treat‐
ment resulted in a significant increase in rostral and caudal migration of NPCs from the injection sites (4.20.50mm)
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compared to vehicle treatment (1.40.4mm)(p0.001, Student’s t test). We also found a 4.6-fold increase in the total
length of rostrocaudal distribution of NPCs in ChABC-treated rats (13.02mmin the best case, average 8.321.5 mm)
compared to vehicle-treated rats (2.24mminthe best case, average 1.820.5mm)(p0.005, Student’s t test). * from Kari‐
mi-Abdolrezaee et al, 2010, J Neurosci 30:1657-1676., with permission
5.3. Possible mechanism of neurorepair/neuroprotection
Although our lab and others have clearly shown that cell-based therapies for SCI can be
beneficial, the mechanisms by which the benefits are achieved still remains an area of debate.
Trophic factor support [40, 135-137] and remyelination [19, 27, 65] as well as other mechanisms
including plasticity and axon integrity have been suggested as possible mechanisms of
recovery with cell-based treatments for SCI.
5.3.1. Trophic factor support
Trophin delivery as a potential mechanism of benefit in cell-based treatments, such as the use
of bone marrow stromal cells (BMSC) following trauma, was first proposed in response to
evidence that there was a degree of neuroprotection despite a lack of survival of transplanted
cells. [40, 135-137] Trophic factors have been shown to have apoptotic effects[138], enhance
axonal regrowth[139], promote endogenous remyelination[140, 141], and neuronal plastici‐
ty[142, 143]. BMSCs as well as aNSPCs have been shown by our lab and others to produces
these trophic factors in vitro, however little evidence to show their involvement in vivo has been
shown. [144]
To study trophin production and involvement in vivo, we examine both brain- and spinal-
derived NPCs, compared them to BMSCs, and transplanted them into injured rat spinal cords.
[145] Candidate trophic factor (NGF, BDNF, NT-3, NT-4/5, GDNF, CNTF, PDGF-A, EGF,
bFGF, LIF, IGF-1, GGF2, TGF-b1, VEGF-A) expression was examined in spinal tissue homo‐
genates as well as specifically in the transplanted cell population by FAC sorting for the eGFP
labeled cells. The neurotrophin levels were increased following SCI and the transplantation of
aNSPC with GF pump further elevated specific trophic factors, in particular, GDNF, LIF and
bFGF. Furthermore, the analysis of the FAC sorted transplanted population of aNSPC showed
increased neurotrophin production, specifically CNTF, EGF and bFGF. The study was the first
to shown that both changes in the host tissue as well as the transplanted aNSPCs can influence
trophic factor levels in vivo. Although further research is required to determine if trophic factor
support is the sole mechanism that conveys neuro-protection or neuro-repair, our research
does shows that it is a likely contributing factor to the functional improvements observed.
5.3.2. Remyelination
Myelin is a critical component of the CNS and is required for its proper functioning. Myelin
is needed for the precise molecular organization of the axon, particularly with regards to nodal
architecture. The arrangement of Na+ channels, K+ channels and contactin-associated protein
at and around the nodes of Ranvier is closely linked to myelin, and a disruption in myelination
results in loss of nodal organization. Furthermore, following SCI there is extensive loss of white




restoring the myelination of these axons can have large effects on the overall outcome and
locomotor function since relatively few spared axons can have a tremendous effect on
improving neural outcomes.
These data suggest that the remyelination could be the mechanism by which aNSPC trans‐
plantation is able to repair the injured spinal cord. Following our subacute intervention as well
as chronic injury with combinatorial therapy, we observed migration of engrafted cells to white
matter tracts, mature oligodendrocytic differentiation and expression of myelin basic protein
(MBP) by these cells associated with axons. ([19]; Figure 6) Furthermore, the exogenous
myelination was confirmed by electron microscopy to form multilayer compact myelin around
axons and to restore the nodal architecture as shown by immune labeling for Kv1.2 and panKa.
Figure 6. Exogenous remyelination following subscute SCI with aNSPC transplantation: YFP-NPC-derived oligo‐
dendrocytes generate MBP and ensheath the injured axons of the spinal cord. A–C, Confocal images of longitudinal
sections of an injured spinal cord 8 weeks after transplantation. The area grafted with YFP-NPCs (green) displays a
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robust expression of MBP (red) in the white matter of an injured spinal cord. Cell bodies of donor cells are surrounded
with MBP. Triple-labeling experiments on longitudinal (D–G) and cross (H–K ) sections of spinal cord white matter
showed that MBP-expressing YFP-NPCs ensheathed the injured axons (identified by NF200; blue). These images (D–G)
clearly show the oligodendrocyte morphology of one grafted YFP cell (arrowheads) that extends its processes and ex‐
presses MBP around an injured axon and the close proximity of these cells with newly myelinated axons. L, M, Images
taken by deconvolution confocal microscopy show a higher-magnification image confirming axonal ensheathment of
MBP-expressing YFP-NPCs around the injured axons. *from Karimi-Abdolrezaee et al, 2006, J Neurosci 26:3377-3389,
with permission
Although exogenous myelination has been proposed as a mechanism for aNSPC-mediated
recovery, potential endogenous myelination cannot be ruled out. There is still extensive
research required to delineate the precise role of remyelination and specifically the role of
remyelination induced by transplanted cells.
5.3.3. Other mechanisms
In addition to the roles of trophic support and myelination, other mechanisms have been
proposed. It is possible that effects on axon integrity and neuronal plasticity play key roles in
SCI recovery. We noted positive effects in these areas following our combinatorial strategy of
ChABC and aNSPC in the chronically injured spinal cord.[65] Cortiospinal tract (CST) labeling
using PKC-g and anterograde tracing showed evidence of enhanced axonal integrity and
collateral spouting. This phenomena was seen only at the local level with long-distance CST
regeneration beyond the lesion not observed. Promotion of plasticity of serontonergic (5HT)
fibers was observed with ChABC and aNSPC therapy as noted by a significant increase in its
immunointensity rostral to the injury epicenter. The 5HT positive fibers were observed in areas
of aNSPC engraftment. Many mechanisms are likely working in concert to elicit the behavioral
and functional outcomes observed by our lab and others after application of aNSPC therapy.
6. Conclusions
Spinal cord injury pathology creates a situation where cell-based interventions are attractive
as potential treatments to promote repair and regeneration. There are a variety of cell sources
available for this aim, however, in our research experience, NSPCs are the most likely to
provide lasting and appropriate neurological recovery. Both adult brain and spinal tissue are
sources of NSPCs for transplantation along with the pluripotent cells (ESC and iPSC) when
differentiated in vitro to a restricted NSPC identity. Once transplanted into the injured spinal
cord, the spinal niche directs the NSPCs to terminally differentiated neural cell types, both
neuronal and glial. Our work suggests remyelination via oligodendrocytes is the principal
mechanism of recovery although trophic support as well as neuronal lineages that are created
are other possible mechanisms by which NSPC treatment is beneficial in SCI. Our results with
chronic SCI, which is characterized by cavitation and glial scarring, has shown that stem cell
therapy alone may be of limited benefit. Thus, combinatorial stem cell approaches with
bioengineered strategies, such as use of chondroitinase, will be a key area of future research
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1. Introduction
During development, ESCs in the inner cell mass of the blastocyst undergo progressive fate
restriction and sequentially give rise to tissue-specific multipotent progenitor cells [1-3]. In
the nervous system, neural progenitor cells (NPCs) are defined as multipotent cells capable
of differentiating into neurons and glia, the latter of which include astrocytes and oligoden‐
drocytes. NPCs undergo sequential fate restriction during nervous system development
[4-6]. During early embryonic development, NPCs give rise exclusively to neuronal cell
types, however at later stages they differentiate into glial cell types [7, 8]. Understanding
how ESCs differentiate into neuronal or glial cell types, thus, constitutes a fundamental as‐
pect of nervous system development.
ESCs possess two cardinal cellular characteristics: self-renewal capacity and pluripotency [2,
3]. ESCs, when undifferentiated, maintain a unique gene expression profile which keeps
themselves in a pluripotent state [3, 9-12]. When ESCs begin to differentiate, however, this
profile is dramatically altered without changes in the DNA sequence, allowing initial cell
lineage specification to take place [11, 13-15]. Studies on lineage choice and differentiation of
stem cells suggest that the crosstalk between transcription factors and epigenetic mecha‐
nisms plays pivotal roles in maintaining the existing transcriptional profile or changing it in‐
to a new transcriptional profile [16, 17].
Chromatin in eukaryotes is organized into arrays of nucleosomes, which are comprised of
DNA wrapped around a histone octamer containing 2 copies of individual core histones,
H2A, H2B, H3, and H4 [18]. Chromatin can be tightly or loosely packed to alter its accessi‐
bility to transcription factors and RNA polymerases, thereby ultimately modulating the effi‐
ciency of gene transcription [19-23]. Epigenetic mechanisms act to change this accessibility
both locally and globally through modifications of nucleosomes, and by remodeling of nu‐
© 2013 Shimomura and Hashino; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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cleosomes [21, 24, 25]. In addition to epigenetic modifications and chromatin remodeling,
epigenetic regulators have been recently extended to non-coding RNAs (ncRNAs), because
ncRNAs can affect chromatin structure and transcriptional activation by regulating expres‐
sion of key nucleosome modifiers [26]. These epigenetic controls appear to influence gene
expression profiles, which are essential for self-renewal and differentiation capacities of
ESCs. Thus, a clear understanding of the epigenetic mechanisms underlying gene expres‐
sion patterns will provide significant and novel insights into cell fate specification of ESCs
directed to differentiate into neurons. Furthermore, the epigenetic mechanisms are believed
to be capable of responding to extrinsic signals such as morphogens and cytokines [8].
Therefore, knowledge of the epigenetic mechanisms is also important for our understanding
of neural differentiation by extrinsic factors. In this review, we will describe the major epige‐
netic processes that underlie the acquisition of the NPC fate from ESCs as well as the subse‐
quent neuronal subtype specification. The focus of this review is weighted on neuronal cell
lineage specification, and not on glial cell specification.
2. Epigentic mechanisms
2.1. Post-translational modifications of histones
Post-translational chemical modifications of histones in chromatin are diverse and include
methylation, acetylation, phosphorylation, sumoylation, ubiquitilation, and ADP-ribosyla‐
tion [25, 27]. Here, we will focus on histone methylation and acetylation because these modi‐
fications are considered to be most important and widespread for influencing biological
processes during neural differentiation.
Histone methylation occurs mainly at lysine and arginine residues on the tails of the histone
H3 and H4 [28]. Histone methylation is reversible. Methylation at these sites has been asso‐
ciated with not only transcriptional activation and repression [27, 29] but also multiple bio‐
logical processes, including heterochromatin formation and genomic imprinting [27, 28].
The differences in the effects of methylation depend on the lysine residues. For example,
methylation of histone H3 lysine 9 (H3K9), H3K27, or H4K20 is generally linked to forma‐
tion of gene silencing [30, 31], whereas methylation on H3K4, H3K36, and H3K79 is associat‐
ed with actively transcribed regions and gene activation [29, 32, 33]. In addition, lysine
residues can be mono-(me1), di-(me2), or tri-methylated (me3). These differentially methy‐
lated lysine residues lead to different levels of transcriptional activation or repression, re‐
sulting in diverse functional outcomes. For example, H4K20me1 plays an important role in
transcriptional repression and X inactivation, while H4K20me2 and H4K20me3 are linked to
DNA repair of double-stranded DNA damage [34].
All core histones can be dynamically acetylated on lysine residues in their tails and occa‐
sionally within the globular core. Histone acetylation removes the positive charge on the
histones, thereby weakening the interaction with negatively charged DNA [25, 29]. As a con‐
sequence, chromatin is transformed into a more relaxed structure, which is associated with
transcriptional activation. Like methylation, histone acetylation is reversible. This reversible
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acetylation in histones is an important mechanism of controlling gene expression because
histone acetylation and deacetylation are linked to transcriptional activation and inactiva‐
tion, respectively [25, 27].
2.2. DNA methylation
DNA methylation is one of the major repressive epigenetic pathways. Methylation occurs at
the cytosine residues followed by a guanine (CpG dinucleotides) in the DNA sequence. CpG
DNA methylation of gene promoters is a well-known hallmark for transcriptionally inactive
genes, and is generally associated with stable gene silencing, such as genomic imprinting
and X chromosome inactivation [35, 36]. The DNA methylation state is established during
embryogenesis by several DNA methyltransferases (DNMTs) [35]. In mammals, 2 types of
DNMTs have been identified. DNMT3A and DNMT3B establish de novo DNA methylation,
while DNMT1 maintains DNA methylation patterns during DNA replication [37]. These
DNA methylation sites then recruit methyl-CpG-binding proteins, including methyl-CpG-
binding domain (MBD) proteins [38, 39], which bind the histone deacetylase (HDAC)-con‐
taining repressor complex, and consequently repress transcription [40, 41].
2.3. Chromatin remodeling
Chromatin structure is not static, but subject to change in response to internal and external
developmental signals [23]. Dynamic changes in the chromatin structure are regulated by
ATP-dependent chromatin remodelers, which allow the transcriptional machinery to access
its targets more or less effectively [42-44]. Using energy derived from ATP hydrolysis, ATP-
dependent chromatin remodelers relocate nucleosomes either by mobilizing or restructuring
nucleosomes [45, 46]. Thus, ATP-dependent chromatin remodelers can function both in tran‐
scriptional activation and repression via their nucleosome remodeling activity. Nearly all
ATP-dependent chromatin remodelers are multi-protein complexes that contain an ATPase
subunit, which belongs to the sucrose non-fermenting 2 (SNF2) family of ATPases. Based on
the homology between their ATPase domains, ATP-dependent chromatin remodeling com‐
plexes are divided into 4 groups: switch/sucrose non-fermenting (SWI/SNF), imitation
switch (ISWI), chromo helicase DNA binding (CHD), and inositol auxotroph 80 (INO80)
[42-44].
Genetic and biochemical studies indicate that some ATP-dependent chromatin remodeling
complexes contain epigenetic factors such as HDAC and MBD proteins. For example, nucle‐
osome-remodeling deacetylase (NuRD) is a multi-subunit complex that includes a SWI2/
SNF2 helicase/ATPase domain-containing Mi2 protein, HDAC1, HDAC2, and MBD3 [47].
The NuRD complexes promote the establishment of a specific chromatin structure at rRNA
genes that are transcriptionally inactive but are poised for transcriptional activation and
control transcription of these genes [48]. Thus, ATP-dependent chromatin complexes play
essential roles in epigenetic regulation of transcription along with several histone-modifying
enzymes and/or modified histone codes.




Apart from the role of histone modifications and DNA methylation, another form of epige‐
netic regulation involves non-coding RNAs (ncRNAs). A large variety of ncRNAs can be
classified into 2 major classes based on their transcript size: small ncRNAs (less than 200 nu‐
cleotides) and long ncRNAs (greater than 200 nucleotides) [49]. Each of these classes can be
further divided into subclasses. Micro RNA (miRNA) is a subgroup of small ncRNA mole‐
cules ~22 nucleotides in length. miRNAs post-transcriptionally regulate gene expression by
binding to complimentary or uncomplimentary sequences on target mRNA transcripts,
which results in either mRNA degradation or inhibition of translation [50]. In animal cells,
miRNA genes tend to be clustered in the genome, and are widely distributed [51]. Approxi‐
mately half of the human miRNA genes are located in the introns of protein-coding genes.
Expression studies have revealed that the clustered miRNA genes are often co-expressed,
suggesting that they are jointly transcribed as a polycistron [52, 53].
3. Transition from ESCS to NPCS
3.1. Histone modifications
Expression of pluripotency genes, such as OCT4 or NANOG, is a hallmark of undifferentiated
ESCs. The promoters and/or enhancers of these pluripotency genes are marked by H3K4me3,
which is strongly associated with transcriptionally active genes. In contrast, the majority of
genes, whose upregulation leads to differentiation, are inactivated or expressed at very low
levels [54, 55]. These genes loci are maintained in a transcriptionally competent but inactive
state characterized by both active (H3-K4me3) and repressive (H3-K27me3) histone marks, a
configuration described as a ‘‘bivalent domain’’ (Figure 1) [54, 55]. Bivalent histone methyla‐
tion in the promoters of proneural genes, such as Neurogenins (Ngns), Pax6, and Mash1, has
been reported in undifferentiated ESCs [56]. H3K27 and H3K4 methylation is catalyzed by
Polycomb-group (PcG) and Trithorax-group (TrxG) proteins, respectively [57]. PcG proteins
form a complex referred to as the Polycomb Repressor Complex (PRC). PRCs can be biochem‐
ically subdivided into 2 groups: PRC1 and PRC2. PRC1 and PRC2 are essential for the repres‐
sion of key developmental genes and maintenance of pluripotency in ESCs [58, 59]. The PRC2
complexes, which contain Enhancer of Zeste Homolog (EZH), a histone methyltransferase
(HMTase), catalyze tri-methylation of H3K27 [60]. This histone mark leads to the recruitment
of PRC1, thereby contributing to a repressive chromatin state [61, 62]. Consistent with this,
ESCs deficient in a PRC2 component display de-repression of tissue-specific genes, including
neural-associated genes [59]. TrxG proteins also act as large multimeric complexes [57]. TrxG
complexes possess methyltransferase activity directed specifically towards H3K4, thereby
leading to increased levels of H3K4me3 [57]. Dpy-30 is a mammalian homolog of the Drosophi‐
la  TrxG protein,  and a core component of  myeloid/lymphoid or mixed-lineage leukemia
(MLL) histone methyltransferase complexes. Depletion of Dpy-30 in ESCs results in a defect in
their neural lineage specification through reduced H3K4 methylation at bivalent domains of
key developmental loci [63]. Collectively, these findings suggest that the bivalent domain
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mediated by PcG and TrxG proteins plays a key epigenetic role in maintenance of the undif‐
ferentiated state and suppress neural differentiation.
Figure 1. Schematic diagram of transcriptional states during neuronal fate acquisition from ESCs. In ESCs, pluri‐
potency genes are transcriptionally activated (green "ON”). Key developmental genes are transcriptionally silent, yet
competent for expression (orange “OFF”). This silencing ensures rapid reactions to extracellular inductive signals.
Upon neural lineage choice, the transcriptional states of various developmental genes are altered. Pluripotency genes
and genes associated with other lineages become repressed during the transition from ESCs to neurogenic NPCs (red
“OFF”). Such a state of transcriptional repression is maintained over a long period. Gene activation and repression cor‐
relates with the presence of H3K4 tri-methylation (green flags) and H3K27 tri-methylation (red flags). DNA methyla‐
tion (shocking pink stars) contributes to repression in combination with H3K27 tri-methylation.
Genome-wide mapping by chromatin immunoprecipitation has revealed that differentiation
of ESCs is generally accompanied by global changes in histone methylation [55, 56]. In the
course of neural lineage commitment, the promoters of many neural lineage genes have
been shown to lose H3K27me3 from the bivalent domain, retain H3K4me3, and become acti‐
vated. At the same time, the promoter loci of non-neural lineage genes maintain H3K27me3
in the bivalent domain, while removing H3K4me3, which results in a stable silent state. The
promoters of some pluripotency genes such as SOX2, POU5F1, and NANOG shift from
modification by H3K4me3 alone to neither H3K4 nor H3K27 methylation as they are re‐
pressed during differentiation. As ESCs differentiate into NPCs, H3K27 specific demethy‐
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lase JMJD3 is recruited to and resolves the bivalent domain at the promoters of neuron-
specific genes such as nestin [64]. The majority of the JMJD3 target genes are key inducers of
neurogenesis, including Pax6 and Sox1. Knockdown of the H3K4me2/3 demethylase JAR‐
ID1B results in upregulation of stem cell-specific genes in ESC-derived NPCs [65]. Further‐
more, JARID1B knockdown ESCs fail to progress beyond the NPC stage [65]. These results
suggest that JARID1B promotes ESCs to differentiate towards a neural lineage by silencing
genes associated with pluripotency. Thus, when ESCs are committed to a neural lineage, bi‐
valent domains appear to be resolved in a lineage-specific fashion by leaving methyl marks
either being activated or repressed. This mechanism is believed to allow rapid transcription
of developmental genes in response to a variety of extrinsic cues.
Other repressive histone marks have also been reported to play important roles during dif‐
ferentiation. A sustained increase in silent chromatin marked by H3K9 methylation is ob‐
served in ESC-derived cells undergoing differentiation [66], suggesting that repressive
histone marks H3K9me2/3 is essential for promoting differentiation. Additionally, it is pos‐
sible that H3K9me2/3 marks play an important role in the establishment of an expression
profile of neuron specific genes in response to extracellular signals [67]. Ciliary neurotrophic
factor (CNTF), an astrocyte differentiation factor, is incapable of inducing expression of glial
fibrillary acidic protein (GFAP), an astrocytes-specific marker gene, in NPCs, because the
GFAP promoter is marked by H3K9 methylation. However, fibroblast growth factor 2
(FGF2) confer NPCs with responsiveness to CNTF by adding active H3K4 methylation and
removing H3K9 methylation at the GFAP promoter. Thus, H3K9 methylation controls the
timing of astrogliogenesis through regulation of CNTF-mediated signaling.
In addition to histone methylation, histone acetylation also appears to be an important epi‐
genetic modification during neural differentiation from ESCs, as ESCs generally undergo
striking changes in the global pattern of histone acetylation during neural differentiation
[68]. Histone acetylation is catalyzed by histone acetyltransferase (HAT), while histone de‐
acetylation is catalyzed by histone deacetylase (HDAC) [69]. Generally, HATs induce the
transcriptional activation of their target genes. However, the 60-kDa HIV-Tat interactive
protein (Tip60) histone acetyltransferase has been implicated in both transcriptional repres‐
sion and activation [70]. Tip60-p400 chromatin remodeling complexes containing Tip60 are
necessary to maintain characteristic features of ESCs [71]. Tip60-p400 complexes acetylate
histone H4 on the promoters of both activated and repressed genes. Additionally, distribu‐
tion patterns of p400 in ESCs strongly correlate with H3K4me3 marks on the promoters of
both active and inactive genes. These results suggest that Tip60-p400 complex-mediated his‐
tone acetylation functions as an active mark in the bivalent domain together with the active
H3K4me3 mark in ESCs.
3.2. DNA methylation
Genome-wide mapping of DNA methylation patterns has revealed dynamic DNA methyla‐
tion states at gene promoters during ESC differentiation (Figure 1) [72, 73]. The most pro‐
nounced changes in the DNA methylation state occur during neural lineage commitment
[74], suggesting that alterations in the DNA methylation state more strongly correlate with
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neural lineage commitment and loss of pluripotency than with terminal neural differentia‐
tion. The promoters of highly expressed housekeeping and pluripotency genes in ESCs ex‐
hibit low methylation levels [75]. By contrast, most key developmental and tissue-specific
genes exhibit high methylation levels, and are transcriptionally repressed [75]. As ESCs un‐
dergo differentiation, significant changes in DNA methylation patterns are observed. De no‐
vo methylation occurs on the promoter regions of pluripotency-associated factors [74].
DNA methylation potentially accompanies histone modifications during neural differentia‐
tion from ESCs. Cross-referencing DNA methylation patterns with mapping of histone
H3K27me3 in ESCs and ESC-derived neurons has revealed that, upon differentiation, the re‐
gions marked by H3K27me3 acquire DNA methylation in a sequence-independent manner
[74, 75]. H3K27me3 and DNA methylation are compatible throughout most of the genome
[76]. Furthermore, deficiency of DNMT in ESCs causes widespread H3K27me3 genomic
changes [76]. Taken together, these data suggest that DNA methylation, in cooperation with
histone modifications, may function as a protective gear by repressing pluripotency and oth‐
er lineage-specific genes during differentiation.
3.3. Chromatin remodeling
In addition to histone modifications and DNA methylation, the ATP-dependent chromatin
remodeling complexes also play a pivotal role in the maintenance of ESC pluripotency. As
previously described, Tip60-p400 chromatin remodeling complexes appear to be necessary
for the maintenance of ESCs, including pluripotency [71]. Subunits of the NuRD complexes
have also been shown to be important for ESC pluripotency and differentiation [77, 78]. Fur‐
thermore, ESCs contain another specialized ATP-dependent chromatin remodeling complex:
the Brahma-associated factor (BAF) complex. The BAF complexes are characterized by 2
SWI2/SNF2-like ATPases, BRG1 and BRM. The BAF complexes in ESCs have a unique subu‐
nit composition (termed esBAF) that is not seen in other tissues, such as NPCs and post-mi‐
totic neurons [79]. This specialized subunit composition is essential for establishment and
maintenance of ESCs. The esBAF complexes contain BRG1 but not BRM, and BAF155 but
not BAF170 (Figure 2). As ESCs differentiate into NPCs, these complexes undergo several
subunit exchanges. The esBAF complexes incorporate BRM and excludes BAF60B, thereby
forming the neural progenitor-specific BAF (npBAF) complexes in NPCs. The npBAF com‐
plex-specific subunit is necessary and sufficient for amplification of NPCs [80].
3.4. Non-coding RNAs
Increasing evidence demonstrates contributions of specific miRNAs in establishing ESC
properties and their transitioning to NPCs. The miR-290-295 cluster codes for miRNAs are
the most abundant in mouse ESCs and constitute over 70% of their entire miRNA popula‐
tion [81]. Consistent with their high expression levels, miR-290-295 miRNAs are involved in
many functions in ESCs. For example, miR-290-295 miRNAs promote the transition from
mitosis to S phase by targeting G1/S transition inhibitors such as Cdkn1a [82]. Furthermore,
miR-290-295 miRNAs have been shown to target the Rbl2 gene, which controls the expres‐
sion of the DNA methyltransferases, DNMT3A and DNMT3B, thereby establishing de novo
Epigenetic Regulation of Neural Differentiation from Embryonic Stem Cells
http://dx.doi.org/10.5772/53650
311
DNA methylation in ESCs [83]. miR-9 is gradually upregulated during neural differentiation
from ESCs [84, 85]. Furthermore, miR-9 performs diverse functions in different aspects of
neuronal differentiation [86]. For example, during neural differentiation of human ESCs,
miR-9 expression is not detectable in embryoid bodies, but is turned on in NPCs [84]. Inhibi‐
tion of miR-9 activity has been found to suppress proliferation and simultaneously promote
migration of NPCs [84]. Collectively, miRNAs could regulate multiple developmental proc‐
esses at the post-transcriptional level.
Figure 2. A switch in subunit composition of the BAF complexes during neuronal differentiation from ESCs. The
exchange of the components is essential for the transition from ESCs to post-mitotic neurons. The exchangeable subu‐
nits are colored as follows: esBAF complex-specific subunit, ocher; npBAF complex-specific subunit, red; and nBAF
complex-specific subunit, yellow. Cell type-specific BAF complexes have distinct functions that are indispensable for
their properties. The BAF complex in ESCs, NPCs, and neurons are defined as esBAF, npBAF, and nBAF, respectively.
The microRNA miR-124, binds to BAF53A mRNA transcripts to suppress its expression, thereby facilitating the replace‐
ment of BAF53 in the npBAF complexes.
4. Transition from NPCs to neurons
4.1. Histone modifications
After being committed to a neural lineage, NPCs exit the cell cycle and sequentially undergo
neural and glial differentiation. Wnt signaling, which plays important roles in the mainte‐
nance of embryonic and adult stem cells, promotes differentiation of neurogenic ESCs to
neurons, but does not promote differentiation of astrogenic NPCs into neurons [8]. In neuro‐
genic NPCs, one of the target genes for Wnt signaling is the proneural gene Ngn1, which
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promotes neurogenesis and inhibits astrocytic differentiation [87]. During the transition
from neurogenic NPCs to astrogenic NPCs, the level of repressive H3K27me3 mark at the
promoter of the Ngn1 gene gradually increases, leading to gene silencing [88]. Therefore, ac‐
tivation of the Wnt signaling does not lead to transactivation of Ngn1 at later developmental
stages. This illustrates how histone methylation can modulate responsiveness of NPCs to ex‐
tracellular cues, thereby rendering NPCs to switch from neurogenesis to astrogenesis.
CREB-binding protein (CBP), one of the most extensively studied HAT proteins, has been
found to play an essential role in motor neuron differentiation by interacting with retinoic
acid (RA) signaling [89]. Retinoic acid receptors (RARs) are DNA-binding proteins and form
a complex with Neurogenin2 (Ngn2) on the promoter of a motor neuron enhancer gene.
Binding of RA to RARs triggers recruitment of CBP on the promoter, which leads to acetyla‐
tion of core histone proteins and activation of the motor neuron enhancer gene. These re‐
sults indicate that neuronal subtype specification is regulated, at least in part, by the
interplay between intrinsic epigenetic mechanisms and extrinsic cues.
Histone deacetylation by HDACs also plays essential roles in neuronal differentiation, as
evidenced by studies using histone deacetylase inhibitors, such as valproic (VP) and trichos‐
tatin A (TSA) [90-92]. VPA promotes neuronal differentiation from adult hippocampal NPCs
by inducing the proneural genes, Ngn1, Math1, and NeuroD, and histone H4 acetylation,
while inhibiting glial differentiation [92]. A combination of TSA with sonic hedgehog (Shh),
fibroblast growth factor 8 (FGF8) and Wnt instructs non-mesencephalic NPCs to give rise to
dopaminergic neurons [93]. Inhibiting the activity of all HDAC1, 2, and 3 in NPCs leads to
suppression of oligodendrocyte differentiation, while HDAC2 activity alone inhibits astro‐
cyte differentiation. On the other hand, the HDAC1 activity is required for neural differen‐
tiation [94]. HDACs are generally present within large multi-subunit protein complexes in
the nucleus [69]. Among them in association with neuronal differentiation is the HDAC/
CoREST/REST repressor complex. The repressor element 1-silencing transcription factor
(REST) is a vertebrate zinc finger transcriptional repressor protein, which plays a fundamen‐
tal role in neurogenesis [95-97]. REST is expressed in both ESCs and NSCs, but is not ex‐
pressed in ES-derived neurons [98]. REST binds to an evolutionally conserved DNA motif
known as the repressor element 1 (RE1) [96, 97]. REST represses the expression of RE1-con‐
taining neuronal genes via recruitment of HDAC/CoREST complexes containing HDAC1
and HDAC 2 [97]. Thus, RE1 motif-associated neuronal genes in ESCs and NPCs appear to
be suppressed by REST. This repression could block premature expression of genes associat‐
ed with terminal differentiation at earlier stages than needed. Recently, a genome-wide
binding site analysis revealed the target genes of REST during cholinergic, GABAergic, glu‐
tamatergic, and medium spiny projection neuronal specification from NPCs [99]. A large
number of the identified REST target genes are unique for each neuronal subtype, strongly
suggesting that histone deacetylase plays essential roles in epigenetic control of neuronal
subtype specification as well as neuronal lineage commitment.
4.2. DNA methylation
DNA methylation has been shown to suppress astrocyte-specific genes in NPCs during ear‐
ly stages of development. Promoters of many astrocyte-specific genes contain the signal
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transducer and activator of transcription (STAT) binding elements. With this, astrocyte-spe‐
cific genes are transcriptionally activated through the Janus kinase (JAK)-STAT pathway,
one of whose ligands is the cytokine leukemia inhibitory factor (LIF). However, neurogenic
NPCs are not competent to differentiate into astrocytes even when they are grown with LIF,
because the STAT-binding elements within astrocyte-specific genes promoters are methylat‐
ed [100, 101]. This DNA methylation inhibits the association of activated STATs with the
promoter of astrocyte-specific genes, thereby repressing their transcription. Conditional de‐
letion of DNMT1 in embryonic NPCs results in DNA hypomethylation and alteration of the
timing of astrocytogenesis [101]. In addition, knockdown of DNMT3B in ESCs alters the tim‐
ing of their neural differentiation [102]. These findings suggest that DNA methylation con‐
trols the timing and developmental switch from neurogenesis to astrogliogenesis of NPCs
by altering responsiveness to their extracellular developmental cues.
4.3. Chromatin remodeling
As NPCs exit the cell cycle and differentiate into mature neurons, BAF60C is incorporated
into the npBAF complexes [80, 103]. BAF45A and BAF53A in the complexes give way to
BAF45B/C and BAF53B, respectively (Figure 2) [80, 103], establishing the post-mitotic neu‐
ron-specific nBAF complexes. Preventing the exchange of npBAF and nBAF components im‐
pairs neuronal differentiation, indicating that a switch in subunit composition of the BAF
complexes is required for the transition from pluripotent ESCs to post-mitotic neurons [80,
103]. The nBAF complexes, along with Ca2+-responsive dendritic regulator CREST, also play
a role in regulating the activation of genes essential for activity-dependent dendritic out‐
growth, suggesting that the nBAF complexes are required for morphological/synaptic devel‐
opment of neurons [103, 104].
The BAF complexes incorporate the BAF57 subunit containing DNA-binding HMG-box do‐
mains [105]. In addition, the BAF complex subunits contain motifs known to bind to modi‐
fied histones, including chromo-, bromo-, and PHD domains [103]. The bromodomain can
bind acetylated histones [106]. The chromo- and PHD domains function as lysine-methylat‐
ed histone-binding domains [106]. The esBAF and npBAF complexes contain different chro‐
modomain proteins (BAF155 or BAF170) [103], whereas the npBAF and nBAF complexes
contain different PHD domain proteins (BAF45a or BAF45b) [80, 103]. Thus, changes in sub‐
unit composition could alter targets of the BAF complexes, thereby causing changes in gene
expression patterns during neuronal differentiation.
4.4. Non-coding RNAs
A number of miRNAs involved in cell fate decision during stem cell differentiation is also
highly expressed in the nervous systems. Among these is miR-9, which is expressed specifi‐
cally in neurogenic areas of the embryonic and adult brains [107, 108]. TLX, an orphan nu‐
clear receptor, is essential for maintaining a self-renewable and undifferentiated state [109],
as well as cell cycle progression [110] of NPCs in the developing brain. TLX is highly ex‐
pressed in NPCs, but its expression is down-regulated upon neural differentiation [111].
Conversely, miR-9 expression increases during neural differentiation [111]. Furthermore,
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miR-9 has been shown to negatively regulate NPC proliferation and accelerate differentia‐
tion through targeting TLX transcription [111]. These findings suggest that miR-9 can switch
from undifferentiated to differentiated state of NPCs by downregulating TLX expression.
Another miRNA, miR-124, has been reported to promote neuronal differentiation by target‐
ing several genes involved in selection of non-neuronal cell fates. For example, miR-124 reg‐
ulates the BAF complex subunit composition during differentiation from NPCs to neurons
(Figure 2) by binding and thus suppressing BAF53A mRNA transcripts, which allows facili‐
tation of a switch between BAF53 subunits [112]. These studies indicate that miRNA expres‐
sion should be strictly controlled to ensure proper differentiation of ESCs into neurons.
Consistent with this assumption, miR-124 is expressed in neurons, but not in astrocytes
[113], and the miR-124 level increases during neural differentiation [84]. Remarkably, the
control of miR-124 expression itself is mediated by an epigenetic mechanism. The promoter
of the miR-124 gene contains a functional RE1 site. In ESCs and NPCs, REST occupies the
miR-124 gene locus and represses its expression [114], allowing persistent expression of non-
neuronal mRNAs. However, once NPCs start to differentiate into neurons, REST is downre‐
gulated, thereby disinhibiting miR-124 expression. miR-124 then triggers degradation of
non-neuronal mRNA transcripts, which promotes differentiation towards a neuronal line‐
age. One of the known target genes for miR-124 is C-terminal domain phosphatase 1 (SCP1),
which represses transcription of RE1-containing neuronal genes by REST, thereby prevent‐
ing cells from adopting a neuronal lineage and producing non-neural tissues [115]. Togeth‐
er, miR-124 is a target for REST, but at the same token also targets the REST co-repressor.
This represents the presence of a negative feedback loop between miRNA and a REST si‐
lencing complex, and such a mechanism may be broadly used to ensure proper cell fate
transitions during development.
Neurons derived from different human ESC lines exhibit distinctive cellular properties due
to the fact that human ESC lines were established under diverse conditions and from em‐
bryos with different genetic backgrounds. Comparison of neurons derived from HSF1 and
HSF6 ESC human lines has revealed that the HSF1 line produces forebrain neurons with
GABAergic and dopaminergic neurotransmitter phenotypes, while HSF6-derived neurons
produce midbrain/hindbrain neurons bearing dopaminergic, cholinergic, serotonergic, non-
forebrain GABAergic, and glutamatergic phenotypes [116]. Significant differences in the
miRNA expression profile was noted between these 2 human ESC lines [116], suggesting
that miRNA expression patterns might dictate in defining various neuronal subtypes arisen
from ESCs.
5. Conclusions
Epigenetic mechanisms are regulatory processes that control gene expression via changes in
chromatin structure without alterations in the DNA sequence. Changes in chromatin struc‐
ture alter the accessibility of transcription factors and RNA polymerase to genes packed into
chromatin, thereby modulating the efficiency of gene transcription. Epigenetic mechanisms
act to control this accessibility through histone modifications, DNA methylation, chromatin
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remodeling, and non-coding RNAs. Each of these epigenetic events interacts with intrinsic
(ex. transcription factors) and/or extrinsic factors (ex. developmental cues such as morpho‐
gens and cytokines). Studies so far have suggested that, during sequential transitions from
pluripotent ESCs to terminally differentiated neurons, epigenetic mechanisms play critical
roles in not only maintaining self-renewal capacity and pluripotency of ESCs, but also re‐
stricting cell lineage choices. Further investigation will therefore help clarifying the mecha‐
nisms that control pluripotency and neuronal/glial fate specification. Furthermore, the
knowledge will be used in harnessing ESCs safely and effectively for clinical applications.
Ackknowledgments
The authors wish to thank the financial support of JSPS KAKENHI Grant Number 24592567
(to A. S.) and NIH RC1 DC010706 (to E.H.).
Author details
Atsushi Shimomura1 and Eri Hashino2*
*Address all correspondence to: ehashino@iupui.edu
1 Department of Anatomy I, Fujita Health University School of Medicine, Toyoake, Aichi,
Japan
2 Department of Otolaryngology-Head and Neck Surgery, Stark Neurosciences Research In‐
stitute, Indiana University School of Medicine, Indianapolis, IN, USA
References
[1] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse
embryos. Nature 1981;292(5819) 154-156.
[2] Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet
2007;8(4) 263-271.
[3] Chen L, Daley GQ. Molecular basis of pluripotency. Hum Mol Genet 2008;17(R1)
R23-27.
[4] Temple S. The development of neural stem cells. Nature 2001;414(6859) 112-117.
[5] Temple S. Division and differentiation of isolated CNS blast cells in microculture.
Nature 1989;340(6233) 471-473.
Trends in Cell Signaling Pathways in Neuronal Fate Decision316
[6] Kilpatrick TJ, Bartlett PF. Cloning and growth of multipotential neural precursors: re‐
quirements for proliferation and differentiation. Neuron 1993;10(2) 255-265.
[7] Hirabayashi Y, Gotoh Y. Stage-dependent fate determination of neural precursor
cells in mouse forebrain. Neurosci Res 2005;51(4) 331-336.
[8] Hirabayashi Y, Gotoh Y. Epigenetic control of neural precursor cell fate during de‐
velopment. Nat Rev Neurosci 2010;11(6) 377-388.
[9] Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B,
Liu J, Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, Kuznetsov VA,
Robson P, Stanton LW, Wei CL, Ruan Y, Lim B, Ng HH. The Oct4 and Nanog tran‐
scription network regulates pluripotency in mouse embryonic stem cells. Nat Genet
2006;38(4) 431-440.
[10] Zhou Q, Chipperfield H, Melton DA, Wong WH. A gene regulatory network in
mouse embryonic stem cells. Proc Natl Acad Sci U S A 2007;104(42) 16438-16443.
[11] Walker E, Ohishi M, Davey RE, Zhang W, Cassar PA, Tanaka TS, Der SD, Morris Q,
Hughes TR, Zandstra PW, Stanford WL. Prediction and testing of novel transcrip‐
tional networks regulating embryonic stem cell self-renewal and commitment. Cell
Stem Cell 2007;1(1) 71-86.
[12] Young RA. Control of the embryonic stem cell state. Cell 2011;144(6) 940-954.
[13] Heo J, Lee JS, Chu IS, Takahama Y, Thorgeirsson SS. Spontaneous differentiation of
mouse embryonic stem cells in vitro: characterization by global gene expression pro‐
files. Biochem Biophys Res Commun 2005;332(4) 1061-1069.
[14] Loring JF, Porter JG, Seilhammer J, Kaser MR, Wesselschmidt R. A gene expression
profile of embryonic stem cells and embryonic stem cell-derived neurons. Restor
Neurol Neurosci 2001;18(2-3) 81-88.
[15] Bhattacharya B, Puri S, Puri RK. A review of gene expression profiling of human em‐
bryonic stem cell lines and their differentiated progeny. Curr Stem Cell Res Ther
2009;4(2) 98-106.
[16] Stein GS, Stein JL, Van Wijnen AJ, Lian JB, Montecino M, Croce CM, Choi JY, Ali SA,
Pande S, Hassan MQ, Zaidi SK, Young DW. Transcription factor-mediated epigenetic
regulation of cell growth and phenotype for biological control and cancer. Adv En‐
zyme Regul 2010;50(1) 160-167.
[17] Lunyak VV, Rosenfeld MG. Epigenetic regulation of stem cell fate. Hum Mol Genet
2008;17(R1) R28-36.
[18] Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of
the nucleosome core particle at 2.8 A resolution. Nature 1997;389(6648) 251-260.
Epigenetic Regulation of Neural Differentiation from Embryonic Stem Cells
http://dx.doi.org/10.5772/53650
317
[19] Yuan GC, Liu YJ, Dion MF, Slack MD, Wu LF, Altschuler SJ, Rando OJ. Genome-
scale identification of nucleosome positions in S. cerevisiae. Science 2005;309(5734)
626-630.
[20] Muthurajan UM, Bao Y, Forsberg LJ, Edayathumangalam RS, Dyer PN, White CL,
Luger K. Crystal structures of histone Sin mutant nucleosomes reveal altered pro‐
tein-DNA interactions. EMBO J 2004;23(2) 260-271.
[21] Lieb JD, Clarke ND. Control of transcription through intragenic patterns of nucleo‐
some composition. Cell 2005;123(7) 1187-1190.
[22] Bell O, Tiwari VK, Thoma NH, Schubeler D. Determinants and dynamics of genome
accessibility. Nat Rev Genet 2011;12(8) 554-564.
[23] Bai L, Morozov AV. Gene regulation by nucleosome positioning. Trends Genet
2010;26(11) 476-483.
[24] Anderson JD, Lowary PT, Widom J. Effects of histone acetylation on the equilibrium
accessibility of nucleosomal DNA target sites. J Mol Biol 2001;307(4) 977-985.
[25] Strahl BD, Allis CD. The language of covalent histone modifications. Nature
2000;403(6765) 41-45.
[26] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines,
indicates that thousands of human genes are microRNA targets. Cell 2005;120(1)
15-20.
[27] Kouzarides T. Chromatin modifications and their function. Cell 2007;128(4) 693-705.
[28] Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay be‐
tween different covalent modifications of the core histone tails. Genes Dev
2001;15(18) 2343-2360.
[29] Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14(14)
R546-551.
[30] Nishioka K, Rice JC, Sarma K, Erdjument-Bromage H, Werner J, Wang Y, Chuikov S,
Valenzuela P, Tempst P, Steward R, Lis JT, Allis CD, Reinberg D. PR-Set7 is a nucleo‐
some-specific methyltransferase that modifies lysine 20 of histone H4 and is associat‐
ed with silent chromatin. Mol Cell 2002;9(6) 1201-1213.
[31] Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenu‐
wein T. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitu‐
tive heterochromatin. Genes Dev 2004;18(11) 1251-1262.
[32] Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev
2002;12(2) 198-209.
[33] Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol
Cell Biol 2005;6(11) 838-849.
Trends in Cell Signaling Pathways in Neuronal Fate Decision318
[34] Wang Y, Jia S. Degrees make all the difference: the multifunctionality of histone H4
lysine 20 methylation. Epigenetics 2009;4(5) 273-276.
[35] Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epige‐
nomics. Nat Rev Genet 2008;9(6) 465-476.
[36] Eden S, Cedar H. Role of DNA methylation in the regulation of transcription. Curr
Opin Genet Dev 1994;4(2) 255-259.
[37] Law JA, Jacobsen SE. Establishing, maintaining and modifying DNA methylation
patterns in plants and animals. Nat Rev Genet 2010;11(3) 204-220.
[38] Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Targeting specific gene repres‐
sion. Eur J Biochem 2001;268(1) 1-6.
[39] Wade PA. Methyl CpG-binding proteins and transcriptional repression. Bioessays
2001;23(12) 1131-1137.
[40] Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J,
Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress tran‐
scription. Nat Genet 1998;19(2) 187-191.
[41] Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Tran‐
scriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone
deacetylase complex. Nature 1998;393(6683) 386-389.
[42] Cairns BR. Chromatin remodeling: insights and intrigue from single-molecule stud‐
ies. Nat Struct Mol Biol 2007;14(11) 989-996.
[43] Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, ge‐
nomics and mechanisms. Cell Res 2011;21(3) 396-420.
[44] Smith CL, Peterson CL. ATP-dependent chromatin remodeling. Curr Top Dev Biol
2005;65 115-148.
[45] Varga-Weisz PD, Blank TA, Becker PB. Energy-dependent chromatin accessibility
and nucleosome mobility in a cell-free system. EMBO J 1995;14(10) 2209-2216.
[46] Ito T, Bulger M, Pazin MJ, Kobayashi R, Kadonaga JT. ACF, an ISWI-containing and
ATP-utilizing chromatin assembly and remodeling factor. Cell 1997;90(1) 145-155.
[47] Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of
the NuRD subunits reveals a histone deacetylase core complex and a connection with
DNA methylation. Genes Dev 1999;13(15) 1924-1935.
[48] Xie W, Ling T, Zhou Y, Feng W, Zhu Q, Stunnenberg HG, Grummt I, Tao W. The
chromatin remodeling complex NuRD establishes the poised state of rRNA genes
characterized by bivalent histone modifications and altered nucleosome positions.
Proc Natl Acad Sci U S A 2012;109(21) 8161-8166.
Epigenetic Regulation of Neural Differentiation from Embryonic Stem Cells
http://dx.doi.org/10.5772/53650
319
[49] Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell
Biol 2009;21(3) 416-425.
[50] Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Bi‐
ochem Soc Trans 2008;36(Pt 6) 1224-1231.
[51] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes
coding for small expressed RNAs. Science 2001;294(5543) 853-858.
[52] Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing
and subcellular localization. EMBO J 2002;21(17) 4663-4670.
[53] He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S,
Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as
a potential human oncogene. Nature 2005;435(7043) 828-833.
[54] Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM, Gouti M, Casanova
M, Warnes G, Merkenschlager M, Fisher AG. Chromatin signatures of pluripotent
cell lines. Nat Cell Biol 2006;8(5) 532-538.
[55] Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A,
Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. A biva‐
lent chromatin structure marks key developmental genes in embryonic stem cells.
Cell 2006;125(2) 315-326.
[56] Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P,
Brockman W, Kim TK, Koche RP, Lee W, Mendenhall E, O'Donovan A, Presser A,
Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C, Lander ES, Bernstein
BE. Genome-wide maps of chromatin state in pluripotent and lineage-committed
cells. Nature 2007;448(7153) 553-560.
[57] Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and
Trithorax group proteins. Annu Rev Genet 2004;38 413-443.
[58] Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B,
Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker
JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte AP, Vol‐
kert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA. Control of devel‐
opmental regulators by Polycomb in human embryonic stem cells. Cell 2006;125(2)
301-313.
[59] Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wer‐
nig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young RA, Jae‐
nisch R. Polycomb complexes repress developmental regulators in murine
embryonic stem cells. Nature 2006;441(7091) 349-353.
[60] Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in
histone H3. Curr Opin Genet Dev 2004;14(2) 155-164.
Trends in Cell Signaling Pathways in Neuronal Fate Decision320
[61] Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang
Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science
2002;298(5595) 1039-1043.
[62] Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of ge‐
nomic programmes. Nat Rev Genet 2007;8(1) 9-22.
[63] Jiang H, Shukla A, Wang X, Chen WY, Bernstein BE, Roeder RG. Role for Dpy-30 in
ES cell-fate specification by regulation of H3K4 methylation within bivalent domains.
Cell 2011;144(4) 513-525.
[64] Burgold T, Spreafico F, De Santa F, Totaro MG, Prosperini E, Natoli G, Testa G. The
histone H3 lysine 27-specific demethylase Jmjd3 is required for neural commitment.
PLoS One 2008;3(8) e3034.
[65] Schmitz SU, Albert M, Malatesta M, Morey L, Johansen JV, Bak M, Tommerup N,
Abarrategui I, Helin K. Jarid1b targets genes regulating development and is involved
in neural differentiation. EMBO J 2011;30(22) 4586-4600.
[66] Meshorer E, Yellajoshula D, George E, Scambler PJ, Brown DT, Misteli T. Hyperdy‐
namic plasticity of chromatin proteins in pluripotent embryonic stem cells. Dev Cell
2006;10(1) 105-116.
[67] Song MR, Ghosh A. FGF2-induced chromatin remodeling regulates CNTF-mediated
gene expression and astrocyte differentiation. Nat Neurosci 2004;7(3) 229-235.
[68] Meshorer E, Misteli T. Chromatin in pluripotent embryonic stem cells and differen‐
tiation. Nat Rev Mol Cell Biol 2006;7(7) 540-546.
[69] Hayakawa T, Nakayama J. Physiological roles of class I HDAC complex and histone
demethylase. J Biomed Biotechnol 2011;2011 129383.
[70] Sapountzi V, Logan IR, Robson CN. Cellular functions of TIP60. Int J Biochem Cell
Biol 2006;38(9) 1496-1509.
[71] Fazzio TG, Huff JT, Panning B. An RNAi screen of chromatin proteins identifies
Tip60-p400 as a regulator of embryonic stem cell identity. Cell 2008;134(1) 162-174.
[72] Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bern‐
stein BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R, Lander ES. Genome-scale DNA
methylation maps of pluripotent and differentiated cells. Nature 2008;454(7205)
766-770.
[73] Isagawa T, Nagae G, Shiraki N, Fujita T, Sato N, Ishikawa S, Kume S, Aburatani H.
DNA methylation profiling of embryonic stem cell differentiation into the three germ
layers. PLoS One;6(10) e26052.
[74] Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, Schubeler D.
Lineage-specific polycomb targets and de novo DNA methylation define restriction
and potential of neuronal progenitors. Mol Cell 2008;30(6) 755-766.
Epigenetic Regulation of Neural Differentiation from Embryonic Stem Cells
http://dx.doi.org/10.5772/53650
321
[75] Fouse SD, Shen Y, Pellegrini M, Cole S, Meissner A, Van Neste L, Jaenisch R, Fan G.
Promoter CpG methylation contributes to ES cell gene regulation in parallel with
Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell
2008;2(2) 160-169.
[76] Brinkman AB, Gu H, Bartels SJ, Zhang Y, Matarese F, Simmer F, Marks H, Bock C,
Gnirke A, Meissner A, Stunnenberg HG. Sequential ChIP-bisulfite sequencing ena‐
bles direct genome-scale investigation of chromatin and DNA methylation cross-talk.
Genome Res 2012;22(6) 1128-1138.
[77] Kaji K, Caballero IM, MacLeod R, Nichols J, Wilson VA, Hendrich B. The NuRD
component Mbd3 is required for pluripotency of embryonic stem cells. Nat Cell Biol
2006;8(3) 285-292.
[78] Kaji K, Nichols J, Hendrich B. Mbd3, a component of the NuRD co-repressor com‐
plex, is required for development of pluripotent cells. Development 2007;134(6)
1123-1132.
[79] Ho L, Ronan JL, Wu J, Staahl BT, Chen L, Kuo A, Lessard J, Nesvizhskii AI, Ranish J,
Crabtree GR. An embryonic stem cell chromatin remodeling complex, esBAF, is es‐
sential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci U S
A 2009;106(13) 5181-5186.
[80] Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staahl BT, Wu H, Aebersold R,
Graef IA, Crabtree GR. An essential switch in subunit composition of a chromatin re‐
modeling complex during neural development. Neuron 2007;55(2) 201-215.
[81] Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther
MG, Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL,
Gupta S, Love J, Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young RA. Connecting
microRNA genes to the core transcriptional regulatory circuitry of embryonic stem
cells. Cell 2008;134(3) 521-533.
[82] Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem
cell-specific microRNAs regulate the G1-S transition and promote rapid prolifera‐
tion. Nat Genet 2008;40(12) 1478-1483.
[83] Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG,
Zavolan M, Svoboda P, Filipowicz W. MicroRNAs control de novo DNA methylation
through regulation of transcriptional repressors in mouse embryonic stem cells. Nat
Struct Mol Biol 2008;15(3) 259-267.
[84] Delaloy C, Liu L, Lee JA, Su H, Shen F, Yang GY, Young WL, Ivey KN, Gao FB. Mi‐
croRNA-9 coordinates proliferation and migration of human embryonic stem cell-de‐
rived neural progenitors. Cell Stem Cell 2010;6(4) 323-335.
[85] Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Specific microRNAs modulate
embryonic stem cell-derived neurogenesis. Stem Cells 2006;24(4) 857-864.
Trends in Cell Signaling Pathways in Neuronal Fate Decision322
[86] Gao FB. Context-dependent functions of specific microRNAs in neuronal develop‐
ment. Neural Dev 2010;5 25.
[87] Hirabayashi Y, Itoh Y, Tabata H, Nakajima K, Akiyama T, Masuyama N, Gotoh Y.
The Wnt/beta-catenin pathway directs neuronal differentiation of cortical neural pre‐
cursor cells. Development 2004;131(12) 2791-2801.
[88] Hirabayashi Y, Suzki N, Tsuboi M, Endo TA, Toyoda T, Shinga J, Koseki H, Vidal M,
Gotoh Y. Polycomb limits the neurogenic competence of neural precursor cells to
promote astrogenic fate transition. Neuron 2009;63(5) 600-613.
[89] Lee S, Lee B, Lee JW, Lee SK. Retinoid signaling and neurogenin2 function are cou‐
pled for the specification of spinal motor neurons through a chromatin modifier CBP.
Neuron 2009;62(5) 641-654.
[90] Marin-Husstege M, Muggironi M, Liu A, Casaccia-Bonnefil P. Histone deacetylase
activity is necessary for oligodendrocyte lineage progression. J Neurosci 2002;22(23)
10333-10345.
[91] Balasubramaniyan V, Boddeke E, Bakels R, Kust B, Kooistra S, Veneman A, Copray
S. Effects of histone deacetylation inhibition on neuronal differentiation of embryonic
mouse neural stem cells. Neuroscience 2006;143(4) 939-951.
[92] Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibi‐
tion-mediated neuronal differentiation of multipotent adult neural progenitor cells.
Proc Natl Acad Sci U S A 2004;101(47) 16659-16664.
[93] Rossler R, Boddeke E, Copray S. Differentiation of non-mesencephalic neural stem
cells towards dopaminergic neurons. Neuroscience 2010;170(2) 417-428.
[94] Humphrey GW, Wang YH, Hirai T, Padmanabhan R, Panchision DM, Newell LF,
McKay RD, Howard BH. Complementary roles for histone deacetylases 1, 2, and 3 in
differentiation of pluripotent stem cells. Differentiation 2008;76(4) 348-356.
[95] Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altshuller
YM, Frohman MA, Kraner SD, Mandel G. REST: a mammalian silencer protein that
restricts sodium channel gene expression to neurons. Cell 1995;80(6) 949-957.
[96] choenherr CJ, Paquette AJ, Anderson DJ. Identification of potential target genes for
the neuron-restrictive silencer factor. Proc Natl Acad Sci U S A 1996;93(18) 9881-9886.
[97] Ballas N, Mandel G. The many faces of REST oversee epigenetic programming of
neuronal genes. Curr Opin Neurobiol 2005;15(5) 500-506.
[98] Sun YM, Greenway DJ, Johnson R, Street M, Belyaev ND, Deuchars J, Bee T, Wilde S,
Buckley NJ. Distinct profiles of REST interactions with its target genes at different
stages of neuronal development. Mol Biol Cell 2005;16(12) 5630-5638.
[99] Abrajano JJ, Qureshi IA, Gokhan S, Zheng D, Bergman A, Mehler MF. REST and
CoREST modulate neuronal subtype specification, maturation and maintenance.
Epigenetic Regulation of Neural Differentiation from Embryonic Stem Cells
http://dx.doi.org/10.5772/53650
323
PLoS One 2009;4(12) e7936. http://www.plosone.org/article/info%3Adoi
%2F10.1371%2Fjournal.pone.0007936 (accessed 7 December 2009)
[100] Takizawa T, Nakashima K, Namihira M, Ochiai W, Uemura A, Yanagisawa M, Fujita
N, Nakao M, Taga T. DNA methylation is a critical cell-intrinsic determinant of as‐
trocyte differentiation in the fetal brain. Dev Cell 2001;1(6) 749-758.
[101] Fan G, Martinowich K, Chin MH, He F, Fouse SD, Hutnick L, Hattori D, Ge W, Shen
Y, Wu H, ten Hoeve J, Shuai K, Sun YE. DNA methylation controls the timing of as‐
trogliogenesis through regulation of JAK-STAT signaling. Development 2005;132(15)
3345-3356.
[102] Martins-Taylor K, Schroeder DI, Lasalle JM, Lalande M, Xu RH. Role of DNMT3B in
the regulation of early neural and neural crest specifiers. Epigenetics 2012;7(1) 71-82.
[103] Yoo AS, Crabtree GR. ATP-dependent chromatin remodeling in neural development.
Curr Opin Neurobiol 2009;19(2) 120-126.
[104] Wu JI, Lessard J, Olave IA, Qiu Z, Ghosh A, Graef IA, Crabtree GR. Regulation of
dendritic development by neuron-specific chromatin remodeling complexes. Neuron
2007;56(1) 94-108.
[105] Wang W, Chi T, Xue Y, Zhou S, Kuo A, Crabtree GR. Architectural DNA binding by
a high-mobility-group/kinesin-like subunit in mammalian SWI/SNF-related com‐
plexes. Proc Natl Acad Sci U S A 1998;95(2) 492-498.
[106] Yun M, Wu J, Workman JL, Li B. Readers of histone modifications. Cell Res
2011;21(4) 564-578.
[107] Deo M, Yu JY, Chung KH, Tippens M, Turner DL. Detection of mammalian micro‐
RNA expression by in situ hybridization with RNA oligonucleotides. Dev Dyn
2006;235(9) 2538-2548.
[108] Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH, Wilson SW. Micro‐
RNAs show a wide diversity of expression profiles in the developing and mature
central nervous system. Genome Biol 2007;8(8) R173.
[109] Shi Y, Chichung Lie D, Taupin P, Nakashima K, Ray J, Yu RT, Gage FH, Evans RM.
Expression and function of orphan nuclear receptor TLX in adult neural stem cells.
Nature 2004;427(6969) 78-83.
[110] Li W, Sun G, Yang S, Qu Q, Nakashima K, Shi Y. Nuclear receptor TLX regulates cell
cycle progression in neural stem cells of the developing brain. Mol Endocrinol
2008;22(1) 56-64.
[111] Zhao C, Sun G, Li S, Shi Y. A feedback regulatory loop involving microRNA-9 and
nuclear receptor TLX in neural stem cell fate determination. Nat Struct Mol Biol
2009;16(4) 365-371.
Trends in Cell Signaling Pathways in Neuronal Fate Decision324
[112] Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chroma‐
tin-remodelling complexes in neural development. Nature 2009;460(7255) 642-646.
[113] Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG. Regulation of
miRNA expression during neural cell specification. Eur J Neurosci 2005;21(6)
1469-1477.
[114] Conaco C, Otto S, Han JJ, Mandel G. Reciprocal actions of REST and a microRNA
promote neuronal identity. Proc Natl Acad Sci U S A 2006;103(7) 2422-2427.
[115] Yeo M, Lee SK, Lee B, Ruiz EC, Pfaff SL, Gill GN. Small CTD phosphatases function
in silencing neuronal gene expression. Science 2005;307(5709) 596-600.
[116] Wu H, Xu J, Pang ZP, Ge W, Kim KJ, Blanchi B, Chen C, Sudhof TC, Sun YE. Integra‐
tive genomic and functional analyses reveal neuronal subtype differentiation bias in
human embryonic stem cell lines. Proc Natl Acad Sci U S A 2007;104(34) 13821-13826.





Neural Fate of Mesenchymal Stem Cells
and Neural Crest Stem Cells: Which Ways
to Get Neurons for Cell Therapy Purpose?
Virginie Neirinckx, Cécile Coste,
Bernard Rogister and Sabine Wislet-Gendebien
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53260
1. Introduction
The treatment of neurological disorders represents a critical issue in clinical research, since
no complete recovery of patients can be achieved with actual therapeutic means, despite
symptomatic improvements. Indeed, whereas restricted brain areas still house cells compe‐
tent to generate newborn neurons in adulthood, those neural stem cells are present in re‐
stricted amounts. Moreover, this limited neurogenesis does not seem to be sufficient to
enable neuronal regeneration in cases of traumatic, ischemic or degenerative lesions of the
central nervous system. Therefore, other sources of neural cells have to be considered in a
cell therapy objective.
Stem  cells  are  characterized  as  cells  endowed  with  continuous  self-renewal  ability  and
pluri- or multipotentiality, and could consequently give rise to a wide panel of cell types.
Non-germinal stem cells  are classified into different categories:  (1)  Embryonic stem cells
(ES) are found in the inner cell mass of blastocyst and are pluripotent stem cells that can
generate any mature cell  of  each of the three germ layers;  (2)  Induced pluripotent stem
cells  (iPS)  are adult  somatic  cells  that  are reprogrammed into pluripotent cells  with ES-
like abilities; (3) Somatic stem cells are tissue-specific and more restricted than ES cells in
terms of differentiation capabilities. They can be isolated from various fetal and adult tis‐
sues,  which make them an attractive  supply  of  material  for  cell  therapy.  Indeed,  while
neurons have already been successfully generated from ES cells [1] or iPS cells [2, 3], the
use of adult somatic stem cells definitely remain of significant interest regarding technical,
ethical and immunological issues concerning cell transplantation for brain diseases. In this
© 2013 Neirinckx et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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regard, mesenchymal stem cells (MSCs) and neural crest-derived stem cells (NCSCs) that
can be  found in  various locations of  the  adult  organism (and even in  perinatal  tissues)
represent an important source of easily-accessible multipotent cells to use in a cell therapy
purpose.
In this chapter, we will describe the major features of MSCs and NCSCs isolated from five
different tissues, which constitute the main exploited and accessible sources for cell isolation
in an objective of cell therapy protocols for neurological disorders (Figure 1). Moreover, we
will detail the multiple ways they can generate neuron-like cells in vitro. Indeed, numerous
culture conditions and differentiation protocols do exist and are demonstrated as efficient,
supporting the fact that neural differentiation can occur through different cellular signaling
mechanisms. Therefore, we will review the various signaling pathways that could trigger
the neural fate adoption of MSCs and NCSCs, and the related cell-based therapy experi‐
ments that have been done downstream.
2. Different types of mesenchymal stem cells
Mesenchymal stem cells (MSCs) are plastic-adherent, fibroblast-like cells, which are conven‐
tionally able to self-renew and differentiate into tissues of the mesodermic lineage, such as
bone, adipose tissue and cartilage. Whereas those cells have traditionally been isolated from
bone marrow stroma, many reports have now described the presence of MSCs in a variety
of fetal, perinatal and adult tissues, including peripheral blood, umbilical cord Wharton’s
Jelly and blood, fetal liver and lungs, adipose tissue, skeletal muscles, amniotic fluid, syno‐
vium and circulatory system, where they work as supportive cells and maintain tissue ho‐
meostasis.
2.1. Bone marrow mesenchymal stem cells
The initial study of non-hematopoietic bone marrow (BM) cells was performed by Frieden‐
stein et al. in the late 80’s [4, 5]. After establishing single cell suspensions of BM, they
showed that those cells were able to generate colonies of adherent fibroblast-shaped cells
when cultured in vitro. They demonstrated that these colony-forming unit - fibroblasts
(CFU-F) presented the ability to undergo osteogenic differentiation [5, 6]. These bone mar‐
row mesenchymal stem cells (BM-MSCs) were then demonstrated as multipotent progeni‐
tors that were able to self-renew [7] and could differentiate into any cell of the mesodermic
lineage, like osteoblasts, chondrocytes, or adipocytes [8, 9]. More interestingly, it has been
showed that BM-MSCs were able to “trans-differentiate” into cells with endodermal or ecto‐
dermal characteristics [10], and particularly into neuron-like cells [11-15]. These stem cells
are therefore raising huge interest, since they represent a promising source of material for
cell therapy protocols, such as mesenchymal tissue engineering or neurological disorder
treatments as well.
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Figure 1. Mesenchymal and neural crest stem cells from different perinatal and adult tissues. The upper part describes
the presence of mesenchymal and/or neural crest stem cells in various adult tissue. The lower part describes cell fate
that have been demonstrated for each type of stem cells regarding the mesodermic, endodermic or ectodermic cell
lineage.
The main debate concerning BM-MSCs resides in the lack of exact phenotypic characteriza‐
tion, due to the absence of specific membrane markers and non-standardized culture meth‐
ods. Consequently, several groups described BM-MSCs with a wide variety of different
phenotypes: Verfaillie’s group described a rare population of cells in human BM stroma as
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mesodermal adult progenitor cells (MAPCs)[12, 16]; D’Ippolito and collaborators cultured
cells in low oxygen tension and characterized marrow isolated adult multilineage inducible
(MIAMI) cells [17, 18]; whereas a lot of other groups kept the mesenchymal stem cell con‐
cept as defined by Pittenger et al. [9].
In addition to the phenotypic differences of BM-MSCs which are inherent to culture settings,
it has been demonstrated that BM stroma was a mixed population of cells arising from dif‐
ferent embryonic lineages. Although adult BM-MSCs were commonly considered to be of
mesodermal origin (bone marrow mesenchymal stem cells) [19], several studies have shown
that some adult BM-MSCs derive from the embryonic neural crest [20-24] (see paragraph be‐
low). Hence, the different studies that are detailed below often describe BM-MSCs without
distinguishing mesenchymal and neural-crest derived cells.
2.2. Adipose tissue stem cells
Similarly to the main part of BM stroma, adipose tissue derives from mesodermic lineage
and contains stem cells able to differentiate into bone, cartilage, fat and muscle. Likewise,
adipose tissue mesenchymal stem cells (AT-MSCs) can adopt a neural-like phenotype [25,
26], which makes them another potential source of cells to use in replacement therapy.
2.3. Umbilical cord blood and Wharton’s jelly mesenchymal stem cells
Wharton’s jelly constitutes the gelatinous matrix of umbilical cord. Mainly composed of col‐
lagen fibers, proteoglycans and stromal cells, this tissue has also been described to enclose
mesenchymal cells endowed with stem cells properties (WJ-MSCs); They are easily cultured
and expanded in vitro, and are able to differentiate into a wide range of cell types, including
neural cells [27-29].
Whereas adult peripheral blood only contains a tiny number of MSCs, umbilical cord blood
is a richer source and allows to culture adherent MSCs more efficiently. These umbilical
cord blood MSCs (UCB-MSCs) are considered as a more primitive population, but can be
largely expanded and maintained in long term culture [30], and were described to be an os‐
teogenic, adipogenic, chondrogenic and even a neurogenic cell population [31-33]. Altogeth‐
er, these data confirmed umbilical cord as a new source of cells for cellular therapeutics for
stromal, bone, and, potentially, neural repair [34].
3. Different types of neural crest stem cells
During embryonic development of vertebrates, neural crest is specified at the border of the
neural plate and the non-neural ectoderm after gastrulation. During neurulation, the neural
folds both join at the dorsal midline to form the neural tube. Subsequently, neural crest cells
(NCC) from the roof plate of the neural tube undergo an epithelial to mesenchymal transi‐
tion (EMT), delaminating from the neuroectoderm. Those multipotent NCC then migrate to‐
wards different locations in the body where they differentiate into various cell types,
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including melanocytes, craniofacial cartilage and bone, smooth muscle, peripheral and en‐
teric neuron, and glia.
In the past few years, multipotent and self renewing neural crest stem cells (NCSCs) have
been described to persist in the adult organism. Those post-migratory NCSCs were found in
the gut [35], the skin [36-38], the cornea [39], the heart [40], the teeth [41, 42], the dorsal root
ganglion and the bone marrow [21, 22, 43]. As the skin, the teeth and the bone marrow con‐
stitute the most easily-accessible and available sources of NCSCs to use in therapy protocols,
we will describe those three tissues more precisely.
3.1. Bone marrow neural crest stem cells
Regarding the striking similarities of bone marrow stromal cells and embryonic NCSCs con‐
cerning their neural differentiation potential, the question of the presence of a neural crest-
derived cell subpopulation in bone marrow was raised. Indeed, the mesodermal origin of
bone marrow stromal cells was definitely queried since a study of Takashima et al. demon‐
strated that a first wave of mesenchymal stem cells in the embryo derives from the Sox1-
positive neuroepithelium through a neural crest stage [20].
Lately, convincing evidence for the subsistence of NCSCs in bone marrow emerged from
a study by Nagoshi et al. They isolated neural crest-derived cells from the bone marrow
using Wnt1-Cre/FloxedEGFP mice for  in vivo  fate  mapping.  Those cells  could be propa‐
gated in sphere cultures for a couple of passages.  A bit  more than 3% of these isolated
EGFP+ cells had the capacity to differentiate into neurons, glia,  and smooth muscle cells
(this  proportion  was  sustainably  increased  by  collagenase  treatment,  suggesting  their
tight contact with bone surface) [21, 22]. The same group used another transgenic mouse
(P0-Cre/FloxedEGFP) to isolate NCSCs among the bone marrow stromal cells,  and dem‐
onstrated their  ability  to  differentiate  into neural  crest  lineages  but  also into mesenchy‐
mal  lineages  such  as  adipocytes,  chondrocytes  and  osteocytes  [22].  Using  a  Wnt1-Cre/
FloxedLacZ transgenic mouse,  the group of Wislet-Gendebien generated neural-crest  de‐
rived clones  of  passage 5  bone marrow stromal  cells,  and compared them with mesen‐
chymal clones. They showed that the two types of populations were surprisingly similar
at the transcriptomic level and in terms of differentiation abilities, and that both of them
could  give  rise  to  neurons  [43].  Altogether,  the  different  results  about  bone  marrow
NCSCs  make  those  cells  as  exciting  as  their  MSCs  neighbors  in  a  context  of  therapy.
Moreover, their neural crest origin may confer them particular additional properties in a
perspective of nervous system repair.
3.2. Skin-derived neural crest stem cells
Using the same type of Wnt1-Cre reporter mice, the groups of Sieber-Blum and Toma identi‐
fied neural crest-derived stem cells in the facial skin of adult mice and humans [36, 37, 44,
45]. Those skin-derived precursors (SKPs) are located in the dermal papillae and in the hair
follicle, and are able to differentiate in vitro into neurons, smooth muscle cells, Schwann cells
and melanocytes.
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Other skin-derived NCSCs, termed epidermal NCSCs (EPI-NCSCs) were isolated from the
bulge region of whisker follicles. Similarly to SKPs, EPI-NCSCs can give rise to neurons,
smooth muscle cells, Schwann cells and melanocytes [37, 44, 46]. As an easy-accessible au‐
tologous source of highly multipotent stem cells, the skin and its SKPs and EPI-NCSCs are
of significant interest in cell therapy.
3.3. Dental neural crest stem cells
The dental pulp is the connective tissue that forms the inner part of the teeth, and contains
ondotoblasts which are responsible of dentin formation. Few years ago, a population of
stem cells has been identified in dental pulp, and is thought to arise from the embryonic cra‐
nial neural crest [47, 48]. These dental pulp stem cells (DP-SCs) are endowed with high pro‐
liferative potential, self-renewal ability and multi-lineage differentiation [42, 49], making
them an attractive tool for stem cell therapeutic strategies. Whereas the DP-SCs are isolated
from the adult teeth, the same type of stem cells can be found in the human exfoliated decid‐
uous teeth (SHED cells), identified as immature DP-SCs.
The properties of self-renewal and multi-lineage differentiation ability of all described stem
cells make them truly attractive candidates for cell therapy. Furthermore, they offer the non-
negligible advantage of being easily obtained without invasive method. Indeed, whereas
umbilical cord is usually intended to trash after birth and can rather be preserved in order to
collect cells, bone marrow aspiration, lipo-aspiration, or teeth extraction are non-heavy pro‐
cedures that are commonly performed in clinical context. Those procedures could even be
performed in patients when needed, allowing autologous grafts and avoiding immunologi‐
cal rejects. Additionally, the use of MSCs/NCSCs, from either adult origin or isolated from
umbilical cord, get round the ethical problems related to fetal cells use. Moreover, those cells
are supposed to be safer than embryonic stem cells or induced pluripotent stem cells in
terms of tumorigenicity and genomic modifications [24, 50].
4. Signaling pathways involved in neural differentiation of MSCs and
NCSCs
As already mentioned, a wide range of culture settings for MSCs/NCSCs neural differentia‐
tion were commonly experienced, with some of them giving rise to substantial results.
Hence, it can be inferred that MSCs/NCSCs can give rise to neuronal cells through the acti‐
vation/deactivation of many intracellular signaling pathways. In this chapter, we will focus
on the analysis of several differentiating protocols that highlighted specific signaling path‐
ways in neuronal fate decision. We will dissect those pathways from the ligand molecules to
the different cellular and molecular effectors that are involved within, up to the gene expres‐
sion modulation. We will then describe the different downstream effects experimentally ob‐
served after activation of those pathways, in the context of neural fate adoption by different
type of MSCs/NCSCs and summarized in Figure 2 and Table 1.
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4.1. Cyclic-adenosine-monophosphate and PKA signaling pathway
Cyclic-adenosine-monophosphate (cAMP) is a well-known intracellular messenger, which is
physiologically synthesized from adenosine-triphosphate by a membrane-anchored adenyl‐
yl cyclase, when this last is induced by an active G protein-coupled receptor. In the cyto‐
plasm, cAMP essentially activates the protein kinase A (PKA), which then reach the nucleus
where it supports the phosphorylation of a transcription factor (cAMP responsive element
binding protein, or CREB protein). Once phosphorylated, CREB protein binds CREB-bind‐
ing protein (CREBB protein or CBP), and with the support of different co-factors, join specif‐
ic DNA sequences and regulate the expression of different genes (coding for c-fos, brain
derived neurotrophic factor (BDNF)[51], or tyrosine hydroxylase (TH)[52]). The destruction
of intracellular cAMP is mediated by phosphodiesterases (PDE), which convert cAMP into
AMP, then regulating cAMP cytoplasmic concentrations. This cAMP-dependent pathway
has been demonstrated to be fundamental in embryonic development, neural cells survival
and other processes like long term memory and neuronal plasticity [53-55].
cAMP is frequently used in culture media to induce MSCs/NCSCs into neural lineage, as
well as other molecules which raise the intracellular cAMP levels. For example, forskolin ac‐
tivates adenylyl-cyclase, dibutyryl-cAMP (db-cAMP) and 3-isobutyl-1-methylxanthine
(IBMX) both act as inhibitors of phosphodiesterases, and 8-bromo-cAMP activates PKA and
is long-acting because of its resistance to degradation by phosphodiesterases.
The main cytoplasmic target of cAMP, which is the PKA, has effectively been demonstrated
to mediate neural differentiation. Wang et al. studied the impact of PKA activation on neu‐
rite outgrowth and on neural markers glial acidic fibrillary protein (GFAP) and neurofila‐
ment (NF) expression. They observed that the complete inactivation of this kinase led to a
total absence of neural differentiation in UCB-MSCs, while the level of phosphorylated
CREB was upregulated in forskolin-treated cells (this effect was inhibited in presence of
PKA inhibitor) [56]. The involvement of PKA in the neural differentiation of MSCs was also
confirmed by several others studies [57,58].
According to Lepski et al., neuronal differentiation of human BM-MSCs resulted from a spe‐
cific mechanism dependent upon the PKA pathway. Indeed, they demonstrated that the
presence of a PKA inhibitor in the induction medium impaired the differentiation process
(induced by IBMX, coupled with brain-derived neurotrophic factor (BDNF), see paragraph
3.4.), and that CREB was phosphorylated in differentiated MSCs [59]. Moreover, MSC-de‐
rived cells showed significant voltage-dependent ionic currents (Na+, K+ and Ca2+ currents).
Besides, UCB-MSCs were induced to neural outcome with db-cAMP and IBMX treatment,
which was demonstrated to be necessary and sufficient for neurite-like outgrowth and for
nuclear receptor related 1 protein (Nurr1) expression. Nurr1 is known to play a key role in
dopaminergic system maintenance. In addition, those data showed evidence for cAMP-
pathway control on differential phosphorylation of TH isoforms [60].
Lin et al. studied the ability of granulocyte-macrophage colony-stimulating-factor (GM-CSF)
to promote neural differentiation in BM-MSCs through the phosphorylation of CREB [61].
Indeed, GM-CSF-treated BM-MSCs expressed higher levels of neuron specific enolase (NSE)
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over time, whereas transiently increased nestin expression. In parallel, a substantial increase
of phosphorylated-CREB level was observed in the GM-CSF-treated BM-MSCs compared
with control (CREB levels were not different between the two groups), and that the kinetics
of this increase was consistent with the progress in neural differentiation.
Figure 2. Different signaling pathways are involved in neural differentiation of MSCs and NCSCs.Each pathway and
modulating substances are described in the text.
While cAMP pathway is supposed to be involved in neural differentiation of MSCs, its pre‐
cise role in this differentiation process still needs to be defined. Zhang et al. showed evi‐
dence for the involvement of cAMP in two differentially-regulated processes, which are
early transient neuron-like morphology changes, like cytoskeleton rearrangement, and later
neural markers expression associated with neuronal function, but demonstrated that cAMP-
treated BM-MSCs did not achieve complete differentiation [62]. Another hypothesis was
made by Rooney et al., who examined the effect of intracellular cAMP elevation on BM-
MSCs’ fate [63]. They demonstrated that forskolin and 8-bromo-cAMP induced a transient
increase in βIII-tubulin expression and changes in cell morphology, but no expression of
growth associated protein 43 (GAP-43) [64] was seen in the neural-like BM-MSCs, excluding
authentic neurite formation. They therefore concluded that this effect was mostly due to a
modification of culture conditions rather than in a differentiation process.
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(“ns” indicates that the passage or the incubation length are not specified. “No” indicates that no electrophysiological results
are described in the study or that no inhibitor has been tested to confirm the pathway). Hedgehog signaling pathway
Table 1. In vitro protocols for neural differentiation of different types of MSCs/NCSCs and detailed results.
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The hedgehog-mediated signalization is involved in the embryonic development, and its
main ligand, Sonic Hedgehog (SHH) plays a role of morphogenic factor, defining which fate
has to be applied to cells at each place of the embryo: its role in the nervous system organi‐
zation is crucial and depends on precise concentration gradients which are essential for a
correct patterning of the embryo. Indeed, SHH signaling is the chief actor in the definition of
the dorsoventral axis of the nervous system. This signalization mostly takes place in cell cil‐
ia, and implies two different receptors that, once activated, generate a tricky reorganization
of cytoplasmic protein complexes. SHH binds its receptor Patched1 (Ptc), relieving Ptc-
mediated inhibition of a second receptor Smoothened (Smo): Ptc leaves the cilium where
Smo then accumulates and induces the activation of Gli family of transcription factors (Gli1,
Gli2, and Gli3) [85, 86].
SHH was used to induce dopaminergic differentiation of human BM-MSCs, as demonstrat‐
ed by Trzaska et al. After a 12-days incubation with SHH, coupled with fibroblast growth
factor 8 (FGF8) and basic fibroblast growth factor (bFGF), a great number of cells turned into
putative dopaminergic neurons, as showed by tyrosine hydroxylase (TH) expression and
electrophysiological features. Those cells showed higher expression of neuronal markers,
and downregulated genes which are involved in cell cycle regulation, like cyclin-dependent
kinase 2 (CDK2) and proliferating cell nuclear antigen (PCNA), indicating that they entered
a post-mitotic fate [65, 66].
Qi and al. analyzed the abilities of rhesus monkey BM-MSCs to differentiate into cholinergic
neural cells. While SHH alone in the culture medium did not trigger any modification of
resting potential, they demonstrated that BM-MSCs exhibited neuronal resting membrane
potential when retinoic acid (RA) was present in the culture medium, and under the combi‐
nation of both SHH and RA. Moreover, cells from the SHH+RA inducing group expressed
higher levels of synapsin and acetylcholine (ACh), indicating that the combination of both
signals was the best way to obtain cholinergic neurons [67].
Many other studies demonstrated a synergic role of SHH and RA in neural induction of BM-
MSCs. Kondo et al. identified those two signals as sensory factors, showing that SHH+RA
application leaded to the expression of glutamatergic sensory neuron markers (including
GATA3, Sox10 or GluR4) by treated BM-MSCs [68]. On the other hand, the combination of
SHH+RA added to FGF8 (before neurotrophin incubation) was showed to promote dopami‐
nergic fate in MIAMI cells [69], which expressed TH and other molecules involved in dopa‐
minergic differenciation, like Nurr1.
Human AT-MSCs were induced to neural differentiation through the action of SHH and
RA. After induction, immunochemical labeling showed βIII-tubulin, choline acetyltransfer‐
ase (ChAT), and NSE expression. The differentiated cells were then characterized by RT-
PCR and results showed that those cells were restricted to a ventral spinal fate (Nkx2.2,
Pax6, Hb9, and Olig2), suggesting that those cells could be good candidates for motoneur‐
ons generation, in the context of spinal cord injuries therapy [70].
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4.2. Retinoic acid signaling pathway
Retinoic acid (RA) is physiologically metabolized from retinol, thanks to the sequential ac‐
tion of cellular retinol-binding protein (CRBP), retinol dehydrogenase (RoDH) and retinal‐
dehyde dehydrogenases (RALDHs). Once in the cytoplasm, RA is bound by cellular RA-
binding protein (CRABP) and enters the nucleus to bind its specific receptors (RARs) and
the retinoid X receptors (RXRs), which themselves heterodimerize and bind to DNA sequen‐
ces known as the RAREs (RA-response elements). This activates transcription of target genes
(Hox genes, Oct4,...) [87]. This RA signalization is involved in brain development and more
particularly in the definition of the anterio-posterior axis of the nervous system, by regulat‐
ing the expression of Hox genes in defined localized domains of the embryo [88].
Whereas SHH was often coupled with RA in cell culture differentiation medium, the impli‐
cation of RA signaling in neuronal differentiation was also studied without a combination
with SHH. RA was demonstrated to act on the up-regulation of NF-L expression in UCB-
MSCs, while applied with IBMX, db-cAMP, nerve growth factor (NGF) and bFGF [60]. This
study also highlighted the role of RA and cAMP/PKA pathways in the differential phos‐
phorylation of TH during differentiation. Indeed, neurally differentiated cells express neu‐
ronal markers as Tau or NSE, whereas TH and Nurr-1 expression assessed their
dopaminergic profile.
In the study of Scintu et al., two different protocols were used to differentiate BM-MSCs into
neuronal cells. The first one was carried out by activating the cAMP and PKC pathway
(with forskolin, TPA and IBMX), whereas the second one consisted in RA treatment. Both
protocols leaded to NSE, βIII-tubulin, GFAP and NF positive cells [71].
Similarly, pre-treatment with RA before incubation with forskolin leaded BM-MSCs to ex‐
press higher levels of nestin, NSE, and microtubule associated protein 2 (MAP2) and exhibit
neural-like resting membrane potential and increased intracellular calcium concentration
[72]. They also demonstrated that only RA specific receptors RARa and RARc were ex‐
pressed in native BM-MSCs. Conversely, the expression of RARb was significantly increased
in differentiated neurons, suggesting its major role in neural differentiation.
Arthur et al. performed RA treatment of human DP-SCs, which subsequently showed neu‐
ral morphology and expression of βIII-tubulin, NF-M and NF-H, and more interestingly ex‐
hibited electrophysiological activity characteristic of sodium voltage-gated channels,
assessing for their potential ability to give rise to functional neurons [41].
4.3. Neurotrophic factors and downstream signaling pathways
Neurotrophins are secreted growth factors that are involved in the development of neurons
in the nervous system, as well as in their survival and functionality. This family of proteins
is constituted by the “prototypical” nerve growth factor (NGF), brain-derived growth factor
(BDNF), and the neurotrophins (NT-) 3, 4/5 and 6. Those members promote neural cells to
survive, grow, differentiate and function through the activation of high-affinity tyrosine-
kinase (tropomyosin-related) receptors (TrkA, TrkB and TrkC are respectively bound by
NGF/NT-6, BDNF/NT-4, and NT-3), and through the activation of a common low-affinity re‐
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ceptor, the p75LNR, which has no intrinsic kinase property. While p75LNR activation is suffi‐
cient to induce events like neurite formation, its role seems to facilitate the binding of
neurotrophins to Trk receptors. After trans-phosphorylation, Trk receptors function as acti‐
vators of three main signaling pathways, respectively mitogen-activated protein kinases
(MAPKs), phospholipase C (PLC) and phosphatidyl-inositol-3-kinase (PI3K) [89,90].
Briefly,  the  MAPKs  pathway  consists  in  a  set  of  sequentially-activated  kinase  proteins
grouped  in  three  main  connected  cascades,  involving  regulators  of  alpha-foetoproteins
(Raf), extracellular-regulated kinases (ERK), p38 or jun-kinase 1/2/3, resulting in the phos‐
phorylation  of  transcription  factors  and  then  regulating  gene  expression.  MAPKs  are
abundantly expressed in the central  nervous system (CNS),  and ERKs are known to be
involved  in  different  processes,  including  neuronal  maturation,  survival,  and  synaptic
functions.
The PLC signalization pathway mostly induces intracellular calcium mobilization, but fur‐
thermore stimulates protein kinase C (PKC) via the production of diacylglycerol (DAG). The
PKC can also be directly activated by 12-O-tetradecanoylphorbol-13-acetate (TPA), and is al‐
so able to activate MAPKs pathway.
Finally, PI3K controls another downstream kinase called Akt (also named protein kinase B
or PKB) that is a crucial player in cell survival through the regulation of apoptosis among
other roles.
Several additional neurotrophic factors are regrouped in a second family, the GDNF family
of ligands (GFL). Briefly, the glial neurotrophic factor (GDNF) is a protein that has been
shown to promote the survival and differentiation of dopaminergic neurons and motoneur‐
ons, and constitutes then an important potential actor in the management of neurological
diseases such as Parkinson’s disease [91, 92], amyotrophic lateral sclerosis or spinal cord in‐
juries. Neurturin, artemin and persephin are similar ligands that also play a role in cell sur‐
vival, neurite outgrowth, and cell differentiation migration. Those four members act by the
activation of a tyrosine kinase receptor RET, which in association with a co-receptor (GFRα),
triggers auto-transphosphorylation and downstream signaling processes.
A cocktail of the three main neurotrophins (BDNF, NGF and NT-3) was used to direct neu‐
ral differentiation of MIAMI cells, which began to develop a complex neuritic arborization
and to express neuronal markers, e.g. NF-L or NeuN [69]. Moreover, those differentiated
cells showed inward Na+ and outward K+ currents. This study also highlighted the impor‐
tance of NT-3 in the neural commitment and differentiation step, through the demonstration
of a dramatic decrease in viability, βIII-tubulin expression, neuron-like morphology and
branching of differentiated cells without NT-3 treatment. Those results were then further de‐
tailed and showed the enhanced neural specification from MIAMI cells thanks to epidermal
growth factor (EGF) and bFGF pre-treatment [73]; the implication of Rho-GTPase Rac1,
which was thought to regulate Mek1/2-Erk1/2 phosphorylation, mediating transcription of
genes involved in neural differentiation versus proliferation during NT-3-induced neuronal
commitment [74].
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The first assessment of the ability of SKPs to generate neural cells was achieved by the
group of Toma, who first described that about 9,4% of SKPs were NF-M, GAP43, βIII-tubu‐
lin and MAP2 positive after being treated with NGF, BDNF and NT-3 [37].
When co-cultivated with immature cerebellar granules, nestin-positive BM-MSCs are able to
differentiate into functional neuronal cells [93], as showed by βIII-tubulin expression and ac‐
tion potentials firings. After characterizing two subpopulations of BM-MSCs which were re‐
spectively derived and non-derived from the embryonic neural crest (after generating clonal
cultures), Wislet-Gendebien and collaborators demonstrated that the neural differentiation
of BM-NCSCs in co-culture conditions was abolished in the presence of a MAPKs inhibitor.
Those results confirmed the importance of MAPKs pathway in neural differentiation of
adult BM-NCSCs [43].
After adding NGF in the culture medium of human SKPs, Bakthiari et al. obtained NF-M,
βIII-tubulin, S100 and GFAP positive cells, and that after different conditions of cryopreser‐
vation [75].
Lim et al. demonstrated the important role of BDNF in neural differentiation of human
UCB-MSCs, and provided a deeper study of the different involved pathways. Addition of
BDNF in the induction medium leaded to the phosphorylation of Raf-1 and ERK, then to the
downstream up-regulation of p35 expression, which was not observed when ERK was
blocked with a specific inhibitor. p35 is known as an anti-apoptotic factor able to block pro‐
caspase maturation and to protect neurons from cell death [94, 95].
They also analyzed the contribution of BDNF to cell viability, and demonstrated an up-regu‐
lation of the anti-apoptotic gene Bcl2, which was mediated by the activity of PI3K and Akt
phosphorylation [76]. Few years later, after genetically modifying UCB-MSCs through trans‐
fection with a BDNF-expressing plasmid, they showed the expression of βIII-tubulin, NeuN,
GFAP and myelin basic protein (MBP) in differentiated cells, associated with an up-regulat‐
ed phosphorylation level of TrkB, Raf-1 and ERKs [77].
BDNF was also used to induce bi-multipolar morphology and MAP2 expression in WJ-
MSCs. When used in combination with hippocampal cholinergic neurostimulating peptide
(HCNP) and/or denervated hippocampal extract (rDHE), WJ-MSCs turned into Choline-ace‐
tyltransferase (ChAT) positive cells [96].
Coupled with IBMX, BDNF was able to induce GFAP and βIII-tubulin expression in AT-
MSCs, as demonstrated by Ying et al. [79]. The same combination of IBMX and BDNF was
used to differentiate DP-SCs into GFAP, c-fos, NF, HNK1, enolase-2, βIII-tubulin, MAP2,
Sox2, Tenascin-C, Connexin-43 and nestin positive cells [80].
Neural induction of DP-SCs was achieved by Kiraly et al. through the activation of both
cAMP and PKC signaling pathways. After reprogramming by 5-azacytidine treatment, cells
where treated with IBMX, db-cAMP, forskolin, TPA, NGF and NT-3, and showed an in‐
crease in neurogenin-2, βIII-tubulin, NSE, NF-M and GFAP expression, while electrophysio‐
logical recordings revealed voltage dependent sodium channels activity [81].
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The study of Zhang et al. demonstrated that RA induced SKPs to neural differentiation
through the up-regulation of the transcription factor NeuroD and the cell-cycle regulatory
protein p21 [82]. In the meantime, RA also induced p75NTR up-regulation that leaded to
apoptotic cell death. They showed that when treated with NT-3 after RA induction, the sur‐
vival and neural differentiation of SKPs were improved significantly, and cell apoptosis in‐
duced by RA was decreased. These effects were reversible as confirmed by the way of a
p75NTR inhibitor Pep5 instead of Trk receptor inhibitor K252a.
The three pathways of RA, cAMP and NT were recruited together to differentiate SKPs into
neuronal cells. After adding RA, db-cAMP, NGF, BDNF and NT-3 to the culture medium,
Lebonvallet et al. identified NF and PGP9.5 positive cells, which were also able to incorpo‐
rate FMI-43 staining, indicating the presence of synaptic vesicles. Furthermore, they showed
an overexpression of neuron-related genes in differentiated SKPs [83].
Kim et al. studied the involvement of non-neurotrophin-activated MAPKs pathway. They
showed that cAMP and PKA (resulting of forskolin treatment) promoted the phosphory‐
lation/activation of  B-Raf,  MEK and ERK [58].  Confirmation was specified with the  use
of an inhibitor of MAPKs pathway that induced a significant decrease in neural features
of forskolin-treated BM-MSCs. The same observation was carried out by Jori  et  al.,  con‐
firming that  neural-like  BM-MSCs reverted  to  uncommitted  cells  when cultured with  a
MEK-ERK inhibitor [57].
4.4. Wnt signaling pathway
The Wnt signaling pathway is constituted by a network of proteins that are involved in the
regulation of multiple developmental events during embryogenesis, but also in adulthood,
in several physiological processes and tissue homeostasis through cell fate specification, dif‐
ferentiation, or proliferation..
Wnt proteins act on cells by binding Frizzled (Fzd)/low density lipoprotein (LDL) recep‐
tor-related protein (LRP) receptor complex. When Wnt signal is inactive, the levels of cy‐
toplasmic  transcription  factor  β-catenin  are  kept  low  through  continuous  proteasome-
mediated  degradation,  which  is  regulated  by  a  complex  including  glycogen  synthase
kinase-3β (GSK-3), Axin, and Adenomatous Polyposis Coli (APC). Once Wnt ligands acti‐
vate Fzd/LRP, the degradation pathway is inhibited (through the activity of Dishevelled
(Dsh))  and β-catenin accumulates  in  the  cytoplasm.  After  nuclear  translocation,  it  inter‐
acts with T-cell specific transcription factors (TCF) among others, which allows transcrip‐
tion regulation [97, 98].
Kondo et al. exposed that BM-MSCs induced to neural differentiation (with forskolin and
IBMX) showed significant dose-dependent upregulation of sensory neurons markers Ngn1,
NeuroD, Brn3a and P2X3 when the induction medium was supplemented with recombinant
Wnt1 (whereas Wnt3a exhibited comparable but slighter effects)[84]. Glutamate receptors
GluR2 and GluR4 were also up-regulated in those conditions.
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5. Implications in cell therapy
With regards to their accessibility and their multipotentiality, adult and perinatal MSCs and
NCSCs constitute ideal stem cells to use in cell therapy. As it has been shown that those cells
could give rise to neuron-like cells via multiple ways of induction, we can infer that they
could be of valuable interest in the treatment of neurological lesions. In this paragraph, we
will collect the results of some studies that focused on cell therapy of Parkinson’s disease
and spinal cord injuries, using different types of MSCs/NCSCs and different ways to differ‐
entiate them into neurons before being transferred in animal models. Those results are sum‐
marized in the Table 2.
5.1. Dopaminergic neurons and Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alz‐
heimer’s disease, with a prevalence of 0,3% of the population in industrialized countries,
reaching 1% after 60 years of age [110]. This pathology is characterized by typical clinical
symptoms, like bradykinesia, rigidity, gait troubles and resting tremor, while the main
pathological feature is the loss of dopaminergic neurons in the Substantia Nigra pars com‐
pacta (SNpc), associated with ubiquitinated protein aggregates called Lewy bodies in differ‐
ent locations of the brain [111, 112].
In the last 80’s, clinical trials have been started, using fetal mesencephalic dopaminergic
neurons to transplant in PD patients [113, 114]. Despite the demonstration of several benefits
in terms of clinical symptoms and pathology, few problems remain. Fetal tissue heterogenei‐
ty, influence of harvesting methods on the graft efficiency, need of too much fetuses for only
one patient, altogether coupled with ethical concerns, left no option but finding other ways
to proceed. One of the main goals in this field relies in the replacement of lost dopaminergic
neurons in the nigrostriatal system, which could be achieved through the use of different
types of stem cells. As explained earlier, MSCs/NCSCs are interesting candidates in this ob‐
jective [115].
In this paragraph, we will review the results of some studies aiming to differentiate diverse
types of MSCs and NCSCs in dopaminergic neurons before grafting those cells in vivo, using
animal models mimicking the symptoms of PD (which are required to study the putative
usefulness of stem cells in regenerative therapy).
After in vitro differentiation of WJ-MSCs in dopaminergic neural cells using a SHH and
FGF8 treatment (in combination with brain-conditioned medium), Fu et al transplanted
those differentiated cells inside the striatum of hemiparkinsonian rats, previously treated
with 6-hydroxydopamine (6-OHDA). 20 days after transplantation, TH positive cells were
found around the implantation site, and those cells were shown to be grafted WJ-MSCs.
Moreover, the number of amphetamine-induced rotations (giving idea of motor performan‐
ces of hemiparkinsonian rats) was decreased, and this decrease was gradual over time,
showing an important improvement in the nigrostriatal pathway function [99].
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Cell type Differentiation protocol Animal model Histology Behavioral aspects Ref.
Dopaminergic neurons - Parkinson’s Disease
WJ-MSCs
SHH, FGF8 (+ brain-
conditioned medium)
6-OHDA rat
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(“No” indicates that no behavioral testing is described in the study. Protocols describing in vitro differentiation in the
meantime than in vivo studies are also included in the table, as well as some in vivo studies using non-differentiated
cells).
Table 2. Different results obtained in cell-based therapy experiments using MSCs and NCSCs.
On the other hand, Khoo et al showed that neuronal-primed human BM-MSCs (with SHH,
FGF8, GDNF and other growth factors) did survive transiently in the brain of 6-OHDA-
treated rats, but no further differentiation in functional dopaminergic neurons was ob‐
served, even when a co-transplantation with olfactory ensheating cells (OECs) was
performed to enhance to graft efficiency [100].
The same cocktail was used by Wang et al. to differentiate SHED cells (DP-SCs) into dopa‐
minergic neurons, this time supplemented with forskolin. Differentiated cells were βIII-tu‐
bulin, MAP2 and TH positive in vitro. They further characterized naïve SHED cells by
transplanting them into the striatum of a hemiparkinsonian rat. While some TH-positive cell
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bodies were found in the graft zone, a significant decrease in apomorphine-induced rota‐
tions was observed, attesting of a beneficial effect of the cell transplantation [101].
cAMP pathway was recruited to differentiate BM-MSCs (after EGF/bFGF-induced sphere
formation) in dopaminergic neurons, using forskolin, IBMX and db-cAMP (coupled with the
PKC activator TPA) [102]. Differentiated cells showed in vitro expression of βIII-tubulin,
neurofilament, Nurr-1, TH, AADC and GIRK2. After transplantation into the striatum of 6-
OHDA rats, few cells were βIII-tubulin and TH positive, whereas a higher number of graft‐
ed cells became GABA-positive (maybe due to the striatal environment mainly composed of
GABA neurons). Unfortunately, no behavioral observation was described by Suon et al.
5.2. Motoneurons and spinal cord injuries
Whereas peripheral nerves are able to regenerate when a lesion occurs, the motoneurons
and nervous fibers in the spinal cord can’t be replaced in case of spinal cord injury (SCI).
Indeed, traumatic spinal cord injury results in a wide panel of pathophysiological events
counteracting any possibility of neural regeneration, and those events are generally grouped
in two phases. The primary injury phase can be due to either contusion or compression, and
is characterized by section of axons, necrosis, degeneration, oligodendrocytes apoptosis,
gliosis and macrophage infiltration. Altogether, those events lead to secondary lesions like
ischemia, inflammation, alteration of ion balance, insult of the blood-brain-barrier, lipid per‐
oxidation and glutamate-induced excitotoxicity. Despite a slight spontaneous recovery, all
those events collectively constitute an environment that hampers axonal regeneration [116].
Since the clinical consequences of such lesions are dramatic and rarely reversible (para-,
hemi-, tetraplegy, respiratory problems, loss of sphincters control, all leading to important
socio-economic issues), it’s crucial to find out efficient therapies to improve the recuperation
of motor function.
Stem cell grafting has been suggested as a therapeutic strategy for spinal cord repair, hence
the obtainment of mature motoneurons is critical.
Human BM-MSCs were induced to differentiate into neural cells through the activation of
cAMP signaling pathway, via the addition of 8-bromo-cAMP and Rolipram (inhibitor of
phosphodiesterases) in the culture medium. Those neurally-induced BM-MSCs were then
transplanted into a segment of the spinal cord of rats, previously wounded by contusion.
After confirming neural nature of differentiated cells by immunostaining of A2B5, NCAM,
B3T, in vitro as well as in vivo after transplantation, behavioral testing of rats revealed that
the motor recovery (assessed by hind limb stepping and weight support) was significantly
different at 2 to 12 weeks post-recovery in the group that was transplanted with neurally-
induced BM-MSCs when compared with the control groups that received non differentiated
BM-MSCs and saline solution [103].
Another protocol was tested by Zhang et al.,  who treated BM-MSCs with RA before ge‐
netically  modifying them to overexpress  the gene coding for  the neurotrophin 3  (NT-3)
[104].  Once they’ve showed that  RA pretreatment enhanced NT-3 expression and secre‐
tion by MSCs after genetic engineering, they transplanted cells into the transected spinal
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cord  of  rats.  Some  transplanted  cells  were  positive  for  MAP2,  NF  and  GFAP  labeling.
Moreover, cell transplantation leaded to the reduction of cystic cavity, improvement of lo‐
cal environment, rescue of surviving neurons from retrograde atrophy, and improvement
of hind limb locomotion.
Liqing et al. induced AT-MSCs to neural fate through the action of SHH and RA, and
showed that those cells expressed the transcription factors Nkx2.2, Pax6, Hb9, and Olig2,
suggesting those cells as attractive nominees to become mature motoneurons [70]. While no
in vivo testing has been performed in this study, another experiment focusing on ventral spi‐
nal-specific transcription factors was carried out by Park and al., who genetically modified
human BM-MSCs to express Hb9 and Olig2, just before treating them with neural induction
medium consisting in sequential incubation with RA, forskolin, SHH and FGF. In vitro,
those cells were excitable and were able to connect muscle fibers; while after transplantation
into an injured organotypic spinal cord slice culture, they survive and integrate the slice,
while expressing motoneurons-specific markers, e.g. ChAT [105].
Pedram et al. performed comparative study of the potencies of BM-MSCs to take part in the
repair of spinal cord damages, either when neurally-differentiated than when used in their
native state [106]. BM-MSCs were cultured following a multi-step protocol, in presence of
RA and bFGF, db-cAMP, forskolin and IBMX. After assessing the neural nature of differenti‐
ated cells (expression of MAP2, NSE, nestin, and βIII-tubulin), they transplanted cells into
the lesion cavity of contused rat spinal cords. Either undifferentiated BM-MSCs or neurally-
induced BM-MSCs transplantation leaded to a reduced cavity, but a significant improve‐
ment in motor performances was observed in rats that received neurally-differentiated BM-
MSCs (compared to control group and native BM-MSCs-transplanted group).
Obtaining myelinating glial cells is another way to manage spinal cord injuries. In that pur‐
pose, Biernaskie et al. studied the effect of SKPs on spinal cord lesions, when transplanted in
their naïve state or when pre-differentiated into Schwann cells (using forskolin and neure‐
gulin-1β) [108]. They showed that a graft of both the naïve SKPs and SKPs-derived Schwann
cells leaded to a reduced cystic cavity size, and that the cells myelinated host axons and re‐
cruited host Schwann cells. Still, the SKPs-derived Schwann cells were the only ones to gen‐
erate a bridge across the lesion and to induce a growth-permissive environment, while a
substantial improvement was observed at the behavioral level (Increased BBB score and Bas‐
so locomotor subscore and decrease in the number of hind limb errors).
Significant enhancement of functional locomotor abilities was observed by Schira et al. af‐
ter transplantation of unrestricted UCB-MSCs into the surrounding area of a hemisection
injury,  accompanied  by  cell  accumulation  near  the  lesion,  reduction  in  its  size  and en‐
hanced axon regrowth [107]. This study gives an example of what can be observed using
naïve stem cells in cell therapy, without any pre-differentiation. In the same way, Sieber-
Blum et al. transplanted EPI-NCSCs in the core of a spinal cord lesion, and observed βIII-
tubulin,  GAD67,  RIP  and MBP positive  cells  among the  grafted  cells.  Those  cells  were
tightly close to endogenous neuritis, but did not show any sign of proliferation nor migra‐
tion in the tissue [109].




Mesenchymal  stem  cells  (MSCs)  and  neural  crest  stem  cells  (NCSCs)  are  multipotent
cells  that  are  able  to  generate  a  wide  range  of  cell  types,  including neural  cells,  which
makes  them  incredibly  interesting  in  restorative  therapies  for  patients  suffering  from
neurological diseases. A lot of induction protocols indicate that many signaling pathways
may be involved in the neural fate of MSCs and NCSCs. Indeed, the signalization path‐
ways of cAMP, Retinoic acid, Hedgehog, Wnt and the neurotrophins-activated pathways
have been implicated into the maturation of adult MSCs/NCSCs into neural-like cells. Af‐
ter  an  induction process  consisting  in  various  activators,  lengths  and conditions  of  cul‐
ture, treated cells adopt a neural morphology express markers (at the transcriptome level
as well as at the protein level) that are usually described to characterize neurons at dif‐
ferent developmental stages [117, 118] in MSCs as well as in NCSCs. Despite the expres‐
sion of those specific neural markers, only a tiny number of in vitro  protocols were able
to provide convincing evidence for a neuron-specific electrophysiological signature of the
differentiated cells.
During neural  development,  immature neural  cells  undergo a differentiation process to‐
wards functional neurons through different stages that are accurately defined by specific
electrophysiological  features.  Briefly,  the  first  currents  that  occur  in  the  cell  consist  in
voltage-dependent outward potassium currents. As maturation proceeds, voltage-depend‐
ent  inward calcium and sodium currents  arise  sequentially.  The  ultimate  step is  finally
characterized by the elicitation of action potential through the activity of several mature
voltage-gated sodium channels: an important depolarization triggers intracellular modifi‐
cations,  proteins activation, and vesicular trafficking that are required for proper synap‐
tic chemical and electrical function/transmission [119-121]. As clearly observed in Table 1,
even if a few data attest of electrophysiological activity in MSCs/NCSCs-derived neuron-
like cells (as showed by sodium and potassium currents),  there is no sufficient evidence
for action potential firings and for an appropriate neuronal function.
As  showed  by  the  diagram  on  the  figure  3,  most  of  the  collected  studies  describe  the
cAMP  signaling  pathway  to  play  a  key  role  in  the  neural  differentiation  of  MSCs/
NCSCs.  On  the  other  hand,  neurotrophins  are  often  used  for  neural  differentiation,
whereas  MAPKs  have  been  shown  to  be  involved  too.  RA  represents  the  third  most
used  signaling  molecule.  We  can  see  that  the  most  part  of  studies  showing  significant
electrophysiological  recordings use RA treatment for  differentiation,  suggesting its  note‐
worthy role  in  this  process  (16,1  % of  the total  number of  studies  (5/31)  and 62,5  % of
the  number  of  studies  showing  significant  electrophysiological  recordings  (5/8)).  Addi‐
tionally,  a  major  number  of  protocols  were  performed in  association  with  cAMP path‐
way  activation.  On  the  other  hand,  40%  of  the  differentiation  protocols  using  SHH
signalization (2/5 studies) were able to induce changes in electrical activity (see Table 1).
That presumably raises the question of a role for RA and SHH in the last stages of ma‐
turation of MSCs/NCSCs into neural-like cells.
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Figure 3. Percentages of differentiation protocols involving cAMP, RA or neurotrophins/MAPKs signaling pathways
among the 31 detailed studies. Percentages are expressed in regard to the total number of studies. Numbers in red
indicate the percentages of studies describing significant electrophysiological recordings.
Overall, we tend to conclude that although the cells express neural-specific proteins and ex‐
hibit a preliminary electrical activity [122, 123], MSCs and NCSCs do not seem to be able to
fully differentiate and generate functional neurons in order to reach the objective of cell-
based therapy in human neurological treatments.
However, several in vivo studies based on MSCs/NCSCs-derived neural cells demonstrate a
significant improvement of symptoms and lesions in animal models of neurological disor‐
ders, such as Parkinson’s disease or spinal cord injury [24]. In these studies, the transplanta‐
tion of differentiated MSCs/NCSCs leads to the limitation of the lesions and the recovering
of motor functions. Regarding other successful cell therapy experiments based on the trans‐
plantation of non-differentiated MSCs/NCSCs, we can infer that the experimental enhance‐
ment is more likely to be due to the intrinsic properties of the grafted cells, and not to a
genuine differentiation process nor to an authentic neuronal electrical activity. Indeed, even
if their ability to generate neurons is present but quite limited, they still display important
immunomodulatory and anti-inflammatory properties, they secrete a lot of growth and neu‐
rotrophic factors, they modulate apoptosis processes, and promote endogenous precursors
recruitment [124-128]
In conclusion, those observations confirmed the significance of MSCs and NCSCs use in cell
therapy procedures to treat several neurological disorders, sustaining their high capacity to
protect or restore neural tissue through many proceedings that are probably more owed to
intrinsic abilities than to neuronal differentiation.
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